Player FM - Internet Radio Done Right
74 subscribers
Checked 12d ago
जोड़े गए five सालो पहले
Lynn Marie Morski, MD, and JD द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Lynn Marie Morski, MD, and JD या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!
Player FM ऐप के साथ ऑफ़लाइन जाएं!
पॉडकास्ट सुनने लायक
प्रायोजित
If you're interested in getting occasional news, behind the scenes content, and interesting fandom content, sign up to the newsletter ! Head to: https://www.thewesterosiprimer.com/newsletter What if one strategic marriage could end a war and change the course of Westeros? Join Liz on the Westerosi Primer as she explores the reign of Daeron II Targaryen. This king would later be remembered as Daeron the Good. This episode kicks off with an some listener feedback on the best and worst Targaryen kings. Liz starts with Daeron's formative years. She discusses his education and the union with Myriah Martell. This marriage brought peace with Dorne and paved the way for a new generation of Targaryens. The tension that marked Daeron's relationship with his father, Aegon IV, are explored. Daeron demonstrates his intelligence as he sidestep his father’s reckless actions. The episode also includes first Blackfyre Rebellion. Liz delves into the intricacies of loyalty, legitimacy, and power. Daemon Blackfyre had privileges he wouldn't have gotten if not for his parentage. Despite a thriving family life, Daemon becomes a challenger to his brother Daeron II. The Blackfyre Rebellion was fueled by discontent among the nobility and questions about Daeron's legitimacy. Daemon adopts the reversed Targaryen sigil and instigates the first of many rebellions. The Rebellion ends with the crucial Battle of the Redgrass Field. Daemon’s advance is ultimately thwarted by Brynden Rivers. Support this podcast at — https://redcircle.com/the-westerosi-primer/donations…
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski explicit
सभी (नहीं) चलाए गए चिह्नित करें ...
Manage series 2687899
Lynn Marie Morski, MD, and JD द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Lynn Marie Morski, MD, and JD या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Curious about the possible therapeutic benefits of psychedelic medicines? The Psychedelic Medicine Podcast with Dr. Lynn Marie Morski has you covered with the latest in scientific research, medical practices, and legal developments involving these substances and their incredible therapeutic potential. Covering the full range of psychedelic therapies, including psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and more, this podcast serves as an auditory encyclopedia of information for anyone interested in learning about the safe, therapeutic uses of these medicines.
…
continue reading
171 एपिसोडस
सभी (नहीं) चलाए गए चिह्नित करें ...
Manage series 2687899
Lynn Marie Morski, MD, and JD द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Lynn Marie Morski, MD, and JD या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Curious about the possible therapeutic benefits of psychedelic medicines? The Psychedelic Medicine Podcast with Dr. Lynn Marie Morski has you covered with the latest in scientific research, medical practices, and legal developments involving these substances and their incredible therapeutic potential. Covering the full range of psychedelic therapies, including psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and more, this podcast serves as an auditory encyclopedia of information for anyone interested in learning about the safe, therapeutic uses of these medicines.
…
continue reading
171 एपिसोडस
सभी एपिसोड
×1 Encore episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c) 1:08:52
1:08:52
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:08:52In this episode of the Psychedelic Medicine Podcast, Adam Aronovich, PhD(c) returns to discuss issues of psychedelic self-absorption—and how to avoid these traps. According to Adam, he is a PhD candidate in medical anthropology, the creator and curator of Healing from Healing, a trophy husband and dad. In this conversation, Adam revisits his previous discussion of psychedelic narcissism and explains why he’s now somewhat more critical of the term. However, Adam still sees issues around cultivating epistemic humility and acknowledging the political dimensions of healing in psychedelic contexts. He explains the issues he takes with forms of New Age, Neoliberal spiritual perspectives he sees as pervasive and typically unacknowledged amongst many engaging with psychedelics. He also discusses how some pop psychology terms have worked their way into the psychedelic realm and what impacts that has had. In this episode: The “spectacle” of filmed psychedelic experiences on social media The intersection of medical and spiritual cultures in psychedelics and how this can create issues of access The cheapening and overuse of the idea of “trauma” in popular discourse and the birth of “traumadelic” culture Why approaches focusing on excavating supposed repressed traumatic memories from childhood should be approached with a degree of skepticism Quotes: “One of the main things with plant medicine—particularly when people are sharing about it—is that people want to be really vulnerable and people want to be very authentic… But at the intersection with the spectacle, that vulnerability and authenticity become part of the spectacle in the sense that they become 100% performative.” [19:01] “The people who don’t have that modicum of self awareness and epistemic humility to really understand, with intellectual honesty, the scope of their understanding and knowledge, then it is very easy to overdo it. And then we do a disservice, not only to the actual traditions that we purport to be portraying, but also to the people that we’re working with.” [37:56] “If you don’t understand that your healing is political, because individual health, and individual happiness, and individual everything is intrinsically related to collective health, and social health, and cultural health, and environmental health, then you need to go back to square one because you haven’t understood anything. ” [40:02] “If we can’t even fathom that perhaps my own wellbeing is in constant dialogue with the wellbeing of a society, and the wellbeing of a culture, and the wellbeing of an environment—that nobody can be healthy and happy unless everybody else is relatively healthy and happy—then we are in big trouble and we haven’t really learned everything.” [40:20] Links: Healing from Healing website Healing from Healing on Instagram Healing from Healing on Facebook Adam on Instagram Society Of The Spectacle by Guy Debord Wikipedia entry on the Satanic panic Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich Previous episode: How Western Medicine and Indigenous Traditions Differ in their Approach to Mental Health and Healing with Adam Aronovich Psychedelic Medicine Association Porangui…
1 Psilocybin for Obsessive-Compulsive Disorder (OCD) with Sorcha O'Connor, PhD(c) 35:33
35:33
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
35:33In this episode, Sorcha O'Connor, PhD(c) joins to discuss the research into the use of psilocybin to address obsessive-compulsive disorder (OCD). Sorcha is completing her neuroscience PhD at Imperial College London, specialising in mental health research. She led PsilOCD, a pioneering study investigating low-dose psilocybin as a treatment for both the clinical symptoms and cognitive features of OCD. In this conversation, Sorcha introduces obsessive-compulsive disorder and discusses the ways medical professionals are currently thinking about this and other related conditions. She mentions that current therapies for OCD often only minimally improve symptoms, emphasizing the need for better treatment options. This led to studies exploring psilocybin as a treatment for OCD - and Sorcha emphasizes that the early trials have shown positive results, often with significant decreases in OCD symptoms. In conclusion, Sorcha discusses the protocol for the PsilOCD study at Imperial College London, with results from this study soon to be published. In this episode you'll hear: The features of obsessive-compulsive disorder (OCD) The history and development of treatments for OCD The theory behind the hypothesis that psilocybin may be effective for OCD Trials exploring the efficacy of psychedelic treatments for OCD Why psilocybin has come to the fore more than LSD or ketamine for prospective OCD studies How patients are evaluated for OCD Quotes: “[OCD] is this complex behavioral pattern and certain medications moderately help and nothing seems to be highly effective yet and that definitely points to the need for novel pharmacotherapy.” [12:46] “[By utilizing lower doses of psilocybin], people who maybe fixate on their health and on their mental health and sensations and things can benefit from psilocybin without having to overcome that barrier.” [18:25] Links: Sorcha on LinkedIn PsilOCD Study details on the Imperial College London website Dr. Michael J. Greenberg’s website Psychedelic Medicine Association Porangui…
1 Ending Pill Shaming: How Psychedelics and Pharmaceuticals Can Both Support Healing with Erica Zelfand, ND 45:42
45:42
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
45:42In this episode, Erica Zelfand, ND joins to discuss the important topic of pill shaming in psychedelic communities and how psychedelic medicine and traditional pharmaceuticals can both support healing. Dr. Erica Zelfand specializes in integrative mental health, bridging the gaps between conventional and alternative medicine. In addition to seeing patients in private practice, she also teaches facilitation internationally and leads retreats through Right to Heal. In this conversation, Dr. Zelfand tackles the issue of pill shaming in psychedelic communities, showing why this rhetoric falls short and ultimately harms patients. She discusses complementary roles for psychedelic and traditional pharmaceutical medicines, suggesting that a medicine like ketamine may be particularly effective in contexts of acute intervention, whereas an SSRI antidepressant may be most effective for maintenance. Dr. Zelfand notes, however, that drug-drug interactions can be a significant concern and stresses the need for medical expertise and supervision in the context of concomitant usage of pharmaceuticals and psychedelics. In closing, she emphasizes that what is ultimately important is that patients are able to progress in healing, and any tools that are able to safely and effectively support this goal have an important role to play and should not be denigrated. In this episode you'll hear: The pill shaming rhetoric in psychedelic and cannabis communities Pharmaceutical contraindications to psychedelic therapy and the necessity of medical supervision for tapering off such medications Why comparing traditional antidepressant pharmaceuticals to psychedelic medicines is often an apples to oranges comparison The issues with “no pain, no gain” rhetoric in healing Psychiatric support for processing repressed memories uncovered during psychedelic journeys Quotes: “When I went into medicine, I actually specifically went into integrative medicine, functional medicine, because I didn’t like that patients were being in this position of having to choose: the conventional route or the alternative medicine route. Both routes have their merits and both routes have their shortcomings and I felt like we all deserve to be able to access both and have it be an integrated model.” [3:06] “The only form of ketamine that is FDA approved for depression—which is Spravato—is only approved in the context in which the person is also taking an oral antidepressant.” [20:48] “We have data showing that if you feel really really freaked out and anxious during your [psychedelic] trip, your outcomes aren’t necessarily as good. And the biggest predictor of having a positive experience is actually feeling awe. You don’t have to do the ego death thing, but if you can feel awe, if you can feel inspiration during a trip, your outcomes are better. And there’s even data showing that individuals who are on an SSRI and then trip—they may actually have better outcomes than people who don’t take medication.” [24:12] “I think part of this trepidation is we don’t want to harm anybody through a dangerous, or potentially lethal, drug-drug interaction. That’s one thing. It’s another thing to be like ‘yeah but if you’re using these [pharmaceutical] drugs you’re doing it wrong and you’re not healing right.’ And I think the one often is used as a camouflage for the other—and they’re two separate things.” [38:59] Links: Dr. Zelfan’s website Dr. Zelfand on Instagram Dr. Zelfand on Twitter Dr. Zelfan on LinkedIn Right to Heal website Psychedelic pill-shaming article by Jules Evans and Shayam Suseelan Previous episode: Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan Previous episode: How to Choose a Psychedelic Facilitator or Retreat Center with Joël Brierre Psychedelic Medicine Association Porangui…
1 Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA, LPC 40:17
40:17
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:17In this episode of the Psychedelic Medicine Podcast, Keith Kurlander, MA, LPC, joins to discuss the important topic of integration practices for challenging psychedelic experiences. Keith is the Co-Founder of the Integrative Psychiatry Institute, the largest professional education company specializing in integrative mental health and psychedelic therapy. In this conversation, Keith begins by exploring the different types of challenging psychedelic experiences and various lingering effects one may experience following a difficult psychedelic journey. He discusses these from a trauma-informed perspective, explaining how a traumatized nervous system can lead to dissociation on the other side of an intense ego-disrupting experience. Keith also shares practices and insights from internal family systems (IFS) for integrating challenging psychedelic experiences. In closing, he emphasizes that psychedelics are not lazer-targeted therapies, so they do carry inherent risks, but through effective integration practices, patients can make healthy meaning out of even negative experiences. In this episode you'll hear: Lingering issues with ego fragmentation and connections to the dissociative disorder spectrum Persisting psychotic disorders following psychedelic experiences The difference between CPTSD and PTSD Uncovering repressed traumatic memories during psychedelic journeys Trauma stemming from difficult psychedelic experiences Challenging spiritual experiences Quotes: “The concept of pendulation [is] that we can be more flexible to ease our way into these overwhelming states. So once we are totally overwhelmed, we have to work our way back out gracefully, but as we are doing that, you get a gem as you are coming back… you learn something as you are coming out of that state.” [18:02] “If people have a psychotic disorder that emerged after their psychedelic use, you need a psychiatrist at that point… If it’s really a psychotic emergence, whether a previous psychotic disorder got triggered or whatever, you need a psychiatrist to work with you on that.” [20:07] “I believe all these mental health conditions have a trauma process underneath them. I don’t know how you isolate a trauma process from a mental health condition” [25:30] “It’s about working with a person’s meaning-making structure: is the meaning they’re making creating more psychological flexibility or less psychological flexibility? That’s a really important question to hold as a therapist because people will make all kinds of meaning up from these experiences but if they’re creating meaning that’s creating more rigid structures of how they see the world, then they get disappointed more often.” [34:21] Links: Psychiatry Institute website Keith’s website Keith on Instagram Higher Practice podcast Previous episode: The Challenging Psychedelic Experiences Project with Jules Evans Psychedelic Medicine Association Porangui…
1 Crafting Soundscapes for Psychedelic Transformation with East Forest 41:07
41:07
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
41:07In this episode of the Psychedelic Medicine Podcast, East Forest joins to discuss several aspects at the intersection of music and psychedelics, including how he created the music that so many have used when facilitating psychedelic journeys. East Forest’s latest project, a feature length documentary film called Music For Mushrooms, follows him through the psychedelic renaissance on a mission to pair music with psychedelics to bring about transformative healing to a world in crisis. In this conversation, East Forest discusses how he first got started making music for psychedelic journeys and the considerations that go into curating the right sound to best support these types of deep inner experiences. He emphasizes the importance of avoiding music that sounds overly sentimental and lacks the depth and richness important for effective psychedelic exploration. He also discusses the importance of maintaining the container, whether in the context of psychedelic facilitation or purely music-focused ceremonies, and suggested that sternness and fortitude have an important function in this context. In closing, East Forest suggests that music is so powerful because of the way it is able to be a point of connection to integrate experiences and bring people together. In this episode you'll hear: Composing soundtracks for psychedelic journeys with different substances Integrating nature sounds into compositions Flow states and music Bringing live elements of music and sound into a psychedelic ceremony Singing as a regulating technique during a psychedelic journey The intersection of music, technology, and psychedelics Quotes: “If we look at psychedelic experiences and ceremonies from indigenous use, all of them that I know of were guided by music.” [3:16] “I think it’s more the intention behind the music. I don’t think there’s a particular thing you have to do or not do, but I don’t think you can just play any music. So I think it’s the intention of the music and the intention of the room and the intention of the participants… There has to be an invitation on all of those fronts for that doorway to open.” [16:11] “I think we’re looking for music and for space that is supportive of that through-line and gives us enough time to be in a process—and that’s another advantage of having these longform, intentional, bespoke songs because they are probably going to give more of that time and space for these processes to occur.” [32:43] Links: East Forest’s website East Forest on Instagram East Forest on Tik Tok Music for Mushrooms documentary website Music for Mushrooms Official Documentary Soundtrack Winter Solstice Retreat at Esalen Music for Psychedelic Therapy by Jon Hopkins Psychedelic Medicine Association Porangui…
1 The Roles of Music in Psychedelic Sessions with Eric Sienknecht, PsyD 46:47
46:47
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
46:47In this episode of the Psychedelic Medicine Podcast, Eric Sienknecht, PsyD joins to discuss the roles of music in psychedelic sessions. Dr. Sienknecht is a licensed clinical psychologist and co-founder and lead trainer at Polaris Insight Center, a ketamine-assisted psychotherapy clinic and training center. He has worked as sub-investigator and study therapist on the Lykos-sponsored MDMA-AT clinical trials for PTSD and currently is also a supervisor and educator in MDMA-AT for various clinical trial sites. Dr. Sienknecht has a deep interest in the role and use of music in ketamine and MDMA sessions and specializes in curating playlists for psychedelic experiences. In this conversation, Dr. Sienknecht discusses how he first realized the importance of music in psychedelic experiences. He shares insights on how different genres and moods of music may be better suited to certain phases of the psychedelic experience and how he works individually with clients to better tailor a session playlist to their personal taste. Dr. Sienknecht even discusses how to strategically include shadow elements in a playlist to facilitate a client going deeper in their journey. In closing, he emphasizes how the intersection of psychedelic experiences and music remains understudied with only a few book chapters and articles dealing directly with the topic, so there is much yet to learn and explore in this exciting niche. In this episode you'll hear: What is universal vs what is individual when it comes to music and psychedelics Why Dr. Sienknecht avoids music with lyrics in a participant’s native language for psychedelic sessions The research on different genres of music for psychedelic journeys Balancing planning music in advance and adapting to the specific pace and mood of the client’s experience Utilizing nature sounds alongside or within music during psychedelic sessions Binaural beats and brainwaves Quotes: “There’s generally better tracks to use for the opening phase of a [psychedelic] journey, for the peak phase of a journey [etc], and there’s been some research into that as well.” [6:05] “Taste is so subjective… Knowing your client and talking with them beforehand about their taste and letting that information really inform how you create the playlist is really important.” [27:02] “One of the benefits of doing psychedelic therapy is that you can surrender control over elements of set and setting—not that those aren’t negotiable and ongoingly negotiable, as they should be—but there’s something about [the fact that the therapist] has got the music taken care of, the room set up, everything is in its right place. All I have to do is fast from food for a few hours, have my intention, and step into the journey—and that can help someone to really just trust and surrender more into the experience.” [30:20] Links: Integral Psychedelic Therapy edited by Jason A. Butler, Genesee Herzberg, and Richard Louis Miller Dr. Sienknecht on LinkedIn Polaris Insight Center on LinkedIn Polaris Insight Center website Music for Ketamine-Assisted Psychotherapy Sessions training with Dr. Sienknecht at Polaris Insight Center Previous episodes: Psychedelics and Nature: The Symbiotic Relationship with Dr. Sam Gandy Psychedelic Medicine Association Porangui…
1 Can the Gut Microbiome Predict your Response to Psychedelics? with Giorgia Caspani, PhD 30:02
30:02
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
30:02In this episode of the Psychedelic Medicine Podcast, Giorgia Caspani, PhD joins to discuss the intersection of psychedelics and the gut microbiome and ramifications for future personalized medicine. Dr. Caspani is a neuroscientist and computational biologist working at the intersection of gut microbiome, psychedelics and personalized medicine. In this conversation, Dr. Caspani discusses her research published in the article “Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.” She shares what we know about how psychedelics impact the gut microbiome from initial studies and what questions remain unanswered. She draws connections between the way the gut microbiome metabolizes SSRI drugs and how serotonin impacts the gut microbiota to hypothesize the potential ways psychedelics interact with this complex living system. In closing, Dr. Caspani discusses the possibility of predicting responses to psychedelic treatments using data from the microbiota, and the research currently happening to make this possible. In this episode you'll hear: How human beings and our gut microbiome co-evolved and the benefits achieved through this symbiotic relationship The correlation between the gut microbiome and stress levels The effects of psychedelics on immune responses Why personalized medicine may be a more effective approach for treating depression How personalized medicine could help make psychedelic therapies more accessible and effective Quotes: “Without our gut microbes… We wouldn't be able to really perform a lot of the metabolic functions that we rely on as humans.” [4:26] “The gut microbiome is different in every person—it’s very unique. And so every person carries this unique microbial signature that can potentially map out to all of the treatment options that we already have available; it’s just a matter of understanding and identifying markers that can predict which patient will benefit from a specific drug.” [18:22] “[We hypothesize that] the gut microbiome shapes individual responses to psychedelic treatment. And so if that [hypothesis] is correct, if that is true, we could potentially target the microbiome, change the composition of the gut microbiome like we wanted to, to be able to maximize the effectiveness of these [psychedelic] drugs.” [25:14] Links: Dr. Caspani’s article, “Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis” Dr. Caspani on LinkedIn Dr. Caspani on X Onaya Science website Psychedelic Medicine Association Porangui…
1 Using Psychedelic-Assisted therapy to Address Intergenerational Trauma with Star Rose Bond, LCSW 34:41
34:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
34:41In this episode of the Psychedelic Medicine Podcast, Star Rose Bond, LCSW joins to discuss the topic of using psychedelic-assisted therapy to address intergenerational trauma. As seen in Huffpost, Vice and Psychology Today, Star Rose is a Renegade Psychotherapist, Social Activist, Clinical Supervisor for PEARL Institute and Co-Founder of Life Camp. With a Bachelor’s degree from NYU and a master’s from Columbia, Star brings 15 years of clinical trauma therapeutic services and experience serving marginalized, under-resourced and at risk populations specializing in harm reduction and PTSD recovery. In this conversation, Star introduces the topic of intergenerational trauma and explores how psychedelic experiences may be leveraged to address this pernicious condition. She begins by explaining what intergenerational trauma means, how it gets passed down, and how it manifests. Star talks about the importance of psychedelic therapists and facilitators having awareness of trauma-informed modalities in order to better serve these populations. She also discusses the complexities of addressing generational trauma, and how it can often be difficult to process sensitive topics within the family unit. However, in conclusion, Star emphasizes that the capacity to heal is an intrinsic aspect of human existence, and that even in particularly dark moments, it is possible to get in touch with this possibility. In this episode you'll hear: How the conditions of Capitalism produce and exacerbate chronic stress The profound impact of neglect and abuse in early childhood The unique experience of intergenerational trauma for BIPOC peoples and the recent rekindling of a spirit of connection in these communities due to psychedelic medicines How processing intergenerational trauma can transform familial relationships Ethical and practical considerations for facilitators and therapists guiding clients through psychedelic experiences aimed at resolving deep-seated trauma What to look for in a psychedelic-assisted therapist or facilitator Quotes: “Just because you have several students or several clients who’ve experienced the same trauma, don’t make the assumption that they’re all experiencing it the same way. Or maybe you’ll meet a client who has had trauma similar to yours—don’t assume that they have undergone the same emotional impact or psychological impact as you. The truth of the matter is we are complex beings. We have so many different moving variables that go into our psychology and that essentially indicate or play a role in how we respond to things.” [8:43] “We can’t always express or understand why things happen the way they do. But, we can start to make meaning through a spiritual understanding which in turn lends itself to a sense of ease and comfort.” [22:20] “When you are going into these experiences as a facilitator—whatever your background is—it is of the utmost importance that you are hyper cognizant and hyper aware of the harms that can be caused by not being aware of the ways in which you can navigate someone else’s trauma as it shows up.” [25:02] Links: Star’s website Star on Instagram Previous episode: Can Your Genes Predict Response to MDMA Therapy? with Dr. Dave Rabin MD, PhD Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan Previous episode: How to Choose a Psychedelic Facilitator or Retreat Center with Joël Brierre My Grandmother's Hands: Racialized Trauma and the Pathway to Mending Our Hearts and Bodies by Resmaa Menakem SHINE Support website Psychedelic Medicine Association Porangui…
1 Psychedelics' Potential in Sports Psychology with L.J. Lumpkin III, MA LMFT 36:30
36:30
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:30In this episode of the Psychedelic Medicine Podcast, L.J. Lumpkin III, MA LMFT joins to discuss the potential of psychedelic medicine in the context of sports psychology. L.J. is a therapist, adjunct professor at Pepperdine University, a coach, author, speaker, and the CEO of Nomad Healing Practices. In this conversation, L.J. shares his personal experience as an athlete and discusses the difficult transition to a new life once an athlete’s career has concluded. He compares the need to reinvent oneself in this context to ego death and explains how psychedelic-assisted therapy may be helpful for navigating this transition. L.J. also discusses the intense pressure athletes are under to perform, mentioning that the drive to win can often overpower the more basic mode of play at the heart of athleticism. This is an area where he finds ketamine to be a particularly powerful medicine, as its dissociate quality can help athletes tune out the high pressure expectations. L.J. also discusses leveraging the critical learning period provided by psychedelic therapies to institute new healthy habits, something which could benefit athletes both on and off the field. In this episode you'll hear: How ketamine-assisted therapy may be able to help athletes with their unique psychological challenges Integrating mindfulness to prepare for psychedelic therapies Leveraging the somatic component of psychedelic therapies to address pain The importance of integration practices and support systems The differences between working with psilocybin versus ketamine Drowning out critics and sports commentary and getting back to basics with the help of psychedelic therapy Quotes: “If you’ve been paid millions of dollars to hit and be aggressive for so long and that’s how you’ve dealt with your emotions—and it wasn’t a problem because you were being rewarded for it—what do you do when you’re not getting rewarded for that anymore? When you have to actually change how you process emotion—there’s not a playbook for that.” [7:46] “Just talking about [mental health] and normalizing it—all of a sudden you’re allowed to get help, you’re allowed to heal, you’re allowed to go to practices that have been practiced throughout human civilization. We’re bringing [psychedelics] back and I think that athletes are the ones who are really going to be the ship of normalization.” [22:38] “Especially if you’re off season, those other medicines [besides ketamine] I think they’re going to be even more helpful because that might encourage the rest, it might encourage being able to connect with family systems. I think for some of the more acute stuff, the ketamine does serve a great purpose in that.” [28:16] Links: L.J. on Instagram L.J. on LinkedIn Nomad Healing Practices website Psychedelic Medicine Association Porangui…
1 Fifth Anniversary Episode: Five Years Later... Where and How to Legally Access Psychedelic Medicines 26:22
26:22
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
26:22In this episode of the Psychedelic Medicine Podcast, podcast host Dr. Lynn Marie Morski comes on the mic to provide a five-year update on the podcast and share the changes in the legal landscape of psychedelics in the past half-decade. Lynn Marie Morski, MD, JD is the president of the Psychedelic Medicine Association and host of the Psychedelic Medicine Podcast. She sits on the advisory boards of Psychedelics Today, Cybin, VETS, Inc (Veterans Exploring Treatment Solutions), the Oxenberg Foundation, and the Ketamine Task Force. Dr. Morski is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor. In this anniversary episode you’ll hear about the legally-accessible forms of psychedelic therapy which have come to prominence as potential mainstream therapeutics in recent years. Dr. Mroski shares Information on the legal adult use framework for psilocybin in Oregon, including licensing, costs, and exclusion criteria. She also discusses programs in Australia and Canada that will allow certain patients to access psychedelic therapies such as psilocybin- and MDMA-assisted therapy. In addition to classic psychedelic medicines, Dr. Morski also shares information on the medicine which is currently most accessible: ketamine. She discusses the difference between S-ketamine and R-ketamine and on-label and off-label uses of this substance. In closing, Dr. Morski presents some of the finer details of the current landscape of insurance coverage for ketamine. In this episode you'll hear: The difference between decriminalization and legalization The FDA decision to deny the Lykos Therapeutics’ new drug application for MDMA-assisted therapy for PTSD The upcoming Colorado psilocybin program Psychiatric licenses to administer MDMA and LSD to patients in Australia The Special Access Program for psychedelic therapies in Canada Legal ketamine access in the United States How the Psychedelic Medicine Podcast chooses guests Quotes: “I wanted to focus mostly on what is legal because we know that’s the way things are going to be the most monitored and therefore safely accessible.” [20:45] “People are in this industry because they want other people to feel better and they want to help and they’re so generous with their time” [25:31] Links: clinicaltrials.gov - the place to find information on upcoming clinical trials for psychedelic medicine for which you may qualify Insurance Coverage for Psychedelic Therapy by Vincent Joralemon SPRAVATO withMe Patient Support Program Enthea insurance Previous episode: How to Choose A Psychedelic Facilitator or Retreat Center with Joël Brierre Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan Previous episode: Ketamine Scientific Research with Dr. Jason Wallach Psychedelic Medicine Association Porangui…
1 Can Your Genes Predict Response to MDMA Therapy? with Dr. Dave Rabin MD, PhD 41:36
41:36
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
41:36In this episode of the Psychedelic Medicine Podcast, Dr. David Rabin, MD, PhD joins to discuss whether genes can be predictive of one’s response to MDMA Therapy. Dr. Rabin, a board-certified psychiatrist and neuroscientist, is the co-founder & chief medical officer at Apollo Neuroscience. In addition to his clinical psychiatry practice, Dr. Rabin is also the co-founder & executive director of The Board of Medicine, and a psychedelic clinical researcher currently evaluating the mechanism of psychedelic-assisted psychotherapy in treatment-resistant mental illnesses. In this conversation, Dr. Rabin shares his research into epigenetic responses to MDMA-therapy, exploring topics of trauma, gene expression, and personalized, data-driven medicine. He discusses the seminal discovery that trauma can cause epigenetic changes in the structure and function of the cortical system and his own research findings that uncovered a reversal of these changes associated with MDMA-assisted therapy. Dr. Rabin hopes further research in this area may allow for leveraging epigenetic data to determine which psychedelic medicine a particular patient may be most likely to respond to and track how effective a given treatment has been. In closing, he expresses excitement about bringing objective biological precision to mental health treatment, drawing a parallel to the discovery of antibiotics which allowed for much more tailored treatments of infections which has saved countless lives. In this episode you'll hear: Response rates to psychedelic-assisted therapy for PTSD versus conventional therapies The consequences of ineffective treatment for PTSD MDMA-assisted therapy as preventative care and the societal cost savings involved Genetics, epigenetics, and gene expression Using epigenetic data from simple saliva swabs to better gauge response to MDMA-assisted therapy for PTSD Quotes: “Most of the treatments we have available today for PTSD—that are the FDA-cleared, considered gold standard treatments—only actually induce remission from illness… in about 30% of people. So of the 100% of the millions of people every year that are getting treated for PTSD, with the best treatments that we have that are currently available, only 30%—at best—are getting better long term. Everyone else has a diagnosis of PTSD for life.” [3:55] “MDMA-assisted therapy for people with PTSD is having an effect that’s similar to what we saw with the discovery of antibiotics for infection.” [8:07] “Folks with severe PTSD who went through this trial, when they received MDMA-assisted therapy, [the researchers] saw a statistically significant change—in terms of repair—of the cortisol receptor’s epigenetic code which reflects improved structure and function of that receptor site. But not only that—we saw that the amount that people got better… was directly correlated with… the amount of remodeling and repair at the receptor site.” [18:36] “Epigenetic code is actually something that can be modified by experiences in our environment. And trauma—or PTSD diagnoses, a series of significant traumas over time—can in fact change epigenetic code of the cortisol receptor gene. And that changes how the cortisol receptor gene gets made, and it changes its function.” [29:52] “PTSD is a disorder of learned fear. How do we treat PTSD? In animals and humans, we provide the same stimulation that they were getting that they are now afraid of in the context of safety. That’s how exposure therapy works, that’s how MDMA therapy works to some extent—all of these tools and techniques work to treat PTSD effectively… in the same way. It’s called safety conditioning.” [36:48] Links: Dr. Rabin’s article: Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD Dr. Rabin’s website Dr. Rabin on LinkedIn Dr. Rabin on Instagram Dr. Rabin on Twitter Apollo Neuroscience website Psychedelic Medicine Association Porangui…
1 Ketamine: The Promise and the Peril with Mark Braunstein, DO 38:17
38:17
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
38:17In this episode of the Psychedelic Medicine Podcast, Mark Braunstein, DO joins to discuss the promise and the peril of ketamine. Dr. Braunstein graduated medical school in 1997 then completed a General Psychiatry Residency at the University of New Mexico and then a fellowship in Child and Adolescent psychiatry at Maine Medical Center in 2002. Upon graduation from his fellowship and becoming board certified in general psychiatry he established a private practice in Durango, Colorado where plant medicine became part of his everyday integrative psychiatric practice. In this conversation, Dr. Braunstein shares some of the developments in the world of ketamine in the past three years since his previous episode, drawing on his own experience providing ketamine-assisted therapies. He stresses issues of grandiosity that can arise both when working with ketamine and when taking the medicine—issues which in the worst case and fuel ketamine use disorders. Dr. Braunstein stresses the importance of clinicians providing ketamine treatments being realistic and upfront about the potential harms of ketamine when advising prospective patients. In closing, he warns against the dangers of being in an echo chamber which reinforces potentially pathological substance use, especially for clinicians in the ketamine space. In this episode you'll hear: Why ketamine has an addictive potential and how ketamine addiction presents Ways to treat ketamine use disorder The importance of informed consent What patients should look for when seeking a ketamine provider The importance of ketamine providers working with multiple modalities and having multiple tools in the toolbox besides ketamine Quotes: “Here’s what’s scary to me about ketamine: these people that I’ve seen having problems [with ketamine use] are largely lifetime recreational psychedelic/drug users without problems. And these are people who have made it to age fifty, smoking [cannabis], tripping a little bit, their whole life without having a problem—then at fifty years old, find themselves hooked on something for the first time.” [12:30] “[Ketamine] is not a microdosing medication… There is no such thing as ketamine microdosing. You think of microdosing as sub-perceptual. Everyone that I’ve met that’s abusing ketamine, it was not a sub-perceptual effect—they were very much abusing it to have that perceived effect. Maybe not a psychedelic effect—usually an intoxicated wonky effect is what they’re going for. And people refer to that as microdosing. It’s not microdosing. It’s abusing small doses.” [17:11] “What do I see that makes me concerned with someone I’m talking to—a clinician or a client? That grandiosity. So that gets me concerned right away when I hear about these ‘downloads’ because that’s where … other psychedelics can have dependency too. You see people … they go for aya ceremonies every week after week after week. So there can be an addiction to the download or to the release.” [34:35] “The people I know that have been successful in this line of work (from a patient standpoint), whether they’re a clinician or not, have been the ones that have embraced the work. And just knowing that this is going to be a process and I’m in it to win it, for life. I’m working on myself.” [35:40] Links: Dr. Braunstein on LinkedIn Ketamine Research Foundation website NeuPath Mind Wellness website Ketamine Training Center website Previous episode: Ketamine for Alcohol Use Disorder with Steven Mandel, MD Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c) Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich Previous episode: Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT Psychedelic Medicine Association Porangui…
1 5-MeO-DMT for Trauma and PTSD with Steve Rio 47:47
47:47
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
47:47In this episode of the Psychedelic Medicine Podcast, Steve Rio joins to discuss 5-MeO-DMT for Trauma and PTSD. Steve is a psychedelic facilitator and Co-Founder of Enfold, which offers a groundbreaking psychospiritual model that combines psychedelic intensives, coaching, and community to help individuals heal trauma and reach their full potential. In this conversation, Steve shares his journey of how he got into facilitating 5-MeO-DMT experiences and insights on working safely and effectively with this medicine over the course of his practice. He discusses the screening procedure he uses before clearing clients for facilitated 5-MeO-DMT experiences to ensure safety as much as possible when working with this powerful psychedelic. Steve also talks about how he tailors his work with clients based on the state of their nervous system and their unique personality. In closing, Steve emphasizes the somatic quality of 5-MeO-DMT experiences, sharing different types of experiences people typically have on the medicine and how these can best be integrated. In this episode you'll hear: Preparation for safe and effective 5-MeO-DMT experiences Stories of transformation following 5-MeO-DMT healing for PTSD and focused integration practices How common 5-MeO-DMT reactivations are, and when they typically happen Issues of spiritual bypassing in underground psychedelic facilitation How to navigate informed consent in the context of facilitating psychedelic experiences Quotes: “At the peak of the 5-MeO experience, there is no mind… When people talk about the death and the rebirth experience with 5-MeO, what we’re really talking about is relaxing and essentially dissolving the ego entirely so there is no experience of ‘you’ in the experience—you become one with the experience. But… what’s possible there is that we then access the nervous system and we see these very dramatic energetic releases and people often are physically reliving traumatic experiences and physically releasing the fight, flight, freeze response that may have happened or not happened.” [6:52] “Trauma is complex and for some people it’s not that simple. For some people, they go through a six- to twelve-month process after 5-MeO-DMT that is really challenging.” [22:37] “So [we’re] helping people… build sensitivity in their nervous system—reconnect with sensitivity and slowing things down and building more awareness and learning how to notice their emotions as sensations in the body before they become thought patterns.” [32:00] “I think one of the challenges in all of this is that people will lie to you to get to your experience because they’re desperate for the healing. And you have to be really careful about the conversations you have and asking open-ended questions and really listening to your intuition—and really being grounded in that.” [40:28] “What we’re doing here I would say there’s obviously a psychological component to it, but often that happens in the weeks and months afterwards. What’s happening here is a much more somatic experience and it can be very confusing and challenging for the mind of a person… you’ve paid all this money, you’ve prepared for weeks and months, you’ve been thinking about it, you come have this experience… Right after the ceremony for some people, the thought is ‘what just happened?’ and ‘did anything happen?’ and ‘did it work?’ because there’s very rarely like an immediate insight on ‘here’s how you’re going to make your life better’—that’s not what comes out of this experience. What comes out of this experience is a dramatic shift in how your body feels and often people will report feeling emotionally lighter or that they lost ten pounds. It’s hard to explain, but the way peoples’ eyes light up the day after the ceremony is so different—like they often just look different coming in and leaving.” [42:56] Links: Enfold Website Enfold on Instagram Enfold on YouTube Still In It: 5-MeO-DMT Stories Previous episode: Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT Previous episode: Psychedelic Adjunct Series: Somatic Therapy with Jenna Valentine, DACM, LAc Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT Previous episode: When *Not* to Proceed with a Planned Psychedelic Journey with Rick Barnett, PsyD Psychedelic Medicine Association Porangui…
1 Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT 46:06
46:06
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
46:06In this episode of the Psychedelic Medicine Podcast, Sunny Strasburg joins to open the conversation of leveraging lower doses of psychedelic substances for more effective healing. Sunny Strasburg, LMFT, a licensed psychotherapist, educator, and pioneering author, specializes in psychedelic therapies and training clinicians to be skilled and trauma-informed psychedelic therapists. As the founder and author of The Theradelic Approach, she equips clinicians with trauma-informed psychedelic-assisted therapy methods, blending IFS, EMDR, archetypal psychology, trauma-informed care, and her extensive experience. In this conversation, Sunny shares insights drawn from Internal Family Systems (IFS) and explores how these perspectives can help inspire more effective psychedelic work, especially with lower doses. She emphasizes the importance of adequate preparation and not over-valorizing intense psychedelic experiences, noting that these therapies themselves can be traumatic if not handled with care. Sunny also discusses how one’s own internal protectors have adaptive rolls and display a lot of compassionate intelligence, so even though these parts may initially provide a barrier to deep trauma work, it is important for therapists to work collaboratively with these parts of a client’s psyche. In closing she talks about how to better set reasonable expectations in group psychedelic therapy and retreat settings, where integration can easily turn into a competition of who had the most intense experience, with things like ego dissolution becoming the barometer for healing. In this episode you'll hear: How “protector systems” and “rubber band effects” manifest in high-dose psychedelic therapy sessions Uncovering previously unknown traumas during psychedelic therapies and how therapists can be better prepared for this situation How therapists can skillfully work with symbolic material that arises in psychedelic journeys The importance of slowing down and letting the client guide the pace when addressing serious traumas in particular Differences between ketamine, MDMA, and the classic psychedelics in terms of effects on the fear center of the brain Leveraging critical learning periods in therapy to reprocess traumatic memories Quotes: “Being a trauma therapist, you have to be skilled enough to know what is symbolic in a psychedelic journey, what’s a literal memory… You don’t want to do any kind of leading or prompting the client to fill in anything or directing them to anything—you’re really tracking where they are and letting them uncover their own path. Again, at the speed in which their protector system is ready for that.” [22:43] “These parts want people to remember. They want to heal, they want to let their stories be told. And so our job as therapists is to clear the clutter so we can really hear the system and trust the system. The system knows.” [28:02] “Trauma is like a sliver that’s buried in the arm—like in the deep skin of your arm and it’s got an infection around it. And all of your coping mechanisms, all of your protectors (using IFS language), is like building a giant layer of scar tissue on top of that. And you could just go through life with that, and you could just put lotion on the top of that scar and just try to make it look pretty—and that’s okay. But you could go in and surgically remove the sliver that’s been offending your system the whole time. And once you remove that sliver, you will start to heal—your arm will heal, it won’t have an infection anymore, right? But removing that sliver hurts. It’s painful. It’s a process. But you don’t have to deal with that sliver anymore. And that’s kind of how I imagine going through trauma work.” [31:08] “I’ve had clients that I’ve worked with using EMDR, IFS for years, we’ve made some progress, but then we get ketamine on board and it’s totally helped them and amplified the benefit.” [35:13] “Trust your protector system. Slow down. I promise, if you slow down and really get curious about what your protectors need, you will go so much further with these medicines. It really is not a race. It’s slow and steady, and you’re going to be able to get more work done.” [40:23] Links: Sunny’s website Sunny on LinkedIn Sunny on Instagram Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT Psychedelic Medicine Association Porangui…
1 Encore episode: Psychedelics and the LGBTQIA2S+ Community with Dr. Angela Carter 37:41
37:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:41This episode of the Plant Medicine Podcast welcomes Dr. Angela Carter (they/them) to discuss the intersection of the LGBTQIA2S+ community and psychedelics. Dr. Carter is a queer, transgender, and genderqueer naturopathic primary care physician who also works as a midwife, sexual assault examiner, and health equity advocate in Portland, Oregon. They also serve as both the vice-chair and the equity in training subcommittees co-chair of the Oregon Psilocybin Advisory Board. In addition to these positions, Dr. Carter serves as the chair of the Transgender Health Program Community Advisory Board at Oregon Health & Science University. They also volunteer with many organizations including the Fireside Project, Black Rock City Emergency Services, and Queerdome. Dr. Carter begins this conversation by sharing exciting new research currently being conducted which involves LGBTQIA2S+ individuals and psychedelic therapies. While this particular area of research remains small, it is growing and the fruits of these studies will be an important step for better understanding how these new therapies can serve gender and sexuality minorities, and help facilitators understand the unique concerns of people in the LGBTQIA2S+ community. Dr. Carter illustrates these types of concerns by discussing the prevalence of gender binaries within psychedelic spaces. They describe how in a clinical setting it is prevalent to have both a male and a female facilitator, but this leaves no room for gender-nonconforming people to guide experiences—something which could be preferable if the patient themselves shares this identity. Dr. Carter also discusses this gender binary in traditional contexts. It is common for ayahuasca ceremonies to provide separate spaces for men and women, again leaving no space for gender-nonconforming people. This reification of the gender binary and the often patriarchal organization of the ayahuasca ceremony can have serious impacts on the set and setting, especially for people in the LGBTQIA2S+ community. Dr. Carter emphasizes the importance of making space for folks in the community so that they are able to receive therapy, attend ceremonies, and participate in integration with others who share similar identities. This shared identity, they emphasize, ensures that LGBTQIA2S+ people don’t feel out of place in contexts that ought to be healing. Dr. Carter closes by discussing how members of the LGBTQIA2S+ community experience disproportionate rates of mental illness, further illustrating the crucial importance of equity in accessing psychedelic medicine. In this episode: Problems of representation and access for LGBTQIA2S+ individuals in the psychedelic space Current research being done on the intersection between psychedelic therapies and unique issues faced by gender and sexuality minorities Preparations to take before guiding a psychedelic experience for LGBTQIA2S+ people, particularly if you do not come from the community How plant medicines could have unique benefits for the LGBTQIA2S+ community Issues of poverty faced by marginalized peoples and how to support equity of access to emerging psychedelic therapies Quotes: “For some people that idea of melding, of becoming one and losing all of those unique pieces of themselves, doesn’t fit their paradigm of a spiritual connecting experience.” [10:47] “It’s precious, that centering of our community—to be able to sit with people who just understand.” [19:42] “Psychedelics offer the opportunity for connection of the self to something greater, something outside, a bigger community, spirituality, and really do a huge amount to heal peoples’ relationships with substances.” [25:20] “Marginalized communities have been really impacted, largely, by the war on drugs, which has put millions of people in jail for drug offenses and stolen their ability to make income, stolen their ability to connect with community and we really need to heal that.” [33:34] Links: Chacruna Institute Queering Psychedelics 2019 Conference Queerdome on Facebook Portland Psychedelic Society Psychedelic Medicine Association Porangui…
1 The Potential of Non-Dissociative Ketamine with Hans Eriksson MD, PhD, MBA 31:20
31:20
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
31:20In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca. In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine. In this episode you'll hear: The history of ketamine The pharmacology of ketamine’s dissociative effect The relationship between ketamine dose and antidepressant effect The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials How Dr. Eriksson thinks about combining psychotherapy with ketamine treatments Quotes: “We are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation.” [10:58] “Our view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites.” [23:19] Links: Dr. Eriksson on LinkedIn HMNC Brain Health on LinkedIn HMNC Brain Health website Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD Psychedelic Medicine Association Porangui…
1 Ketamine-Assisted Couples Therapy with Chandra Khalifian, PhD 32:11
32:11
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
32:11In this episode of the Psychedelic Medicine Podcast, Chandra Khalifian, PhD joins to explore ketamine-assisted couples therapy. Dr. Chandra Khalifian is a clinical psychologist, researcher, educator and Co-CEO of Enamory, a clinic and community focused on providing expansive relationship education and therapy including psychedelic-assisted couple-therapy. In this conversation Dr. Khalifian explores the intricacies of ketamine-assisted couples therapy, sharing why she thinks psychedelics, and ketamine in particular, could be a good fit for couples therapy. She discusses the various contexts where ketamine-assisted therapy may be a good fit for couples pursuing therapy, the therapeutic modalities well-suited to this work, and the different dosing and administration routes of ketamine. In closing, Dr. Khalifian explores situations where couples may be better suited to pursuing this therapy individually and also contexts where ketamine-assisted couples therapy would not be an appropriate intervention. In this episode you'll hear: How Dr. Khalifian got involved in couples therapy The various models of ketamine-assisted couples therapy, and how to decide what is most appropriate The importance of preparation and integration How to navigate the two people in the couple having very different ketamine experiences When Dr. Khalifian uses intramuscular ketamine infusions versus ketamine lozenges Why Dr. Khalifian leans towards using third-wave cognitive behavioral therapy for ketamine-assisted therapy The tendency for people to make major relationship decisions following intense psychedelic experiences Quotes: “Ketamine is great because—in the same way with individuals—with couples it’s going to pull us out of that pattern so that we can then see the pattern and talk about the pattern from this observer perspective rather than being stuck in the ‘it’s me versus you’ we can look at it together and the couple can say ‘ah, there’s that thing that we do when we feel distressed, and now we can work together on that thing since we can see it from a little more distance.’” [4:43] “Similar to MDMA, people are less likely to express criticisms in a hurtful way and less likely to receive constructive criticism and be defensive [during ketamine therapy].” [9:05] “I had one couple [as patients for ketamine therapy] that the partner was like ‘I just felt this liquid compassion. I finally understood why she was engaging in these behaviors. And so everything made sense and I was able to talk about it in a different way.’” [17:49] Links: Enamory website Enamory on Instagram Previous episode: MDMA-Assisted Couples Therapy with Kayla Knopp, PhD Psychedelic Medicine Association Porangui…
1 Psychedelics and Seizure Disorders with Evan Lewis, MD, FRCPC 32:57
32:57
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
32:57In this episode of the Psychedelic Medicine Podcast, Dr. Evan Cole Lewis joins to explore the topic of psychedelics and seizure disorders. Dr. Lewis is a Canadian Neurologist and holds an appointment as Assistant Professor in the Department of Paediatrics at the University of Toronto. He has special interest in the treatment of neurologic disorders, including functional seizures, with psychedelic therapies. In this conversation, Dr. Lewis shares his expertise on a number of topics at the intersection of psychedelics and seizure disorders. He discusses the neurology behind psychedelics and functional neurological disorders more broadly, explaining why he thinks this is a very promising area of research. He explains that currently very little is known about the topic of psychedelics and seizure disorders, as almost all studies have had epilepsy as an absolute contraindication, leaving researchers with only case reports. However, there are some promising indications in the preclinical data which warrant further investigation. In closing, Dr. Lewis sheds light on potential seizure risks resulting from interactions between psychedelics and other medications. In this episode you'll hear: The different between epileptic seizures and functional seizures How Dr. Lewis started exploring the topic of psychedelics and functional seizures Why Dr. Lewis thinks psychedelic science has the potential to rebuild bridges between neurology and psychiatry Dr. Lewis’ experiences treating epileptic patients with ketamine The potential for co-administered lithium and psychedelics to cause seizures Quotes: “I tell people psychedelics are brain network medicine—they kind of dissolve those networks. If the thinking is that FND [Functional Neurological Disorder] is due to dysfunctional connection or hyperconnectivity in certain networks, what we have to do is we have to repair those networks, but first we have to take them apart and build them back up.” [11:03] “Regardless, even if there isn’t even a condition in which psychedelics are utilized in neurology, we need the neurologists to be able to indicate that these patients are safe—or at least do the work and be involved in the clinical team.” [21:05] “Things like drug interactions we pick up with psychedelics again are going to be a big piece of the puzzle that needs to be answered going forward.” [29:17] Links: Dr. Lewis on LinkedIn Dr. Lewis on YouTube Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks by Dr. Lewis et al. Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine assisted-therapy by Dr. Lewis et al. Psychedelics, epilepsy, and seizures: a review by Dr. Lewis et al. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review by Kelan Thomas, Benjamin Malcolm, et al. Psychedelic Medicine Association Porangui…
1 Psychedelic Adjunct Series: Somatic Therapy with Jenna Valentine, DACM, LAc 57:10
57:10
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
57:10In this episode of the Psychedelic Medicine Podcast, Dr. Jenna Valentine joins to explore the intersection of psychedelics and somatic therapy. Dr. Valentine is a doctor of Chinese Medicine who incorporates both functional medicine and somatic experiencing within her practice to help achieve optimal wellness. In this conversation, Dr. Valentine introduces somatic therapy, drawing parallels to psychedelic work and exploring how this modality may support more healthy and holistic psychedelic experiences. She explains how somatic therapy proceeds by tuning into the body, with therapists helping to guide clients’ awareness of the intelligence in their bodies. Dr. Valentine emphasizes the importance of not forcing things in somatic work - with gentler, slower practices often being best to align with health. In closing, she outlines how somatic therapy can be used for preparation and integration of a psychedelic experience, and also explores the possibilities of somatic modalities being used during psychedelic therapy. In this episode you'll hear: The different forms of somatic therapy The overemphasis on the mind in our culture Why there aren’t contraindications for somatic therapy Somatic therapy as a modality for working with patients diagnosed with biploar disorder or schizophrenia The intersection of healing and re-learning to be playful The importance of “doing less” Why glorifying “heroic doses” of psychedelics can be counterproductive to healing Shadow work and somatic therapy Quotes: “There’s many different definitions of [somatic therapy] but the one I love the most is: guiding yourself back to your body as your primary resource.” [4:02] “A lot of the work is making sure people learn that they don’t have to feel afraid of themselves—no part of you is ‘coming to get you’ … no part of you is trying to trick you or hurt you or surprise you. Sometimes I’ll describe it as I’m helping people guide themselves back to themselves and find a safe home there again.” [13:05] “We have lost our relationship with discomfort, and a lot of this work is uncomfortable. And the work is being in the discomfort and building a larger capacity for being uncomfortable, and learning the difference between uncomfortable and unhelpful, because that’s not something we’re trained in.” [23:41] “There’s learning that can happen in everything … The expectation is to have no expectation: we can have a loose intention, and then let the body lead.” [47:18] Links: Dr. Valentine on Instagram Dr. Valentine’s website Psychedelic Medicine Association Porangui…
1 Psychedelics for Sexual Functioning and Intimacy with Tommaso Barba, PhD(c) 36:04
36:04
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:04In this episode of the Psychedelic Medicine Podcast Tommaso Barba joins to explore the topic of psychedelics for sexual functioning and intimacy. Tommaso is a PhD candidate at the Centre for Psychedelic Research at Imperial College London where his research is focused on understanding the potential role of psychedelic drugs for well-being. Tommaso authored the first paper on the effects of psychedelics on sexual functioning. In this conversation, Tommaso shares results from the multiple studies into psychedelics and sexual functions he has been involved in. He reports that in both a trial comparing psilocybin and escitalopram and a survey of naturalistic psychedelic use, respondents reported positive impacts on sexual functioning following psychedelic experiences. He also speculates about aspects of the psychedelic experience that are interpreted as “erotic” in the midst of the altered state and the reported shifts to experiencing sexual connection as more “spiritual” following psychedelic experiences. In closing, Tommaso discusses the promise of psychedelic journeys for healthy couples and the difficulties of researching this topic since there is no clear pathology being addressed. In this episode you'll hear: How Tommaso got interested in the intersection of psychedelics and sexual functioning Why SRRIs often have side effects of inhibiting sexual function How psychedelic neuropharmacology may help explain improved sexual functioning following psychedelic experiences The upcoming studies exploring the effects of psychedelic journeys on couples who undergo the experience together The possible differences between MDMA and classic psychedelics in terms of mechanism and impact when it comes to effects on sexual function Quotes: “When we looked at the positive affect symptoms—like wellbeing, connectedness, ability to feel emotions, and so on… Psilocybin outperformed escitalopram. And given so, we were really curious to investigate further the sex lives of these patients, because an active sex life is a key component of people’s wellbeing, and a very overlooked one.” [7:34] “What we found was that people treated with psilocybin reported improvements in sexual pleasure, in capacity to communicate sexual desires with their partner, in sexual arousal, sexual satisfaction, and similar components of sexual functioning, while people treated with escitalopram did not report any of these changes and tended to report deterioration in this aspect of functioning.” [11:10] “[These psychedelic treatments may] work because it disentangles couples and its capable of individuating the two patients into the context of their relationship so that they start to develop a better identity in the context of the relationship instead of being completely fused into each other and not capable of really developing themselves and communicating their desires and what they want.” [31:15] Links: Tommaso on Twitter Tommaso on LinkedIn Imperial College Centre for Psychedelic Research online survey study: psychedelics and couples Previous episode: Microdosing and the Placebo Effect with Balázs Szigeti, PhD Psychedelic Medicine Association Porangui…
1 MDMA-Assisted Couples Therapy with Kayla Knopp, PhD 34:53
34:53
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
34:53In this episode of the Psychedelic Medicine Podcast Kayla Knopp joins to explore the topic of MDMA-Assisted Couples Therapy. Dr. Kayla Knopp is a clinical psychologist and researcher specializing in non-traditional couples and relationships. She specializes in making couple therapies more inclusive, accessible, and effective, including MDMA- and ketamine-assisted couple therapy. In this conversation, Dr. Knopp introduces MDMA-assisted couples therapy, discussing why this entactogen is a good fit for couples therapy. She discusses how MDMA helps couples explore issues by dissolving typical defensive boundaries and encouraging empathy. She emphasizes that not all couples may be a good fit for this therapy, however, and especially cautions against couples therapy in contexts of abuse where connecting with resources for safety and pursuing individual courses of therapy is more appropriate. In closing, Dr. Knopp discusses the importance of screening and the responsibility the psychedelic community has to ensure these substances are being used in safe and effective therapeutic contexts overseen by qualified and caring facilitators. In this episode you'll hear: The history of MDMA-assisted couples therapy When couple therapy is and is not appropriate Integrating MDMA-assisted therapy with cognitive-behavioral conjoint therapy for PTSD Therapeutic modalities which may be well-suited to MDMA-assisted couples therapy Quotes: “[MDMA] does so many things that are facilitative of the primary goals of couples therapy, which are to reduce defensiveness, to increase the flexibility that we have in taking our partner’s perspective, increase the empathy and intimacy we feel with other people, increase the reward that we get from positive interpersonal interactions.” [4:33] “When we treat relationship dysfunction, we know mental health often improves as a result of that and conversely, we also know that sometimes when we do mental health treatments, if we ignore the relational context that somebody is living in, we only give them part of what they need in order to fully heal psychiatrically. So, couple-based interventions for mental health disorders, including PTSD, are up-and-coming as a really effective way to address mental health concerns.” [8:14] “MDMA tends to increase our window of tolerance for emotional experiences—it makes it safer and easier for us to remain in contact with feelings that might otherwise feel pretty overwhelming.” [23:48] “I think there’s absolutely a lot of ego and a toxic guru model that can show up in psychedelic-assisted therapy that, as a community, as practitioners, as participants, we need to keep an eye out for and keep ourselves accountable as a community to make sure that we’re not giving folks a pass.” [31:17] Links: Dr. Knopp on Instagram Enamory website Enamory on Instagram Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c) Psychedelic Medicine Association Porangui…
1 Encore episode: The Dark Side of Ketamine (and how to Stay in the Light) with Dr. Mark Braunstein 31:40
31:40
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
31:40In this episode of the Plant Medicine Podcast, Dr. Mark Braunstein returns to discuss potential concerns surrounding the use of ketamine, especially use which is not overseen by a knowledgeable medical professional. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. Additionally, Dr. Braunstein is involved in multiple projects focused on expanding access, awareness, research, and safety in the field of psychedelics. To begin this conversation, Dr. Braunstein shares how his original exposure to ketamine wasn’t in a medicinal context, but rather as a recreational drug of abuse. However, since then he has seen the transformative effects this substance can have on patients when used in a physician-directed context and for therapeutic purposes. Nonetheless, Dr. Braunstein stresses that this does not mean ketamine use does not come with certain risks. Ketamine can be addictive and even carries a risk of overdose, particularly when used recreationally in a context where the purity of the substance is unknown. Dr. Braunstein distinguishes recreational and therapeutic uses of ketamine, explaining that recreational doses are often lower and dosing is more frequent, whereas ketamine is used in high doses in a therapeutic context, with extended periods between sessions. Dr. Braunstein stresses both the responsibility of physicians and of patients to ensure ketamine is prescribed responsibly and used as directed. Despite the dangers posed by recreational ketamine use Dr. Braunstein describes in this conversation, it is still a medicine he believes can have significant positive impacts for patients. This requires, however, that it not be treated merely as yet another quick fix pill. Instead, Dr. Braunstein emphasizes that ketamine treatment ought to coincide with psychotherapeutic work. This combination, he says, will maximize the therapeutic potential of ketamine while also helping to ensure that the medicine is used responsibly, under the close direction of a medical professional. In this episode: The addiction and overdose potential with recreational ketamine use How dosage can dramatically change the effects of ketamine Responsible prescribing practices for physicians working with ketamine The psychological and physiological harms of ketamine abuse How Dr. Braunstein talks to his patients about responsible use before prescribing ketamine The importance of combining psychedelic medicines with psychotherapeutic work Quotes: “Part of why ketamine works is because it lights up your brain in all these different ways and when done occasionally, intentionally, it moves you. But if you’re always doing that, it ends up having the reverse effect, causing damage.” [12:56] “This is a heavy-duty medication that, if you cross the line, can cause you to stop breathing and then die. So there is an actual, real danger to ketamine.” [16:25] “I think the organ that is most prone to damage from overuse of ketamine is the same organ we are touting it fixing: the mind.” [18:39] “When we think about these medications, we should think about combining them with therapy and not just taking these medications as medications… So that’s why with ketamine I’m really recommending it with therapy.” [25:04] Links: Reconscious Medical Psychedelic Medicine Association Porangui…
1 Psychedelics for Postpartum Mood Disorders with Melissa Whippo, LCSW 36:01
36:01
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:01In this episode of the Psychedelic Medicine Podcast we discuss the topic of psychedelics and postpartum mood disorders. Melissa Whippo is a licensed psychotherapist who specializes in the intersection of women's health and psychedelics. She founded a non-profit, Deva Collective, which has fiscal sponsorship with MAPS, and is currently conducting research about perimenopause and microdosing San Pedro. In this conversation, Melissa shares the details of existing research into psychedelic treatments for postpartum populations. She discusses the findings from her study on “ The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women ,” reporting that ketamine was not detected at all in breast milk twelve hours after dosing. She also shares information on parents’ intentional use of microdosing and what motivates them to take up this practice. In closing, Melissa discusses her upcoming research on microdosing San Pedro among perimenopausal populations and why she decided to focus on San Pedro for this study. In this episode you'll hear: The early research into ketamine for postpartum depression and whether ketamine remains in breast milk The prevalence of mood concerns in the postpartum population Issues of access with ketamine treatments for new mothers Improvements in postpartum mood patients following ketamine treatments that Melissa has seen in her practice Hormone changes after giving birth and how this might relate to mood concerns Ketamine for postpartum pain Quotes: “The reason why ketamine and other psychedelics appeal to me more [than other treatments for postpartum depression], is it’s not a medicine you have to take every day and it’s not a medicine that’s going to cause a significant separation [with the newborn] like a hospital admission would.” [5:55] “More SSRI—which is still considered safe by the medical profession—passes through the breastmilk than ketamine. Probably nanograms. And ketamine has such a short half-life in the system, particularly with the intramuscular route of administration, that twelve hours after dosing, the breast milk was completely clear.” [14:22] “That’s what ketamine does so well—it gives people a different view of some of the things they’re really struggling with that they can’t quite break through. Some of these more recursive ruminations that seem to befall mothers quite a bit—and they’re usually pretty negative. But the medicine space gives them a different view.” [18:52] Links: Melissa’s study: The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites Melissa’s article in the Washington Post: Some moms are microdosing mushrooms for anxiety and depression Melissa’s website Deva Collective website Melissa on Instagram Plant Parenthood website Previous episode: Psychedelics and Women’s Health with Allison Feduccia, PhD Psychedelic Medicine Association Porangui…
1 Psychedelic Assisted EMDR Therapy with Hannah Raine-Smith and Jocelyn Rose 40:41
40:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:41In this episode of the Psychedelic Medicine Podcast, Hannah Raine-Smith and Jocelyn Rose join to discuss the psychedelic assisted EMDR therapy. Hannah is an integrative psychotherapist and independent researcher specializing in psychedelic integration using EMDR therapy. Jocelyn is a research therapist working on psychedelic clinical trials. She also works in private practice, and has a special interest in exploring the unfolding potential of EMDR as a scalable, trauma focused psychedelic assisted therapy. In this conversation, Hannah and Jocelyn introduce the basics of eye movement desensitization and reprocessing (EMDR) therapy and its possible utility in adjunct to psychedelic assisted therapies. They discuss the overlapping mechanisms between EMDR and psychedelic therapies, with both engaging the serotonin 5-HT2 system and promoting neuroplasticity. Hannah and Jocelyn explain their excitement around integrating EMDR with psychedelic therapy, stressing that this may make these treatments more accessible for the patients who could benefit most from psychedelic therapy. In closing, the researchers call for additional investigation of the intersection of psychedelic therapy and EMDR and invite collaboration from anyone else exploring these promising treatments. You can contact Hannah and Jocelyn at info@bridgetothematrix.com In this episode you'll hear: How EMDR works to help people process traumatic memories Similar neurological effects of psychedelic therapies and EMDR Understanding the adaptive information processing (AIP) framework Hannah and Jocelyn’s novel hypothesis for the basis of hallucinogen persisting perception disorder (HPPD) Using EMDR as an integration therapy for past psychedelic experiences Making psychedelic treatments more accessible and inclusive Quotes: “Like with indigenous shamanic practices, EMDR uses simple rhythms to alter consciousness. So EMDR is like an ancient healing mechanism that’s been adapted to treat the modern soul.” [4:56] “When we reprocess these memories using bilateral stimulation of the brain, you start thinking and feeling differently about the same events. So trauma therapy isn’t about changing the past, it’s about how you think and feel about those experiences.” [5:26] “Some of the resistance that would normally be present in an EMDR session is diminished when someone has had a recent psychedelic experience.” [12:02] “Research has shown that EMDR taps into the same mechanisms as REM [sleep]. It’s like adding the healing benefits of dreaming whilst on psychedelics but being more in control of what gets reprocessed.” [14:42] “The people who are most likely to have adverse drug reactions to psychedelics—whether that’s HPPD or tolerance—tend to be the people who also have adverse childhood experiences or have traumatic complexity in their biographical content. And so we recognize that there’s a need for trauma-focused psychedelic treatments if we’re going to make these treatments available to the people who need them most and make them scalable—and we think EMDR is a good enough fit for that work to happen.” [25:46] Links: Hannah and Jocelyn’s article: “Psychedelic-assisted EMDR therapy (PsyA-EMDR): A memory consolidation approach to psychedelic healing” Bridge to the Matrix: A Memory Consolidation Approach to Psychedelic Healing website Hannah on LinkedIn Jocelyn on LinkedIn Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT Psychedelic Medicine Association Porangui…
1 Ketamine for PTSD with Steven Radowitz, MD 36:22
36:22
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:22In this episode of the Psychedelic Medicine Podcast, Steven Radowitz, MD joins to discuss the state of the research into ketamine treatments for PTSD. Dr. Steven Radowitz is the Chief Medical Officer and Co-Founder, Nushama. He believes psychedelic medicine’s framework of neuroscience, mystical experience, and integration therapy is the future of mental wellness, and current solutions often fall short, treating symptoms without addressing underlying issues. Dr. Radowitz and the Nushama team have administered thousands of ketamine journeys for mood disorders and are known to be best-in-class and among the most experienced globally. In this conversation, Dr. Radowitz shares the journey of his career in medicine and how he got involved in the treatment of mood disorders with ketamine. He discusses the way he works with patients to determine the best dosing of ketamine for their unique therapeutic needs and the way dosage intersects with the durability of the changes. Dr. Radowitz emphasizes how ketamine promotes neuroplasticity, which allows patients with PTSD to open a critical response window when confronted with triggers and re-code memories of trauma. In closing, Dr. Radowitz discusses the importance of integration and highlights the way psychedelic therapies empower patients to be their own healers. In this episode you'll hear: Using both psycholytic and psychedelic doses of ketamine and how therapeutic approach differs between the two Stories of transformation from Dr. Radowitz’s ketamine practice The practices Dr. Radowitz recommends for patients following ketamine infusions How Dr. Radowitz uses music in his ketamine practice Quotes: “As much as we segregate all these mood disorders into separate disease entities… there’s actually a common seed for them all—there’s just different manifestations. But I say about 95% of the people who come in here [for ketamine treatments] have some type of trauma.” [4:56] “The dose doesn’t always correlate with the experience—it usually doesn’t. I can give people the same dose, with the same music, same everything, and they'll have completely different experiences each time.” [13:23] “What we do here is to create a medically safe and an emotionally safe environment for [patients]. But the medicine is them—they’re the therapists in the end. … I want them to realize it’s all coming from them. They have everything they need within themselves to heal.” [32:15] Links: Nushama website Nushama on LinkedIn Nushama on Instagram Nushama on Facebook Nushama on TikTok Dr. Radowitz on Linkedin The Untethered Soul: The Journey Beyond Yourself by Michael A. Singer Letting Go: The Pathway of Surrender by David R. Hawkins Psychedelic Medicine Association Porangui…
1 Exploring Endogenous DMT with Rick Strassman, MD 52:41
52:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
52:41In this episode of the Psychedelic Medicine Podcast, Rick Strassman, MD joins to discuss the topic of endogenous DMT. Dr. Strassman is adjunct associate professor of psychiatry at the University of New Mexico in Albuquerque and author of DMT: The Spirit Molecule and The Psychedelic Handbook . His DMT and psilocybin studies in the early 1990s initiated the renewal of human research with psychedelics in the U.S. In this conversation, Dr. Strassman discusses the finer details of DMT, from endogenous production in humans and animals, to visionary experiences and theological implications. Dr. Strassman also covers the research that's been done regarding endogenous DMT, clarifying what we do and don’t know about the role of the pineal gland and how this might relate to what is reported during near-death experiences. He also discusses the personal and relational quality of psychedelic experiences induced by DMT, mentioning that unitive mystical experiences were actually rare in the trials he conducted, with more experiences having a personal quality, drawing upon the life experiences and interests of the participants. In closing, Dr. Strassman shares his thoughts on the origins of the visions that many report during DMT use. In this episode you'll hear: The overlap between psychedelic experiences and meditation techniques The relationship between fear, self-awareness, and difficult DMT experiences The placebo effect and psychedelic research Dr. Strassman’s thoughts on non-hallucinogenic psychedelics DMT as a possible treatment for strokes to prevent damage and speed recovery Effects of microdosing in animals and humans Quotes: “I think the best term for these compounds is psychedelic, which means mind manifesting or mind disclosing, because only one of our fifty-five or so normal volunteers had what one might call a mystical unitive state. … Everybody basically had an experience that was totally dependent on them. It was not inherent in the drug.” [9:45] “You could still speculate that to the extent that non-drug states resemble those brought on by giving DMT… that DMT plays a role in the production of those states. But the data aren't there yet. That's why we need more people doing this research.” [24:16] “If psychedelics are super placebos and if we have a psychedelic drug in our brain, it's attempting to speculate that normally the placebo effect could be mediated by endogenous DMT.” [27:42] “If you starve neurons of oxygen they start dying, but if you add DMT they survive much longer. So there seems to be some neuroprotective effect of DMT on ischemic damage to neurons, at least in the test tube.” [32:27] Links: Dr. Strassman’s website The Psychedelic Handbook by Dr. Strassman DMT: The Spirit Molecule by Dr. Strassman DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible by Dr. Strassman Dr. Strassman on Facebook Previous episode: Exploring DMT Entities with Matthew Johnson, PhD Psychedelic Medicine Association Porangui…
1 Psilocybin for Anorexia Nervosa with Stephanie Knatz Peck, PhD 40:26
40:26
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:26In this episode of the Psychedelic Medicine Podcast, Stephanie Knatz Peck, PhD joins to discuss the research on psilocybin for anorexia nervosa. Dr. Stephanie Knatz Peck is a clinical psychologist and Associate Clinical Professor at the University of California, San Diego with an expertise in eating disorders. She conducts clinical research on novel treatments for eating disorders and has been involved with clinical research evaluating psychedelics across a variety of mental health indications in the capacity of researcher and therapist. She also published the first ever report on a clinical study evaluating psilocybin for anorexia nervosa. In this conversation, Dr. Peck discusses the difficulties of treating eating disorders and the emerging evidence around the safety and efficacy of psychedelic-assisted therapies for these conditions. She discusses the results from a study she conducted on the safety and tolerability of psilocybin therapy for females with anorexia nervosa , finding that the treatment was safe and generally well tolerated amongst the trial group. The study additionally found positive treatment outcomes following the psilocybin therapy in a number of participants. In closing, Dr. Peck discusses how psychedelics are able to open a “behavior change window” following dosing sessions—something which may be crucial to their efficacy in treating eating disorders. In this episode: Dr. Peck’s work treating patients with eating disorders The lesser known diagnostic categories orthorexia and eating disorder not otherwise specified (EDNOS) Genetic predisposition for eating disorders Why the participants in Dr. Peck’s study thought they could benefit from additional psilocybin dosing sessions How transformative psychedelic experiences can help shift values and identities to promote eating disorder recovery Quotes: “We think that there are specific personality features that predispose someone to engage in dietary restrictive processes or behaviors or actions or modify their lifestyle around exercise and food—and then they fall into anorexia. And the thing that distinguishes those people is that sometimes they have these predisposing factors like a lot of anxiety or preoccupation, an ability to be highly self disciplined… There’s a lot of processes in place that can cause a diet to go awry and turn into anorexia.” [12:29] “Something that distinguishes anorexia from other psychiatric illnesses is that it is an illness that really results in a lot of physiological vulnerability—across all body systems. And so while it might be fine to just assume that with some other psychiatric illnesses we can reliably assume safety, with this particular population there’s cardiac issues, there’s serotonergic things that affect cardiac issues that we really needed some safety data on.” [19:13] “We really need better treatments [for eating disorders] that treat from the inside out, meaning like what is happening on an underlying psychological level, neuropharmacological level, that’s causing someone to want to engage in these behaviors and I think that is the value of these [psychedelic] treatments is that we are treating from a different direction.” [27:25] Links: Dr. Peck’s study: Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study Current eating disorder studies at UCSD BrightMind Therapy website Dr. Peck on Twitter Psychedelic Medicine Association Porangui…
1 What are Psychosomatodelics? with Ben Malcolm, PharmD, MPH 43:42
43:42
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:42In this episode of the Psychedelic Medicine Podcast, Ben Malcolm, PharmD, MPH joins to discuss why he prefers the term “psychosomatodelics” for psychedelics. Dr. Malcolm is a psychopharmacology consultant, psychedelic educator, founder of Spirit Pharmacist, LLC and a board member of the Psychedelic Medicine Association. In this conversation, Dr. Malcolm shares the meaning of the term psychosomatodelic as well as the history of the different terms used to refer to psychedelics. He emphasizes the ways that these substances manifest mind and body together, rather than only focusing on the mind-altering aspects of the experience. He also suggests that the line between side effects and therapeutic opportunities is blurry in psychedelic therapy, discussing the ways in which nausea and purging in the context of ayahuasca ceremonies can contribute to the sense of healing and psychosomatic catharsis. In closing, Dr. Malcolm suggests some directions for future research regarding serotonergic psychedelics' interaction with the gut-brain axis and the autonomic nervous system. In this episode: The meanings of more newer, more specified terminology such as psychoplastogen, entactogen, and more Trauma-resolving aspects of psychedelic experiences How psychedelics impact transmodal cortices of the brain The somatic side effects of psychedelics Quotes: “The psychedelic experience is inherently larger than either brain or mind, and it’s more of a mind-body kind of experience. And it would be worth recognizing the mind-body contribution that is happening as far as the types of experiences persons are having, and maybe even the ways that psychedelics are working to provide a true, felt sense of relief for persons.” [3:51] “Why do we wear a blindfold for psychedelic therapy? Well, you’re actually trying to limit the sensory input from certain unimodal sensory cortices like vision and you’re trying to amplify sensory content—maybe from the body, maybe from the viscera, maybe from inside. It’s to heighten the internal landscape. That’s why you’re actually shutting out these kinds of external sensory inputs.” [17:19] “Particularly if you’re approaching psychedelics for healing of trauma, then thinking of them as energetic purgatives that have a psychosomatodelic, or full mind-body manifesting type of experience, might allow you to wrap your head around the psychedelic experience or what its doing a little bit easier.” [31:53] Links: Spirit Pharmacist website Spirit Pharmacist on Facebook Spirit Pharmacist on Instagram Spirit Pharmacist on YouTube Previous episode: Medical Literature Regarding Psychedelics, Pregnancy, and Breastfeeding with Ben Malcolm, PharmD Psychedelic Medicine Association Porangui…
1 Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT 51:35
51:35
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
51:35In this episode of the Psychedelic Medicine Podcast, Nick Brüss, EdD, LMFT joins to discuss the possibilities of leveraging ketamine-assisted psychotherapy for accelerated growth. Dr. Brüss is a psychedelic therapist licensed in CA, NY and TX. He was a MAPS clinician and supervisor on the historic phase 3 MDMA for PTSD study, and is the director of psychedelic medicine advocacy for the TREAT California ballot initiative. In this conversation, Dr. Brüss explains the intricacies of the internal family systems (IFS) model of therapy which he uses in conjunction with ketamine to help lead clients towards transformation and growth. Dr. Brüss explains how he helps clients work with their various “parts” both leading up to ketamine experiences and while they are under the influence of the dissociative, explaining how the ketamine experience helps to facilitate this work. He emphasizes the non-pathologizing, self-compassion focus of the IFS model and sees this as a natural fit for psychedelic-assisted work. In closing, Dr. Brüss shares details of the TREAT California ballot initiative, which has the potential to provide five billion USD in funding for research and affordable access to mental health treatments using psychedelic medicines. In this episode: Different forms of ketamine-assisted therapy The importance of preparation for both psycholytic and psychedelic forms of ketamine therapy Why Dr. Brüss finds the combination of IFS and ketamine therapy so powerful Working with “parts” using IFS Stories of client healing and transformation following ketamine-assisted therapy with IFS The meaning of “protector parts” and “exile parts” in IFS and how to work with these The mechanisms of ketamine “softening protector parts” and facilitating self-love Quotes: “[Internal family systems] is so synergistic with psychedelic-assisted work because it holds as part of one of its assumptions that we all naturally have this multiplicity of minds… And we also hold this capacity, this inner-knowing that we can open to and relate to and even bring a loving, compassionate embrace to all of our parts.” [4:59] “This work is a training for people to get to know themselves, so we work with the biggest pieces, the things that have been holding them down or blocking them in some way—blocking their full expression—and after that, they are now trained to work with any number of parts.” [26:52] “One of the things that I wish I could have told my earlier, younger self is to really focus on these areas where if there’s a part of myself that I can’t love or care for or deeply respect, then that really needs my attention.” [33:52] “Even with the most seemingly scary parts, as we get to know them, we can learn from them.” [36:00] Links: Dr. Brüss website, A Practice of Freedom TREAT California ballot initiative website Dr. Brüss on Instagram Dr. Brüss on LinkedIn Your Symphony of Selves: Discover and Understand More of Who We Are by James Fadiman and Jordan Gruber Psychedelic Medicine Association Porangui…
1 Supporting Survivors of Psychedelic Abuse with Erica Siegal, LCSW 55:44
55:44
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
55:44In this episode of the Psychedelic Medicine Podcast, Erica Siegal, LCSW returns to discuss the important topic of supporting survivors of psychedelic abuse. Erica is a psychedelic-assisted psychotherapist, community organizer, and harm reduction advocate. In 2019 she founded NEST Harm Reduction, a California-based mental health and psychedelic support organization that provides psychotherapy, outreach, education, and integration. Erica also recently founded SHINE Collective to support survivors of psychedelic harm and abuse. In this conversation, Erica unpacks the complexities around various forms of abuse that exist in psychedelic spaces. One major form of abuse she identifies is financial coercion, where clients of psychedelic facilitators come to feel that one’s spiritual access has a paywall, or that they are having to make major financial decisions while under altered states of consciousness. Erica also discusses problematic sexual and romantic dynamics that can arise, drawing a clear line in the sand that there should never be any form of sexual contact between psychedelic facilitators and clients. In closing, she shares more about the work SHINE Collective is doing to support survivors of psychedelic abuse, and discusses ways that listeners can help support this important work. In this episode: What inspired Erica to start SHINE Collective Issues of financial coercion in psychedelic spaces Different forms of spiritual abuse Ways identify the dynamics of spiritual abuse and guard against them Why Erica is skeptical of husband-wife teams of psychedelic therapists or facilitators Issues of sexual dynamics between psychedelics facilitators and clients Training and integration needed prior to skillfully and safely facilitating psychedelic experiences What SHINE Collective is doing to support survivors of psychedelic harm Quotes: “You also see people who are like ‘oh well if you want to keep working with me it's this price’ and then all of a sudden the access to psychedelics—the spiritual access—now becomes ‘well I have to be paying this person $1,000 a month to just be on their mailing list because they are the person that is acting as the point between me and my spiritual access.’” [11:19] “If you’re facilitating, you should have a consultation group of other facilitators in which you consistently welcome constructive feedback. … And be able to have case consultations, and be able to have reflection.” [26:43] “Psychedelic facilitators should not be having sex with people they are facilitating psychedelic ceremonies for.” [30:35] Links: NEST Harm Reduction website NEST Harm Reduction on Instagram NEST Harm Reduction on Twitter SHINE Collective website SHINE Collective on Instagram Erica on LinkedIn Erica on Instagram Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c) Article by Jules Evans and Joseph Holcomb Adams: “Blurred Lines: improving the ethics of psychedelic fund-raising” The Emerald Podcast by Joshua Michael Schrei on Spotify Psychedelic Medicine Association Porangui…
1 Psychedelic Training and Education with Kyle Buller and David Drapkin, LCSW 43:58
43:58
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:58In this episode of the Psychedelic Medicine Podcast, Kyle Buller and David Drapkin, LCSW of Psychedelics Today join to discuss psychedelic training and education. David is a licensed clinical social worker, the director of education and training at Psychedelics Today, and one of the creators of their 12-month training program, Vital. Kyle is the co-founder of Psychedelics Today and VP of training and education. In this conversation, Kyle and David share an overview of the current state of psychedelic training programs and education. Kyle shares his own background with psychedelic education, discussing how he got involved in this field and what he’s found most beneficial and effective in psychedelic training. Kyle and David also discuss the complexities of weighing different programs, considering medicine-specific versus general programs, programs focused on specific modalities, programs geared towards specific professions, and more. They also discuss the details of how they created Psychedelics Today’s training program, Vital. In closing, David reiterates the value of diversity in psychedelic education, both in enriching the learning experience and extending the impact of this education. In this episode: The variety of psychedelic education programs The vision behind the Psychedelics Today Vital course What to look for in psychedelic education programs Equity and diversity in training programs Medicine-specific vs. medicine-general programs Dealing with the uncertainties around working with psychedelics as legal landscapes develop Psychedelic training program scholarships Quotes: “Something we put a lot of emphasis on with Vital, is that it be experiential and inner-directed—a process of understanding self and coming out of Vital with more refined questions and a clearer sense of where to go next.” [8:31] “If the psychedelic movement is going to continue to grow, we need people to be educated in all realms so that we can help to reduce the stigma.” [11:42] “If you want to start working with these medicines, building those foundational elements is so important. Like learning how to work with your body, learning how to use your breath to navigate experience.” [31:12] Links: Psychedelics Today website Psychedelics Today Vital course Psychedelic Medicine Association Porangui…
1 Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c) 1:08:52
1:08:52
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:08:52In this episode of the Psychedelic Medicine Podcast, Adam Aronovich, PhD(c) returns to discuss issues of psychedelic self-absorption—and how to avoid these traps. According to Adam, he is a PhD candidate in medical anthropology, the creator and curator of Healing from Healing, a trophy husband and dad. In this conversation, Adam revisits his previous discussion of psychedelic narcissism and explains why he’s now somewhat more critical of the term. However, Adam still sees issues around cultivating epistemic humility and acknowledging the political dimensions of healing in psychedelic contexts. He explains the issues he takes with forms of New Age, Neoliberal spiritual perspectives he sees as pervasive and typically unacknowledged amongst many engaging with psychedelics. He also discusses how some pop psychology terms have worked their way into the psychedelic realm and what impacts that has had. In this episode: The “spectacle” of filmed psychedelic experiences on social media The intersection of medical and spiritual cultures in psychedelics and how this can create issues of access The cheapening and overuse of the idea of “trauma” in popular discourse and the birth of “traumadelic” culture Why approaches focusing on excavating supposed repressed traumatic memories from childhood should be approached with a degree of skepticism Quotes: “One of the main things with plant medicine—particularly when people are sharing about it—is that people want to be really vulnerable and people want to be very authentic… But at the intersection with the spectacle, that vulnerability and authenticity become part of the spectacle in the sense that they become 100% performative.” [19:01] “The people who don’t have that modicum of self awareness and epistemic humility to really understand, with intellectual honesty, the scope of their understanding and knowledge, then it is very easy to overdo it. And then we do a disservice, not only to the actual traditions that we purport to be portraying, but also to the people that we’re working with.” [37:56] “If you don’t understand that your healing is political, because individual health, and individual happiness, and individual everything is intrinsically related to collective health, and social health, and cultural health, and environmental health, then you need to go back to square one because you haven’t understood anything. ” [40:02] “If we can’t even fathom that perhaps my own wellbeing is in constant dialogue with the wellbeing of a society, and the wellbeing of a culture, and the wellbeing of an environment—that nobody can be healthy and happy unless everybody else is relatively healthy and happy—then we are in big trouble and we haven’t really learned everything.” [40:20] Links: Healing from Healing website Healing from Healing on Instagram Healing from Healing on Facebook Adam on Instagram Society Of The Spectacle by Guy Debord Wikipedia entry on the Satanic panic Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich Previous episode: How Western Medicine and Indigenous Traditions Differ in their Approach to Mental Health and Healing with Adam Aronovich Psychedelic Medicine Association Porangui…
1 Ketamine Assisted Psychotherapy for Chronic Pain with Michelle Weiner, DO MPH 35:30
35:30
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
35:30In this episode of the Psychedelic Medicine Podcast, Dr. Michelle Weiner joins to discuss the research on ketamine assisted psychotherapy for chronic pain conditions. Dr. Weiner is Double board-certified in Interventional Pain Medicine, Physical Medicine and Rehabilitation and the Director of Integrative Pain Management at Spine and Wellness Centers of America. She uses a unique personalized approach to treat the root cause of one's pain using a biopsychosocial model including lifestyle and plant medicine to empower her patients to cultivate health, optimize quality of life and decrease pharmaceuticals. In this conversation, Dr. Weiner discusses her recent research into ketamine therapy for chronic pain and comorbid depression, which compared psychedelic and psycholytic doses of the dissociative. She emphasizes the importance of a biopsychosocial approach to pain treatment and sees the psychotherapy aspect of the ketamine treatments as crucial to their efficacy, as this approach allows doctors to have a better understanding of the complex etiology of the patients pain beyond just what shows up on imaging and empowers patients to actively take ownership of their pain management. While the results from Dr. Weiner’s study were very encouraging, she mentions that ketamine therapies typically require maintenance and that more longitudinal research is needed to further understand how durable these changes are. In this episode: The issue of central sensitization in chronic pain The difference between psychedelic and psycholytic doses What led Dr. Weiner to study chronic pain and comorbid depression Neuropathic, nociceptive, and nociplastic forms of pain The influence of trauma and stress on chronic pain The intersection of pain and identity Dr. Weiner’s biopsychosocial approach to pain treatment The differences between cannabis and ketamine as pain treatment medications Quotes: “A lot of [patients’] pain is really similar to fear—fear in the brain—and… if we’re not able to understand where this fear is coming from we’re not able to extinguish their pain. So I really changed the way I practice and use ketamine because I started to think more about how the psychiatrists are using it, in terms of preparation and integration.” [6:59] “What I’ve seen is that ketamine does require maintenance in the sense that even if we do six sessions, a lot of patients do need to come back after a few weeks or a few months for maintenance treatment with ketamine as well as therapy.” [20:09] “Pain doctors [should try to] be a little bit more aware of the set, setting, and preparation and integration so that we don’t need to use benzos and [patients] can actually have this dissociative experience to allow them to have hope or get out of that fight or flight.” [33:04] Links: Dr. Weiner's study: Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches Dr. Weiner’s website Dr. Weiner on Instagram PMA webinar with Dr. Weiner: Treating Pain and Functional Neurologic Disorders with Psychedelics Spine and Wellness Centers of America Psychedelic Medicine Association Porangui…
1 The Challenging Psychedelic Experiences Project with Jules Evans 53:10
53:10
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
53:10In this episode of the Psychedelic Medicine Podcast, Jules Evans joins to discuss his work with the Challenging Psychedelic Experiences Project. Jules is a research fellow at the Centre for the History of Emotions at Queen Mary University of London and author of four books including The Art of Losing Control and Breaking Open: Finding a Way Through Spiritual Emergency. He is also the Director of the Challenging Psychedelic Experiences Project and the editor of the substack Ecstatic Integration. In this conversation, Jules shares how he first became interested in psychedelics and the kinds of ecstatic experiences they can produce, as well as what prompted him to turn his attention to the challenging experiences that can result from consuming these substances. He discusses the initial research from the Challenging Psychedelic Experiences Project, sharing the typical ways challenging experiences manifest, as well as the coping strategies people employ to work through these experiences. In closing, Jules reiterates the newness of the psychedelic field, encouraging more research into difficult forms of ecstatic experience and ways to effectively navigate the challenges these pose. In this episode: What got Jules interested in the topic of difficult psychedelic experiences Common impacts of challenging psychedelic experiences Depersonalization vs derealization What helped people integrate challenging psychedelic experiences How people used “cognitive self care” to process challenging experiences The history and meaning of the term “spiritual emergency” Psychedelic “flashbacks” and hallucinogen persisting perception disorder (HPPD) Quotes: “30% of our respondents reported anxiety, panic attacks, social anxiety—and then all these sub-themes related to fear like fear of losing your mind, fear of dying, fear of the experience repeating, fear of being alone.” [17:04] “Feeling you don’t have anyone to talk to about [a psychedelic experience] will make extended difficulties more likely. Not knowing the dosage that you take seems like it makes extended difficulties more likely.” [24:44] “The overwhelming majority [of people who had challenging psychedelic experiences], like more than 85%… still believe in the therapeutic potential of psychedelics.” [32:41] “Our culture has a lot of ecstatic illiteracy. We’ve lost the maps and guides and safe places to having ecstatic experiences, so we’re ecstatically naive. And we need to develop ecstatic literacy to learn to get better at having these kinds of experiences.” [51:11] Links: Challenging Psychedelic Experiences Project website The first study from the Challenging Psychedelic Experiences Project: Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands Ecstatic Integration Substack Jules’ book: Breaking Open: Finding a Way Through Spiritual Emergency Jules on LinkedIn Jules on Twitter Jules on Instagram Centre for the History of Emotions at Queen Mary University of London Psychedelic Medicine Association Porangui…
1 Managing Medical Risk in Patients Seeking Psilocybin Therapy with Reid Robison, MD, MBA 46:09
46:09
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
46:09In this episode of the Psychedelic Medicine Podcast, Dr. Reid Robison joins to discuss managing medical risk in patients seeking psilocybin therapy. Dr. Robison is a board-certified psychiatrist and Chief Clinical Officer at Numinus, overseeing the company's psychedelic and mental health services across the US and Canada. He has led over 200 clinical trials in neuropsychiatry, including the MAPS-sponsored MDMA-assisted therapy for eating disorders study, and several other psychedelic studies with psilocybin, LSD and DMT. In this conversation, Dr. Robison begins by sharing how researchers have been determining guidelines for managing medical risks associated with psilocybin and how this guidance may shift as research continues in real-world settings at larger scales. He also discusses the intricacies of psilocybin’s pharmacokinetics and how the substance interacts with common psychiatric medications such as SSRI antidepressants. In closing, Dr. Robison emphasizes the importance of keeping a close eye on potential psychological risks of psilocybin and other psychedelics, especially amid the excitement stemming from the incredible potential of these medicines. In this episode: The emerging medical indications for psilocybin therapy How the research into psilocybin has developed in the past few years The pharmacokinetics of psilocybin Medication interactions with psilocybin Risks of serotonin syndrome Absolute vs relative contraindications Psilocybin’s effect on QT interval and heart valves The Psychedelic Medicine Association’s “Psilcobyin-Informed Clinicians” database comprised of practitioners who have completed the course Quotes: “There’s a lot to learn [about the interaction of psilocybin and SSRIs] and it's a little bit unpredictable. And some people anecdotally would say that their SSRI interfered with their trip or diminished the experience and others would say it did not.” [26:22] “Psychological risks are nontrivial, including the risk of a difficult experience—something that may even need some mental health treatment afterwards, something that may be meaningful, nontrivial for the individual for a while, and can coexist with the mystical experience. And having the most meaningful experience of your life can coincide with the most difficult.” [40:43] Links: Course: Managing Medical Risk in Patients Seeking Psilocybin Therapy Dr. Robison’s website Dr. Robison on Twitter Dr. Robison on Instagram Numinus website Previous episode: Psychedelics for Eating Disorders with Reid Robison Psychedelic Medicine Association Porangui…
1 Psychedelics for Substance Use Disorder with Kevin Franciotti, MA 48:32
48:32
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
48:32In this episode of the Psychedelic Medicine Podcast, Kevin Franciotti, MA joins to discuss the intricacies of psychedelic-assisted therapies for substance use disorder. Kevin Franciotti is a Denver-based writer, therapist, advisor, and thought leader in the fields of psychology, psychedelics, and substance abuse counseling. In this conversation, Kevin shares his expertise on the existing research on psychedelic medicines for substance use disorder (SUD) and also discusses the limitations of the results of this research. He talks about the difficulties of designing trials and protocols for psychedelic therapies that target SUD, touching on how this disorder can interact with the neuro-physical and psychological effects of psychedelic medicines. He also contrasts emerging psychedelic treatments for SUD with dominant abstinence-based models and shares where he thinks psychedelic therapies may be a healthier alternative. In closing, Kevin reiterates that it is crucial to continue integrating harm reduction perspectives as psychedelic therapy continues to gain more mainstream traction. In this episode: Contraindications which can arise during detox periods which may require a person to be fully detoxed prior to pursuing any psychedelic-assisted therapy for SUD The neuro-physical effects and the psychological effects of psychedelic substances The role of peer support in psychedelic-assisted therapy for SUD The stigma around psychedelic therapies within traditional recovery programs and communities How psychedelic therapy protocols interface with current guidelines from the American Society of Addiction Medicine The future of insurance coverage for psychedelic therapies Issues of “psychedelic exceptionalism” Quotes: “Ibogaine has somewhat of a miraculous quality of being able to attenuate some of the most painful, acute symptoms of opiate withdrawal—but that is only specific to opiate withdrawal.” [11:33] “What’s miraculous about a medicine like ibogaine or even psilocybin… is it's designed to enhance somebody’s ability to confront their underlying issues.” [16:57] “The future of addiction treatment embracing psychedelics is really going to hinge on the treatment industry being willing to construct innovative ideas.” [30:37] “Drugs are drugs. Drugs don’t have an inherent moral quality around them. [What’s important to highlight] is the risk of stratifying people who use drugs as somehow being superior or inferior based on which category of socially accepted drugs that they’re doing.” [42:39] Links: Kevin’s website Kevin on Twitter Kevin on Instagram Kevin on LinkedIn Psychedelics in Recovery Journey Colab All Points North (APN) “Dispelling Lies the Psychedelic Community Believes About Drugs” presentation by Carl Hart, PhD at Horizons 2019 Psychedelic Medicine Association Porangui…
1 Leveraging Psychedelics for Queer Liberation with Wilhelmina De Castro, LCSW 30:40
30:40
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
30:40In this episode of the Psychedelic Medicine Podcast, Wilhelmina De Castro, LCSW joins to discuss the ways psychedelics may be used to support goals of queer liberation. Wilhelmina is a psychedelic therapist in the San Diego area and serves as a DEI officer for Integrative Psychiatry Institute. She is also lead faculty for the Psychedelic Research and Training Institute and is committed to creating access to psychedelic healing for historically marginalized populations. In this conversation, Wilhelmina discusses the major topics at the intersection of psychedelic healing and queer identities. She shares her own journey of how psychedelics helped with self-discovery and acceptance of her queer identity, discussing the ways these substances can help gender and sexual minorities step outside of forms of normativity that are enforced in the culture. She also discusses creating safe spaces for queer folks where they can access psychedelic healing with facilitators and other participants of a similar background. In closing, Wilhelmina reiterates the continuing issues of access and trust queer people face in the current psychedelic landscape, emphasizing the significant work which must be done to improve this situation. In this episode: How psychedelics can help with self discovery and self exploration What inspired Wilhelmina to begin working professionally with psychedelics Creating spaces for psychedelic healing tailored to queer-identified people Dealing with microaggressions in the context of a psychedelic retreat Working with a therapist or facilitator who shares a queer identity The queerness of psychedelics Quotes: “When I began to explore with psychedelics, there were moments of this connection beyond… the way I was socialized or conditioned to think was normal. I was able to just be myself [and] found that this attraction and this embodiment that I was feeling was actually where I was supposed to be.” [4:41] “Psychedelics can be really helpful in challenging, in questioning, in dissolving those oppressive narratives that keep people oppressed, that keep them from accessing their liberation. And so if we can do this consciously, and if we can do this in a safe space where harm is not perpetuated, then we actually have this beautiful opportunity for collective liberation” [14:25] Links: Wilhelmina's practice, Integrate Integrate on Instagram Integrative Psychiatry Institute Psychedelic Research and Training Institute Queering Psychedelics: From Oppression to Liberation in Psychedelic Medicine SoundMind Institute Psychedelics and Identity Initiative Queer Psychedelic Society Psychedelic Liberation Collective Previous episode: Psychedelics and the LGBTQIA2S+ Community with Dr. Angela Carter Psychedelic Medicine Association Porangui…
1 Considerations for Safety When Working with 5-MeO-DMT with Joël Brierre 39:28
39:28
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
39:28In this episode of the Psychedelic Medicine Podcast, Joël Brierre joins to discuss the important topic of safety when working with 5-MeO-DMT. Joël is the founder and CEO Tandava Retreats and co-founder of the 5-MeO-DMT education and training platform F.I.V.E. Joël and his team are focused on shepherding 5-MeO into the world in a safe and effective manner. In this conversation, Joël shares his expertise on the screening that should be done prior to 5-MeO-DMT experiences, discussing both physical and psychological considerations. He also talks about synthetic 5-MeO-DMT vs the extract from the Bufo alvarius toad and explains why his retreat center only uses the synthetic version. In closing, he discusses the nuances around drug-drug interactions and how he navigates these with participants, exploring the nuances of the pharmacology involved. In this episode: What inspired Joël to start F.I.V.E. The physical medical considerations when screening patients for 5-MeO-DMT Why it is theorized that 5-MeO-DMT could trigger conditions like multiple sclerosis to recur Psychological red flags for people seeking 5-MeO-DMT experiences Joël's thoughts on navigating psychedelic narcissism Safety considerations working with patients with significant trauma Determining the dosage of 5-MeO-DMT and why Joël thinks there’s a lot of value in lower doses Alternative routes of administration for 5-MeO-DMT other than smoking Quotes: “It’s very important to us that [5-MeO-DMT] is shepherded out into the world in a safe and effective way, with a good understanding of how it can go wrong—because another bad headline can really harm the progress that it has seen.” [7:14] “Where we used to feel you really had to work your way up to 5[MeO-DMT], we found with the right amount of prep and with a good individualized approach it’s right for anyone—as long as they’re in the right place for it. So if they make it through the screening and intake process, we’re good to go.” [23:09] “There’s no need to turn it into a goal-oriented thing where [the participant] needs to get to a full release. We see plenty of full resolutions happen where we never even have to take a participant to a mystical experience.” [29:43] Links: Tandava Retreats website F.I.V.E. website Previous episode: How to Choose a Psychedelic Facilitator or Retreat Center with Joël Brierre Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich Psychedelic Medicine Association Porangui…
1 The Role of Peer Support in the Psychedelic Ecosystem with Joshua White, JD 42:16
42:16
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
42:16In this episode of the Psychedelic Medicine Podcast, Joshua White returns to discuss the role of peer support in the psychedelic ecosystem. Joshua (he/him) is founder and executive director of Fireside Project and has prior experience as a volunteer counselor on a hotline and as a volunteer at the Zendo Project. He has also practiced law as a deputy city attorney at the San Francisco City Attorney’s Office, where he focused on suing business exploiting vulnerable communities. He also co-taught a nationally-renowned clinic at Yale Law School. In this conversation, Joshua shares updates from the first two years of Fireside Project, the psychedelic peer support hotline. He mentions that the hotline has grown nearly 1,000% since their first month, with the number receiving 1,500 calls this past month. Joshua also discusses the intricacies of peer support, sharing why he thinks this form of support is particularly well-suited to psychedelic experiences and how he understands the relationship between psychotherapy and peer support. In closing, Joshua reminds listeners that Fireside Project is available to take calls from anyone working through a psychedelic experience—whether they are in the midst of an altered state of mind or seeking to integrate a past experience. In this episode: When to call the psychedelic peer support hotline The history of peer support and when it may be helpful Why Joshua believes its important for peer support volunteers to have had their own psychedelic experiences The ways peer support and psychotherapy differ The limits of peer support How peer support is similar to the methods used in MDMA-assisted therapy Critiques of peer support Joshua has heard and his responses The relationship between peer support and theoretical frameworks in psychotherapy Quotes: “In non-psychedelic peer support, often the peer-ness starts with a pathology—alcohol use disorder, tobacco use disorder, etc. Psychedelic peer support, the idea is that having had a psychedelic experience by itself is the layer of peer-ness that’s needed to go deeper with someone regardless of other aspects of your identity you may have.” [8:55] “One of the, I think, key parts of peer support is that we don’t interpret a caller’s experience for them. We are present with them so that they can interpret their experience and we can create a safe and non-judgmental space for them to engage in that kind of interpretation.” [18:32] “I think especially with an experience as vast as the type that can be precipitated by psychedelics, having multiple forms of support is essential.” [22:23] Links: Fireside Project website Fireside Project on Instagram Fireside Project on Twitter Previous episode: Insights Gained from the First Year of Fireside Project with Joshua White Previous episode: Fireside Project: The World’s First Psychedelic Hotline with Joshua White and Hanifa Nayo Washington Psychedelic Medicine Association Porangui…
1 Group Ketamine Assisted Psychotherapy for Frontline Healthcare Workers with Hannah Cross, LCSW 36:07
36:07
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:07In this episode of the Psychedelic Medicine Podcast, Hannah Cross, LCSW joins to discuss group ketamine assisted psychotherapy for frontline healthcare workers. Hannah is a licensed clinical social worker and therapist who specializes in trauma healing and psychedelic integration, including work on LSD and psilocybin clinical trials. In this conversation, Hannah shares details from the study exploring group ketamine therapy in a cohort of ten frontline healthcare workers, discussing the study design, the intricacies of group therapy, and the specific dosing protocol and therapy regimen for the patients. She reveals the very promising results of this early study and also shares a number of emotional stories of transformation from the patients. In closing, Hannah discusses the early indicators of the durability of positive effects from this kind of ketamine assisted therapy and lists a number of additional on-going and upcoming studies of group ketamine treatments for other populations. In this episode: The inspiration for this ketamine study How the frontline healthcare workers in the study were chosen What makes a person a good candidate for group therapy The protocol for the ketamine assisted therapy used in the study Why the therapy began with a low, sublingual dose of ketamine How psychotherapy was integrated with ketamine treatments in this study The reductions in PTSD, depression, and anxiety that resulted from the ketamine assisted therapy Why Hannah sometimes sees an increase in anxiety towards the beginning of the therapeutic process Quotes: “Ketamine can help people access more of that self-healing energy and when that’s present in a group setting and people are essentially able to shine this healing energy on each other, there’s this exponential healing I think can happen.” [7:16] “When you wrap a ketamine experience up in experienced and effective therapy, there is this safety in the container that really allows people to have the inward focused journey under ketamine for that forty-five minutes to an hour.” [20:03] Links: Full study: Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers with COVID-19-Related Burnout and PTSD: A Case Series of Effectiveness/Safety for 10 Participants Numinus website Group ketamine assisted therapy by Numinus Hannah’s private practice, Wild Sunflower Counseling Cedar Psychiatry website Psychedelic Medicine Association Porangui…
1 Addressing the Stress of Life Transitions through Ketamine Therapy with Arsalan Azam, MD 29:29
29:29
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
29:29In this episode of the Psychedelic Medicine Podcast, Dr. Arsalan Azam joins to discuss the potential of ketamine therapy for helping to address the stress of major life transitions. Dr. Azam is a board-certified Emergency Medicine physician and medical director of Daydream MD. He attended medical school as a Dean’s Scholar at Case Western Medical School and completed his clinical rotations at the Cleveland Clinic. He has also worked as an emergency medicine physician around the country, including as a relief physician for hospitals impacted by staffing shortages. In this conversation, Dr. Azam shares patient experiences from his own ketamine practice and discusses the complexities of different approaches to ketamine treatment and different indications, including how some individuals may benefit especially from ketamine assisted therapy, while others may be well served by stand-alone ketamine infusions, especially considering the cost differential of these treatments. Additionally, Dr. Azam explores the role integration and peer support can play in the context of ketamine treatments, mentioning these may be less cost-prohibitive ways for patients to get the most out of their experiences. In this episode: The kinds of life transitions ketamine is helpful with in Dr. Azam’s experience What kinds of patients Dr. Azam’s practice serves The unique mechanism of ketamine Leveraging ketamine treatment to navigate breakups or professional transitions Ketamine assisted psychotherapy vs stand-alone ketamine infusions, and when having the extra support of therapy may be especially beneficial The role of integration and peer support in ketamine treatments The research into ketamine treatment for suicidal ideation How Dr. Azam sets up treatment programs for different kinds of patients Quotes: “The magic of this neurobiology is that, unlike our existing tools which take weeks to kick in often, this one works within hours. And so it really becomes more of a rescue medication or a supportive medication for these transitions of life that works quickly.” [8:32] “Think of our mind and our mental patterns as a piece of cold steel—and it’s kind of locked in that structure, in that pattern. Psychedelics, like ketamine and others, can heat that steel up, and make it much more moldable and then when it cools back down it’ll maintain a persistent new structure. So ketamine assisted therapy is a tool that helps us leverage that hot piece of steel to mold it into something else.” [11:56] “Ketamine works very quickly to reduce suicidal thinking and its degree of effect directly corresponds to the degree of symptoms. So someone who has really severe suicidality is more likely to experience a response to ketamine and is more likely to experience a significant response to ketamine.” [18:36] Links: Daydream MD website Daydream MD on Instagram Fireside Project website Psychedelic Medicine Association Porangui…
1 Medical Literature Regarding Psychedelics, Pregnancy, and Breastfeeding with Ben Malcolm, PharmD 49:40
49:40
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
49:40In this episode of the Psychedelic Medicine Podcast, Ben Malcolm, PharmD joins to discuss the research surrounding the intersection of psychedelics with pregnancy and nursing. Dr. Malcolm is a psychopharmacology consultant, psychedelic educator, founder of Spirit Pharmacist, LLC and a board member of the Psychedelic Medicine Association. Dr. Malcolm recently wrote an overview article on the existing research into psychedelics, pregnancy and breastfeeding. In this conversation, Dr. Malcolm shares the current state of research that he explored in his article, highlighting the few points where data does exist while emphasizing that there are still major unknowns. Overall, Dr. Malcolm describes how most are very conservative when it comes to psychedelic use while nursing or pregnant, though pregnancy seems to present more concerns than nursing. Dr. Malcolm also discusses ketamine and the interesting findings in patients who were given this substance as an anesthetic for cesarean sections. In conclusion, Dr. Malcolm suggests moving beyond a black and white perspective on this topic, emphasizing that there are also opportunity costs to not pursuing healing. However, in this area especially, more research is needed before clear guidelines can be developed. In this episode: The lack of treatment options for postpartum depression Why it is likely for a fetus or infant to be exposed to psychedelics if a mother ingests them while pregnant or nursing Psychedelics and the developing brain Ritual use of ayahuasca and mushrooms among pregnant women in traditional ceremonial contexts The research into negative impacts of ecstasy use during pregnancy and the variables that confound the results The unknowns about microdosing while nursing The research into whether LSD is a teratogen The effects of psychedelics on hormones Pregnancy as an aspect of set and setting Quotes: “Psychoactive drugs or psychotropic drugs typically end up in breastmilk more than other types of substances because they are usually more fat-soluble. Usually to get into brain tissue they have to be a little more fat-soluble than drugs that act in the periphery.” [10:15] “In the nursing period I think that there’s more potential to use psychedelics safely and without really taking much risk as far as exposing the [child], whereas in pregnancy, yeah, you just don’t really have that choice—the fetus is going to be exposed.” [24:42] Links: Dr. Malcolm’s recent article: “Psychedelics, Pregnancy, and Breastfeeding” Spirit Pharmacist website Spirit Pharmacist on Facebook Spirit Pharmacist on Instagram Spirit Pharmacist on YouTube Psychedelic Medicine Association Porangui…
1 Encore episode: Psychedelics and Women’s Health with Allison Feduccia, PhD 43:03
43:03
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:03In this episode of the psychedelic medicine podcast, Allison Feduccia, PhD joins to discuss the intersection of psychedelic medicine and women’s health. Dr. Feduccia is a neuropharmacologist, psychedelic researcher, and builder of virtual and in-person communities. She is cofounder of two prominent organizations, psychedelic.support and Project New Day, and is additionally a scientific advisor for Eastra. Alli has been researching psychedelics since 2004 when she first began studying MDMA and has subsequently been involved in the field through work at numerous universities, the NIH, and MAPS. In this work she seeks to spread evidence-based knowledge, connection to resources, and strategies for individuals to maximize potential therapeutic benefits of psychedelics through safe and responsible practices. In this conversation, Alli responds to questions touching on all areas of women's health and the impact psychedelics could have specifically for female patients. A major theme of the discussion is the interplay between psychedelics and hormones. While this is a topic with little in the way of scientific research, Alli shares some interesting ideas about how the neuromodulation of psychedelics could interact with endocrine systems, and how serotonin receptors within the uterus could explain certain anecdotal reports of various effects of psychedelics on menstrual pains or irregularities. In a similar vein, Alli discusses some of the physiological effects of psychedelics, particularly in relation to blood flow, and how these non-experiential features of these compounds could actually be helpful properties for women with certain conditions. This insight leads to interesting avenues for future drug development and also stresses the importance of studying psychedelics at different doses so that the positive health effects can be isolated. Alli also talks about the potential for psychedelic healing in the context of postpartum depression, sharing an evocative family story which illustrates simply how crucial and overlooked this issue has been in healthcare. The advances in mental healthcare coming out of psychedelic research provide a promising path forward for such conditions, however. In this episode: How psychedelics could help with premenstrual discomfort Concerns about taking psychedelic substances while pregnant Psychedelics and postpartum depression How psychedelics could impact hypoactive sexual desire disorder Psychedelics interactions with menopause Potential role for hormones alongside set and setting for impacting the psychedelic experience Quotes: “It may be that psychedelics could really affect women’s moods as they go through these different life stages, and help them feel better.” [4:45] “Maybe this concept of neurotransmitter modulation with our sex hormones may be a target for drug development work as well.” [23:42] “This is also pertinent to transgender women who may be using hormones. This type of modulation on mood or physiological symptoms—this could be really applicable too for helping to really have the body adjust and be more balanced to changes in hormonal fluctuations in the body.” [26:59] Links: Psychedelic.support website Project New Day website Eastra Health Psychedelic Medicine Association Porangui…
1 How Psychedelics Affect the Brain with Manesh Girn, PhD(c) 38:02
38:02
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
38:02In this episode of the Psychedelic Medicine Podcast, PhD candidate and psychedelic science YouTuber Manesh Girn discusses his recent research on psychedelic brain action. Manesh is in the final stages of obtaining his PhD in neuroscience at McGill University and is an author on over a dozen peer-reviewed articles on psychedelics and related topics. He is also chief research officer at EntheoTech Bioscience and runs the YouTube channel the Psychedelic Scientist. In this conversation, Manesh discusses his recent article in Trends in Cognitive Sciences titled “A complex systems perspective on psychedelic brain action.” He explains the complexity science approach used in the article, which emphasizes the brain is a holistic, interconnected system, rather than individual component networks that can be isolated. From this standpoint, Manesh critiques some simplistic explanations of the neural mechanisms of psychedelics which focus exclusively on interactions with the default mode network isolated from other brain systems. He also explains how individual some of the neural effects of psychedelics are, citing different findings from different studies and observed variations between brain scans of different people. By better understanding these individual differences, and placing these different responses into a complexity science framework, Manesh believes that more individually-tailored psychedelic therapies are possible once the systems involved are more comprehensively understood. Manesh closes this discussion by explaining the difference between genuine complexity and sheer chaos. Complexity, he explains, is a delicate balance of novelty and order, which is why psychedelic experiences can be both destabilizing and productive of novel insights and personal transformation. In this episode: The research into psychedelics and the default mode network Using frameworks from complexity science in psychedelic research Measuring entropy in the brain Differences in neurological effects from taking between different studies and different individuals How a complexity science approach to neuroscience could better inform precision psychiatry Quotes: “You can’t just look at a specific brain region or network [in psychedelic research], you’ve gotta talk about the brain as a whole, in this sense of seeing the brain as a system of interacting parts.” [4:49] “The core idea of this paper is that psychedelics put our brain into this state that is more dynamically flexible, it’s more diverse in its activity patterns, and it’s more sensitive to inputs that come in.” [14:17] “What we find in the brain imaging findings is that different studies disagree, but also if you look at individual people, they can have radically different effects on their brain—almost opposite.” [21:37] Links: Manesh’ recent article in Trends in Cognitive Sciences: “A complex systems perspective on psychedelic brain action” Psilocybin vs Placebo Brain Connectivity Diagram from Dr. Robin Carhart-Harris The Psychedelic Scientist YouTube Channel The Psychedelic Scientist on Instagram The Psychedelic Scientist on Twitter Manesh on LinkedIn EntheoTech website Psychedelic Medicine Association Porangui…
1 Therapeutic Uses of Ketamine for Adolescents with Johnathan Edwards, MD 33:06
33:06
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
33:06In this episode of the psychedelic medicine podcast, Dr. Johnathan Edwards joins to discuss the potential of ketamine treatments for mental health conditions in adolescent populations. Dr. Edwards is a board-certified anaesthesiologist and author with a key focus on treating mental health conditions with ketamine. He has provided ketamine in his practice for over 20 years and has worked with psychiatrist Dr. Sam Zand to help patients with mental health conditions. In this conversation, Dr. Edwards shares the current state of research exploring ketamine for adolescents, mentioning that there are currently 120 studies of ketamine treatments for mental illness in this population. He shares how he works with these young patients to ensure they are well prepared to experience the effects of the dissociative anesthetic, saying that adolescents typically do very well when adequately prepared. From Dr. Edwards’ experience, treatment resistant depression, suicidal ideation, and eating disorders seem to be the conditions where ketamine seems to have the biggest effect for adolescents. In closing, Dr. Edwards emphasizes how significant it is to be able to help kids struggling with these hard to treat conditions, especially as teen suicide remains a significant issue, so he’s hopeful that pediatricians, psychiatrists, and anaesthesiologists can continue to collaborate to safely bring ketamine therapy to more patients. In this episode: The existing research on ketamine in adolescent populations The danger of airway obstruction during ketamine infusions among people prone to sleep apnea Preparing adolescents for ketamine journeys Historical and cross-cultural precedents for psychedelic journeys in adolescents and young adults Potential indications for ketamine treatments in adolescents Is there an established protocol for adolescent ketamine therapy? Quotes: “I go through a lot to reassure the parents, to reassure the child, ‘Hey, this is gonna be a different voyage for you and you’re gonna be in a different place but tell yourself at all times you’re safe…’ and it goes very well.” [5:06] “As long as you have a medical clearance from your pediatrician and a medical clearance from the psychotherapist/psychiatrist/psychologist… and you put those two together, along with parental consent, you’re pretty well covered to go ahead and do a ketamine treatment on a child… It’s not standard of care but again, you’re trying to save a kid’s life.” [24:39] Links: Dr. Edwards’ website Dr. Edwards’ forthcoming book: The Revolutionary Ketamine: How a Little-Known Drug Can Cure Depression and Prevent Suicide Previous episode: Psychedelics for Eating Disorders with Dr. Reid Robison Psychedelic Medicine Association Porangui…
1 Optimal Delivery of Psychedelic Experiences with Paul Thambi, MD 37:16
37:16
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:16In this episode of the Psychedelic Medicine Podcast, Paul Thambi, MD joins to discuss insights on the optimal delivery of psychedelic experiences stemming from his recent trial on psilocybin therapy for cancer patients suffering from major depressive disorder. Dr. Thambi is a medical oncologist with nearly 20 years of experience treating patients in a private practice. He now serves as CMO Sunstone Therapies, a company focused on how to best deliver psychedelic therapies. In this conversation, Dr. Thambi shares the details of the design of his recent study, which involved two preparatory sessions, a treatment session, and two integration sessions. He also discusses the efficiency of delivering psychedelic therapy to a group rather than to individuals, allowing the therapist to help more patients at once while still providing focused one-on-one guidance during the psychedelic experience. Additionally, Dr. Thambi discusses the importance of music and space design to provide an optimal state of mind going into the therapy and while under the influence of the psychedelic. Dr. Thambi is happy to report very positive data from this initial trial, with both patients with active cancers and those with no current signs of disease showing great improvement in depression scores. He looks forward to continuing to work to better optimize the delivery of psychedelic therapies, not only for the patients but also for the therapists. Currently, he is pursuing a new “diad trial” of psychedelic therapy for cancer patients and a loved one which may have the potential to ease the suffering caused to a family system by these diseases. In this episode: The design of Dr. Thambi’s study of psychedelic therapy for cancer patients struggling with depression Group versus individual forms of psychedelic therapy Crafting an ideal setting for psychedelic therapy with music, artwork, etc. Changes in depression scores, anxiety, and pain amongst the participants in Dr. Thambi’s trial Optimizing the experience for psychedelic therapists as well as patients Dr. Thambi’s on-going “diad trial” for cancer patients and a loved one Quotes: “What we were trying to do was create something that… could be used when it needed to be for a lot of people—something that was scalable. So something that was efficient, but still had compassion to it. And that’s how we came up with the [study design].” [22:16] “80% of [participants] had their MADRS score cut in half or greater within one week of the treatment. And half of those people had what we called a sustained remission, which means a MADRS score of less than or equal to ten on each of the measurements we took, including the last one, which was done at week eight.” [23:54] Links: Sunstone Therapist website “Psychedelics may ease cancer patients’ depression, anxiety” article by Manish Agrawal California Institute for Integral Studies (CIIS) Certificate in Psychedelic-Assisted Therapies and Research Previous episode: Psychedelics and the Chemistry of Connection with Dr. Julie Holland Previous episode: How Setting Can Affect Psychedelic Journeys with Frederick Barrett, PhD Psychedelic Medicine Association Porangui…
1 Psychedelics' Potential to Address Spinal Cord Injury with Joel Castellanos, MD and Jim Harris 57:16
57:16
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
57:16In this episode of the Psychedelic Medicine Podcast, Dr. Joel Castellanos and Jim Harris join to discuss the possibilities of addressing spinal cord injuries using psychedelic medicine. Dr. Castellanos is a board certified physical medicine and rehabilitation and pain management physician and an associate professor in the department of anesthesiology at University of California, San Diego School of Medicine. Jim Harris is a National Geographic photographer who suffered a spinal cord injury during one of his adventures who became notable in the psychedelic space with the article in Outside “Jim Harris Was Paralyzed. Then He Ate Magic Mushrooms.” Jim starts off by sharing his own backstory of how he broke nine vertebrae in his spine during a 2014 ski expedition in Patagonia, Chile, leading to significant loss of motion and sensation. After some promising success in traditional rehabilitation and physical therapy settings, Jim details his surprising experience of healing with psilocybin. In this vein, Dr. Castellanos discusses the importance of neuroplasticity in healing for spinal cord injury patients. He talks about how forming new neural pathways can help a patient regain function and sensation in a part of the body that had previously been paralyzed, and leveraging this neuroplasticity using psychedelics and other tools may be a promising way to improve outcomes among these traditionally underserved patients. Considering the unique needs of spinal cord injury patients, Jim wonders whether lower doses of psychedelics may be more beneficial for this population, as it would allow them to maintain a greater degree of sobriety and groundedness to pursue physical therapy and rehabilitation activities while under the influence of the substance. Dr. Castellanos expresses excitement about the possibilities of psychedelic therapies for these patients, as not only does early anecdotal evidence such as Jim’s story suggest that these substances may be effective in helping to facilitate regain of function and sensation, but also because of the mental changes brought on by a psychedelic experience. Patients may feel more optimistic and eager to apply themselves following a psychedelic experience, which will facilitate healing beyond just what occurs as a result of the effects of the substance itself. He is also encouraged by current research into different forms of neuroplasticity which have different mechanisms. Dr. Castellanos suggests employing these in combination, such as using psychedelic therapy alongside vagus nerve stimulation, may offer more effective treatment options for spinal cord injury patients. At the end of this conversation, Jim poses Dr. Castellanos a fascinating question: whether there may be any downsides to over-encouraging neuroplasticity. Dr. Castellanos responds that there could be certain risks of increasing pain in patients, as neuroplasticity encourages new connections to be formed in the brain, but it matters what specifically becomes more interconnected. As such, there is reason to proceed with caution even as neuroplasticity offers significant benefits. In closing, Jim shares some hard reduction tips for other spinal cord injury patients interested in exploring psychedelic healing. Both he and Dr. Castellanos are optimistic at the possibilities of psychedelic therapies used in conjunction with other treatments for patients like Jim. In this episode: Leveraging neuroplasticity using psychedelics and other tools to help physical medicine and rehabilitation patients regain function Anecdotes of other spine injury patients who’ve regained function or sensation following a psychedelic experience The connection between spasticity and psychedelics How the response to psychedelics has changed over time for Jim Connecting physical therapy and psychedelic therapy to improve efficacy of rehabilitation How different mechanisms of neuroplasticity may be used in concert to promote recovery Harm reduction tips Quotes: Jim: “[when I first took psilocybin] all of a sudden I had an ability to contract my hamstring and… lift my heel off the ground, like up toward my butt, and I hadn’t been able to do that up until that time.” [9:12] Joel: “My primary focus is on neuroplasticity and ways that we can creatively modulate the nervous system to optimize recovery and optimize quality of life, whether that’s from a pain perspective or a regaining motor strength perspective.” [13:34] Joel: “If we can demonstrate that through psychedelics we can optimize and improve and make recovery more efficient, it is something that will be a huge deal for a great number of patients, and make my job as a rehab physician easier.” [14:37] Jim: “The reason I’ve become interested in psychedelics as medicine has been trying to figure out… what are all the ways that I can have some sort of personal efficacy in my own recovery.” [19:22] Jim: “I do know of other anecdotes kinda similar to mine, of people—maybe especially it seems like with a first psychedelic experience—suddenly regaining sensory or motor functions.” [22:41] Jim: “It seems there’s maybe some reason to suspect that some of the nerve plasticity that psychedelics can allow may reopen the critical period of this pivotal mental state where, say having a psychedelic and doing physical therapy in that state and maybe even the days afterwards, might result in a bigger functional change than just doing the therapy alone.” [24:28] Jim: “My hypothesis would be that a useful physical therapy dose [of psychedelics] might be a lot less than what Johns Hopkins and other institutions are dosing as a therapeutic dose. It seems to me that maybe a really high dose psychedelic experience is going to make it harder to stay connected to your body, connected to doing a task.” [29:17] Joel: “If I can identify three or four different ways to open up neuroplasticity that each have different mechanisms, it allows me to leverage those to give robust functional recovery and that’s what I’m interested in.” [33:56] Joel: “If psychedelics can reframe someone’s cognition and reframe their situation where that gives them a little bit of hope, along with having a supportive therapy team, along with it working on descending inhibition and activating muscles that were previously paralyzed, that’s multiple different levels of approaching someone that just had the worst thing in their whole life happen to them… It builds resilience and then it’s also working on the neuromuscular pathway to improve functional recovery.” [37:30] Joel: “I don’t think just taking a psychedelic or other medication on its own is always going to be efficacious in solving that maladaptive pattern. But, when combined with specific and guided therapy, whether that’s physical therapy, or psychotherapy, or cognitive therapy, I think that’s where you can guide those neurons to a healthier connection through neuroplasticity.” [50:17] Links: “Outside article: Jim Harris Was Paralyzed. Then He Ate Magic Mushrooms.” Psychedelics and Health Research Initiative at University of California San Diego Dr. Castellanos on Twitter Jim on Instagram Previous episode: Psychedelic Therapies for Pain with Joel Castellanos, MD Fireside Project website Psychedelic Medicine Association Porangui…
1 Applications of Virtual Reality in Psychedelic Therapy with Agnieszka Sekula, MSc 55:28
55:28
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
55:28In this episode of the Psychedelic Medicine Podcast, Agnieszka Sekula joins to discuss her research into the applications of virtual reality in psychedelic-assisted therapy. Agnieszka is a researcher at Swinburne University and co-founder of Enosis Therapeutics. Her research focuses on investigating therapeutic mechanisms in psychedelic treatment that can be strengthened through experience design and translating findings of this research into real-life applications by developing virtual reality scenarios. Additionally, she has recently conducted the first ever case study of VR and psychedelics. In her research, Agnieszka considers many possible uses of virtual reality in the context of psychedelic therapy, as well as potential dangers. The first application she discusses is using VR to promote relaxation prior to a psychedelic journey. Similar to the synergy between psychedelics and meditation, Agnieszka suggests that the immersive experience of VR could be useful in promoting states of calmness which are ideal for a person about to enter into a psychedelic experience. Additionally, she suggests that the otherworldly imagery and soundscapes possible with VR technology can help prime a client for the shifts and intensifications of perception caused by psychedelics. Having the opportunity to explore these states prior to the experience helps the patient to feel more prepared for the experiences, especially since with VR these explorations occur in a context where one maintains a connection with sober consciousness and can easily opt out if things become overstimulating. Next Agnieszka discusses the potential of augmenting peak psychedelic experiences with VR. Considering both psychedelics and virtual reality have the potential to occasion dramatic shifts in consciousness and affect, pairing these together is likely to be synergistic in promoting mystical experiences in the therapeutic process—something which appears to be closely tied to the efficacy of psychedelic-assisted therapy. Though little research currently exists in this area, Agnieszka believes that VR may have the potential to more reliably facilitate experiences of ego dissolution and deep awe during the psychedelic journey. Perhaps one of the most novel proposals in Agnieszka’s research is using VR to facilitate greater recollection of the psychedelic journey in order to promote more effective integration. She proposes that by building models of the psychedelic experience in the VR space, a patient can more readily return to the experience in sober consciousness by encountering these same stimuli again in virtual reality. The immersive experience of virtual reality may help facilitate access to feelings, memories, and intuitions which arose during the psychedelic session, leading to an easier process of integration. However, Agnieszka’s research also considers potential dangers in combining VR and psychedelics. These include the risk of overstimulation and the potential of a trauma being triggered by certain imagery or auditory input. More mundanely, there is also the possibility of “cyber-sickness” and physical discomfort caused by the VR headset. Despite these potential drawbacks, however, Agnieszka is confident there are powerful applications of VR in psychedelic therapy, particularly in allowing for a more holistic and integrated approach to the altered states of consciousness theorized to be at the center of the efficacy of these new treatments. In this episode: Using VR to induce relaxation in preparation for psychedelic journeys Augmenting peak psychedelic experiences with VR VR as a technology which may promote therapeutic alliance Using VR to store memories of psychedelic experiences to facilitate integration Transitioning between normal consciousness and altered states with the help of VR VR as a “digital diazepam” for decreasing the intensity of a psychedelic experience without pharmacological intervention The potential dangers of overstimulation or triggering traumas with VR and psychedelics Quotes: “VR in itself is just a tool—it’s a method of delivery—but in itself it's not the active ingredient. So whenever we speak of VR we think about the way of delivering the content, and the content is that active ingredient.” [2:22] “The best way to prepare someone for what an altered state experience feels like is by actually experiencing an altered state, and here again VR can be very helpful in approximating… what that psychedelic experience might feel like.” [18:51] “VR is used as a multi-sensory canvas where the patient is building the model of their psychedelic experience so that they can store it for themselves and return to it later.” [28:17] “Using VR just as beautiful content, or… contextual design for the entire experience might not be beneficial because it might work more as a distraction than as something that supports the journey.” [49:15] “For me the most important thing is to start looking at psychedelic treatment as an experience in its totality and to look a little bit more deeply into design principles that could be used to maximize that experience of the patient, of the client.” [53:46] Links: “Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy” Enosis Therapeutics website Agnieszka on LinkedIn Psychedelic Medicine Association Porangui…
1 Elements of Comprehensive Psychedelic-Assisted Psychotherapy with Andrew Penn, PMHNP 48:10
48:10
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
48:10In this episode of the Psychedelic Medicine Podcast, Andrew Penn joins to discuss the recent BrainFutures white paper on the elements of psychedelic-assisted therapy which he co-authored. Andrew is a psychiatric nurse practitioner and a professor at UC San Francisco who is also a psychedelic psychotherapy researcher and nationally invited speaker. Additionally, Andrew is the co-founder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses). In this conversation, Andrew discusses his white paper and breaks down the five key elements which need to be present in all psychedelic-assisted psychotherapy to ensure safety and efficacy. These five elements are safety and establishing set & setting; screening and assessment; preparation; the medication session; and integration. In terms of screening and assessment, Andrew mentions the interesting place the field finds itself in currently, as up to this point screening practices have been rather intensive and erring on the exclusionary side since this is the standard when drugs are being tested in clinical trials. However, with psychedelic therapy continuing to become more accessible with patient options outside of these trials on the horizon, the field will need to decide what makes the most sense in terms of balancing accessibility with potential risks, and in doing so more data will be collected which will give a better picture of exclusion criteria. Andrew also stresses the need for psychiatric screening in addition to focusing on medical consideration, mentioning that it’s essential for a psychedelic therapist to know a patient’s trauma history, as this is something that may come up in a session and the more preparation the better. When it comes to preparation, Andrew suggests that this should include establishing a relationship of trust, educating the patient, obtaining informed consent, and establishing safety measures. On the topic of consent, Andrew discusses the intricacies of dealing with this gracefully in a context where a patient will be undergoing a drug experience where consent cannot be adequately given in that moment. As such, he stresses the importance of explicit conversations between the patient and therapist around topics such as whether or not the patient would want their hand held during an intense moment. Rather than dry, procedural conversations, Andrew thinks discussions of consent are actually crucial moments where the therapist and patient can establish a relationship of trust and also more thoroughly explore the possibilities of what may come up for the patient in the session so that they feel better prepared. In terms of the psychedelic therapy sessions and integration, Andrew suggests that the therapists play different roles in these two contexts, with the medicine sessions being more about supporting the patient in their experience without providing too much direction or prompting so that the experience may unfold naturally and autonomously, whereas in integration the therapist can take a more active role in helping the patient explore what the experiences brought up. One interesting feature about psychedelic therapy, and a reason why integration is so important, is that the intensity of the medicine experiences and the insights triggered during sessions can actually be destabilizing initially. As such, Andrew maintains that integration is a crucial aspect of psychedelic therapy in order to better ensure that these experiences can lead to deep and lasting healing. Andrew hopes that this white paper can introduce the crucial elements of psychedelic therapy to a wider audience and encourage a standard of practice. In this episode: How might screening and assessment change once psychedelic therapies are more widely authorized and not only accessible as clinical trials? Reckoning with the exclusion criteria around psychedelic therapies The importance of thorough preparation in achieving the best patient outcomes The dynamics of consent in preparation versus in the midst of the session and how therapists can more intentionally approach these questions What should therapists do when a patient is not in a calm state of mind at the time of the scheduled psychedelic therapy? Why integration is critical to facilitating healing in psychedelic therapy Quotes: “Trauma is likely to come up during the session and we want to at least know if there’s something there then we can anticipate that and also start to create a safer environment for that patient.” [7:53] “We’re gonna have to figure out what is the right dose of medical screening, and then, certainly, introducing some level of psychological screening will be really important.” [10:27] “Informed consent is this ongoing conversation with the patient where the patient can withdraw their consent at any time—they can revoke that—but people really need to know what they’re getting into if they’re going to make meaningful informed consent.” [16:12] “What we’ve learned from psychedelic therapy is that there’s a lot of value in just letting things unfold… really the goal of the therapist should be to support that inward focus, and not try to influence the session itself in one direction or another other than to maintain safety.” [33:19] “Psychedelics are things that tend to shove your face in whatever you’ve been avoiding and that’s something that therapists need to be really aware of—that they might encounter patients who get worse after the session, at least for a transient period of time.” [44:41] Links: Andrew's full white paper on BrainFutures: "An Expert-Informed Introduction to the Elements of Psychedelic-Assisted Therapy" Previous episode: When *Not* to Proceed with a Planned Psychedelic Journey with Rick Barnett, PsyD OPENurses website Psychedelic Medicine Association Translational Psychedelic Research Program - TrPR Porangui…
1 Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD 29:33
29:33
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
29:33In this episode of the Psychedelic Medicine Podcast, Dr. Kurt Rasmussen joins to discuss the potential benefits of non-hallucinogenic psychedelic drugs currently in development. Dr. Rasmussen is the Chief Scientific Officer at Delix Therapeutics and was previously at the National Institutes of Health where he led the Division of Therapeutics & Medical Consequences since 2018. Here, he directed the medications development program and played an integral role in evaluating the safety and efficacy of pharmacotherapies, behavioral therapies, and devices to treat substance use disorders. He is also Fellow in the American College of Neuropsychopharmacology and has over 100 publications and patents to his name. Dr. Rasmussen begins by discussing the ways psychedelics can bring out physical changes to brain structure, mentioning that this is an important mechanism for the therapeutic effect of these medicines. He mentions that these structural changes are theorized to be relatively distinct from the experiential, hallucinogenic component of psychedelics, and as such it may be possible to develop new drugs which condition the same cascade of events in neuronal structure without leading to intense subjective experiences and major alterations in perception. But what would the benefits of such drugs be? Dr. Rasmussen explains that the availability of non-hallucinogenic psychedelics could have the potential to significantly increase the accessibility of these substances and their associated therapies—both in populations for whom contraindications exist for traditional psychedelic medicines (such as patients with schizophrenia) and for individuals who may be resistant or fearful of the hallucinogenic experiences that can come with psychedelics. Rather than attempting to replace traditional, hallucinogenic psychedelics, Dr. Rasmussen hopes that these non-hallucinogenic alternatives would be able to serve populations or conditions where current psychedelics are not the best option. In fact, Dr. Rasmussen suggests that perhaps hallucinogenic and non-hallucinogenic psychedelics could be used powerfully in conjunction with one another, hypothesizing that the personally meaningful journeys conditioned by traditional psychedelics may be more effective for kickstarting healing from a condition like depression, but perhaps the non-hallucinogenic substances could be more convenient maintenance, as they would not require regular intense experiences facilitated by specially trained therapists to continue promoting neuroplasticity. Dr. Rasmussen does emphasize, however, that a psychotherapeutic component would still be recommended even with non-hallucinogenic psychedelics, as the combination of medication and therapy leads to greater efficacy. But, this also depends on the particular condition being treated. A patient with a mental health condition will likely benefit from the addition of therapeutic work, but a patient who is exploring psychedelic treatment for something like migraines or cluster headaches may only need the structural changes caused by these substances in the brain in order to feel better—another reason why non-hallucinogenic psychedelics may be preference for certain patients with various conditions. In closing, Dr. Rasmussen reiterates that the exploration of non-hallucinogenic psychedelics is all about increasing patient options and broadening the cools in the psychiatric toolbox to tailor treatments to particular patients and conditions. Whether hallucinogenic on non-hallucinogenic, Dr. Rasmussen sees psychedelic medicine as an important and promising paradigm shift in psychiatry. In this episode: How both hallucinogenic and non-hallucinogenic psychedelics may be used together to reach a greater patient population Why the hallucinogenic component of psychedelics may not be necessary for their efficacy Contraindications involving the hallucinogenic component of psychedelics Potential cardiovascular concerns with regular psychedelic use due to action on serotonin receptor 5-HT2B Why it may be desirable to have a range of psychedelic medications which produce different intensities of subjective effects to treat a wider range of patients Quotes: “There are changes in your brain as a result of administration of these compounds that occur. It’s not just a sensory and emotional experience, but actually there are physical changes in your brain, in different circuits, very specific circuits.” [5:28] “SSRIs and other antidepressants can have effects by themselves, psychotherapy can have an effect by itself, but the real efficacy, the magic is when you combine the two and I have no doubt that these compounds [non-hallucinogenic psychedelics] will benefit from psychotherapy associated with it.” [11:07] “We need more options for patients for sure, and hopefully the psychedelic medications with the hallucinations will help a certain set of patients and hopefully we’ll have other non-psychedelic compounds that are neuroplastic that will help patients.” [18:25] “I think different compounds will be affecting different circuitry or different microcircuits… in the brain so that different compounds will have varying levels of efficacy for different indications, and like I said the indications can be from neurology to psychiatry.” [25:58] Links: Dr. Rasmussen with his puppy Ruby Dr. Rasmussen on LinkedIn Delix Therapeutics website Psychedelic Medicine Association Porangui…
1 Psychedelics and Learning to Let Go with Dr. Max Wolff 40:44
40:44
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:44In this episode of the Psychedelic Medicine Podcast, Dr. Max Wolff joins to discuss his 2020 study exploring how psychedelics can facilitate the healing process of “letting go.” Dr. Wolff is a psychologist, psychotherapist and head of psychotherapy training and research at the MIND Foundation. He is also therapist and researcher in the EPIsoDE Study, a government funded clinical trial investigating psilocybin-augmented psychotherapy for treatment resistant depression at CIMH Mannheim and Charité Universitätsmedizin Berlin. In this conversation, Dr. Wolff shares insights from his study, “ Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance ,” which appeared in Frontiers in Psychiatry in February 2020. In this paper Dr. Wolff and colleagues explore how psychedelic assisted therapies can help patients work through maladaptive avoidant behaviors at the root of many mental health conditions. Dr. Wolff explains that there are two fundamental motivations systems at work in human beings—the approach system and the avoidance system. In healthy individuals, both of these have important and adaptive roles to play as people work towards goals and seek balance in life. However, adverse experiences in unsafe environments can cause individuals to develop unhealthy avoidance, often leading to mood disorders such as anxiety and depression in more severe cases. One of the goals of psychotherapy—psychedelic or otherwise—is to facilitate a safe container where an individual can work through avoidance, says Dr. Wolff. Psychedelic assisted therapy may be especially effective to this end, as the introspective nature of the experience precludes avoidant thought patterns or behaviors and there is nothing to use as a distraction in the therapeutic context. However, this isn’t the only way psychedelics facilitate the process of letting go. Dr. Wolff also discusses the effect of psychedelics on relaxing the beliefs of the patient. This recent theory, called “relaxed beliefs under psychedelics” (REBUS), considers how psychedelics encourage an open mindedness and curiosity around perceptions and ideas that would often be dismissed or ignored in sober states due to rigid structures of beliefs and assumptions. This is important in the context of avoidance, Dr. Wolff explains, as it means that the patient is primed to explore issues where typically an avoidant response would be triggered due to a fixed belief about the stressfulness of the topic at hand. As a result, psychedelic assisted psychotherapy can be particularly effective in empowering patients to revise avoidance-related beliefs at the root of many mental health conditions. By helping patients work through fear and let go of traumas and stress around tender topics, Dr. Wolff thinks psychedelic therapy can make an important contribution to the broader field of psychotherapy. In this episode: The approach and avoidance systems of human motivation How avoidant behaviors can develop into mental illnesses How working through avoidance is crucial for both conventional and psychedelic therapies The experience of avoidance in psychedelic therapy and how this can be conducive to acceptance How the idea of relaxed beliefs under psychedelics intersects with avoidance Different mechanisms for MDMA and classic psychedelics for facilitating letting go Quotes: “The less favorable the environment is, or the conditions in which we develop are, the more likely we are to have interactions with our environment that are threatening to our psychological needs, or even perhaps violating to our psychological needs—that is where a lot of avoidance behaviors or avoidance schemas can develop.” [5:43] “Only by withstanding the urge to run away, and only by breaking this vicious circle of avoidance, you get the chance of revising the assumptions that underlie the anxiety.” [27:42] “In psychedelic experiences, one factor that may work in concert with this operant conditioning process of learning to let go is the emotional depth and richness that comes with psychedelic experiences and also the increased likelihood of actually encountering deeply felt fears.” [30:00] Links: Dr. Wolff’s study: “Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance” MIND Foundation website MIND Foundation training for aspiring psychedelic therapists Psychedelic Medicine Association Porangui…
1 The Interplay between Psychedelics and Attachment Styles with Rabbi Aaron Cherniak, MA 36:12
36:12
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:12In this episode of the Psychedelic Medicine Podcast, Aaron Cherniak joins to discuss the intersection between psychedelic experiences and psychological attachment styles. Aaron is a clinical psychologist and researcher who examines a variety of topics in psychedelic science, including subjective experiences, outcomes, and mechanisms. He is also a Rabbi and the director of the JPSYCH lab of Jewish spirituality and mental health. His recent research looks at how psychedelic experiences are integrated into peoples’ narratives of life-long religious and spiritual development and contribute to culturally competent therapeutic models. In this conversation, Aaron shares the science of attachment styles and explores its implications in psychedelic therapeutic contexts. He frames attachment theory as a form of personality psychology, mentioning that someone’s attachment style is typically something that stays consistent for long periods of time, though certain traumatic events such as abusive relationships can influence one to develop insecure attachment. The two forms of insecure attachment are avoidant attachment and anxious attachment, which are two different behavioral expressions resulting from an underlying sense of insecurity or lack of safety within a relationship. This is contrasted with a secure attachment style in which a person feels safe in a relationship and does not feel a compulsion to engage in either avoidant or anxious behaviors out of a sense of self-preservation. Aaron explains that there are many potential points of relevance for exploring psychedelic experiences and attachment styles together. For example, it may be the case that therapeutic psychedelic experiences could actually shift a person away from insecure attachment—a finding which would be very significant considering how stable attachment styles typically are. Another idea would be to consider the existing attachment style of a patient entering into psychedelic-assisted psychotherapy, and explore how this could affect the patient-therapist relationship and the efficacy of the therapy. In the context of spirituality and religiosity, Aaron explains that a person’s attachment style often influences how they hold spiritual beliefs. In an Abrahamic religious context, a person with a secure attachment style stemming from a healthy home life is more likely to interpret God through lenses that emphasize divine love and God’s all-embracing concern, whereas someone with an insecure attachment that developed out of an early childhood experience that was colored by neglect or even abuse is more likely to see God primarily as responsible for bad experiences and potentially even capricious. In the context of spirituality outside of traditional religion, this could be the difference between a person viewing the universe as having a purpose and meaning within it, or seeing the cosmos as only cold and uncaring towards the wellbeing of the creatures within it. Aaron suggests this is relevant for psychedelic research as patients often report transcendent experiences of divine realities during psychedelic experiences, but how such experiences can be integrated may vary significantly based on a person’s interpretation of religion and spirituality stemming from their attachment style. Though this work is still in the theoretical stage, Aaron is excited about the potential findings from research into psychedelic experiences and attachment styles. In this episode: What are the different attachment styles? Could attachment style influence the connection between a patient and a psychedelic therapist? How attachment styles impact peoples’ interpretations of mystical experiences Psychedelic research as an opportunity to study the psychology of spiritual experiences Quotes: “Attachment theory has provided a very fruitful model of life-long personality development generally, and specifically religion and spirituality.” [5:41] “If a psychedelic session can change something that is normally stable over 35 years, that would be a very impressive finding.” [14:12] “People talk about the psychedelic substance in attachment terms—people talk about the grandmother or the plant healer… An attachment figure is a stronger, wiser other to whom we seek proximity for closeness, to help us overcome challenges.” [19:47] “I think we have a responsibility to develop therapeutic frameworks to help people translate those experiences of safety, of love and all those things into long lasting therapeutic change.” [34:55] Links: Aaron’s article: Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal Aaron on Twitter JPSYCH Attached: The New Science of Adult Attachment and How It Can Help You Find—and Keep—Love Psychedelic Medicine Association Porangui…
1 Encore episode: Navigating Psychedelic Narcissism with Adam Aronovich 1:00:27
1:00:27
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:00:27In this episode of the Plant Medicine Podcast, Adam Aronovich returns to discuss the phenomenon of psychedelic narcissism. Adam is a doctoral candidate at the Universitat Rovira i Virgili in Spain, focusing on Medical Anthropology and Cultural Psychiatry. He is an active member of the Medical Anthropology Research Center (MARC) and part of the Ayahuasca Community Committee at the Chacruna Institute for Psychedelic Plant Medicines. In the last four years he has conducted extensive fieldwork in the Peruvian Amazon, where he has been doing qualitative research in collaboration with ICEERS, the Beckley Foundation, and, more recently, the Centre for Psychedelic Studies at Imperial College. Beyond his work conducting and coordinating research, Adam regularly facilitates workshops at the Temple of the Way of Light, a prestigious healing center in the Iquitos area. In this wide-ranging conversation, Adam unpacks some of the darker sides of the modern psychedelic movement, discussing the psychosocial dynamics around psychedelic use which can lead to things such as ego inflation, conspiratorial thinking, and narcissism. Adam recalls his own experiences slipping into messianic fantasies during a period of initial enthusiasm around psychedelic experiences. He views issues of alienation and lack of social support as being instrumental in leading to these types of delusions following profound spiritual experiences. While it is difficult to reach people who’ve slipped into psychedelic narcissism, Adam suggests that communal support is the best safeguard against these dangers and the most effective strategy for grounding people who’ve lost touch with reality. Drawing on his academic expertise, Adam distinguishes traditional uses of plant medicines from the Western paradigm for approaching psychedelics. He stresses the relational and communal aspects of the spiritual traditions which use psychedelics ceremonially. The pro-social aspects of these wisdom traditions, he claims, help safeguard against the traps of psychedelic narcissism and ego inflation, as there are established mechanisms for keeping people grounded following intense spiritual experiences. Adam closes the discussion with an insightful analysis of modern gurus and self-proclaimed shamans. Adam encourages people to beware of deeply held spiritual fantasies, where a master can appear as more than human. Instead, he emphasizes that even skillful and well-intentioned healers are themselves nothing more than human beings, so there will always be imperfection and messiness. This does not, however, mean that impactful work cannot happen—in fact, this insight helps protect against the idolization of charismatic psychedelic personalities, which can lead to harmful experiences. In this episode: Defining psychedelic narcissism Clinical vs colloquial understandings of narcissism The intersections of the psychedelic movement and conspiracy theories The importance of social and communal support for avoiding ego inflation following psychedelic or spiritual experiences How psychedelic experiences can actually deepen ego attachments and accentuate narcissistic tendencies The importance of humor in combating spiritual narcissism Quotes: “Many of the underlying ideologies upon which Western cultures were built, like hyper-individualism and so on, kind of predispose us and prime us for certain aspects of narcissism.” [5:36] “Ego inflation, spiritual narcissism, messianic episodes—all of these are things that are fairly common within both people who are in some sort of spiritual or psychedelic path.” [12:17] “In traditional societies for the most part really there isn’t such a thing as a self-proclaimed shaman. A person doesn’t wake up one morning and is like ‘oh, I’m the shaman’—that’s a title or a role or a recognition given to that person by the community.” [38:03] “The best measure of whether somebody is genuine and helpful is not whatever credentials or titles he assigns to himself, but rather what other people feel. So, you know, you will know a tree by its fruits.” [45:08] “Having these experiences by themselves does not necessarily mean spiritual growth or psychological development or any enhanced benefit if we’re not constantly, painfully, mindful of how we actually integrate and embody those things in daily life over very long periods of time.” [54:29] Links: Adam on Instagram Temple of the Way of Light Psychedelic Medicine Association Porangui…
1 Meaning Making in Psychedelic Healing with Dr. Ben Medrano 52:37
52:37
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
52:37In this episode of the Psychedelic Medicine Podcast, Dr. Ben Medrano joins to discuss the intricacies of meaning making in psychedelic healing. Dr. Medrano is the former senior vice president and US medical director of Field Trip Health and has extensive experience in the evolving field of integrated approaches. He is also the current co-medical director of Nue Life Health where he is continuing his efforts in expanding access to ketamine therapies. Dr. Medrano additionally still serves as medical director of Field Trip NYC and DC clinics while continuing his private practice. Dr. Medrano begins this conversation sharing a bit about his background and how he came to be interested in psychedelic medicine and the issues surrounding meaning making. He talks about his experience growing up in a family where mental illness was prevalent and how this planted the seeds for taking an empathetic approach to treating these conditions in his career as a psychiatrist. He also discusses his initial exposure to psychedelics in the Chicago rave scene of the 1990s. It was then that he first realized both the transformative potential of psychedelic-induced altered states and the potential dangers of using these substances without proper precautions or care for set and setting. Following these formative experiences, Dr. Medrano began a practice of meditation within the Tibetan Buddhist tradition. It was through exposure to these spiritual practices and deep teachings that he began to see the importance of this process of meaning making and cultivate various resources suited to this project. Dr. Medrano stresses the importance of self-awareness in realizing one’s own approach to meaning making and how this has been shaped by unique personal experiences. This self-awareness helps one realize that a given patient may be approaching their own experiences from a very different angle, but there are still ways in which it is possible to support and encourage this personal meaning making. Dr. Medrano stresses the importance of working with narratives in psychedelic healing. Psychedelic-induced peak experiences can be packed with insights and symbols which may be brimming with significance, but there’s a lot of work to be done in understanding this material in light of the personal narratives of a patient’s life. Through therapeutic integration, a patient can use their psychedelic experiences to critically examine their narratives and reflect more personally on the potential meanings of given revelations in light of how they understand themselves. Additionally, Dr. Medrano distinguishes the roles a facilitator should play to support meaning making in high dose versus low dose contexts. When a patient is in the midst of a high dose psychedelic experience, Dr. Medrano emphasizes that the facilitator should primarily seek to affirm the experiences of the patient, being a calming and secure presence that doesn’t introduce any additional complexity or uncertainty into an already intense experience. On the other hand, in lower dose, “psycholytic” experiences, the facilitator may take a more active role, helping facilitate the patient’s meaning making in the midst of the experience through asking questions and engaging with ideas as they arise. In terms of preparation and intentionally building psychedelic experiences more conducive to meaning making, Dr. Medrano emphasizes the importance of ceremony. Through a more ceremonial approach, a psychedelic experience can be given additional structure which may be reassuring for the patient, and additionally this provides an opportunity to more proactively incorporate things which may already be extremely meaningful for a given person. These can be practices such as prayers, or physical objects which have a certain deep personal significance. All of these help to encourage more meaningful content in the psychedelic experience, while also providing something grounding and familiar in the midst of altered consciousness. Because of how effective Dr. Medrano has found various psychedelic therapies to be in helping people make meaning in life, he is primarily focusing his energies on expanding access to these powerful medicines at this stage in his career. In this episode: Dr. Medrano’s background and how he got involved in psychedelic medicine and spiritual practices How does Dr. Medrano help clients make meaning out of drug-induced altered states Why Dr. Medrano refers to ketamine as “the great imitator” The importance of understanding a patient’s cultural and meaning making background How to work more intentionally with set and setting and incorporate ceremonial practices Shifting away from a “goal-oriented” perspective of psychedelic experiences Quotes: “I think telling our stories is part of this process of healing.” [5:20] “Just getting your mind blown by a psychedelic substance is not going to fix things. That’s something I had to learn really quick.” [11:00] “I think for us to do this work, we all need to actually have a good sense of who we are and how we’re approaching the conversation.” [19:01] “Trying to really invite in a sense of inspiration, energy, and support is really what the goal—or part of the goal—of ceremony is.” [28:20] “Really your role as a guide is honoring and affirming the experience. It’s as simple as that. And being supportive. So, having a dialogue is not necessarily encouraged in higher doses.” [31:22] “Basically the process of integration is to not let anything that comes into the experience not be honored or seen in some way, to allow it to be explored, and of course not to push too much.” [38:27] Links: Dr. Medrano’s website Nue Life Nue Network Field Trip Health New article: Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use Previous episode: Psychedelic Apprenticeship: Validating Psychedelic Insights and Revelations with Chris Timmermann, PhD The Body Keeps the Score by Bessel van der Kolk Psychedelic Medicine Association Porangui…
1 MDMA-Assisted Psychotherapy for Alcohol Use Disorder with Dr. Ben Sessa 37:48
37:48
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:48In this episode of the Psychedelic Medicine Podcast, Dr. Ben Sessa joins to share results of his investigation into MDMA-assisted psychotherapy for alcohol use disorder. Dr. Sessa is a trained MDMA and psilocybin therapist and the chief medical officer at Awakn Life Sciences, a biotechnology company researching, developing, and commercializing therapeutics to treat addiction with specific attention on alcohol use disorder in the near-term. Dr. Sessa begins sharing his story of how he got interested in the potential clinical uses of psychedelics as a psychiatrist, discussing his experiences of rave culture and making connections with Rick Doblin and MAPS early in the so-called “psychedelic renaissance,” a term he coined. Looking at the work MAPS was doing, he was inspired by the potential of psychedelics to heal trauma and began looking for ways to further contribute to this research. When it came to alcohol use disorder (AUD) specifically, Dr. Sessa mentions how poor the current best treatments are, with relapse rates sometimes being as high as 90%. This being so, there is significant potential for novel treatments to provide better outcomes, and considering the prevalence of AUD, this could be a huge net positive for society. Dr. Sessa explains that AUD is particularly common in individuals with a history of trauma and/or adverse childhood experiences, so considering the potential of MDMA to address these underlying factors, he immediately saw the potential for psychedelic treatments of this condition. Working off of these hypotheses, Dr. Sessa undertook a study of MDMA for alcohol use disorder which showed some extremely promising results. The study found that only 21% of the trial participants returned to previous levels of drinking following MDMA-assisted therapy. In addition to this, about half of the individuals for whom the treatment was effective were actually able to have an occasional drink without relapsing—an outcome that is exceedingly rare with current treatments, hence the insistence on complete abstinence. Though this was only a safety and tolerability study and thus additional research is needed to confirm these initial findings, Dr. Sessa is extremely encouraged by the potential of this novel treatment and he is happy to report that he and his colleagues have just submitted a clinical trials application for a placebo-controlled study of MDMA for AUD, so additional insights into the efficacy of this treatment are hopefully not far off. Dr. Sessa concludes this conversation with an interesting discussion of MDMA “hangovers”—sometimes referred to as “blue Mondays.” He mentions that it is an established fact that many recreational ecstasy users experience a rather significant drop in mood and sense of wellbeing following using the drug. However he theorizes that this may be due more to confounding factors rather than the drug itself. Considering the typical contexts of recreational MDMA use, things such as lack of sleep, lack of food, excessive exercise, impure sample, and concomitant drug use could all contribute to negative emotion after a drug experience. And Dr. Sessa’s research seems to lend support to this theory, as the MDMA patients in the clinical setting of his study did not experience these side effects, and actually many experienced just the opposite—they felt an “afterglow” following MDMA therapy, where they noted elevated mood for up to a week after the experiences. In this episode: How Dr. Sessa first became interested in MDMA-assisted psychotherapy Why Dr. Sessa decided to focus his work on alcohol use disorder The study design for Dr. Sessa’s MDMA for alcohol use disorder trial The types of talk therapy employed in this MDMA therapy trial Does MDMA-assisted therapy have potential for treating other kinds of addiction? Why patients aren’t seeing a “blue Monday” hangover after MDMA-assisted psychotherapy Quotes: “In the MDMA state you can work with those forbidden, avoidant memories that normally you wouldn’t go to.” [5:20] “In fact, most addictions—apart from perhaps nicotine—have this link with childhood adversity and trauma.” [8:36] “We didn’t just look at drinking outcomes, we looked at mental health, physical health, relationships, quality of life—all these kinds of things… And there were improvements across the board in all of those people who responded well to the MDMA therapy, which was 80% of them.” [20:46] “Across 26 MDMA sessions (which was in 13 patients), we found no comedowns. So they all had MDMA and at the end of the day when the MDMA wore off, they didn’t feel low, they didn’t feel rotten, they felt fine—in fact they felt good.” [26:06] “I think if people took MDMA lying in silent darkness like they take mushrooms, I think we’d see a lot more in the way of mystical, spiritual experiences.” [32:42] “[Psychedelic-assisted therapy] is much more like surgery than it is psychiatry. It’s not daily maintenance treatment with SSRIs for the next sixty years of your life just to suppress symptoms. It’s an intensive, up-front piece of an intervention, like mending a broken bone, that gets you better so you don’t have to sit on antidepressants for the rest of your life.” [36:26] Links: Dr. Sessa’s study on MDMA for Alcohol Use Disorder: First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder Dr. Sessa’s study on MDMA hangovers: Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA Awakn Life Sciences website Dr. Sessa’s website Dr. Sessa on Twitter Psychedelic Medicine Association Porangui…
1 Encore episode: MDMA-Assisted Therapy for PTSD with Rick Doblin, PhD 1:18:53
1:18:53
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:18:53In this episode of the Psychedelic Medicine Podcast, Rick Doblin joins to discuss the past, present, and future of MDMA-assisted therapy. Rick Doblin is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies. He received his doctorate in public policy from Harvard and has also studied under the father of transpersonal psychology Stanislav Grof. Through MAPS, Rick aspires to develop legal contexts for beneficial uses of psychedelics and marijuana as prescription medicines, but also for self-development and personal growth in otherwise healthy individuals. Rick begins this wide-ranging conversation discussing the early days of MDMA. The compound was originally synthesized by famed chemist Alexander "Sasha" Shulgin and, unlike the classic serotonergic psychedelics, it was not scheduled under the Controlled Substances Act in the early 70s. It was during this period of legality that therapeutic uses of MDMA were first developed and it was only later that the drug became repurposed as a recreational substance to be used in social settings, which consequently led to its emergency scheduling by the DEA. Rick recalls his own initial experiences with the empathogenic compound, stating that he was initially skeptical of its value, prior to gaining first-hand experience. Following this experience, however, he became convinced of its therapeutic potential and he shares some of his own early experiences of using MDMA to help people heal, including a very touching tale of his own grandmother’s struggle with depression. From here, Rick discusses the founding of MAPS and his decision to pursue education in policy in order to better understand strategies for furthering MDMA-therapy even while living under prohibition. Since that time, MAPS has gone on to do incredibly impactful work in developing studies researching the safety and efficacy of MDMA-assisted therapy, specifically for post-traumatic stress disorder. Rick shares the progression of these studies, highlighting the results from the most recent phase three investigations which are the last step prior to FDA approval for the therapeutic protocol. These studies show high statistical significance and an amazing effect size resulting from MDMA-assisted therapy, with results being mirrored at all research locations and showing durability over time. Because of this amazing progress, Rick believes we are at the final stretch prior to full FDA approval for MDMA use in a therapeutic context for PTSD, and subsequent rescheduling of the substance by the DEA, which he believes will take place in mid to late 2023. This development will have broad global impacts, spurring other countries to promptly follow suit. Rick closes out this discussion by emphasizing the need for mass mental health in our day and age, and sharing MAPS’ lofty goals of training thousands of therapists to hopefully bring psychedelic therapy to millions of patients in the coming decades. In this episode: Rick Doblin’s personal journey The history of the MDMA’s synthesis and legality Rick’s first experiences with MDMA and early experiments with MDMA therapy MAPS’ “two-pronged” strategy for mass mental health Early efforts to get an MDMA therapy protocol approved by the FDA following prohibition The politics of concerns about MDMA neurotoxicity and how this impacted MAPS’ early approach The results of the first phase three studies of MDMA for PTSD How FDA approval of MDMA will lead to an international cascade of approval and rescheduling Rick’s predictions for psychedelic medicine in the years to come Quotes: “What a lot of people don’t know is that MDMA was a therapy drug before it was a party drug. And it was the party drug nature of it that really got it criminalized.” [7:38] “Seeing what it was like when it was legal and experiencing that, and experiencing situations where people would take it, the kind of experiences and healings, and learnings that people would have, was amazing.” [19:12] “What we need is, I believe, legal access to medicinal MDMA, covered by insurance, by trained professionals, and psychedelic clinics. And we also need a whole different kind of drug policy for non-medical use that involves honest drug education, access to pure substances, harm reduction, peer support, and also treatment on demand.” [21:08] “The irony here is that the first legal move against MDMA was illegal. The DEA did not have the authority to emergency schedule drugs.” [23:43] “FDA is legally bound to approve MDMA for PTSD if these [phase 3] studies generate statistically significant evidence of efficacy, and there are no new safety problems.” [40:27] “We think by the third quarter of 2023 we will have FDA approval assuming the second phase 3 study goes well. And then by the fourth quarter, the DEA has to reschedule [MDMA].” [51:18] “What’s even greater is the 12-month follow-up data was 67% no longer had PTSD. So people kept getting better—not only was it durable, but they kept getting better.” [55:00] “The thing to emphasize here is that MDMA is not the treatment. The treatment is therapy. The MDMA makes the therapy more effective and there can be different kinds of therapy that are used with it.” [1:01:38] Links: MAPS website Rick Doblin on Twitter Trip of Compassion Documentary The Way of the Psychonaut Books by Stanislav Grof Upcoming MAPS Psychedelic Science Conference 2023 Becoming an MDMA-Assisted Therapist with Shannon Carlin, MA, LMFT Psychedelic Medicine Association Porangui…
1 Ketamine for Alcohol Use Disorder with Steven Mandel, MD 29:42
29:42
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
29:42In this episode of the Psychedelic Medicine Podcast, Dr. Steven Mandel returns to discuss ketamine treatments for alcohol use disorder. Dr. Mandel is an internationally recognized expert and pioneer in the use of ketamine-infusion therapy to treat mental health disorders and chronic pain. He is a board-certified anesthesiologist with a masters in psychology and over 40 years of experience working with ketamine. He is the founder and president of Ketamine Clinics Los Angeles and also the Founder and first president of American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3). In this conversation, Dr. Mandel explores the topic of using ketamine to address alcohol use disorder, discussing findings from research and sharing his professional experience with this treatment protocol. He begins by unpacking the specifics of alcohol use disorder before relaying an incredible success story from a client who was able to conquer a very significant alcohol addiction due to ketamine therapy treatment. However, Dr. Mandel notes that actual scientific research for this particular therapeutic use of ketamine is still in the early days, though he notes that the first non-anesthetic use of ketamine was for treating alcoholism in Moscow, and this intervention appeared to be quite effective. He also shares results from animal studies, noting that one study found outcomes of ketamine treatment for alcohol dependent mice was significantly mediated by sex, with the female mice being less responsive to the treatment. However, Dr. Mandel notes that it is too early to know if these same patterns appear in humans. In terms of the theoretical basis for this treatment protocol, Dr. Mandel discusses glutamatergic transmission and the nucleus accumbens as being important in both alcohol use disorder and ketamine treatment. He also mentions that ketamine potentiates the NMDA receptors which are desensitized in the case of chronic alcohol use. But Dr. Mandel insists that these pharmacological mechanisms are not the whole story when it comes to the efficacy of ketamine therapy for alcohol use disorder. At his clinics, treatment consists of a five point model which also addresses things like sleep hygiene and diet to provide a more holistic approach to wellness. He also stresses the importance of including talk therapy in the treatment protocol, as patients are primed for effective therapy following infusions. This is due to the improved neuroplasticity resulting from the neurological effects of ketamine, but since this does not last forever Dr. Mandel maintains there is a sweet spot where therapy will be most effective, which is between a few hours after the ketamine treatment and a few days later. In combination with therapy and other interventions to promote patient wellness, Dr. Mandel is confident ketamine therapy presents a promising treatment option for those struggling with alcohol use disorder, and he thinks it may even be a helpful support for those who’ve shaken their addictions but still struggle with cravings in abstinence. Ketamine Clinics Los Angeles phone number: (310) 270-0625 In this episode: What is alcohol use disorder? Patient success stories from Dr. Mandel’s ketamine treatments The research on ketamine for alcohol use disorder How set and setting differentiates alcohol and ketamine use in important ways The importance of the experiential aspect of ketamine for its clinical efficacy Why Dr. Mandel’s clinic focuses on sleep hygiene and diet alongside ketamine therapy to help achieve the best patient outcomes Dr. Mandel’s protocol for ketamine infusions The history of AA and psychedelic therapies Quotes: “[Ketamine’s] first major use… outside of the operating room for anesthesia was by Krupitsky in Moscow in a government program treating chronic alcoholism. That was the first behavioral use of ketamine! And it was profoundly effective.” [9:25] “We’re really at a frontier here. Just getting ketamine in people and seeing the transformation is amazing. And trying to sort out how to optimize it—we’re not there yet.” [20:41] “There’s a whole other population of people who are successfully abstinent, but are beginning to have cravings. And those people are so helped by a little experience with ketamine. Ketamine is amazing at helping people to resist cravings.” [24:08] Links: Ketamine Clinics Los Angeles American Society of Ketamine Physicians, Psychotherapists & Practitioner Previous Episode: Ketamine Practitioner Methods with Dr. Steven Mandel Psychedelic Medicine Association Porangui…
1 How to Measure Progress in Psychedelic Integration with Tomas Frymann 37:53
37:53
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:53In this episode of the Psychedelic Medicine Podcast, Tomas Frymann joins to discuss his recent paper where he developed scales for measuring dimensions of psychedelic integration. Tomas is a doctoral student at Columbia University’s Spirituality and Psychology Lab and the author of the Psychedelic Integration Scales and the Interbeing Identity Scale. He is also a practicing psychedelic integration coach for Veterans Exploring Treatment Solutions (VETS, Inc.). Tomas begins by discussing the context for this research, mentioning that while integration is frequently considered a crucial element of psychedelic healing, the lack of metrics for analyzing it has meant that there has been comparably little attention given to integration in psychedelic research. As such, he hopes that the scales he proposes can both encourage additional research into this dimension of psychedelic therapy and also aid in the implementation of various integration practices and programs through providing a concrete structure from which such things may be developed. Tomas also talks about the research process, mentioning how his team worked with integration experts working in traditional, medical, and independent psychedelic contexts. The team developed initial ideas that they then discussed with the experts in order to identify major patterns and narrow down their selection of relevant criteria. In the end, Tomas realized there are two separate but related aspects of integration: integration engagement and experienced integration. The former refers to specific actions taken in order to facilitate integration. Tomas divides engagement into the categories of reflection and application. Though there are no hard boundaries between the two, reflection generally refers to contemplative attention given to the psychedelic experience after the fact whereas application is implementing lifestyle changes in accordance with the insights gained from the psychedelic experience. Here Tomas discusses his own experience of desiring to change his dietary habits to include less meat following a psychedelic session where he connected deeply with an animal. When it comes to experienced integration, Tomas is seeking to emphasize the psychological feeling of having integrated a psychedelic journey. He divides this aspect into two subsets as well: feeling settled and feeling harmonized. Feeling settled refers to a sense of being at ease in everyday life again following a psychedelic experience, where one is no longer either struggling with integrating a difficult experience nor experiencing dissonance between the revelations of a beautiful experience and the realities of life. Feeling harmonized he explains as a sense of having drawn connections between the insights of a psychedelic journey and conventional existence, so that it feels like these things fit together in a positive way. In closing, Tomas reiterates his excitement that this work may not only lead to additional scientific research into integration, but may also be a useful pragmatic tool for coaches and individuals as they seek to deepen their integration of psychedelic experiences. In this episode: How quantifying integration could help encourage more research into integration and the implementation of these practices in more psychedelic contexts How Tomas researched integration to begin constructing these scales Tomas’ seed metaphor for integration What it means to be “settled” in the integration process Using these scales to prompt exploration in integration Quotes: “The purpose of the scales is to have a metric so that we can show that integration is important.” [4:32] “When you follow these wisdoms, when you take them into account, when you reflect and apply, the output should be basically an improved wellness” [15:48] “When we were creating the integration scale we were really careful not to say integration has to go in any one direction or not—it’s really just about honoring what came up, and working with that.” [20:28] Links: Tomas' article: "The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences" As We Wake Veterans Exploring Treatment Solutions (VETS, Inc.) Psychedelic Medicine Association Porangui…
1 Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan 36:46
36:46
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:46On this episode of the Psychedelic Medicine Podcast, Juliana Milligan joins to discuss her recent article (co-authored with Joshua White of Fireside Project) on warning signs when selecting a psychedelic facilitator. Juliana is an ibogaine specialist who has been working in the ibogaine treatment community for 10 years. Having been formerly opioid-dependent and incarcerated herself, she currently works at the Center for Optimal Living where she runs the psychedelic education and training program. Juliana additionally works with clients doing preparation and integration of Ibogaine treatments through her business Inner Vision Ibogaine. In this conversation, Juliana discusses each of the 10 red flags she identified in her article. First, she discusses potential issues around sexual misconduct on the part of facilitators, emphasizing that this is a topic which always requires careful and explicit discussion well prior to the psychedelic experience. One ought to also do some individual research, as potential allegations against a facilitator are also a red flag to take seriously. Next, Juliana talks about the importance of facilitators doing a thorough medical intake. This involves getting a medical history from a potential client and checking if there are any contraindications for this person to take a psychedelic, such as dangerous interactions with prescription medications. In a similar vein, Juliana also stresses the necessity of facilitators testing the psychedelics their clients will be consuming whether they themselves provided the psychedelics or if the client brought their own substances. Willingness to test the substances in the presence of the client is definitely a good sign and shows that the facilitator values both transparency and safety. In terms of training, Juliana highly recommends ensuring that a facilitator is trauma-informed before committing to a journey under their guidance. Knowing that a guide will be conscientious and empathetic around issues of trauma helps to ensure that the psychedelic experience doesn’t itself turn in a traumatic direction. Similarly, Juliana emphasizes that facilitators should be open about the training they’ve received—even underground facilitators should ideally have mentors and be involved in a community of practitioners that encourages continued training. In closing, Juliana discusses the dangers of having inflated and unrealistic expectations around the healing potential of psychedelics. Facilitators who use hyperbolic language like “ten years of therapy in one night” may actually be setting up clients for more difficult experiences than they otherwise may have had due to these fantastical claims. Juliana emphasizes that psychedelic healing is a cooperative endeavor, and neither the substance nor the facilitator is solely responsible for any healing that results from the experience. Ultimately, it is the person themselves who does this work, so Juliana highly recommends finding a facilitator who acknowledges their role as primarily supportive of this healing journey, rather than someone who presents themselves as a miracle worker responsible for these positive results. In this episode: Why having a trauma-informed facilitator is important, and what this means The dangers of psychedelic narcissism The importance of the harm reduction practice of chemically testing psychedelics Trusting your intuition and building this capacity Having healthy and reasonable expectations around the healing potential of psychedelics Quotes: “Once you are on a psychedelic, you cannot properly consent to touch—it must be established in advance. And if [a facilitator] is saying ‘well no I need freedom in my work, I need to use my intuition’ that is a major red flag.” [7:19] “It’s really important that the facilitator knows exactly what is contraindicated with the medicine they’re administering, and if they’re not evaluating for this and if they’re not familiar with medical conditions and how they interact with the medicine they’re giving then they’re not properly trained to be giving this medicine.” [10:14] “The only person that can really heal you is yourself and a facilitator is just there to help empower you and support you in guiding yourself. It’s a collaborative relationship.” [13:44] “If a person isn’t willing to be receptive to feedback, self-reflective, and take accountability, psychedelics aren’t necessarily going to make them do that. And so you give psychedelics to somebody with those kinds of narcissistic traits and it can just make the narcissism worse.” [20:15] Links: Juliana's Article with Fireside Project: Warning Signs When Selecting a Psychedelic Facilitator Inner Vision Ibogaine: Guide to Finding an Ibogaine Clinic The Root Ibogaine Collective The Psychedelic Program at The Center for Optimal Living Juliana on Instagram Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich Previous episode: Harm Reduction Through Testing Your Psychedelics with Mitchell Gomez Previous episode: When *Not* to Proceed with a Planned Psychedelic Journey with Rick Barnett, PsyD Previous episode: Fireside Project: The World’s First Psychedelic Hotline with Joshua White and Hanifa Nayo Washington Previous episode: Insights Gained from the First Year of Fireside Project with Joshua White Psychedelic Medicine Association Porangui…
1 Microdosing and the Placebo Effect with Balázs Szigeti, PhD 48:42
48:42
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
48:42In this episode of the Psychedelic Medicine Podcast, Balázs Szigeti, PhD, joins to discuss his research on the intersection of microdosing psychedelics and the placebo effect. Dr. Szigeti studied physics at Imperial College, after which he earned a PhD in computational neuroscience from the University of Edinburgh. He has worked as a biomedical software engineer at the Icahn Genomics Institute and he has conducted the largest placebo-controlled study on psychedelics to date. In his research, Dr. Szigeti uses novel statistical and experimental techniques to explore the intersection of psychedelics and placebo effects. Dr. Szigeti begins this conversation by discussing the design of his placebo-controlled microdosing study, “ Self-blinding citizen science to explore psychedelic microdosing ” which appeared in the journal eLife in March 2021. For this study, Dr. Szigeti and his team employed citizen science to collect placebo-controlled observational data from participants, allowing this experiment to take place outside of a clinical environment. Participants self-blinded by preparing identical psychedelic and placebo microdose capsules and data was submitted using QR codes so that the researchers were knew whether the participant was in the psychedelic group or the control group, while the participants themselves remained in the dark. The results from this study showed a statistically significant improvement of wellbeing among both the microdose and placebo groups, with no statistical significant difference between the two groups in terms of any of the outcomes. Dr. Szigeti talks about the media reception of his research, which tended to present the findings as suggesting microdosing is ineffective since there was no difference between the two groups. However, Dr. Szigeti has a different takeaway. He suggests that the practice of microdosing can indeed lead to improved wellness as the study showed—the takeaway is simply that this effect is harder to distinguish from a placebo than originally anticipated. He emphasizes the very real medical power of this placebo effect, and discusses how triggering one’s own placebo effect either through microdosing or some other practice can be transformative. However, beyond what the data may suggest about the impact of microdosing psychedelics, Dr. Szigeti emphasizes the broader takeaways from his study, which bring into question the efficacy of placebo-controlled studies as a gold-standard in the context of psychedelic trials. Because psychedelics cause notable shifts in perception, trial participants will quickly become aware whether they are in placebo or psychedelic groups, particularly in the case of trials exploring doses beyond the microdose range. This causes an immediate unblinding effect, and makes control groups less useful than in other contexts where a participant does not find out which group they were a part of until the trial’s conclusion. Dr. Szigeti affirms the methodology of placebo-controlled trials as an essential tool for researchers which deserves its reputation for providing high-quality evidence, but he urges the field of psychedelic studies to pay closer attention to questions of methodology, as there may be yet undiscovered modes of scientific investigation which would be better-suited to psychedelic trials. Dr. Szigeti is currently working on a follow-up blinded study on microdosing which he hopes will address some of the shortcomings of the original investigation. In particular, he mentioned that the participants in the original study had high levels of well-being already at the start of the trial, so improvements may have been less significant than in a population with a lower level of well-being to start. As such, he and his team hope to recruit a more diverse sample in this upcoming trial to further explore the extent of both placebo and microdosing impacts on wellness. Information for the upcoming study can be found at the website: https://selfblinding-microdose.org/ In this episode: How Dr. Szigeti set up his self-blinded placebo-controlled study of microdosing outside of a clinical environment What is “citizen science” and how this differs from other methodologies The issue of tolerance in microdosing and how this may differ between LSD and psilocybin How Dr. Szigeti uses statistical analysis to further interpret data where participants realize which group of the study they are in Quotes: “The results of this microdose trial were mixed because you can make an argument that this change over time is the more important outcome and that was statistically significant, but the comparison of the magnitude of change in the placebo group versus the magnitude of change in the microdose group, that was not significant anymore. It was not significant on any of the scales, I should add.” [14:45] “Nobody ever checks whether the placebo control was really working as intended, which is just like—I don’t know how it could have happened. There is such a big emphasis on the methodological superiority of placebo-controlled trials and then nobody is checking whether its really working or not.” [21:09] “With psychedelics this issue [of placebo groups] is going to come to the forefront because, yes with microdosing there is some wiggle room in people recognizing their treatment, but when it comes to 200μg of LDS versus placebo, there is zero uncertainty. Everybody will recognize when you’re in the active placebo treatment.” [28:13] Links: Upcoming trial website Dr. Szigeti’s study: “Self-blinding citizen science to explore psychedelic microdosing" Dr. Szigeti’s recent article: “On the fallibility of placebo control and how to address it: a case study in psychedelic microdosing" Dr. Szigeti on Twitter Psychedelic Medicine Association Porangui…
1 Psychedelics and Breathwork with Kyle Buller 43:58
43:58
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:58This episode of the Plant Medicine Podcast features a conversation with Kyle Buller on psychedelics and breathwork. Kyle is co-founder and host of the Psychedelics Today podcast and he has studied breathwork since October 2010 with Lenny and Elizabeth Gibson of Dreamshadow Transpersonal Breathwork. Kyle earned his BA in transpersonal psychology from Burlington College where he focused on the healthing potential of non-ordinary states of consciousness, exploring topics such as shamanism, reiki, plant medicine, and holotropic breathwork. He has also earned an MS in clinical mental health counseling with emphasis in somatic psychology and has since worked with at-risk teens in crisis and individuals experiencing an early episode of psychosis. Kyle opens this discussion by providing a basic definition of breathwork and sharing his own journey with this modality. He discusses how breathwork can refer to a wide variety of practices, but what unites these disparate techniques is utilizing the breath to induce specific physiological states and experiences. The holotropic style of breathwork has roots in transpersonal psychology and the work of Stanislav Grof and it is this modality which is often compared to psychedelic experiences. Kyle discusses how holotropic breathwork can be an incredibly powerful practice for trauma-healing and inducing visceral experiences—similar to the classical psychedelics. He recounts his own experiences with this practice, describing how he was able to relive the experience of being born in the state conditioned by the method of breathing. Due to the synergy with the psychedelic experience, Kyle mentions that there is a lot of potential for breathwork to help individuals integrate or prepare for psychedelic experiences, as well as being a powerful tool for clinicians involved in psychedelic-psychotherapy to better understand the non-ordinary states of consciousness their patients will be experiencing. Because of the wide variety of breathwork techniques, Kyle discusses the possibilities of tailoring practices to the specific experiences of a client. Everyone has a unique “window of tolerance” depending on their background and constitution, and some people will benefit more from techniques which downregulate the nervous system and allow for peace and relaxation, while others may find more value in techniques which are highly stimulating and provide deeper, emotionally complex experiences that allow for self-exploration. In this episode: What breathwork is an how it relates to psychedelics The origins of holotropic breathwork and Stanislav Grof’s transpersonal framework Breathwork vs meditation How to use breathwork to integrate and prepare for psychedelic experiences The effects of different types of breathing on the nervous system Quotes: “[Breathwork] offered a really great tool for training, for understanding how to sit with people in non-ordinary states of consciousness.” [8:49] “Some breathing techniques, like these more deeply cathartic techniques, they’re bringing up a lot of emotional memory and people are starting to work through a lot of somatic sensations, they are working through trauma.” [13:38] “We really need to look at somebody’s whole picture, where they’re at, how they could potentially benefit, look at their nervous system, attune to that, and really think about what they could tolerate, what’s going on in somebody’s psyche.” [30:29] “The breath is this flexible tool, it’s a vehicle—we can help to regulate our nervous system with it and explore it.” [39:38] Links: Psychedelics Today Psychedelics Today Education Center SettingSun Wellness Dreamshadow Transpersonal Breathwork Psychedelic Medicine Association Porangui…
1 Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD 23:17
23:17
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
23:17In this episode of the Plant Medicine Podcast, Matt Johnson, PhD returns for the final installment to discuss his recent paper “Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine.” Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In his paper, Dr. Johnson explores some concerns around certain norms which have developed in psychedelic therapy, and how these could have potential negative effects. Dr. Johnson raises two main concerns in this conversation. The first is how therapists, guides, and scientific researchers could advance various spiritual or religious beliefs within the therapeutic context or offer metaphysical interpretations of psychedelic experiences beyond what the client suggests. The second concern involves how psychedelic medicine is presented, both on a cultural level and even materially within therapeutic settings. For example, Dr. Johnson suggests that it is inappropriate to have statues of the Buddha displayed in clinical settings, unless this is something requested by the client. He suggests that if psychedelic therapy embraces a certain “New Age” aesthetic wholesale, it could dissuade people who don’t identify with the subculture from taking advantage of these therapies, especially as these medicines become more widely accessible. Additionally, Dr. Johnson points out that not all patients would have the same associations with the Buddha statue in the example, and that the inclusion of any particular religious iconography should be something chosen proactively by the client, rather than assumed by the therapist. Dr. Johnson concludes this conversation by again stressing a client-centered approach to psychedelic therapy, suggesting that this approach is best suited to circumvent these concerning pitfalls. In this episode: The issue with psychedelic therapists or guides bringing their own metaphysical beliefs into the psychedelic experience or its interpretation How the current culture around psychedelic medicine subtly presents these therapies as being for specific kinds of people How a client-centered approach from humanistic psychology can present an effective framework for psychedelic-assisted psychotherapy Quotes: “I think it’s critical that therapists—and scientists at this research phase we’re at now—be client-centered in terms of the therapeutic approach. In other words, not making any assumptions for the participants, for the patients, about what the interpretation of these experiences should be.” [4:36] “You’re there to support them, you’re there to let them lead. If there’s any metaphysical meaning to be made, they are in the driver’s seat. You’re there to create a safe container, to care for their wellbeing, and to allow them to have their experience.” [11:08] “It’s not that you’re denying any of this stuff—it very well may be that any of these people’s framework is ground truth—it’s just not your role to say and we don’t need to.” [15:06] Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson’s Paper: Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine Psychedelic Medicine Association Porangui…
1 Exploring DMT Entities with Matthew Johnson, PhD 26:13
26:13
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
26:13In this episode of the Plant Medicine Podcast, Matt Johnson, PhD returns to discuss previous survey research he conducted regarding DMT entities. Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In this conversation, Dr. Johnson shares findings from his 2020 publication of survey research which investigates peoples’ experiences with DMT entities. To preface these findings, however, Dr. Johnson first lays the groundwork by explaining the limitations of scientific investigation into these kinds of psychic phenomena. He explains that science is unable to answer questions of whether or not DMT entities are ultimately real, or what the fundamental nature of these experiences is. It can, however, employ rigorous methods for analyzing reports of entity encounters in order to document common features of these experiences and the types of effects they can have on individuals. In the survey, around twenty five hundred respondents shared their experiences of encountering an entity during a DMT experience. From the data collected, Dr. Johnson shares some of the common features of these entities. The beings are typically perceived as benevolent though there was a wide variety of ways the entities were conceptualized, ranging from aliens and machine elves to spirits and angels. Often participants believed the entities revealed metaphysical realities and the presence of these beings was frequently accompanied by extrasensory phenomena such as telepathic communication. Due to the dramatic nature of these experiences, Dr. Johnson’s research found some lasting impacts as reported by respondents, and he concludes by briefly discussing the effects of entity encounters on religious belief. In this episode: What questions science can and can’t answer, and the boundaries good scientific research has to take when investigating something such as DMT entities The findings of Dr. Johnson’s survey research—some general trends regarding the qualities of entities described Effects of entity encounters on religious belief Quotes: “My bet is that if people believe that there’s some sort of reality to these disincarnated entities—that it’s not just in their mind—there are certain people that can hold that experience in a positive way that might benefit them… and probably some of these over 2,000 folks, there’s probably some people that—again, aside from whether we know it’s true or not—believing in things that no one else can prove are there is probably a bad thing.” [12:38] “The machine elf thing, I mean, that was Terrence McKenna’s trip. And he described it—and I think he was very honest that that was his experience—and I think people who’ve heard his experience, a good number of them have had machine elf experiences because they heard Terrence McKenna’s experience.” [16:17] “Before the experience, 28% of these people identified as atheist, and then after the encounter that dropped to 10%.” [20:53] Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson’s DMT Entity Study: Survey of Entity Encounter Experiences Occasioned by Inhaled N,N-Dimethyltryptamine: Phenomenology, Interpretation, and Enduring Effects Psychedelic Medicine Association Porangui…
1 The Latest Research on Psilocybin for Depression with Matthew Johnson, PhD 30:58
30:58
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
30:58In this episode of the Plant Medicine Podcast, Matt Johnson, PhD joins to discuss the latest research of psilocybin as a treatment for depression. Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In this conversation, Dr. Johnson shares findings from his recent study in psilocybin treatment for depression and summarizes other major studies investigating this psychedelic’s clinical applications. First, however, he discusses ongoing survey research he is conducting at the Center for Psychedelic and Consciousness Studies. The Psychedelic Change Survey for Anxiety, Depression, or PTSD is seeking volunteers who have intentionally used psychedelics (ayahuasca, mushrooms, LSD) or MDMA to treat these mental health conditions to collect data on the efficacy of these interventions. Dr. Johnson and his team are interested in collecting a variety of responses, so you are encouraged to participate to share your experiences with these substances and whether they provided beneficial results, led to negative outcomes, or anything in between. Dr. Johnson also spends some time discussing study design, as psilocybin research has begun to move into more sophisticated forms of clinical research. He describes the function of a randomized clinical trial such as his own study, and details the double-blind double-dummy setup of the recent psilocybin study at NYU. In his study, Dr. Johnson’s participants were randomly selected for the immediate treatment group or the delayed treatment group, which served as a control. All participants were provided with two sessions of psilocybin assisted psychotherapy, and the data showed that there were large reductions in depression following treatment and these results remained statistically significant at follow ups. In the NYU study, Dr. Johnson describes that participants were given either a genuine psilocybin treatment followed by a placebo antidepressant to take regularly, or they were given a placebo in place of psilocybin followed by an approved antidepressant. This large study is particularly interesting as it directly compares psilocybin treatment for depression with traditional pharmaceuticals used to treat this condition. Here again, Dr. Johnson reports that the psilocybin treatment showed extremely promising results. In this episode: Conditions for participating in Dr. Johnson’s current survey research How Dr. Johnson designs his studies and chooses how he analyzes the data collected The results of the first randomized study examining the use of psilocybin for depression How the preparation process for psilocybin-assisted therapy may be clinically useful as a standalone treatment Quotes: “We and the group at NYU published larger studies with a high dose of psilocybin and found these very large reductions in both depression and anxiety in cancer patients, so that sorta paved the way for, hey if this works in cancer patients let’s look more broadly.” [19:42] “I kind of view psychedelic therapy as sort of having everything we know about general psychotherapeutic processes under a magnifying glass.” [23:12] “I think it’s fallen out of fashion, but if we just had people laying on couches all day with therapists they’ve developed a relationship with—if that was more of a thing, even without psychedelics or placebo psychedelics, that has real benefit.” [28:30] Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson’s Recent Study: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial NYU Psilocybin Study: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Psychedelic Medicine Association Porangui…
1 People of Color and Psychedelics with Ifetayo Harvey & Mary Sanders, LCSW 48:52
48:52
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
48:52In this episode of the Plant Medicine Podcast, Ifetayo Harvey & Mary Sanders, LCSW join to discuss people of color and psychedelics. Ifetayo is a writer, advocate and speaker who founded the People of Color Psychedelic Collective. She has also previously worked with both MAPS and the Drug Policy Alliance. Mary Sanders is a licensed clinical social worker whose work focuses on addressing trauma in communities of color and marginalized populations. She is a founding board member at the People of Color Psychedelic Collective and is a trained psychedelic-assisted psychotherapist from both CIIS and MAPS. Mary is also certified in trauma-focused cognitive behavioral therapy and is currently enrolled at the somatic experiencing trauma institute. This conversation with Ifetayo and Mary touches on many of the important topics in the intersection of the unique experiences of people of color and the use of psychedelic medicines. One immediate concern which has begun to be discussed more openly is that of POC representation in psychedelic spaces. Ifetayo and Mary both discuss this issue, mentioning how representation is especially crucial for something as vulnerable as psychedelic experiences, where facilitators are responsible for navigating a wide range of emotions which naturally arise in a ceremony or therapeutic setting. Having someone from one's own community in these spaces can facilitate healing, as there is less anxiety around needing to explain specific experiences or trauma. Despite these shortcomings of representation, psychedelic medicines have a lot of potential to provide healing for people of color in particular. Ifetayo and Mary discuss the experience of intergenerational trauma in communities of color and how psychedelics are able to shed light on this phenomenon. Ifetayo shares powerful experiences from the first People of Color Psychedelic Collective retreat before the pandemic and explains her own coming to consciousness of the brutality of slavery and Jim Crow and how dysfunctional behaviors which perpetrate intergenerational trauma originally developed as survival mechanisms for the black Americans who lived under these racist systems. Mary also emphasizes that psychedelic healing for people of color needs to emphasize building community and creating strong interpersonal bonds. While the individual experiences provided by plant medicines are incredibly beneficial, the healing will be even more profound if it can be processed and integrated collectively, as people of color aren’t only healing individual ailments, but collective traumas rooted in shared histories of oppression. In this episode: The unique needs of POC not typically addressed in psychedelic ceremonies or integration circles The disconnect between the Western therapeutic paradigm of healing individuals vs the more communal approaches to healing in traditional black cultures and how to bridge this gap How People of Color Psychedelic Collective creates community and fosters opportunities for people of color involved with psychedelics The intersection of intergenerational trauma and psychedelic healing for people of color Quotes: “Taking a medicine is a vulnerable state, where we have to be cautious: am I going to be minimized, are my visions going to be acknowledged and held with support and love and care?” [8:27] “Healing is relational and it’s so important that we not only do the work in the therapy space but that we’re out and about with our friends and our family and our community members, especially our community members that have similar life experiences and histories.” [19:24] “There’s a very very strong stigma around addiction [and] overdose because our communities have been harmed in so many ways by policing and bad drug policies.” [25:22] “I think it’s really about uplifting the people who are already doing the work and then also supporting the folks who want to do the work, like providing them with resources, education, mentorship. Things like that will help usher in a new generation of [POC] healers, practitioners, leaders.” [39:35] Links: People of Color Psychedelic Collective Mary Sanders’ EmPATH Center Drug Policy Alliance Dr. Carl Hart’s Webpage National Harm Reduction Coalition Darren Springer’s Webpage Fruiting Bodies Collective Psychedelic Medicine Association Porangui…
1 Can Ayahuasca Help Promote Palestinian-Israeli Reconciliation? With Dr. Leor Roseman & Antwan Saca 36:15
36:15
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:15In this episode of the Plant Medicine Podcast, Leor Roseman and Antwan Saca join to discuss their recently published paper: Relational Processes in Ayahuasca Groups of Palestinians and Israelis. Leor is a postdoc at the Centre for Psychedelic Research at Imperial College London, where he also received his PhD and masters under the supervision of Dr. Robin Carhart-Harris. Leor has diverse research interests related to psychedelics, ranging from the neuroscientific and therapeutic, to the phenomenological and psychosocial. Antwan is a graduate of the Arab American University of Jenin with a BA in public law and has extensive experience working for justice in Palestine. He has served as the director of programs at Holy Land Trust in Bethlehem and as a program coordinator for Holy Land Christian Ecumenical Foundation. Antwan has also worked as a research assistant for urbanization and geopolitical monitoring at the Applied Research Institute—Jerusalem. In this episode, Leor and Antwan discuss the details of the recent paper they co-authored which deals with impacts of ayahuasca on interpersonal peace building in the context of the Israel-Palestine conflict. The study consists of 31 in-depth interviews with Israelis and Palestinians who’ve participated in joint ayahuasca ceremonies and looks to investigate the impact of this psychedelic experience along three relational themes: unity-based connection, recognition and difference-based connection, and conflict-related revelations. Through open-ended interviews, Leor and Antwan were able to collect qualitative data from participants which allowed research conclusions to arise organically. In the interviews, participants disclosed experiences of profound political revelations, connection with the land, and empathy for the other. Leor and Antwan stress that the initial motivations of the participants typically had little to do with notions of political peace-building and instead they were most often participating in these psychedelic ceremonies for reasons related to personal growth, so these outcomes arose naturally as a result of the intense interpersonal connections spurred by the psychedelic experience. Though these ayahuasca ceremonies had significant positive impacts for both the Israelis and the Palestinian participants, Antwan notes the disparity of access to psychedelic healing for Palestinians and emphasizes that the “love for the other” the Palestinian participants experienced through the ayahuasca ceremonies is complicated due to the pervasive political supression and percarity experienced by Palestinians in their day-to-day lives. The study, however, demonstrates that profound experiences of connection through the use of psychedelic medicines are possible even in the context of a deep and traumatic geopolitical conflict. This opens the door for further study of the potential of psychedelics to facilitate conflict resolution and peace-building. In this episode: How Leor and Antwan developed the idea for this study based on their personal backgrounds Different themes which came up in interviews with the Israelis and Palestinians in the study The moving story of a former Israeli military officer and how he experienced the pain of the Palestinian people during an ayahuasca ceremony How music and prayer in the ceremonies helped to encourage empathy and cultural connection among participants Quotes: “It’s not questionnaires, it’s not about measuring things, it’s about listening to stories and making meaning out of them.” [13:24] “Because the rituals were participatory and music and prayers were shared, a lot of times these opened up for people the strong connection to the other culture or the other people and that was very meaningful for many people.” [21:34] “A lot of us Palestinians end up in the interviews telling you ‘this is all amazing’ and yet there is the reality, yet we live under this kind of suppression.” [29:11] “Not all people that came to the ceremonies came from the peace camp or from left-leaning camps. They come for psycho-spiritual growth, or even for physical illnesses… And they go there regardless of their politics.” [31:37] Links: Full Article: Relational Processes in Ayahuasca Groups of Palestinians and Israelis Psychedelic Medicine Association Porangui…
1 Psychedelics and Nature: The Symbiotic Relationship with Dr. Sam Gandy 41:56
41:56
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
41:56This episode of the Plant Medicine Podcast welcomes Dr. Sam Gandy to discuss the symbiotic relationship between psychedelic experiences and connection with nature. Dr. Gandy holds a PhD in ecological science from the University of Aberdeen and has conducted field research across the globe. He currently works as a research assistant at the Synthesis Institute and as a senior science writer at Wavepaths. He is also a collaborator with the Centre for Psychedelic Research at Imperial College London and was previously a scientific assistant to the director of the Beckley Foundation. In this conversation, Dr. Gandy shares insights from his research into psychedelics and nature relatedness with special emphasis on his 2020 publication “The Potential Synergistic Effects between Psychedelic Administration and Nature Contact for the Improvement of Mental Health” (linked below). Dr. Gandy discusses the numerous overlaps between the experience of nature relatedness—the personal sense of being connected with the natural world—and the experiences induced by psychedelic substances. These overlaps cover a range of domains and all work to promote wellbeing. For example, Dr. Gandy reports that neuroticism decreases both as a result of positive psychedelic experiences and from spending quality time in nature. As high neuroticism can correlate with mental illnesses such as depression and anxiety, interventions that can impact this trait have significant therapeutic potential. In addition to specific overlaps between the psychedelic experience and nature relatedness, Dr. Gandy also discusses how psychedelics and psilocybin in particular seem to increase a sense of nature relatedness. Considering these overlapping benefits and the symbiotic relationship between psychedelics and nature relatedness, Dr. Gandy provides some speculations for how nature can be more intentionally integrated into psychedelic therapies and ceremonies to maximize the therapeutic benefits of both. He mentions that even something as small as decorating a clinical setting with artwork depicting nature can have positive impacts for patients undergoing psychedelic psychotherapy in the space. In this episode: Eudaimonic vs hedonic well being The neurobiological and psychological overlaps between nature relatedness and the psychedelic experience How both psychedelics and nature relatedness promote mindfulness and experiences of awe Ideas for combining psychedelic therapy and experiences of nature to enhance health benefits Quotes: “Nature connectedness is a mediator for some of the benefits to cognition and mood obtained from actually spending time in nature, having contact with nature.” [6:57] “There was a study published last year by a Finnish research group and one of the most common after effects of psychedelic mystical experiences they found was this sustained, positive shift in peoples’ relationship to nature.” [17:35] “Psilocybin has this capacity to facilitate this fairly robust, rapid, but most importantly sustained increase in nature relatedness. And the really mysterious and interesting thing is that it can do this even when it's administered in a clinical setting.” [22:47] “The restorative effect of nature obviously benefits both the person having the therapy and the therapist, and it potentially allows for the outdoor nature-based setting to become part of the therapy itself.” [31:00] “If you’re going to do any kind of psychedelic nature connection, nature immersion therapy, it’s very important to have a cozy, secure structure that people have got as a safe place.” [35:31] Links: Dr. Gandy on Twitter Dr. Gandy’s 2020 article The Potential Synergistic Effects between Psychedelic Administration and Nature Contact for the Improvement of Mental Health Dr. Gandy’s 2019 article From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner Psychedelic Medicine Association Porangui…
1 Kratom: Research Findings and Methods of Use with Dr. Oliver Grundmann 36:18
36:18
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:18This episode of the Plant Medicine Podcast features a conversation about kratom with Dr. Oliver Grundmann. Dr. Grundmann earned his bachelors in pharmacy and European pharmacy license from University of Münster in 2004, after which he pursued graduate studies at the University of Florida, where he is now a clinical professor in the College of Pharmacy. His research interests focus on investigating the use of natural products as novel treatments for a variety of physical and mental conditions. Dr. Grundmann is a leading kratom researcher and has published numerous articles on the substance, examining the plant medicine and its use using a variety of methodologies. In this episode, Dr. Grundmann introduces kratom (scientific name mitragyna speciosa ) and discusses its pharmacology and potential as both a medicine and a drug of abuse. The kratom tree is native to southeast Asia and belongs to the same botanical family as the coffee plant. The leaves of the kratom tree contain a wide variety of active alkaloids and they are consumed orally to produce a psychoactive effect. Dr. Grundmann explains that kratom is unique because the primary alkaloids mitragynine and 7-hydroxymitragynine are opioid agonists, yet the substance does not fit neatly into the opiate category as it lacks certain properties of the classic opioids such as morphine or heroin. For example, respiratory depression is not observed with the use of kratom, while this is a hallmark effect of opioids at high doses—and one of the major dangers associated with the use of these drugs. Another way in which kratom is unique is that its effects are highly dose dependent. At lower doses, Dr. Grundmann explains, the plant tends to have a more energizing effect, while higher doses lead to a more sedating experience. In this conversation, Dr. Grundmann also shares insights into kratom use in America based on survey research he has conducted. While scientific research into kratom remains a small field, this type of survey research helps to give insight into the potential kratom has as a plant medicine through data which shows the variety of conditions people are attempting to treat through kratom use. As kratom consumption increased in the United States and the plant gained notoriety, its use became associated with the treatment of chronic pain and opioid withdrawal. Dr. Grundmann’s research has been showing, however, that users are also turning to kratom for dealing with conditions such as depression, anxiety, and PTSD. These initial findings provide fertile soil for further research into kratom’s potential medicinal applications. In this episode: The pharmacology of mitragyna speciosa The legality of kratom in the United States The current state of scientific research into the effects of kratom consumption Contraindications for kratom use Potential uses for kratom to treat both mental and physical ailments Various methods for kratom consumption Quotes: “Just because a substance binds to an opioid receptor doesn’t mean that it shows all of the same properties as, for example, morphine, or oxycodone, or fentanyl, or heroin.” [14:20] “When we talk here one to five grams per dose, three times a day—the potential to develop a use disorder, kratom use disorder, basically, is relatively low. When we talk about really taking high amounts of an extract or also of the powder for example, let’s say above eight grams, ten grams per dose, more frequently—four, five, eight times a day—then there is the potential to develop a dependence on it.” [18:52] “Between 70%–85%… [of] folks were in the range of one to five grams and didn’t have to go above five grams to maintain alleviation of their symptoms for which they are using kratom… That indicates to me that there’s no risk of tolerance up to five grams per dose.” [22:53] “Surprisingly, we had a large group now in the second survey who were using it to treat—self-treat—symptoms of ADHD or PTSD and nothing else aside from that. So it’s really a very diverse population of users that we’re seeing with kratom.” [25:09] Links: Dr. Grundmann’s Profile at the University of Florida Dr. Grundmann on LinkedIn Psychedelic Medicine Association Porangui…
1 Psychedelics and the LGBTQIA2S+ Community with Dr. Angela Carter 37:41
37:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:41This episode of the Plant Medicine Podcast welcomes Dr. Angela Carter (they/them) to discuss the intersection of the LGBTQIA2S+ community and psychedelics. Dr. Carter is a queer, transgender, and genderqueer naturopathic primary care physician who also works as a midwife, sexual assault examiner, and health equity advocate in Portland, Oregon. They also serve as both the vice-chair and the equity in training subcommittees co-chair of the Oregon Psilocybin Advisory Board. In addition to these positions, Dr. Carter serves as the chair of the Transgender Health Program Community Advisory Board at Oregon Health & Science University. They also volunteer with many organizations including the Fireside Project, Black Rock City Emergency Services, and Queerdome. Dr. Carter begins this conversation by sharing exciting new research currently being conducted which involves LGBTQIA2S+ individuals and psychedelic therapies. While this particular area of research remains small, it is growing and the fruits of these studies will be an important step for better understanding how these new therapies can serve gender and sexuality minorities, and help facilitators understand the unique concerns of people in the LGBTQIA2S+ community. Dr. Carter illustrates these types of concerns by discussing the prevalence of gender binaries within psychedelic spaces. They describe how in a clinical setting it is prevalent to have both a male and a female facilitator, but this leaves no room for gender-nonconforming people to guide experiences—something which could be preferable if the patient themselves shares this identity. Dr. Carter also discusses this gender binary in traditional contexts. It is common for ayahuasca ceremonies to provide separate spaces for men and women, again leaving no space for gender-nonconforming people. This reification of the gender binary and the often patriarchal organization of the ayahuasca ceremony can have serious impacts on the set and setting, especially for people in the LGBTQIA2S+ community. Dr. Carter emphasizes the importance of making space for folks in the community so that they are able to receive therapy, attend ceremonies, and participate in integration with others who share similar identities. This shared identity, they emphasize, ensures that LGBTQIA2S+ people don’t feel out of place in contexts that ought to be healing. Dr. Carter closes by discussing how members of the LGBTQIA2S+ community experience disproportionate rates of mental illness, further illustrating the crucial importance of equity in accessing psychedelic medicine. In this episode: Problems of representation and access for LGBTQIA2S+ individuals in the psychedelic space Current research being done on the intersection between psychedelic therapies and unique issues faced by gender and sexuality minorities Preparations to take before guiding a psychedelic experience for LGBTQIA2S+ people, particularly if you do not come from the community How plant medicines could have unique benefits for the LGBTQIA2S+ community Issues of poverty faced by marginalized peoples and how to support equity of access to emerging psychedelic therapies Quotes: “For some people that idea of melding, of becoming one and losing all of those unique pieces of themselves, doesn’t fit their paradigm of a spiritual connecting experience.” [10:47] “It’s precious, that centering of our community—to be able to sit with people who just understand.” [19:42] “Psychedelics offer the opportunity for connection of the self to something greater, something outside, a bigger community, spirituality, and really do a huge amount to heal peoples’ relationships with substances.” [25:20] “Marginalized communities have been really impacted, largely, by the war on drugs, which has put millions of people in jail for drug offenses and stolen their ability to make income, stolen their ability to connect with community and we really need to heal that.” [33:34] Links: Fruiting Bodies Collective Chacruna Institute Queering Psychedelics 2019 Conference Queerdome on Facebook Portland Psychedelic Society Psychedelic Medicine Association Porangui…
1 Psychedelics and Meditation with Nate Macanian 37:41
37:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:41This episode of the Plant Medicine Podcast features a discussion of psychedelics and meditative practices with Nate Macanian. Nate is a meditation teacher and psychedelic guide from New York with a background in cognitive neuroscience. He also creates mindfulness content for leading meditation apps such as Calm, Simple Habit, and Wellness Coach, as well as retreat centers such as Synthesis and Omega Institute. Nate begins this discussion describing how he was initially exposed to meditation and psychedelics. This first exposure came while Nate was a student at the University of Michigan and his immediate passion for meditation led him to found a student organization to further explore meditative and contemplative practices with his peers. Nate also describes guiding friends through psychedelic experiences in his college arboretum, before he had ever even heard of the idea of trip sitting. Turning to meditative practices themselves, Nate describes how psychedelics can be incorporated into one’s meditation routine in a variety of ways and for a variety of different forms of meditation. What he stresses, however, is to examine the intention behind bringing plant medicines into the practice. But if they are incorporated mindfully, psychedelics can help bring meditative practices into sharper relief—microdoses help to amplify awareness and reveal the habits of the mind while larger doses work to connect one to layers of experience previously hidden to consciousness. While meditation and psychedelics share certain goals and can both be used for therapeutic ends, there are also differences between them. Nate describes psychedelics as an elevator which takes people directly to a destination, whereas meditation is more like a winding staircase as the practice requires continual effort and consistency to progress. Nate also distinguishes meditation and psychedelic experiences phenomenologically. He stresses that the goal of meditative practices is not to mimic the feeling of a trip. Instead, meditation works to focus the attention on the whole spectrum of human experience, some of which can be boring, tedious, or dull. Psychedelics, on the other hand, provide specific kinds of experiences which are intense and colorful, but these differences are what allow meditative practices and psychedelic journeys to have a symbiotic relationship. In this episode: Nate’s journey being introduced to mindfulness and psychedelics The importance of intention in meditation Incorporating plant medicines into one’s meditative practices Psychedelics, meditation, and the default mode network in the brain Why set and setting is also important for meditation Quotes: “If you include a larger dose in your meditation practice, you might find that there are layers that were previously unseen and latent, living under the surface, that start to come up and this is where a lot of shadow work happens.” [14:00] “When the default mode network is off, we have this increased susceptibility to our immediate environment and this is why it's so important to surround yourself with positive people and be in a nice, calm, safe place.” [22:24] “I think there’s absolutely a place for psychedelics to be included in your meditation practice as long as it’s intentional and as long as you feel like your success as a meditator is not attached to your use of any substance.” [26:59] “Meditation as a practice is not about really forcing ourselves to have some experience, but to train our awareness, to become a more whole person, a more fulfilled person, a more loving person.” [33:33] Links: Nate’s website Psychedelic Medicine Association Porangui…
1 Harm Reduction Through Testing Your Psychedelics with Mitchell Gomez 36:53
36:53
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:53On this episode of the Plant Medicine Podcast, Mitchell Gomez of DanceSafe discusses how to reduce harm by chemically testing substances prior to consumption. Mitchell is a graduate of New College of Florida and holds a masters from University of Colorado Denver. He joined the DanceSafe team in 2014 and has been serving as the executive director since 2017. In addition to his work at DanceSafe, Mitchell also acts as a harm reduction consultant for MAPS. In this conversation, Mitchell shares the origin story of DanceSafe and describes the important work they do. He mentions that testing drugs is illegal in many states, but following a precedent set by needle exchanges, the justice system seems to turn a blind eye to DanceSafe’s activity. Transitioning to the present day, Mitchell discusses the current state of the drug market, sharing information on adulterants and false marketing for a variety of substances from ketamine and LSD to cocaine and MDMA. Prohibition is at the root of these issues, he claims, as this is what encourages things such as selling fentanyl while claiming it is another opioid, as fentanyl is more potent and thus easier to smuggle in smaller quantities. Another government-related issue Mitchell mentions is the data the state gathers on drug-induced medical incidents. This data groups a variety of substances together, making it difficult to determine the actual cause of the medical emergency. Turning to the importance of chemically testing drugs, Mitchell stresses the benefits of knowing what you are consuming. While a single test with the right reagent can tell a lot about a substance, Mitchell recommends using a wide variety of tests as many drugs are often adulterated even if they do contain the substance they were sold as. Knowing if a drug is cut with another substance and what this substance could be helps people make more informed decisions about what they put in their bodies. Especially in the era of the opioid epidemic, this kind of information can be legitimately lifesaving. In this episode: The origin of DanceSafe and the services they provide How to use fentanyl test strips Common drugs currently being falsely marketed as MDMA New opioids which are laid on blotters like LSD Why using multiple reagents to test substances is a smart idea Chemically testing mushrooms vs learning mycology to identify species Quotes: “One of the things we know is that the speed at which new drugs are entering the market is accelerating.” [15:08] “Fentanyl, for a non-opioid user, a milligram might be enough to kill you. One milligram. If you’re alone, if there’s nobody there to call 911, that might be enough to impact a non-opioid user’s breathing.” [18:44] “Nobody has ever been arrested for just having a test kit. That’s never happened. If they find a test kit as part of a larger drug investigation, they will include a paraphernalia charge for that test kit as a means of coercing plea deals.” [21:28] “These are problems caused by prohibition. We could have fair trade, organic cocaine in twenty-five days if we just ended the drug war.” [33:00] Links: DanceSafe’s Website DanceSafe on Instagram Psychedelic Medicine Association Porangui…
1 Navigating Psychedelic Narcissism with Adam Aronovich 1:00:27
1:00:27
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:00:27In this episode of the Plant Medicine Podcast, Adam Aronovich returns to discuss the phenomenon of psychedelic narcissism. Adam is a doctoral candidate at the Universitat Rovira i Virgili in Spain, focusing on Medical Anthropology and Cultural Psychiatry. He is an active member of the Medical Anthropology Research Center (MARC) and part of the Ayahuasca Community Committee at the Chacruna Institute for Psychedelic Plant Medicines. In the last four years he has conducted extensive fieldwork in the Peruvian Amazon, where he has been doing qualitative research in collaboration with ICEERS, the Beckley Foundation, and, more recently, the Centre for Psychedelic Studies at Imperial College. Beyond his work conducting and coordinating research, Adam regularly facilitates workshops at the Temple of the Way of Light, a prestigious healing center in the Iquitos area. In this wide-ranging conversation, Adam unpacks some of the darker sides of the modern psychedelic movement, discussing the psychosocial dynamics around psychedelic use which can lead to things such as ego inflation, conspiratorial thinking, and narcissism. Adam recalls his own experiences slipping into messianic fantasies during a period of initial enthusiasm around psychedelic experiences. He views issues of alienation and lack of social support as being instrumental in leading to these types of delusions following profound spiritual experiences. While it is difficult to reach people who’ve slipped into psychedelic narcissism, Adam suggests that communal support is the best safeguard against these dangers and the most effective strategy for grounding people who’ve lost touch with reality. Drawing on his academic expertise, Adam distinguishes traditional uses of plant medicines from the Western paradigm for approaching psychedelics. He stresses the relational and communal aspects of the spiritual traditions which use psychedelics ceremonially. The pro-social aspects of these wisdom traditions, he claims, help safeguard against the traps of psychedelic narcissism and ego inflation, as there are established mechanisms for keeping people grounded following intense spiritual experiences. Adam closes the discussion with an insightful analysis of modern gurus and self-proclaimed shamans. Adam encourages people to beware of deeply held spiritual fantasies, where a master can appear as more than human. Instead, he emphasizes that even skillful and well-intentioned healers are themselves nothing more than human beings, so there will always be imperfection and messiness. This does not, however, mean that impactful work cannot happen—in fact, this insight helps protect against the idolization of charismatic psychedelic personalities, which can lead to harmful experiences. In this episode: Defining psychedelic narcissism Clinical vs coloquial understandings of narcissism The intersections of the psychedelic movement and conspiracy theories The importance of social and communal support for avoiding ego inflation following psychedelic or spiritual experiences How psychedelic experiences can actually deepen ego attachments and accentuate narcissistic tendencies The importance of humor in combating spiritual narcissism Quotes: “Many of the underlying ideologies upon which Western cultures were built, like hyper-individualism and so on, kind of predispose us and prime us for certain aspects of narcissism.” [5:36] “Ego inflation, spiritual narcissism, messianic episodes—all of these are things that are fairly common within both people who are in some sort of spiritual or psychedelic path.” [12:17] “In traditional societies for the most part really there isn’t such a thing as a self-proclaimed shaman. A person doesn’t wake up one morning and is like ‘oh, I’m the shaman’—that’s a title or a role or a recognition given to that person by the community.” [38:03] “The best measure of whether somebody is genuine and helpful is not whatever credentials or titles he assigns to himself, but rather what other people feel. So, you know, you will know a tree by its fruits.” [45:08] “Having these experiences by themselves does not necessarily mean spiritual growth or psychological development or any enhanced benefit if we’re not constantly, painfully, mindful of how we actually integrate and embody those things in daily life over very long periods of time.” [54:29] Links: Adam on Instagram Temple of the Way of Light Psychedelic Medicine Association Porangui…
1 Establishing Safeguards for Psychedelic Therapy with Dr. Julie Holland 26:14
26:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
26:14This episode of the Plant Medicine Podcast is the final installment in a three-part series with Dr. Julie Holland. Dr. Holland is a psychiatrist specializing in psychopharmacology, and she is also the author of many books, including her most recent work Good Chemistry: The Science of Connection, from Soul to Psychedelics which discusses the neurochemistry behind human connection. She is also a medical monitor for several MAPS PTSD studies using MDMA-assisted psychotherapy and has worked for decades on US drug policy reform based on harm reduction principles. In addition to this work, Dr. Holland has nine years experience running a psychiatric emergency room as an attending physician on the faculty of NYU school of medicine and she continues her psychiatric work in her private practice in New York City. In this episode, Dr. Holland speculates on the future of psychedelic therapy and the emerging issues within the broader psychedelic movement. Lamenting the lack of governing organizations and accountability, Dr. Holland discusses the complexities of regulating an industry with a history of operating underground and in legal grey areas. This raises questions such as how to grandfather-in established psychedelic practitioners now that various coursework in psychedelic therapy and systems for credentials are beginning to emerge. Another issue related to legality which Dr. Holland discusses is the relation between the medical establishment and psychedelic therapies. The fact that individuals interested in pursuing plant medicines for therapeutic reasons are not able to easily consult with primary care doctors is a huge hurdle to harm reduction, and, as Dr. Holland points out, this leaves the responsibility for ensuring safety entirely on the psychedelic practitioners. Because these practitioners range from underground ayahuasca circles to clinically approved, legally operating therapists the amount of attention and care paid to harm reduction can vary greatly, which is why it will be essential to establish standards and best practices for psychedelic therapy as demand continues to increase. Dr. Holland also discusses the issues of “psychedelic capitalism” which are coming to the fore as these treatments become more mainstream and more accessible. While there are no clear answers for how to navigate the intersection of psychedelic therapies and capitalist market dynamics, this is an issue that deserves care and attention so that there can be equitable access to these medicines. Dr. Holland closes with a discussion of the parasympathetic nervous system–the “rest and digest” mode–and its importance for not only personal health, but also social well-being. In this episode: Why it is essential to begin establishing best practices and safeguards around emerging psychedelic therapies and other practices involving plant medicines Issues that arise from the intersection of capitalist market dynamics and the emerging psychedelic industry The future of medical consultations prior to consuming plant medicines Activating the parasympathetic nervous system and its pro-social impacts Quotes: “I think part of it is just this fear that if we admit there are some bad actors, that the whole house of cards is gonna fall.” [9:26] “Just because of the way capitalism is, there is IP, there is proprietary information, there is anti-competitive behavior. That to me also really needs to be addressed.” [11:31] “In any interaction there is a choice of being hurtful or helpful, and it’s a choice, everyday.” [20:18] “Anyone who can out themselves should, because it will move this whole thing along a lot more. If you are a soccer mom who also microdoses, put that bumper sticker on your car.” [24:58] Links: Dr. Holland’s website Good Chemistry: The Science of Connection, from Soul to Psychedelics Psychedelic Medicine Association Porangui…
1 Strategies for Tapering Off Antidepressants with Dr. Julie Holland 24:48
24:48
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
24:48This episode of the Plant Medicine Podcast is the second conversation in a three-part series with Dr. Julie Holland. Dr. Holland is a psychiatrist specializing in psychopharmacology, and she is also the author of many books, including her most recent work Good Chemistry: The Science of Connection, from Soul to Psychedelics which discusses the neurochemistry behind human connection. She is also a medical monitor for several MAPS PTSD studies using MDMA-assisted psychotherapy and has worked for decades on US drug policy reform based on harm reduction principles. In addition to this work, Dr. Holland has nine years experience running a psychiatric emergency room as an attending physician on the faculty of NYU school of medicine and she continues her psychiatric work in her private practice in New York City. In this episode, Dr. Holland talks specifically about the nuances of antidepressants and psychedelic medicine. As is commonly known, many prescription antidepressants have contraindications with various psychedelic compounds, meaning there are concerns regarding how people taking such medications will be able to also access psychedelic-assisted therapies. Dr. Holland discusses the specific contraindications for individual psychedelic medicines and suggests some strategies for safely and effectively tapering off antidepressants in consultation with a medical professional. She suggests various wellness practices, such as regular exercise, as particularly helpful during the course of tapering, and even mentions situations where an additional antidepressant is prescribed to support the tapering process, stressing the complexity and delicacy of this process. To give context to this discussion of psychedelics and antidepressants, Dr. Holland provides an overview of the history of psychiatry over the past forty years, showing how antidepressants came to prominence as a therapeutic tool. She also explores additional considerations, such as how things like hormonal birth control interacts with SSRI antidepressants on a psychopharmacological level. The common thread Dr. Holland weaves through this conversation is the importance of connection, both as support for the tapering process and as the end goal of effective therapeutic practice. In this episode: Health and wellness practices which can act as support while tapering off an antidepressant in consult with a medical professional Contraindications between various psychedelics and antidepressants The difference between microdosing and macrodosing psychedelics while taking antidepressants Why falling in love can present a good opportunity to taper off antidepressants under supervision Why Dr. Holland sees the divide between recreational and therapeutic use as a false dichotomy in some cases Quotes: “There was a lot of hand-holding and de-stigmatizing back in the 90s, educating people around antidepressants. But twenty years later most of my work was really around people [who] had been medicated for ten, fifteen, twenty years and wanted to be off meds.” [6:15] “The people who really responded from MDMA-assisted psychotherapy who had PTSD were the people who’d never been on SSRIs. The people who had a muted response who didn’t get as much better as the other group were the ones who had been on SSRIs.” [9:47] “Coming off of psych meds is no easy feat. You really have to do a gradual taper, there has to be somebody who is supervising you, and you’ve got to have other things in place.” [10:42] “You have to have somebody helping you… It’s not the kind of thing you can really go alone. Getting off antidepressants requires somebody who knows what they are doing to help you.” [14:16] “Your brain learns to be sad, your brain learns to be anxious, your brain can learn to be at ease and learn to have joy.” [21:31] Links: Dr. Holland’s website Good Chemistry: The Science of Connection, from Soul to Psychedelics Psychedelic Medicine Association Porangui…
1 Psychedelics and the Chemistry of Connection with Dr. Julie Holland 43:27
43:27
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:27This episode of the Plant Medicine Podcast is the first installment of a three-part conversation with Dr. Julie Holland. Dr. Holland is a psychiatrist specializing in psychopharmacology, and she is also the author of many books, including her most recent work Good Chemistry: The Science of Connection, from Soul to Psychedelics which discusses the neurochemistry behind human connection. She is also a medical monitor for several MAPS PTSD studies using MDMA-assisted psychotherapy and has worked for decades on US drug policy reform based on harm reduction principles. In addition to this work, Dr. Holland has nine years experience running a psychiatric emergency room as an attending physician on the faculty of NYU school of medicine and she continues her psychiatric work in her private practice in New York City. In this first installment with Dr. Holland, the conversation focuses on the idea of connection she explored in Good Chemistry . Dr. Holland begins by discussing the importance of feeling a connection with oneself and details how many things in modern life can get in the way of this connection. Self-connection is important, she stresses, because if we are not grounded in ourselves, it can be difficult to establish healthy connections with others. Dr. Holland explains how various neurotransmitters such as oxytocin and dopamine are involved in connecting with self and others and how pharmaceuticals such as opiates act on some of these same systems to simulate comfort. In addition to discussing human connection from a pharmacological perspective, Dr. Holland also explores the topic through a psychological lens, looking at the role trauma can play in muddying opportunities for connection. This is an area where psychedelics can be particularly impactful, as these substances can disrupt the constant ruminations and patterns of behavior which keep people from pursuing or deepening connections. Dr. Holland then brings some insights from the science of connection to bear on the practice of psychedelic therapy, discussing how group facilitation of psilocybin therapy could be more impactful by allowing the experiences and integration work to happen in community. The conversation closes with a discussion of how psychedelics can impact the connections one feels, especially to the natural world, and some speculations regarding how the feelings of interconnection elicited by psychedelic experiences could impact political convictions. In this episode: How distractions and addictions get in the way of our ability to connect with ourselves How the epidemic of loneliness and the epidemic of overdoses intersect The pharmacological pathways of oxytocin and the function of the dopaminergic system How psychedelic experiences “shake up” one’s sense of self and the therapeutic effect of this process The double-edged sword of the feelings of group cohesion produced by oxytocin The impact of psychedelics on one’s worldview Quotes: “If you’re not in your body, and embodied, and feeling your feelings, you’re not gonna be much use to anybody else in a relationship.” [5:59] “One of the reasons why opiates are so soothing is they really quell that unease, that anxiety, and they really mimic the chemistry and physiology of what we feel when we are taken care of, held, attended to.” [10:40] “We are not healthy when we are disconnected. It is a proinflammatory state when we are disconnected, and it is anti-inflammatory when we feel cared for.” [13:35] “There’s always trauma and everybody carries it around in their bodies to some extent and it really needs to be unearthed and investigated for us to be healthier and happier. So everyone can avail themselves of MDMA-assisted psychotherapy or psilocybin-assisted psychotherapy.” [24:30] “Oxytocin facilitates neuroplasticity, it facilitates learning. And we learn better in group than we do individually. When we are isolated we do not learn as well.” [29:13] “There is actual research to show that people who take psilocybin mushrooms and have psychedelic mystical experiences do feel more connected to the planet and do feel more of a sense of obligation to take care of the planet.” [37:23] Links: Dr. Holland’s website Good Chemistry: The Science of Connection, from Soul to Psychedelics Psychedelic Medicine Association Porangui…
1 Insights Gained from the First Year of Fireside Project with Joshua White 40:19
40:19
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:19In this episode of the Psychedelic Medicine Podcast, Joshua White returns to discuss the first year of the psychedelic peer-support line, Fireside Project. Joshua (he/him) is founder and executive director of Fireside Project and has prior experience as a volunteer counselor on a hotline and as a volunteer at the Zendo Project. He has also practiced law as a deputy city attorney at the San Francisco City Attorney’s Office, where he focused on suing business exploiting vulnerable communities. He also co-taught a nationally-renowned clinic at Yale Law School. Joshua begins this conversation by sharing the success of Fireside Project in its first year of operation. The peer support line has been called over 3,100 times in the 14 months since the launch of Fireside Project, where callers have been able to receive open-ended support from compassionate peers as they navigate a psychedelic experience or attempt to integrate a previous experience. Joshua also shares some details about the kinds of calls the line has received, such as which psychedelic substances were involved in the caller’s experience, how callers were describing their experiences, and what mental health conditions callers self-reported. In terms of substances, psilocybin was the most commonly used by callers, though a wide range of different psychedelics were reported. For mental health conditions, PTSD stood out as the most frequently mentioned, though depression and anxiety were also common. Joshua mentions that he’s hopeful that this data may be incredibly useful in further developing harm reduction strategies, as the dataset may help uncover previously unknown correlations. Another aspiration for Fireside Project is ensuring equity through their Equity Initiative, which allows callers to process past psychedelic experiences with someone of a similar background. Joshua shares that this initiative will also produce original research on this topic, showing for example the kinds of benefits a caller from the BIPOC community might get through having the opportunity to integrate a past experience with a BIPOC peer. Joshua closes this conversation with powerful words about integration and harm reduction, saying that integration is a form of harm reduction. To that end, Joshua is hopeful Fireside Project can continue offering crucial harm reduction and integration services as the organization grows and reaches beyond the niche of psychedelic enthusiasts. In this episode: Who has been calling the peer-support line and what kind of support they are seeking How Fireside Project could potentially offset the burden on emergency services in the case of negative psychedelic experiences The diversity of Fireside Project volunteers The problems of facilitator abuse and neglect in the psychedelic space The future of Fireside Project Quotes: “Reflective listening—which is the core, the foundation of holding space—this is really a skill that we can continue to cultivate.” [8:03] “My hope is that there’s no barrier, there’s no stigma, and there’s no shame to reaching out.” [12:53] “All of the lessons we learn, we really just want to share those with the public in the hope that this will lead to less risky and more fulfilling psychedelic experiences.” [17:30] “One of the things that I’ve noticed is—that we’ve noticed is—even though every single call is different in its own way, especially when someone reaches out to us in a heightened state, really validation, normalization, and reassurance often happen at the very beginning.” [25:34] “It’s amazing how some of our calls are just so short because someone just wants to know that we are there.” [28:44] “As a psychedelic community, people need to stop saying that psychedelics are ten years of therapy in one night. It’s just not true, and it sets people up for serious disappointment and can even be really dangerous for that reason.” [30:01] Links: Fireside Project website Fireside Project app Fireside Project Instagram Fireside Project Twitter Fireside Project Tik Tok Psychedelic Medicine Association Porangui…
1 Preparing for Safe Ibogaine Journeys with Felipe Malacara, MD 35:23
35:23
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
35:23In this episode of the Psychedelic Medicine Podcast, Dr. Felipe Malacara joins to discuss the safety considerations surrounding ibogaine therapy. Dr. Malacara is the chief clinical operations director for Beond, a Mexico-based Ibogaine clinic. He is also a general practice physician with a medical degree from Universidad Autónoma Metropolitana in Mexico City and has over 17 years of experience treating over 1,200 patients with Ibogaine therapy. In this conversation, Dr. Malacara shares important safety information about ibogaine, starting with major contraindications to using the powerful substance. These contraindications fall into three main groups: heart issues, electrolyte deficiencies, and liver problems. As Dr. Malacara explains, all of these have the potential to make Ibogaine dangerous due to the way it interacts with the heart, particularly if there is a metabolism issue. In terms of negative outcomes, cardiac issues are the most common as ibogaine can cause bradycardia—a dangerous slowing of the heart rate. Due to these potential risks, Dr. Malacara encourages a thorough evaluation prior to ibogaine therapy, including full blood work, an EKG, and occasionally an ultrasound of the heart. Another crucial part of the evaluation is taking an inventory of the patient’s prescription medication and drug use. Dr. Malacara explains that patients may need to be weaned off a particular drug or be given a shorter-acting alternative so that they can come into the ibogaine therapy without any substances in their system which could lead to dangerous interactions or render the treatment less effective. In particular, Dr. Malacara notes that SSRIs could interact with ibogaine to produce serotonin syndrome, and while this can be straightforward to treat, diagnosis can be difficult, so avoiding this entirely by weaning off the medication under the direction of a physician is strongly suggested prior to treatment. In closing, Dr. Malacara emphasizes that Ibogaine is not a magic bullet despite its unique efficacy for treating addiction. The will to change on the part of the patient is still crucial, especially as preparation for ibogaine therapy itself requires a lot of commitment and dedication. If that is present, however, Dr. Malacara maintains that the treatment can be extremely effective. In this episode: How Dr. Malacara got involved in Ibogaine therapy The inherent risks of Ibogaine What patients should be evaluated for prior to receiving Ibogaine therapy Weaning patients off drugs or onto different, shorter acting substances in preparation for Ibogaine The types of addictions may be successfully addressed by Ibogaine Monitoring a patient’s heart following Ibogaine, and when they can be released Quotes: “In the event [that a patient] is not able to metabolize ibogaine in an appropriate way, the risk of heart toxicity of the Ibogaine increases.” [9:25] “Something which is important is drug screening before the treatment. We need to know that the patient has no traces of the drugs that we are going to treat in the system, because otherwise the treatment will be more difficult, the recovery will be more difficult, or it will be even ineffective.” [26:48] Links: Beond Psychedelic Medicine Association Porangui…
1 Addressing Military Sexual Trauma through Ayahuasca with Wyly Gray and Andrea Lucie, PhD 48:41
48:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
48:41In this episode of the Psychedelic Medicine Podcast, Wyly Gray and Dr. Andrea Lucie join to discuss the issue of healing military sexual trauma (MST) through ayahuasca. Wyly Gray is a former Marine and founding executive director of Veterans of War, a nonprofit which connects teams of veterans to psychedelic-assisted guided group therapy designed to heal the scars of war in community. Dr. Andrea Lucie is a native of Chile and a third generation healer who has been traditionally and non-traditionally trained in ancient healing practices in the United States and Mexico. She also holds a PhD in mind-body medicine. This conversation begins by discussing the tragic phenomenon of military sexual trauma and the current treatment modalities available for veteran survivors. Wyly explains that the current treatments, which primarily take a talk therapy approach, often fall short of what survivors need as they focus on treating the symptoms as they arise rather than being able to address these conditions at their root causes. Dr. Lucie explains the science behind ayahuasca as a treatment for trauma, highlighting the profound neurological and psychological impacts of this psychedelic medicine. Seeing the particular need for better treatment options among the veteran population, and the potential for ayahuasca to have such a profound positive impact, Wyly founded Veterans of War with the hope of better addressing this need. He shares the details of the six-month fellowship program, which involves a small cohort of veterans who do significant preparatory work together prior to a communal ayahuasca ceremony, followed by many integration sessions after the ceremony. Dr. Lucie explains different forms of mind-body work that may be effective supports before and after ceremony, citing things such as Tai Chi, meditation, and even close relationships with animals. Towards the end of this conversation, Wyly shares some profound stories of transformation he has witnessed first-hand through his work with Veterans of War. He has seen veterans who’ve struggled profoundly with panic attacks become incredibly joyful people, and others who were on the brink of suicide begin to heal and form deep and meaningful relationships. In closing, Wyly discusses plans to establish a healing center in Oregon for Veterans of War to further increase access to these opportunities without the need for international travel. In this episode: The problems of the civilian service-member divide, and how ayahuasca can help break down these barriers The importance of supportive community in the context of ayahuasca therapy for veterans with MST Mind-body practices that can support veterans working through MST before and after an ayahuasca ceremony How trauma changes the brain and the neurological effects of psychedelics that can help reverse these changes Why tackling issues of sexual assault within the military can be so difficult Quotes: “I think that Ayahuasca is unparalleled in its ability to create a safe and effective path towards recovery, but I deeply believe it also needs bookends on either side, or a structure to get the most out of it.” [8:19] “Sometimes we just don’t want to talk. We just want to feel and when we feel and we identify where in the body the trauma is stuck—because the trauma gets stuck in the body—then we know how to release it with movement.” [27:16] “Our response to trauma has seemed to be very one-dimensional. This is an effort to shift that, to start looking at people as whole units and at the same time, start speaking to the needs of that whole unit. If you are able to heal the trigger point of that trauma, you don’t have to heal its expression.” [31:18] Links: Veterans of War website Veterans of War on Instagram Veterans of War on Twitter Psychedelic Medicine Association Porangui…
1 Predicting and Potentiating Peak Psychedelic Experiences with Sam Gandy, PhD 1:03:05
1:03:05
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:03:05In this episode of the Psychedelic Medicine Podcast, Dr. Sam Gandy returns to discuss the topic of psychedelic-induced mystical experiences, looking specifically at how to predict and potentiate these experiences. Dr. Gandy holds a PhD in ecological science from the University of Aberdeen and has conducted field research across the globe. He is a researcher and science writer who is also a collaborator with the Centre for Psychedelic Research at Imperial College London, with a research interest in the capacity of psychedelic substances to influence individuals’ connection with nature. Dr. Gandy begins this conversation by defining the topic of mystical experiences. He explains that while there are a number of competing terms for how to best address this subject, what is important is that the research has consistently shown that these types of experiences are closely correlated with beneficial therapeutic outcomes. Whether brought on by psychedelics or not, mystical experiences tend to produce positive psychological changes, so it is important for psychedelic researchers to take this topic seriously and thoroughly investigate these experiences and where they come from. However, Dr. Gandy notes that there are a number of hurdles to addressing this topic scientifically. Because of the mystical or spiritual quality of these peak experiences, it can be difficult for researchers to develop sufficiently neutral language in surveys while maintaining accurate descriptions of the qualities of the altered states. Similarly, Dr. Gandy explains that therapists have to walk a fine line between not introducing spiritual or religious bias into the session through decoration or suggestion which may prioritize a certain religious tradition, while also preserving a certain type of spiritual atmosphere which is conducive to mystical experiences and thus beneficial therapeutic outcomes. Dr. Gandy then goes on to explain variables which can be predictive of psychedelic mystical experiences. Set and setting are of course crucial, but there are a number of additional parameters to consider. Dr. Gandy explains that dose, of course, is particularly important, stating that a standard has emerged in the research around psilocybin which has found that 25 milligrams of pure synthetic psilocybin is a sweet spot for encouraging mystical experiences without leading to additional adverse reactions due to the intensity of the experience. Additionally, different psychedelic substances produce mystical experiences at different rates, with 5-MeO-DMT being the most likely to lead to these experiences. Besides dose and substance, Dr. Gandy has also found that intention as well as the personality trait known as absorption are both predictive of mystical experiences in psychedelic therapy. To conclude this conversation, Dr. Gandy shares three possible potentiators of psychedelic mystical experiences: music, meditation and spiritual practice, and nature-based settings. Each of these items, if integrated into the experience intentionally can encourage a more immersive and intense mystical experience. For all of these, Dr. Gandy encourages further research for how they could best be integrated into psychedelic therapy practices. In this episode: The psycho-social changes which often follow mystical experiences The connection between mystical experiences and “spiritual emergencies”The difficulty of working with a spiritual element in the context of psychedelic therapy and research How the typical Western protocols for psychedelic therapy encourage an inward experience Why people who rank highly in the personality trait absorption are more likely to have mystical experiences, both spontaneously and while under the influence of psychedelics Ways to train psychological states of surrender and acceptance prior to high-dose psychedelic therapy which can encourage mystical experiences and prevent adverse reactions Quotes: “What makes psychedelics quite interesting is that they—under the right, appropriate conditions and contexts—they can reliably elicit these [mystical] experiences.” [4:39] “The psychedelic 5-methoxy-DMT is definitely an interesting substance to highlight here. … The data that is there shows that when it’s used in a supportive context, it can predict mystical experiences—three quarters of cases, over that in two separate studies that have been done so far.” [31:22] “Entering the experience with an emotional intent or a spiritual motivation seems to predict greater likelihood of mystical experiences” [34:36] “There’s this aspect that negatively predicts mystical experience called mental barriers. And this is where you enter the experience with in some sense an overly rational, analytical way of viewing things, and if you enter the experience like that that’s a potential block on mystical experiences happening.” [44:21] “People with meditation experience or with an ongoing practice, they seem more liable to report states of oceanic boundlessness tied to the mystical experience.” [49:16]“Nature-based settings seem to be quite conducive to mystical and spiritual states, just inherently.” [57:00] Links: Dr. Gandy on Twitter Dr. Gandy’s article: predictors and potentiators of psychedelic-occasioned mystical experiences Dr. Gandy’s Research Gate profile Centre for Psychedelic Research at Imperial College London Previous episode: Psychedelics and Nature: The Symbiotic Relationship with Dr. Sam Gandy Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD Psychedelic Medicine Association Porangui…
1 Psychedelics’ Potential to Improve Health Habits with Pedro Teixeira, PhD 39:49
39:49
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
39:49On this episode of the Psychedelic Medicine Podcast, Dr. Pedro Teixeira joins to discuss the emerging research about the effects of psychedelics on health behavior change. Dr. Teixeira is a professor of physical activity and health at the University of Lisbon and the director of research for the Synthesis Institute in the Netherlands. He holds bachelors and masters degrees in exercise science and a PhD in nutritional sciences. As an academic, Pedro’s main research interest is health behavior change, a field which he is now trying to put into conversation with the latest psychedelic science. In this conversation, Dr. Teixeira shares the basics of the field of health behavior change, which seeks to study how and why people end up developing positive-health-conscious behaviors. This is a field that is of particular interest to clinicians, as doctors are always looking to encourage healthful behaviors in their patients. When it comes to research on the impact of psychedelics on health behavior change, Dr. Teixeira explains that much of the current data is secondary, though some evidence can be drawn from studies that primarily examined psychedelic therapy for tobacco and alcohol cessation. The data that does exist, however, paints a very promising picture, with many psychedelic users reporting positive changes in diet and exercise following experiences with these mind-altering substances—an effect which Dr. Teixeira notes is often observed even if there was no intent for health behavior change prior to the psychedelic experience. However, more research is needed to substantiate these preliminary results. To that end, Pedro shares the idea of “behavioral psychedelics”—a new methodological paradigm in psychedelic research that will focus more on collecting data on concrete behaviors following psychedelic therapy as opposed to the primarily psychometric data which has dominated the field. Dr. Teixeira also emphasizes that the field of health behavior change could be an important vehicle for emphasizing the role of psychedelics as tools for preventative health, taking the field beyond the current paradigm which sees psychedelics as primarily useful for their potential to address acute mental health conditions. Dr. Teixeira can be reached at pteixeira@fmh.ulisboa.pt In this episode: The emerging field of health behavior change Types of health-related behaviors that could be encouraged by psychedelic experiences The new paradigm of “behavioral psychedelics” Possible preventative health roles for psychedelics The evidence from tobacco and alcohol cessation trials for health behavior changes following psychedelic use Quotes: “[Recent observational studies] seem to show that for some reason psychedelic users are not only healthier from a physical health perspective, but there’s also indications that that is caused by some of their behaviors.” [13:13] “What better way to convince future politicians or policymakers than to show that people are actually improving the quality of their lives and their health habits and saving healthcare costs and eating more sustainable diets perhaps, if indeed the studies in Oregon and in the future in other places are showing that there is a preventative aspect, there is a lifestyle enhancement aspect to these experiences.” [21:57] “When you behave from a self-determined perspective, or when you’re motivated more internally as opposed to being more externally motivated, your outcomes will be better. Your behavioral outcomes, but also your health outcomes.” [26:21] Links: Dr. Teixeira's research group website Dr. Teixeira's paper: Psychedelics and Health Behavior Change Lucid News coverage of Dr. Teixeira’s article Study: Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States Article: Behavioral Psychedelics: Integrating Mind and Behavior to Improve Health and Resilience Article: Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users Dr. Teixeira’s talk at INSIGHT 2021: Can Psychedelics Improve Diet, Exercise, Meditation, and Weight Control? Self-Determination Theory website Previous episode: Psychedelics and Nature: The Symbiotic Relationship with Dr. Sam Gandy Psychedelic Medicine Association Porangui…
1 How Setting Can Affect Psychedelic Journeys with Frederick Barrett, PhD 56:57
56:57
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
56:57In this episode of the Psychedelic Medicine Podcast, Frederick Barrett joins to discuss setting and the research into how this variable can affect psychedelic experiences. Fred is an associate professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine where he is also the associate center director of the Center for Psychedelic and Consciousness Research. He has been conducting research at Johns Hopkins since 2013 and is currently leading a number of ongoing studies to better understand the psychological, biological, and neurological mechanisms underlying therapeutic efficacy of psychedelics. In this discussion, Fred unpacks his recent article “ Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature ” which appeared in the February 2022 edition of Current Topics in Behavioral Neurosciences . For this study, Dr. Barrett and colleagues gathered as many studies as they could find which dealt with the topic of the role of setting in psychedelic experiences. While they found over 1,000 articles which discussed the topic in some capacity, the researchers eventually narrowed the selection down to just 43 articles which provided empirical data on this variable. Fred mentions that while ideas of set and setting loom large in psychedelic discussions, this is actually a topic which has received comparably less attention in research contexts. This is beginning to change, however, as researchers have become more certain in the overall efficacy of psychedelic therapies for treating a variety of conditions and are now turning to more specialized investigations, such as looking more closely into the impacts caused by various tweaks to the setting of psychedelic therapies. When it comes to the state of current research on setting, Dr. Barrett reports that music is by far the most studied variable. He discusses different approaches which psychedelic therapists have taken in investigating this topic, with research investigating familiar vs unfamiliar music, or having music vs not having music in a session. He also shares research about expert meditators and how these subjects responded differently to music while under the influence of psychedelics when compared to typical patients. Another variable which Fred discusses is the element of ritual, which is especially prominent in more traditional contexts of psychedelic use. This variable is also interesting because it interacts with participants' expectations, blurring the distinction between set and setting as distinct categories. In closing, Dr. Barrett shares some of his own thoughts about the blurriness of set and setting, suggesting that our understanding of these categories may evolve as empirical research further investigates the roles they play in guiding psychedelic experiences. In this episode: The relationship between ritual and set and setting The difficulties of rigorously studying all the variables of setting in the context of psychedelic experiences The different aspects of setting in traditional, ritualistic contexts for psychedelic experiences versus the context of modern psychedelic therapy Music as an important aspect of setting during psychedelic journeys The blurry distinction between set and setting Quotes: “Out of all of this literature, the one thing that became clear to us was that everybody talks about set and setting, and many papers affirm set and setting are important, but very few actually empirically test an element of set and setting.” [6:49] “One of the elements of set and setting in general that we found to be addressed across a number of different studies was the question of specific ritual or ceremonial settings.” [15:04] “Music seems to play an overwhelming role in shaping—and some people think driving—their psychedelic experience.” [22:25] “Set and setting are both mutable. Your experience at one point in a session, I would argue, is going to influence, or at least has the opportunity to influence the things that happen next.” [41:03] Links: Dr. Barrett’s paper: Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes Johns Hopkins Center for Psychedelic & Consciousness Research Fred on Twitter Previous episode: Can Ayahuasca Help Promote Palestinian-Israeli Reconciliation? with Dr. Leor Roseman & Antwan Saca Previous episode: The Latest Research on Psilocybin for Depression with Matthew Johnson, PhD Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD Previous episode: LSD Scientific Research with Dr. Katrin Preller Psychedelic Medicine Association Porangui…
1 When *Not* to Proceed with a Planned Psychedelic Journey with Rick Barnett, PsyD 47:25
47:25
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
47:25On this episode of the Psychedelic Medicine Podcast, Dr. Rick Barnett joins to discuss when to not proceed with a planned psychedelic journey. Rick is a licensed clinical psychologist and licensed alcohol and drug counselor, trained in psychedelic therapies and research by the California Institute for Integral Studies. He is the cofounder of the psychedelic society of Vermont while also consulting with patients curious about psychedelic research and therapies, including helping people understand the processes of preparing for, experiencing, and integrating the intentional use of psychedelics for personal growth and healing. Dr. Barnett also works with patients in a traditional psychotherapeutic group practice and has also recently begun offering low-dose ketamine therapy. In this conversation, Rick expounds on his recent LinkedIn article of the same title, exploring the various biological, psychological, and social experiences which provide legitimate reasons for postponing a planned psychedelic experience. On the biological side, Rick explains that sudden illness or injury could absolutely constitute sufficient reason to reschedule a therapy session, and that consulting closely with your therapist or guide is essential if the decision isn’t clear cut, as in the case of something which could be a stomach bug or just nervousness manifesting as digestive discomfort. When it comes to the psychological side of things, Rick mentions that it is often a difficult circumstance to navigate, as mental distress is often the reason a patient is pursuing psychedelic therapy in the first place. However, Rick makes a distinction between the typical levels of depression and/or anxiety a patient is accustomed to experiencing, and a much more intense fear which is also qualitatively different that can arise before a session. Again, this is a situation where open communication between patient and therapist or guide is essential in order to help the patient make the best decision, but Rick also stresses that because this is a wholly internal experience, that prudent introspection is ultimately what will guide the decision making.In terms of the social reasons for not proceeding, Rick cites turmoil in personal relationships, traumatic contemporary events, and also recent experiences of death. These can all lead to an individual having a particularly heavy emotional burden going into a session, causing potentially difficult experiences during the psychedelic journey. While sometimes difficult experiences can be very healing in the long term, especially following effective integration, these external stressors have the potential to take people’s focus away from the intended inner work, so postponing until the person is confident they aren’t bogged down by these social factors could be prudent. With all these factors, Rick stresses that a patient can always return to a psychedelic journey at a later time if they decide not to proceed. A good guide or therapist will accommodate and even proactively support a patient in ensuring they are coming to the experience at the right time. In this episode: The importance of examining refund policies of psychedelic retreats or therapy practices Rick’s bio-, psycho-, and social considerations for not proceeding with a psychedelic journey Why these considerations are often molecule-specific What kinds of interpersonal conflicts may warrant postponing a psychedelic journey Distinguishing between overwhelming fear and typical anxiety prior to a psychedelic experience The impacts of traumatic political or social events on mental health and postponing a journey Quotes: “When you speak to a guide, when you speak to a coach, when you speak to a researcher, my hope is and my experience has been that it is always an option on the table at the last minute if you don’t feel quite right that you have permission to opt out.” [5:24] “Ketamine, when it comes to physical illnesses might be a different judgment call because ketamine—dissociative anesthetic, you kind of lose sense of your body—if there’s something going on physically, that might be okay to go ahead with… because you’re not with your body as much, but psilocybin, other high dose classic psychedelics and physical illness or physical pain, that could be different.” [17:59] “People need permission to say ‘you know what, it’s gonna happen’—you’ve done all the preparation, you’ve done all the work. If it’s not going to happen right now, it’s still going to happen.” [32:57] Links: Psychedelic Society of Vermont Rick’s LinkedIn Article: When NOT to Proceed with a Planned Psychedelic Journey Rick on LinkedIn Rick on Twitter Psychedelic Medicine Association Porangui…
1 Encore episode: Exploring DMT Entities with Matthew Johnson, PhD 26:13
26:13
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
26:13In this episode of the Plant Medicine Podcast, Matt Johnson, PhD returns to discuss previous survey research he conducted regarding DMT entities. Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In this conversation, Dr. Johnson shares findings from his 2020 publication of survey research which investigates peoples’ experiences with DMT entities. To preface these findings, however, Dr. Johnson first lays the groundwork by explaining the limitations of scientific investigation into these kinds of psychic phenomena. He explains that science is unable to answer questions of whether or not DMT entities are ultimately real, or what the fundamental nature of these experiences is. It can, however, employ rigorous methods for analyzing reports of entity encounters in order to document common features of these experiences and the types of effects they can have on individuals. In the survey, around twenty five hundred respondents shared their experiences of encountering an entity during a DMT experience. From the data collected, Dr. Johnson shares some of the common features of these entities. The beings are typically perceived as benevolent though there was a wide variety of ways the entities were conceptualized, ranging from aliens and machine elves to spirits and angels. Often participants believed the entities revealed metaphysical realities and the presence of these beings was frequently accompanied by extrasensory phenomena such as telepathic communication. Due to the dramatic nature of these experiences, Dr. Johnson’s research found some lasting impacts as reported by respondents, and he concludes by briefly discussing the effects of entity encounters on religious belief. In this episode: What questions science can and can’t answer, and the boundaries good scientific research has to take when investigating something such as DMT entities The findings of Dr. Johnson’s survey research—some general trends regarding the qualities of entities described Effects of entity encounters on religious belief Quotes: “My bet is that if people believe that there’s some sort of reality to these disincarnated entities—that it’s not just in their mind—there are certain people that can hold that experience in a positive way that might benefit them… and probably some of these over 2,000 folks, there’s probably some people that—again, aside from whether we know it’s true or not—believing in things that no one else can prove are there is probably a bad thing.” [12:38] “The machine elf thing, I mean, that was Terrence McKenna’s trip. And he described it—and I think he was very honest that that was his experience—and I think people who’ve heard his experience, a good number of them have had machine elf experiences because they heard Terrence McKenna’s experience.” [16:17] “Before the experience, 28% of these people identified as atheist, and then after the encounter that dropped to 10%.” [20:53] Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson’s DMT Entity Study: Survey of Entity Encounter Experiences Occasioned by Inhaled N,N-Dimethyltryptamine: Phenomenology, Interpretation, and Enduring Effects Psychedelic Medicine Association Porangui…
1 Psychedelics and Women’s Health with Allison Feduccia, PhD 43:03
43:03
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:03In this episode of the psychedelic medicine podcast, Allison Feduccia, PhD joins to discuss the intersection of psychedelic medicine and women’s health. Dr. Feduccia is a neuropharmacologist, psychedelic researcher, and builder of virtual and in-person communities. She is cofounder of two prominent organizations, psychedelic.support and Project New Day, and is additionally a scientific advisor for Eastra. Alli has been researching psychedelics since 2004 when she first began studying MDMA and has subsequently been involved in the field through work at numerous universities, the NIH, and MAPS. In this work she seeks to spread evidence-based knowledge, connection to resources, and strategies for individuals to maximize potential therapeutic benefits of psychedelics through safe and responsible practices. In this conversation, Alli responds to questions touching on all areas of women's health and the impact psychedelics could have specifically for female patients. A major theme of the discussion is the interplay between psychedelics and hormones. While this is a topic with little in the way of scientific research, Alli shares some interesting ideas about how the neuromodulation of psychedelics could interact with endocrine systems, and how serotonin receptors within the uterus could explain certain anecdotal reports of various effects of psychedelics on menstrual pains or irregularities. In a similar vein, Alli discusses some of the physiological effects of psychedelics, particularly in relation to blood flow, and how these non-experiential features of these compounds could actually be helpful properties for women with certain conditions. This insight leads to interesting avenues for future drug development and also stresses the importance of studying psychedelics at different doses so that the positive health effects can be isolated. Alli also talks about the potential for psychedelic healing in the context of postpartum depression, sharing an evocative family story which illustrates simply how crucial and overlooked this issue has been in healthcare. The advances in mental healthcare coming out of psychedelic research provide a promising path forward for such conditions, however. In this episode: How psychedelics could help with premenstrual discomfort Concerns about taking psychedelic substances while pregnant Psychedelics and postpartum depression How psychedelics could impact hypoactive sexual desire disorder Psychedelics interactions with menopause Potential role for hormones alongside set and setting for impacting the psychedelic experience Quotes: “It may be that psychedelics could really affect women’s moods as they go through these different life stages, and help them feel better.” [4:45] “Maybe this concept of neurotransmitter modulation with our sex hormones may be a target for drug development work as well.” [23:42] “This is also pertinent to transgender women who may be using hormones. This type of modulation on mood or physiological symptoms—this could be really applicable too for helping to really have the body adjust and be more balanced to changes in hormonal fluctuations in the body.” [26:59] Links: Psychedelic.support website Project New Day website Eastra Health Psychedelic Medicine Association Porangui…
1 Psychedelics and Sexual Trauma with Laura Mae Northrup, MFT 1:04:23
1:04:23
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:04:23In this episode of the Psychedelic Medicine Podcast, Laura Mae Northrup, MFT joins to discuss the crucial topic of psychedelics and sexual trauma. Laura is an author, education, and somatic and relational psychotherapist. She brings a spiritual and politicized lens to her therapeutic work and is deeply invested in mentoring healing practitioners and supporting the spiritual integrity of our collective humanity. In addition to her therapeutic practice, Laura is also a podcaster and has addressed the topic of psychedelics and sexual trauma in her show Inside Eyes. In this wide-ranging conversation, Laura addresses the subject from two angles: first, looking at how psychedelic medicine can be effective in helping survivors of sexual trauma heal; and second, examining how sexual abuse is perpetrated within the context of psychedelic therapy. To address the topic of psychedelic healing for survivors, Laura explains how sexual trauma has an affective aspect and an aspect related to the nervous system. With that in mind, it’s clear how psychedelics can be a powerful tool in helping survivors encounter difficult feelings and work with their nervous system. Laura also shares an interesting hypothesis regarding why ketamine—a dissociative substance—is actually often very helpful for people who dissociate in their daily lives as a trauma response. She contrasts this daily dissociation with the ketamine experience by explaining that as a trauma response dissociation works by compartmentalizing experiences and feelings, while the ketamine experience softens those boundaries, allowing the survivor to have a more integrated experience of themself. Laura also emphasizes the necessity to go slow and put in a lot of prep work to ensure any psychedelic healing experiences are as safe and effective as possible for survivors. Because of the dynamics of trauma, it is easy to be eager for an experience of dramatic healing, but because of how powerful psychedelics can be, and because of the power that facilitators and guides have over participants during therapy, these can also be dangerous experiences which could lead to additional traumatic experiences. As such, ensuring a high level of comfort and trust prior to a session is essential, and, if that cannot be achieved, it is safer to pursue other kinds of healing until the right opportunity is available. Finally, Laura discusses the crucial topic of sexual violence within the context of psychedelic therapy. She mentions that even within the more formal context of conventional therapy—with its checks and balances of professional licenses and credentials—there is a shocking amount of sexual misconduct between therapists and clients. Considering that a lot of psychedelic therapy continues to operate underground due to prohibition, there is serious cause for concern about the prevalence of this issue. Laura explains how, especially in the context of the psychedelic experience, it is impossible to give true sexual consent. This is doubly the case due to the power differential between a client and a psychedelic therapist. Laura concludes this discussion by emphasizing that healing for those providing psychedelic therapy is absolutely crucial to address this issue, as it is because these guides and facilitators have not properly addressed their own healing that they continue to perpetrate abuse. In this episode: The state of research on psychedelic healing for survivors of sexual assault The relationship between preparatory work and the efficacy of psychedelic therapies for people with PTSD The difficulty of choosing the right guide or facilitator as a person with trauma Why there isn’t one best medicine to heal sexual trauma Why ketamine may be effective for people struggling with dissociation due to traumatic experiences The importance of the three domains of mind, body, and spirit in psychedelic work The variety of ethical concerns relating to behavior of guides or facilitators Quotes: “I really enjoy supporting survivors to heal, but also we need to be talking about this very, very concerning issue of people sexually abusing their clients.” [6:07] “When we’re talking about healing from trauma, a lot of times what we’re talking about is growing the capacity to experience and endure very big feelings.” [11:00] “Being able to work with trauma is like way more than just a little tiny workshop, I mean it's truly something you’re learning to do throughout your career, it involves a lot of extensive training and consultation and guidance from more seasoned practitioners.” [24:21] “If something is so powerful that it could do that much profound healing for you, man just make it the best it can be. Go with [a facilitator] that you don’t have any reservations about.” [33:00] “You can always pause a therapy. And there can be such an emphasis on ‘no, move forward’—you can just say ‘that was weird for me, I need time.’ You can go and you can talk to your other people.” [45:29] “It’s so complicated because the person you would maybe think is the number-one person you would go to to talk about something like this, is your therapist, who is also the person harming you.” [46:54] “We need to show up to our own healing, because that’s why we abuse people, that’s why we harm people, because we are not doing our own healing work.” [56:48] Links: Laura’s website Inside Eyes Podcast Laura’s forthcoming book Radical Healership: How to Build a Values-Driven Healing Practice in a Profit-Driven World (use code radical35 for 35% off and free shipping) Laura on Instagram Psychedelic Survivors website (new resource referenced at the end of the show) Psychedelic Medicine Association Porangui…
1 Psychedelic Therapies for Pain with Joel Castellanos, MD 29:50
29:50
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
29:50In this episode of the Psychedelic Medicine Podcast, Joel Castellanos joins to discuss the emerging topic of psychedelic therapies for pain-related conditions. Dr. Castellanos is a Board certified physical medicine and rehabilitation and pain management physician and an associate professor in the department of anesthesiology at UC San Diego school of medicine. He earned his medical degree from University of Toledo college of medicine and has since completed a two year program in healthcare administration during his residency at University of Michigan, as well as a fellowship in pain medicine at UC San Diego school of medicine. Most recently he completed the integrative medicine fellowship from the University of Arizona. In this conversation, Dr. Castellanos introduces the topic of psychedelics as a therapeutic modality for various pain conditions. Dr. Castellanos explains that much of the pain management field focuses on neuromodulation as the basis for particular therapeutic techniques, so psychedelics—which have profound modulating effects within the brain—naturally seem promising. However, research into this topic is still developing, with studies from the seventies providing some initial data which is now being corroborated and expanded by contemporary research. Dr. Castellanos shares the details of this work, explaining how combined psychedelic treatment and mirror box therapy could prove to be particularly efficacious for individuals suffering from phantom limb pain. In light of the upcoming trials led by Dr. Castellanos and his colleagues at the Psychedelic Health Research Initiative at UC San Diego, he also discusses certain special considerations for working with amputees as guides or facilitators of psychedelic therapy. The double blind randomized controlled trial investigating the efficacy of psilocybin therapy for phantom limb pain will be conducted first and is currently enrolling. This study seeks to test the efficacy of psilocybin therapy for this condition as well as elucidate its potential mechanism of action through brain imaging. Click here to enroll . In this episode: An overview of the literature on psychedelics and pain Albert Lin’s experience treating his phantom limb pain with combined psychedelic and mirror box therapy Why psychedelics may be a great alternative to many current treatment options for chronic pain Stories of healing resulting from psychedelic therapy in patients who have suffered with chronic pain How to enroll in Dr. Castellanos’ upcoming trial for patients with phantom limb pain Quotes: “It’s really interesting to me that neuromodulation - modulating the nervous system - is such a big part of pain medicine—and no one had really looked at psychedelics as an option when they are something that really modulates the nervous system in a profound way.” [4:24] “I don’t want people to think that this is going to be a panacea, that this is going to be the cure for everything and everyone’s pain because we need to do the research, we need to do the work and really answer the clinical question on who this is going to be most efficacious for.” [7:50] “Where there has been the most evidence so far and the most work done is in the headache patient population, which is definitely needed. There are so many people who suffer from migraines, from cluster headaches, and it can be really debilitating.” [17:45] “In the same way that patients who have had PTSD or have severe anxiety or depression it helps to do some talk therapy with those [psychedelic therapy] sessions, maybe some movement therapy during the psychedelic sessions may be beneficial [for treating pain].” [23:26] Links: Enroll in Dr. Castellanos’ upcoming study through PHRI at UCSD Dr. Castellanos on Twitter Psychedelic Health Research Initiative at UC San Diego Psychedelic Medicine Association Porangui…
1 MDMA-Assisted Therapy for PTSD with Rick Doblin, PhD 1:18:54
1:18:54
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:18:54In this episode of the Psychedelic Medicine Podcast (formerly the Plant Medicine Podcast), Rick Doblin joins to discuss the past, present, and future of MDMA-assisted therapy. Rick Doblin is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies. He received his doctorate in public policy from Harvard and has also studied under the father of transpersonal psychology Stanislav Grof. Through MAPS, Rick aspires to develop legal contexts for beneficial uses of psychedelics and marijuana as prescription medicines, but also for self-development and personal growth in otherwise healthy individuals. Rick begins this wide-ranging conversation discussing the early days of MDMA. The compound was originally synthesized by famed chemist Alexander "Sasha" Shulgin and, unlike the classic serotonergic psychedelics, it was not scheduled under the Controlled Substances Act in the early 70s. It was during this period of legality that therapeutic uses of MDMA were first developed and it was only later that the drug became repurposed as a recreational substance to be used in social settings, which consequently led to its emergency scheduling by the DEA. Rick recalls his own initial experiences with the empathogenic compound, stating that he was initially skeptical of its value, prior to gaining first-hand experience. Following this experience, however, he became convinced of its therapeutic potential and he shares some of his own early experiences of using MDMA to help people heal, including a very touching tale of his own grandmother’s struggle with depression. From here, Rick discusses the founding of MAPS and his decision to pursue education in policy in order to better understand strategies for furthering MDMA-therapy even while living under prohibition. Since that time, MAPS has gone on to do incredibly impactful work in developing studies researching the safety and efficacy of MDMA-assisted therapy, specifically for post-traumatic stress disorder. Rick shares the progression of these studies, highlighting the results from the most recent phase three investigations which are the last step prior to FDA approval for the therapeutic protocol. These studies show high statistical significance and an amazing effect size resulting from MDMA-assisted therapy, with results being mirrored at all research locations and showing durability over time. Because of this amazing progress, Rick believes we are at the final stretch prior to full FDA approval for MDMA use in a therapeutic context for PTSD, and subsequent rescheduling of the substance by the DEA, which he believes will take place in mid to late 2023. This development will have broad global impacts, spurring other countries to promptly follow suit. Rick closes out this discussion by emphasizing the need for mass mental health in our day and age, and sharing MAPS’ lofty goals of training thousands of therapists to hopefully bring psychedelic therapy to millions of patients in the coming decades. In this episode: Rick Doblin’s personal journey The history of the MDMA’s synthesis and legality Rick’s first experiences with MDMA and early experiments with MDMA therapy MAPS’ “two-pronged” strategy for mass mental health Early efforts to get an MDMA therapy protocol approved by the FDA following prohibition The politics of concerns about MDMA neurotoxicity and how this impacted MAPS’ early approach The results of the first phase three studies of MDMA for PTSD How FDA approval of MDMA will lead to an international cascade of approval and rescheduling Rick’s predictions for psychedelic medicine in the years to come Quotes: “What a lot of people don’t know is that MDMA was a therapy drug before it was a party drug. And it was the party drug nature of it that really got it criminalized.” [7:38] “Seeing what it was like when it was legal and experiencing that, and experiencing situations where people would take it, the kind of experiences and healings, and learnings that people would have, was amazing.” [19:12] “What we need is, I believe, legal access to medicinal MDMA, covered by insurance, by trained professionals, and psychedelic clinics. And we also need a whole different kind of drug policy for non-medical use that involves honest drug education, access to pure substances, harm reduction, peer support, and also treatment on demand.” [21:08] “The irony here is that the first legal move against MDMA was illegal. The DEA did not have the authority to emergency schedule drugs.” [23:43] “FDA is legally bound to approve MDMA for PTSD if these [phase 3] studies generate statistically significant evidence of efficacy, and there are no new safety problems.” [40:27] “We think by the third quarter of 2023 we will have FDA approval assuming the second phase 3 study goes well. And then by the fourth quarter, the DEA has to reschedule [MDMA].” [51:18] “What’s even greater is the 12-month follow-up data was 67% no longer had PTSD. So people kept getting better—not only was it durable, but they kept getting better.” [55:00] “The thing to emphasize here is that MDMA is not the treatment. The treatment is therapy. The MDMA makes the therapy more effective and there can be different kinds of therapy that are used with it.” [1:01:38] Links: MAPS website Rick Doblin on Twitter Trip of Compassion Documentary The Way of the Psychonaut Books by Stanislav Grof Upcoming MAPS Psychedelic Science Conference 2023 Becoming an MDMA-Assisted Therapist with Shannon Carlin, MA, LMFT Psychedelic Medicine Association Porangui…
1 Psilocin vs. Psilocybin: Differences & Potential Clinical Uses with Josh Woolley, MD, PhD 46:06
46:06
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
46:06In this episode of the Plant Medicine Podcast, Dr. Josh Woolley joins to discuss the differences between psilocin and psilocybin, and to share upcoming clinical research which will further clarify the safety profiles, subjective effects, and clinical uses of these psychedelic substances. Dr. Woolley is an Associate Professor in Residence in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). He is Board Certified in Psychiatry by the American Board of Psychiatry and Neurology. He is the Director of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) lab at UCSF that focuses on understanding and treating social deficits in neuropsychiatric disorders including schizophrenia, substance use disorders, and mood disorders. He is also the Director of the Translational Psychedelic Research (TrPR) Program at UCSF, which brings together scientists and care providers across disciplines to understand how psilocybin, LSD, ketamine, MDMA, and related compounds impact the brain and other organ systems. In this conversation, Dr. Woolley begins by sharing a bit about TrPR and the upcoming research they will be conducting on psychedelics as a treatment for depression in individuals living with Parkinson's disease. Dr. Woolley then introduces the main topic of psilocin, psilocybin, and the differences between these two compounds. He explains that psilocybin is a prodrug for psilocin, meaning that the human body metabolizes psilocybin into psilocin, which is the compound responsible for the psychoactive effects produced by psilocybin-containing mushrooms. Dr. Woolley’s upcoming research will provide more concrete data on the differences between these two compounds, as TrPR will be testing both psilocybin and psilocin in healthy volunteers, giving each participant both substances on different occasions so that effects can be studied both across the sample pool and within individuals. Dr. Woolley hypothesizes that psilocin could have certain clinical advantages over psilocybin: it could produce more consistent effects person-to-person at a given dose as individual differences in metabolism would be less relevant; it may more quickly induce a psychedelic experience, particularly when administering psilocin sublingually; and it is possible there may be fewer side effects related to the gastrointestinal tract. Dr. Woolley closes out the discussion by sharing other upcoming research to be conducted by TrPR. In addition to the study investigating psilocin and the research into psychedelics for Parkinson's disease, TrPR is also investigating the use of psychedelics to improve quality of life for individuals suffering from chronic pain and they will also be further investigating the interaction between psychedelics and bipolar disorder. In this episode: The approach of the Translational Psychedelic Research (TrPR) Program and its upcoming research The pharmacological differences between psilocybin and psilocin and how the experience induced by the substances may differ In-subject study design and how it is used in Dr. Woolley’s psilocin trials The mechanisms for tolerance with using psychedelic drugs Data on the contraindication of psychedelic use for individuals with bipolar disorder Quotes: “For a long time, when you make [psilocin] synthetically—[...]—psilocin wasn’t stable. So, even if you made psilocin synthetically you would then turn it into psilocybin so it would be stable and then people would take it and it would get turned back into psilocin.” [8:39] “You can’t do sublingual psilocybin because it won’t get broken down easily. But, sublingual psilocin doesn’t need to be metabolized and it can go across your buccal membrane, skipping the gut. That theoretically could be useful because then you might skip the first pass metabolism, it doesn’t have to go to the liver, and it might be faster that way and maybe again more consistent. And fewer side effects—maybe you won’t get any GI side effects if it doesn’t go to the GI tract.” [19:58] “We think that psychedelics—psilocybin in particular—might be able to change people’s relationship to their [chronic] pain. It might be an analgesic too—it might make the pain go away, that would be great. But even if it doesn’t do that, we think that it should allow people to basically find the pain less impairing.” [41:22] Links: The Translational Psychedelic Research (TrPR) Program at UCSF Psychedelic Medicine Association Porangui…
1 Encore episode: Microdosing Q&A with James Fadiman 1:31:57
1:31:57
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:31:57James Fadiman, PhD, was a part of the first wave of pioneering psychedelic researchers in the 1960s in the US. He’s the co-founder of the Institute of Transpersonal Psychology, now known as Sofia University, and he’s the author of several well-known psychedelics books, including The Psychedelic Explorer’s Guide . From his initial rediscovery of microdosing and developing a protocol based on early reports, Dr. Fadiman teamed up with Dr. Sophia Korb to record and pattern-map the microdosing experiences of several thousand individuals from 51 countries. In this episode, Dr. Fadiman answers listener-submitted questions regarding microdosing psilocybin and LSD. He discussed dosing recommendations, tolerance, microdosing's general effects on healthy normals, and its specific effects on a number of conditions, ranging from depression to PMS. He also covered a variety of additional areas where people benefit from microdosing, including academic performance and athletics. In the last part of the episode, Dr. Fadiman discusses his new book, Your Symphony of Selves . He points out that we have not one, but a multitude of selves, and that we can learn to shift between them consciously. Further following this idea, he illustrates how we can save a lot of mental distress by not over-identifying with any particular one of our selves, and how we can extend that concept to those around us. This helps us not only forgive others when one of their selves may have acted in a displeasing way but also helps us forgive and go easy on ourselves when we act in a way that we later find distressing or shameful. In this episode: The reported benefits and risks of microdosing psilocybin mushrooms and LSD. Whether someone’s height and weight makes a difference on their dosage. The overwhelming number of those suffering from depression who reported significant improvements in their survey. Why microdosing may not be advisable for those with anxiety. Dr. Fadminan reports on study findings regarding conditions including depression, PMS, migraine headaches, and bipolar Quotes: “A lot of people have found that when they’re tapering off of an SSRI, which means taking it down very, very slowly over a period of maybe a couple of months from full dose to zero, that microdosing helps. That makes it easier. Makes it maybe even a little faster.” [14:13] “I’m an enthusiast for the effect of microdosing, but I never recommend that anyone microdose. That’s a personal decision based on information, but the nice thing is the risk/reward ratio, which is how dangerous versus how beneficial. It’s very good for microdosing. Meaning, if you take it, it’s very low risk, and yeah, from the reports, we have a lot of possibility of benefits.” [35:00] “What we’ve found is that about 80% of the people who come in with heavy depression, and again, most of them having failed medications or other therapies, we’ve about an 80% turnaround rate where they’re not depressed. That’s really striking.” [42:00] “They (students) say: “Microdosing is very much like Adderall, except with none of the very disturbing side effects.” Adderall includes crashing, by the way. And addiction.” [49:18] “Individual neurons in the laboratory, exposed to microdoses, grow into more healthy, more complex neurons with more dendrites, meaning more communication capacity.” [52:17] In discussing his new book, Your Symphony of Selves : “The inconsistencies you see in yourself and particularly in the people you love are not inconsistencies. It is that they have several selves, and you do too. And if you begin to think in that way, curiously, the world becomes easier. You understand things differently and you are kinder to yourself and more compassionate to others.” [1:10:43] Links: Psychedelic Medicine Association Microdosing Psychedelics James Fadiman’s website and email: jfadiman@gmail.com Cluster Busters - treatment for cluster headaches Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui Studies mentioned: Psychedelics Promote Structural and Functional Neural Plasticity Books Mentioned: A Really Good Day by Ayelet Waldman The Psychedelic Explorer’s Guide by James Fadiman PhD Your Symphony of Selves by James Fadiman PhD, Jordan Gruber JD…
1 Delta-8 THC: Your Questions Answered with Dr. Carey Clark 32:09
32:09
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
32:09This episode of the Plant Medicine Podcast features a conversation with Dr. Carey Clark, discussing delta-8 THC. Dr. Clark is a registered nurse and an expert in cannabis care nursing. She holds a PhD from the California Institute of Integral Studies and is the immediate past president of the American Cannabis Nurses Association. She is also the editor and author of the first nursing textbook on medical cannabis Cannabis: A Handbook for Nurses and has over thirty publications in academic journals. Currently Dr. Clark serves as a professor at Pacific College of Health and Science where she also developed the first college-level, academic certificate in medical cannabis. In this conversation Dr. Clark introduces delta-8 THC, discussing its chemistry, pharmacology, and legal status. She begins by sharing that delta-8 is a minor cannabinoid which exists naturally in small quantities within cannabis and hemp. Delta-8 THC is chemically very similar to delta-9 THC—the primary cannabinoid within cannabis which is known for its mind-altering and medicinal properties—and in fact, delta-9 naturally degrades into delta-8 under certain conditions. Due to the structural similarities, delta-8 produces similar effects to delta-9, and may have similar medical applications. Dr. Clark mentions that delta-8 may be synthesized from CBD, allowing for this compound to be readily produced from legal components. However, the delta-8 which results from these synthesis methods contains traces of unknown compounds, perhaps as a result of the particular solvents used in the reaction, so Dr. Clark cautions that consuming these products could have certain risks, though the delta-8 cannabinoid itself is thought to have a similar safety profile to delta-9 THC. Instead. Dr. Clark emphasizes that whole plant medicines are likely the ideal for patients seeking to treat medical conditions with cannabis, but since delta-8 may be more readily available in certain areas due to its murky legal status it may be the best option for some individuals. While scientific research into delta-8 is currently lacking, Dr. Clark shares the results from a few studies which use animal models and one study looking at the effects of delta-8 in the context of pediatric oncology. In addition to these published studies, Dr. Clark also shares anecdotal reports from patients, saying that these experiences are crucial, preferring to think of these reports as qualitative data which has yet to be systematically studied. In this episode: What delta-8 THC is and how it is made Potential safety concerns with delta-8 products The current research on delta-8 The legal grey-area of delta-8 THC and states which have banned the cannabinoid Differences in the doses and effects of delta-8 and delta-9 THC Quotes: “My hope as well is that people who are able to access whole-plant medicine can really use whole-plant medicine safely and effectively and they have access to safe, effective medicines. That would be my recommendation—if somebody had a choice—over choosing a really synthesized medicine at this point because of the safety issues.” [15:30] “[T]there’s still very little research and most of the patient experience we’re hearing is really anecdotal.” [24:52] Links: Dr. Clark’s faculty page at Pacific College of Health and Science Psychedelic Medicine Association Porangui…
1 The Dark Side of Ketamine (and how to Stay in the Light) with Dr. Mark Braunstein 31:40
31:40
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
31:40In this episode of the Plant Medicine Podcast, Dr. Mark Braunstein returns to discuss potential concerns surrounding the use of ketamine, especially use which is not overseen by a knowledgeable medical professional. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. Additionally, Dr. Braunstein is involved in multiple projects focused on expanding access, awareness, research, and safety in the field of psychedelics. To begin this conversation, Dr. Braunstein shares how his original exposure to ketamine wasn’t in a medicinal context, but rather as a recreational drug of abuse. However, since then he has seen the transformative effects this substance can have on patients when used in a physician-directed context and for therapeutic purposes. Nonetheless, Dr. Braunstein stresses that this does not mean ketamine use does not come with certain risks. Ketamine can be addictive and even carries a risk of overdose, particularly when used recreationally in a context where the purity of the substance is unknown. Dr. Braunstein distinguishes recreational and therapeutic uses of ketamine, explaining that recreational doses are often lower and dosing is more frequent, whereas ketamine is used in high doses in a therapeutic context, with extended periods between sessions. Dr. Braunstein stresses both the responsibility of physicians and of patients to ensure ketamine is prescribed responsibly and used as directed. Despite the dangers posed by recreational ketamine use Dr. Braunstein describes in this conversation, it is still a medicine he believes can have significant positive impacts for patients. This requires, however, that it not be treated merely as yet another quick fix pill. Instead, Dr. Braunstein emphasizes that ketamine treatment ought to coincide with psychotherapeutic work. This combination, he says, will maximize the therapeutic potential of ketamine while also helping to ensure that the medicine is used responsibly, under the close direction of a medical professional. In this episode: The addiction and overdose potential with recreational ketamine use How dosage can dramatically change the effects of ketamine Responsible prescribing practices for physicians working with ketamine The psychological and physiological harms of ketamine abuse How Dr. Braunstein talks to his patients about responsible use before prescribing ketamine The importance of combining psychedelic medicines with psychotherapeutic work Quotes: “Part of why ketamine works is because it lights up your brain in all these different ways and when done occasionally, intentionally, it moves you. But if you’re always doing that, it ends up having the reverse effect, causing damage.” [12:56] “This is a heavy-duty medication that, if you cross the line, can cause you to stop breathing and then die. So there is an actual, real danger to ketamine.” [16:25] “I think the organ that is most prone to damage from overuse of ketamine is the same organ we are touting it fixing: the mind.” [18:39] “When we think about these medications, we should think about combining them with therapy and not just taking these medications as medications… So that’s why with ketamine I’m really recommending it with therapy.” [25:04] Links: Reconscious Medical Psychedelic Medicine Association Porangui…
1 Becoming an MDMA-Assisted Therapist with Shannon Carlin, MA, LMFT 46:36
46:36
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
46:36This episode of the Plant Medicine Podcast features a conversation with Shannon Carlin, MA, LMFT, to discuss how to become an MDMA-assisted therapist, including a discussion of the MAPS training program. Shannon is the Director and Head of Training and Supervision at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit where she oversees the development and implementation of clinical training programs that prepare mental health and medical professionals to deliver MDMA-assisted psychotherapy in approved clinical settings. Shannon started working with MAPS in 2011 before joining MAPS PBC in 2016. In this conversation, Shannon discusses her personal background and some of the nuances of psychedelic-assisted therapy. Shannon shares her experiences being trained as an MDMA facilitator in 2014 when this therapy was much less mainstream and mentions how much the program has grown and evolved since then. In discussing her own background with various forms of therapeutic work, Shannon emphasizes the unique client relationship obtained in the longer sessions of MDMA therapy, saying that this therapy is very well-suited to meeting people in their time of need. Shannon also discusses the details of the 100-hour MDMA-assisted therapy training program she leads and supervises at MAPS. The program consists of an online course, a training retreat with senior MDMA-assisted psychotherapy researchers, and opportunities for experiential and didactic learning. Shannon additionally touches on the topic of MDMA therapists-in-training undergoing this treatment themselves as a learning experience, stating that this is an opportunity MAPS tries to make available and that many of those who have had this opportunity found it beneficial to their future work with MDMA in a therapeutic context. In closing, Shannon discusses MAPS’ commitment to equity and mentions that some scholarships will be available for the training program. The MAPS MDMA Therapy Training Program is now accepting applications from trained mental health and medical practitioners. To learn more, visit https://mapspublicbenefit.com/training In this episode: How MDMA therapy differs from traditional talk therapy The importance of nurses and other paraprofessionals in MDMA-assisted psychotherapy The history of the use of MDMA in therapeutic contexts prior to prohibition Current training programs in psychedelic-assisted psychotherapy The future of legal MDMA use in therapy What skills translate from MDMA psychotherapy to other forms of psychedelic psychotherapy How to enroll in the next round of MAPS MDMA training Quotes: “Our training program really focuses a lot on the therapeutic relationship in MDMA therapy and the ways that that relationship changes, deepens, becomes more complex.” [13:20] “As we do our training program we have a really multidisciplinary group. We have physicians and psychiatrists and we have nurses, we have psychiatric nurses, social workers, therapists, psychologists, clergy people.” [15:56] “We work in a cotherapy model so every session has two providers in the room, so we always have one person who is licensed to practice psychotherapy and then we have flexibility about exactly what the role of the second person is.” [26:09] “We’re looking at possibly MDMA-assisted therapy becoming a legal treatment medicine, not only in the US, but in multiple countries, even as soon as in the next two years.” [28:21] “It’s really difficult to do healthy volunteer therapist studies because the FDA thinks about clinical trials in terms of treating a disease.” [35:21] Links: MAPS MDMA Therapy Training MAPS Public Benefit Corporation Psychedelic Medicine Association Porangui…
1 Psychedelics and Parenting with Rebecca Kronman, LCSW 51:33
51:33
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
51:33This week’s episode of the Plant Medicine Podcast features a conversation with Rebecca Kronman, LCSW on the intersection of psychedelics and parenting. Rebecca is a licensed therapist with a private practice in Brooklyn, New York, where she helps clients integrate and prepare for psychedelic experience, in addition to providing therapeutic care for clients struggling with mental illnesses such as anxiety or depression. Rebecca is also the founder of Plant Parenthood, which is an online and in-person community of parents who use psychedelics, plant medicine and cannabis looking to de-stigmatize the conversation around psychedelics and parenting. In this wide-ranging discussion, Rebecca explores both practical and theoretical issues in the intersection of psychedelics and parenthood. The most controversial of these being, of course, minors using psychedelics themselves. Rebecca discusses the traditional cultural frameworks in societies which use psychedelics and how they handle this matter, contrasting this with the Western medical model where psychedelic use is highly stigmatized yet prescribing amphetamines to children is rather uncontroversial. Rebecca emphasizes that this is a topic which deserves more careful consideration, as ketamine treatments are already available and effective for treatment-resistant depression in teens. She also discusses how psychedelics can help us reparent ourselves and heal generational trauma, both of which can aid in improving parents’ relationship to not only their children, but to their own parents as well. In addition, Rebecca discusses some practical concerns, such as how parents ought to discuss psychedelic use with children. Here she draws a distinction between proactive and reactive conversations, the former being initiated by the parent, the latter by the child. Choosing to pursue a degree of proactive discussion with children around psychedelic use can have a positive impact, both in strengthening trust and openness between parent and child as well as preparing older children for encountering these things in their own lives as accessibility and awareness continue to increase. Rebecca closes this discussion talking about the high levels of scrutiny parents face socially, emphasizing the importance of parents having the opportunity to come together around this topic to determine the best solutions for their own families. In this episode: The future of psychedelic medicines for minors How psychedelics can inform one’s approach to parenting Taking psychedelics with family members Including children in integration practices Proactive vs reactive conversations about substance use with children Plant Parenthood’s upcoming events Quotes: “It’s something that needs to be on our minds: how do we approach this topic without stigmatizing it so that when our children inevitably find out about it, we can have an open dialogue.” [11:39] “A lot of the work of psychedelics, is the work of reparenting yourself. It’s the work of healing intergenerational trauma.” [16:49] “For some parents it’s not a problem for their children to be around during their psychedelic experience itself, and for some parents they feel like ‘you know what, I want this time for myself–this is my time to go inward, to journey into my psyche, and I don’t want to be a parent during that moment.’” [24:25] “We can start talking about plant medicine or substance use or addiction from the very earliest time our kids can understand.” [29:28] “As kids get older it does become more important to be a bit more proactive because the reality is they will be exposed to this, especially as access increases.” [32:43] “There is a level of scrutiny that parents face that is different than what other people face and it makes people more reticent to be honest and to approach these topics in a way that feels healing and that feels complete.” [41:29] “[Psychedelics] make us be able to inhabit that open, neuroplastic state that children naturally inhabit. So in a sense, it makes us be able to understand them better. It makes us be able to get into their experience in a deeper way.” [46:42] Links: Plant Parenthood Website Plant Parenthood Instagram Plant Parenthood Facebook Plant Parenthood YouTube Rebecca’s website Psychedelic Medicine Association Porangui…
1 Psychedelic Apprenticeship: Validating Psychedelic Insights and Revelations with Chris Timmermann, PhD 53:39
53:39
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
53:39In this episode of the Plant Medicine Podcast, researcher Chris Timmermann, PhD joins to discuss his recent publication regarding psychedelic apprenticeship. Dr. Timmermann is a researcher at the Center for Psychedelic Research at Imperial College London where he conducted the first neuroimaging studies of DMT in healthy volunteers to explore potential mental health impacts. He is also the president and founder of the Foundation for the Study of Human Consciousness in Chile. Dr. Timmermann’s paper "Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations" was recently published in December 2020 and it provides a framework for tackling the difficult problem of mediating knowledge gained during psychedelic experiences. In this conversation, Dr. Timmermann breaks down his article and discusses how different contexts for psychedelic use (such as therapeutic, neo-shamanic, and research) each come with their unique concerns in terms of the knowledge these experiences can induce. Highlighting the fact that it is the same mechanism causing both therapeutic benefits and potential distress following psychedelic experience, Dr. Timmerman explains that psychedelic guides and even researchers can profoundly influence the content of a psychedelic experience. His framework for apprenticeship seeks to address how guides and researchers can best wield this influence positively, and provides suggestions for how to better approach the integration of experiences which feature visions or insights that can be difficult to understand and internalize. In this episode: Dr. Timmermann’s framework for psychedelic apprenticeship Why psychedelic revelations can be a double-edged sword Psychedelic insights and vision in therapeutic, neo-shamanic, and research contexts Spiritual bypassing in the psychedelic community What gives psychedelic or mystical visions their sense of authority Quotes: “There is a strong need for an intersubjective component to validate this knowledge, these revelations, these insights.” [8:45] “The striking thing that I thought was really important was that it seems to be the same mechanism which drives the benefits but also drives the complications.” [15:58] “The broader culture is inviting some sorts of narratives and experiences and because the psychedelic state is a permeable state, the system is porous to these narratives and memes.” [33:33] “This process of apprenticeship essentially is a framework for us to understand how we can help make sense of these experiences for people, how they can approach the experience, but with a light touch.” [41:55] “What we’re doing with the science and what we’re doing with these papers and so on is providing some form of context, some form of mediation, some form of knowledge to try to contain these experiences a bit more.” [50:26] Links: Dr. Chris Timmermann on Twitter Center for Psychedelic Research at Imperial College London Dr. Timmermann’s recent paper “Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations” Psychedelic Medicine Association Porangui…
1 Psychedelic Harm Reduction with Erica Siegal, LCSW 52:01
52:01
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
52:01This episode of the Plant Medicine Podcast features a conversation with Erica Siegal about the intricacies of harm reduction. Erica is a licensed clinical social worker and a professional harm reductionist, as well as an MDMA-assisted psychotherapy researcher. She is the founder of NEST Harm Reduction, a California-based clinical practice that offers private therapy, harm reduction training, workplace consulting, and direct care of workers on the frontlines of secondary trauma. In this discussion, Erica shares the basic principles underlying harm reduction while also unpacking the nuances involved in providing care. The four principles Erica shares from the Zendo project are: 1) creating a safe space, 2) sitting, not guiding, 3) talking through rather than talking down, and 4) remembering difficult is not the same as bad. These principles provide a basic framework for providing harm reduction services for someone who has chosen to experiment with psychoactive substances. Erica also discussed the acronym SPACE, which stands for sustainable, patient, authentic, consensual, and empathetic, with each of these terms playing a crucial role in effective harm reduction work. Sustainable refers to the emotional and energetic toll this work can take, and ensuring one isn't spread too thin and heading towards burnout. Patience is necessary when engaging with someone who is going through a challenging experience, especially when their needs are shifting or they are having difficulties communicating. Erica describes authenticity in the harm reduction context as staying grounded in one's training and expertise and not trying to improvise modalities while sitting. Consent is also crucial when providing care, and Erica explains how to approach this topic both in the context of a pre-planned psychedelic experience and when the opportunity for harm reduction arises more spontaneously. Finally the harm reductionist should strive to be empathetic, providing proactive support through open communication and attempting to meet needs as they arise. In this episode: The four guiding principles of psychedelic harm reduction Why romantic partners often don't make the best trip sitters The intricacies of consent in a harm reduction setting Dealing with burnout as a harm reduction professional How to hold space in an authentic, empathetic way Gamifying harm reduction Quotes: "Harm reduction is a movement for people who believe in human rights and dignity for anybody, including people who are actively using drugs." [5:31] "When we go into an altered state or use psychedelics, we are obviously shifting our perspective and therefore we need to make sure we have some safe things that can ground us back into our bodies and our experiences." [11:57] "If you are burning out and you are becoming someone who needs help, you're not actually holding the space to do the work." [19:32] "I think all psychedelic practitioners, whether you are above ground or underground, should provide informed consent to clients." [30:23] "The only things that we do with somebody who is that significantly altered is be patient with them, and wait for them to be able to make decisions for themselves." [36:29] "Make sure you're checking in about peoples' basic needs because they forget. And that could be the thing that shifts it onto the right direction for them." [49:54] Links: NEST Harm Reduction Psychedelic Medicine Association Porangui…
1 Psychedelics for Eating Disorders with Reid Robison 39:04
39:04
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
39:04This first episode of the Plant Medicine Podcast in 2021 features a conversation with Dr. Reid Robison, discussing the potentials of using psychedelics to treat eating disorders. Dr. Robison is a board-certified psychiatrist and the chief medical officer at Novamind. He is also the co-founder of Cedar Psychiatry, founder of the Polizzi Free Clinic, and adjunct faculty at the University of Utah. Dr. Robison serves as the medical director of Center for Change—a top eating disorder treatment center—and he is currently the coordinating investigator for the upcoming MAPS study looking at the potential for MDMA-assisted psychotherapy as a treatment for eating disorders. In this conversation, Dr. Robison dissects the intricacies of various eating disorders and shares his experience using ketamine-assisted psychotherapy. At Center for Change, Dr. Robison conducted an IRB-approved study looking at the use of ketamine as a potential treatment for eating disorders. In the study, participants were regularly administered ketamine in a small group setting with therapeutic and integration work happening between sessions. Dr. Robison shares some anecdotal reports as well as the objective data from the study, both of which show promising results. In particular, Dr. Robison notes how ketamine can promote a sense of embodiment for individuals struggling with eating disorders, helping them return to a more intuitive connection with food and eating. Additionally, Dr. Robison discusses topics such as neuroplasticity and the default mode network as potential key factors explaining why this type of treatment could be effective. Since compounds such as ketamine can promote neuroplasticity and downregulate the default mode network, this gives the therapist a window to do particularly effective work with the patient, as they are in a more malleable state and less burdened by routines and habitual thought patterns. Dr. Robison closes with a discussion of the upcoming MAPS study which will look at the possible efficacy of MDMA-assisted psychotherapy for anorexia and binge eating disorders. In this episode: Dr. Robison's study of ketamine-assisted psychotherapy for eating disorders The therapeutic modalities Dr. Robison's team uses alongside ketamine for addressing eating disorders Psycholytic vs transformative applications of ketamine in psychotherapy The co-occurrence of eating disorders and conditions such as depression, anxiety, and PTSD Details of the upcoming MAPS study on MDMA-assisted psychotherapy for anorexia and binge eating disorder. Quotes: "If you look at eating disorders, they're pretty underfunded and there are no FDA approved medicine treatment options for anorexia, for example." [3:25] "Ketamine and other psychedelic medicines are therapy aids, therapy boosters, accelerators, or catalysts to the therapeutic process." [10:42] "But I do believe that there are lasting benefits, especially when you pair it with the psychotherapy—when you have this window of opportunity of neuroplasticity to do some deeper work." [21:07] "Healing can be disruptive sometimes and you do feel worse before you feel better in some cases." [25:23] "Downregulation of the default mode is such a powerful and welcome break from the day-to-day patterns in these conditions." [37:43] Links: Novamind Cedar Psychiatry Center for Change Upcoming MAPS study on MDMA-Assisted Psychotherapy for Eating Disorders Psychedelic Medicine Association Porangui…
1 ENCORE EPISODE: Psilocybin Scientific Research with Dr. Albert Garcia-Romeu 53:14
53:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
53:14Today’s episode is the first in our series focusing on psilocybin’s potential uses as medicine. You are going to hear from one of the premier researchers into this drug, how he runs his studies, and what he has discovered concerning its effects and uses as a medicine. Dr. Albert Garcia-Romeu is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine and a Guest Researcher at the National Institute on Drug Abuse Intramural Neuroimaging Research Branch. There, he studies the effects of psychedelic drugs in humans with a particular focus of psilocybin as a potential aid in the treatment of addiction. Dr. Garcia-Romeu explains the biochemical effects of psilocybin in the human body. He delves into what his research has uncovered about the drug’s potential to treat addiction disorders. What is noteworthy about his research is that is has shown that psychedelic treatments have been able to help some people make lasting changes in regard to alcohol and nicotine addiction. Dr. Garcia-Romeu also discusses psilocybin’s use in treating anxiety and depression. The research has shown that psilocybin has the potential to help patients with life-threatening and terminal illnesses cope with the psychological burdens of their disease. He also explains some of the ongoing research into the efficacy of psilocybin to have a lasting impact on depression in general. In this episode: How psilocybin works at a biochemical level What the research is saying about the uses of psilocybin to treat addiction disorders Possible reasons why some people respond more significantly to psilocybin treatments than others Psilocybin’s effect on treating mood disorders, such as anxiety and depression Safeguards to avoid possible adverse effects during psilocybin studies Quotes: “Administering high doses of drugs like psilocybin and LSD seemed to really help people make some breakthroughs into having greater insight into their alcohol abuse and having more plasticity in their ability to change their behavior going forward.” [7:06] “The more mystical effects that people are having, the better outcomes you’re seeing.” [23:25] “These were real improvements in the quality of life that were measurable, statistically significant, and enduring.” [28:42] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Johns Hopkins Center for Psychedelic & Consciousness Research clinicaltrials.gov Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 ENCORE EPISODE: Ayahuasca Scientific Research with Dr. Dan Engle 56:34
56:34
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
56:34Dr. Dan Engle is a psychiatrist with a clinical practice that combines aspects of regenerative medicine, psychedelic research, integrative spirituality, and peak performance. His medical degree is from the University of Texas at San Antonio. His psychiatry residency degree is from the University of Colorado in Denver, and his child and adolescent psychiatry fellowship degree is from Oregon Health & Science University. Dr. Engle is an international consultant to several global healing centers facilitating the use of long-standing indigenous plant medicines for healing and awakening. He is the Founder and Medical Director of Kuya Institute for Transformational Medicine in Austin, Texas; Full Spectrum Medicine, a psychedelic integration and educational platform; and Thank You Life, a non-profit funding stream supporting access to psychedelic therapies. Dr. Engle is the author of The Concussion Repair Manual : A Practical Guide to Recovering from Traumatic Brain Injuries, as well as his new book, A Dose of Hope : A Story of MDMA-Assisted Psychotherapy. Dr. Engle shares how he sees ayahuasca and other plant medicines as a bridge between traditional medical practices and contemporary medicine. This is particularly the case in the field of psychology. Ayahuasca can have the ability to create visionary states that lend insight into what individuals find most important at a deep subconscious level. There are ongoing efforts to understand the possible uses of ayahuasca as a tool in integrative therapy. Dr. Engle has particular experience applying it in TBI therapies. He describes what he has observed in how ayahuasca can create synaptic genesis and stimulate the growth of brain cells. This has huge implications for treating neurodegenerative conditions. Dr. Engle goes on to describe some of the scientific research surrounding ayahuasca. Its ability to treat a number of conditions has been closely examined in recent decades. This includes its effects on such a large range of issues including chronic inflammatory bowel conditions, addiction, depression, and brain injury. In this episode: The potential of ayahuasca to lend insight into unconscious desires Uses of ayahuasca in integrative psychology and TBI treatments What ayahuasca is and the active chemicals it contains Known contraindications of ayahuasca The findings of many of the research projects focusing on ayahuasca Ayahuasca’s potential to treat addiction The lasting positive and negative effects of ayahuasca use Quotes: “The opening that happens when medicines are facilitated well is orders of magnitude more powerful than the opening that I had experienced in talk therapy.” [6:30] “If you have brain trauma, or a neuro deficit or hypoactivity, many people feel like their brains come back online.” [19:16] “We started studying it. But we’re still in our infancy of understanding, whereas the traditional cultures have been working with this medicine for thousands of years.” [31:14] “The medicines are not here to save us. They aren’t here to fix us. The medicines are here to show us truth in our path. It’s still our work to do.” [50:05] Links: The Concussion Repair Manual “Fantastic Fungi” DMT: The Spirit Molecule “Embrace of the Serpent” Fellowship of the River Takiwasi Center Revive Centers Being True to You The Third Wave Check out the full episode post Keep up with everything Plant Medicine related here Porangui The information provided in this podcast is for general informational purposes only and does not constitute the practice of medicine or other professional health care services, including the giving of medical advice. The content of this podcast is not intended to be a substitute for professional medical recommendation, diagnosis, or treatment. The use of information in this podcast is at one’s own discretion, and is not an endorsement of use given the complexity inherent in these medicines, and the current variable widespread illegality of their usage.…
1 Cannabis Assisted Psychotherapy with Dr. Mark Braunstein 43:02
43:02
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:02This episode of the Plant Medicine Podcast features a conversation with Dr. Mark Braunstein discussing the potentials of cannabis-assisted psychotherapy. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. In his own practice as a psychiatrist, Dr. Braunstein employs both cannabis and ketamine to meet the individual needs of his patients. Dr. Braunstein stresses how he came to these modalities after becoming disillusioned with the predominant model of psychiatry and its emphasis on treating symptoms with pharmaceuticals without much consideration for the patient as an individual. With cannabis-assisted psychotherapy, Dr. Braunstein started to notice real changes in his patients, allowing them to begin living more fulfilling lives. In this conversation, Dr. Braunstein discusses many of the intricacies of using cannabis in his practice as a psychiatrist, giving particular attention to the intake process he uses to determine which method of ingestion and what dosage would be appropriate for a particular patient given their specific condition and history. Dr. Braunstein also distinguishes between psycholytic and psychedelic applications of cannabis, explaining that the low dose, psycholytic approach is suited to the context of talk therapy, where cannabis helps encourage new insights without being too disorienting, whereas the psychedelic modality uses higher doses to allow the patient to explore their psyche on their own within a safe, supportive context. In this episode: How wilderness therapy made Dr. Braunstein reevaluate his understanding of psychiatry Psycholytic vs psychedelic uses of cannabis for therapeutic purposes How Dr. Braunstein approaches patients as unique individuals when considering treatment options Using cannabis to help patients encounter buried traumas in a safe, therapeutic setting Contradictions for cannabis-assisted psychotherapy Quotes: "It increases someone's ability to be more productive in psychotherapy-you're able to talk, see things in a different way, have different perceptions." [13:15] "Cannabis is so readily accessible for so many people and they can safely do it in the comfort of their home while they engage in teletherapy." [14:40] "We want to put people into categories of usage to help come up with a protocol of what dose we're going to start them on." [19:18] "Sometimes we'll actually do some cannabis-assisted psychotherapy first to help them process and move through some of the trauma, and then we'll move on to the ketamine to work on the depression." [26:20] "Yes, guidelines are important, but I think that having well-educated physicians, having extensive, well-educated conversations with our patients, and making the right decisions is the best way to go." [34:08] Links: Reconscious Medical Psychedelic Medicine Association Porangui…
1 The Art of Microdosing with James Fadiman & Adam Bramlage 58:34
58:34
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
58:34In this episode of the Plant Medicine Podcast, Dr. James Fadiman and Adam Bramlage join to discuss the finer points of microdosing and their upcoming Microdosing Movement course. Dr. Fadiman is a world-renowned psychedelic researcher and transpersonal psychologist who has made seminal contributions to the contemporary understanding of microdosing coach with clients from a wide range of backgrounds to help craft individualized protocols to best harness the potentials of microdosing. Together with the San Francisco Psychedelic Society and Jakobien & Hein of The Microdosing Institute, they will be leading the upcoming six-week Microdosing Movement course. In this discussion, Dr. Fadiman and Adam touch on many nuanced topics relating to microdosing, ranging from individualized protocols to current research. Dr. Fadiman tells of his experience gathering information on microdosing through his own study and how this originated what became known as the Fadiman protocol for microdosing. Dr. Fadiman also discusses some conclusions that can be drawn from experience reports, such as the efficacy of microdosing for combatting conditions such as addiction or depression. Additionally, Adam shares the details of the Microdosing Movement course, emphasizing how building community is foregrounded in the course design. In addition to lectures by experts like Dr. Fadiman, participants will have the opportunity to socialize with other students, integrate the content, and ask questions at weekly communiTEA gatherings over Zoom. The microdosing movement course runs from Sunday, December 13th through Tuesday, January 19th. Additional information and registration linked below: Dr. Fadiman can be reached at jfadiman@gmail.com . In this episode: How Dr. Fadiman developed his microdosing protocol What we know about tolerance when it comes to psychedelics Recent research findings suggesting microdosing could also be effective in treating pain Details of the upcoming microdosing movement course How community enriches microdosing outcomes Quotes "The most important thing to get across is that each person is an individual and no one protocol is going to work for everybody. Everybody has different needs." [12:42] "And particularly people are saying, not that meditation improves your microdosing, but that microdosing absolutely improves your meditation." [15:36] "We're just seeing extremely positive results across the board, and we're seeing that the longer people microdose, the less often they need to microdose." [41:40] "There's so many different applications for this, with so many different conditions, and each day I get new emails or new contracts from people who are using it for totally new things." [43:54] Links The Microdosing Movement Course Microdosing Psychedelics Website Dr. Fadiman's Website Psychedelic Medicine Association Porangui…
1 Fireside Project: The World's First Psychedelic Hotline with Joshua White and Hanifa Nayo Washington 38:55
38:55
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
38:55This week's episode of the Plant Medicine podcast focuses on the new Fireside Project. Joining to discuss the launch of this peer-to-peer psychedelic hotline are the founder and director Joshua White and cultivator of beloved community Hanifa Nayo Washington. Joshua is a trial lawyer with experience both as a hotline crisis counselor and as a psychedelic peer support volunteer at the Zendo Project. Hanifa is a certified Usui/Holy Fire Reiki Master Practitioner with over twenty years of experience developing community-serving initiatives. Together with the rest of the Fireside Project team, they are working towards the April 14th launch of the world's first psychedelic hotline. Fireside Project aims to offer broad support for people using psychedelic substances, with volunteers able to both assist during difficult experiences and offer integration assistance after the fact. Users will also be able to choose between a phone call, texting, or a live chat to connect with a volunteer, allowing individuals in the midst of a vulnerable experience the ability to choose whatever form of communication they find most comfortable. In addition to this crucial support, Fireside Project also hopes to contribute to the psychedelic movement by imagining a more equitable future. Through efforts to recruit a diverse group of volunteers from groups often under-represented in the psychedelic community, Fireside Project hopes to contribute to building a new generation of diverse healers. This is the impetus behind the Fireside Equity Fund, which provides scholarships to volunteers who wish to pursue careers in psychedelic healing. Fireside Project launches April 14th, 2021 and the number is 1-833-2FIRESIDE. in the meantime, they are recruiting volunteers. If you are interested in being a volunteer, there are A&A sessions on December 9th at 5 p.m. PST and January 9th at 10:00 a.m. PST- register at https://firesideproject.org . In this episode: What services the Fireside Project will provide How Fireside Project will make psychedelic integration more accessible What it means to "cultivate beloved community" How Fireside Project will promote diversity within the psychedelic movement How to become a volunteer for Fireside Project. Quotes: "Volunteering at the Fireside Project...will provide an opportunity to have a much longer-term experience helping people with their psychedelic experiences." [10:30] "We open up this opportunity for continued support, continued deepening, by following up the next week." [12:49] "It's just simply so beautiful to be with someone during such a moment of deep need and to provide support for them." [23:28] "And maybe you're having a beautiful psychedelic experience and your heart is just bursting to connect with someone, please reach out to us in that circumstance as well." [27:34] "Our hope is to compassionately hold someone in a space so that they can figure out the meaning of the medicine and so that they can feel empowered and comfortable." [33:06] Links: Fireside Project Website Psychedelic Medicine Association Porangui…
1 Encore episode: DMT Scientific Research with Dr. Chris Timmerman 1:00:19
1:00:19
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:00:19Chris Timmermann, PhD, is a researcher at Imperial College, where he conducted the first neuroimaging studies of DMT in healthy volunteers and its potential for mental health interventions. He is also conducting research concerning the effects that psychedelics have on belief systems and the ethical implications associated with the mainstreaming of these substances. In this episode, Chris Timmerman discusses what happens neurologically when DMT is administered. He talks about his research into neuroimaging and how the brainwaves change during DMT experiences, and how those changes can help elucidate some of the mechanisms of psychedelic states. He also breaks down the concept of cortical activation and how DMT experiences lead to a pattern of cortical activation that mimics that of visual stimulation. Dr. Timmerman also discusses how DMT experiences are often compared to what happens to the body when it has a near-death experience. He explains some of the difficulties of studying these effects and how to ethically study the phenomenon of near-death experiences. In addition to his work on DMT, Dr. Timmerman also shares some of his research on the impact of music in psychedelic therapy, and how it can help comfort people facing trauma. In this episode: How DMT interacts with our physiology Current scientific research on DMT The correlation between DMT and near-death experiences How alpha, delta and theta brain waves are affected by DMT Why people think DMT use can lead to tolerance The role of music in psychedelic therapy What psychedelic apprenticeships are and how they can help with healing Quotes: "DMT is incredibly unique because it is able to generate simulations of sorts. The level of immersion is radical, complete. People with their eyes closed, they feel kind of detached from their environment, but they are experiencing a world of experience." [5:52] "We developed a map of this DMT story for each participant. We found three main components: one there was a visual component in the experience, we found a bodily component [a somatic effect], and an emotional effect. And we found that these different parts of the DMT story - the visual, the bodily, and the emotional - had different brain signatures." [18:55] "There have been some animal studies, or very promising ones, in which not only DMT but also LSD and ketamine has been shown to have important properties associated with neurogenesis." [35:09] "The use of psychedelics by western populations is fairly new. We don't have that know-how or that expertise like some indigenous cultures, has for generations." [46:49] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' Follow Dr. Timmerman on Twitter Follow Dr. Timmerman (and check out his music) on InstagramFollow Chris on Instagram and listen to his music Center for Psychedelic Research at Imperial College Porangui…
1 How to Choose A Psychedelic Facilitator or Retreat Center with Joël Brierre 40:36
40:36
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:36This week's episode of the Plant Medicine podcast features a discussion of what to look for in a psychedelic retreat center or facilitator to ensure the experience is as safe, comfortable, and effective as possible. Joining the conversation is Joël Brierre, who shares his expertise as a 5-MeO-DMT facilitator to provide some concrete tips. Joël is the founder and CEO of Kaivalya Kollectiv, an educational platform that offers transformational retreats and training for plant medicines, yoga, meditation, and more. Joël has spent two decades studying yogic practice and has been a teacher for 15 of those years. In this conversation, Joël shares personal stories and his expertise as a facilitator to help guide you in making good decisions when choosing psychedelic services. Joël starts by bringing up the idea of the "container," which is a term to describe the atmosphere, preparation, and expertise involved in the facilitation of psychedelic experiences. The idea of a container is helpful for evaluating what situations facilitators would be prepared to navigate: Do the providers have training to respond in case of an emergency? Do they have systems in place to prevent emergencies from happening in the first place? Joël then dives into the specifics of what makes for a good container. As safety is always important, especially when working with a substance as powerful as 5-MeO-DMT, Joël recommends facilitators have training to ensure they are able to respond to medical emergencies should they arise. Similarly, retreat centers should have professionals available to respond to any psychological emergencies, both during and after ceremonies. Joël also suggests that facilitators ought to have grounding in some practice or philosophy which allows them to respond with wisdom. And of course, facilitators should have deep personal familiarity with the substances they facilitate. In this episode: What you should look out for when choosing a retreat center How to verify that a facilitator is qualified and experienced The importance of the intake process for retreats and facilitators How standards of practice developed around 5-MeO-DMT Quotes: "I think people being extremely mindful of and holding space for those traumas and how they come up is really important." [8:03] "There is nothing more dangerous than an ego that thinks it's enlightened." [22:43] "Ask them what their preparation protocol is and ask them what their aftercare and integration protocol is. And they should have an answer ready for you." [24:57] "Discussion and boundaries are quite essential for a safe container." [35:50] Links: Joël's Website Kaivalya Kollectiv 5-MEO-DMT: A Recommended Model for Best Practices from The Conclave Psychedelic Medicine Association Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui…
1 The Psychedelic Election Winners with Noah Potter 26:41
26:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
26:41This week's episode of the Plant Medicine Podcast offers an overview of the three psychedelic ballot measures which passed this past election cycle. Attorney Noah Potter joins to share his expertise in psychedelic law and describes the details of Initiative 81 in DC and Measures 109 and 110 in Oregon. Noah is a New York-based attorney, media commentator, and psychedelic legalization strategist who has been discussing topics of psychedelic law on his blog for the past decade. Noah has also advised Decriminalize Denver with their successful Denver Psilocybin Mushroom Initiative and is involved in policy reform advocacy in New York for 2021. In this conversation, Noah describes the details of these three psychedelic measures, sharing what is accomplished by each. In DC, Noah explains how Initiative 81, Entheogenic Plants and Fungus Measure, follows the example of previous successful ballot measures dealing with psychedelics by focusing on a decriminalization approach that places activity involving entheogenic plants among the Metropolitan Police Department's lowest law enforcement priorities. Along with this success on the east coast, Oregon saw two psychedelic ballot measures pass on election day: Measure 109, Psilocybin Mushroom Services Program Initiative, and Measure 110, Drug Decriminalization and Addiction Treatment INitiative. In terms of Measure 109, Noah explains how the broad nature of the ballot initiative leaves many of the specifics to be determined by the Oregon Health Authority, with the measure focusing on determining a legal structure for providing psilocybin-based therapeutics services. This measure does not, however, legalize or decriminalize psilocybin for personal use. Measure 110, on the other hand, does focus on the decriminalization of a wide array of substances, as well as addiction treatment. In the last minutes of the conversation, Noah describes the interplay between these two intiatives as well as some of the objections given for the particular approaches they take. In This Episode: Learn the details of the three psychedelic measures which passed this election cycle The difference between decriminalization and legalization How the DC measure is more limited due to city funding being controlled by Congress What Measure 109 in Oregan will allow in terms of psilocybin therapy The interplay between Measure 109 and Measure 110 in Oregon. Quotes: "Decriminalization is a far narrower approach. You're simply either removing criminal penalties or you're downgrading criminal penalties." [5:24] "[Measure 109] is a model for clinical, on-site consumption —you don't walk into a dispensary and take your medicine home. It's very narrowly focused on that inpatient clinical model." [13:15] "The [Oregon] health authority isn't even going to start accepting applications for any of the license categories until January 2nd, 2023." [19:50] "So you've got a fairly limited decriminalization and it doesn't apply to sale or distribution...that's the very simple version of [Measure] 110." [23:59] Links: Noah's Blog on Psychedelic Law Noah's Website Psychedelic Medicine Association Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui…
1 Psychedelics and Autoimmune Disease with Caitlin Thompson 32:14
32:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
32:14On this week's episode of the Plant Medicine Podcast, Caitlin Thompson joins to discuss her recent article "Psychedelics as a Novel Approach to Treating Autoimmune Conditions" published in Immunology Letters . Caitlin is the founder of the nutritional supplement company EntheoZen, a certified kambo practitioner, and a research associate at the UCSD school of medicine. Drawing on personal experience with an autoimmune condition, Caitlin hopes her scientific research investigating psychedelics and kambo can help give credence to these healing modalities, allowing for more effective treatments of autoimmune conditions. In this conversation, Caitlin discusses the five major findings from her literature review published in Immunology Letters . Her findings draw important connections between the serotonergic mechanism of classic psychedelics and the immunomodulating function of the serotonin 5-HT2A receptor. Additionally, she discusses the impact of psychosocial stress and the gut microbiome on the immune system. As psychedelics can definitely improve psychosocial stress and may even impact the microbiome through serotonergic mechanisms, Caitlin sees significant potential for these compounds as treatments for autoimmune conditions. Caitlin closes by discussing kambo, which remains an under-investigated healing modality. She explains what little is known about how kambo is able to clear microbes from the body while at the same time being inert in relation to human cells. Now that her literature review has been published, Caitlin hopes to focus her research on kambo, and since kambo is not regulated like psychedelics, she will have more freedom to conduct original research leading to new discoveries. In this episode: An overview of Caitlin's recent article published in Immunology Letters How the serotonin 5-HT2A receptor modulates immune responses The impact of stress on physiological processes How psychedelics impact the gut microbiome Why kambo is often an effective treatment for autoimmune conditions Quotes "What's actually really fascinating is how important serotonin is for regulating all sorts of processes that are related to immune function." [8:40] "There are very real scientific explanations for the way that stress can influence our physical health." [12:32] "It's a bit useless to go through all these treatments, to have this pristine diet, to take all these supplements if you're not also approaching the core thing that compromised the person in the first place." [15:35] "When people are able to actually, consciously resolve and find peace with traumatic experiences, it actually completely changes how the nervous system responds." [22:41] Links: EntheoZen Caitlin's article: Psychedelics as a Novel Approach to Treating Autoimmune Conditions Psychedelic Medicine Association Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui…
1 Cannabis and CBD for PTSD with Dr. Mike Hart 45:42
45:42
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
45:42On this episode of the Plant Medicine Podcast, Dr. Mike Hart joins to discuss the therapeutic benefits of cannabis, focusing on his clinical work using this medicine to help treat PTSD. Dr. Hart is a Canadian family medicine doctor who opened the first cannabis clinic in London, Ontario - ReadyToGo Clinic. In his practice, Dr. Hart draws on his family medicine background and his cannabis expertise to help his patients tackle their unique conditions and make lifestyle improvements. In this conversation, Dr. Hart discusses his work using cannabinoid medicines, such as CBD and THC, to help veterans with PTSD better treat their symptoms. He talks about the different features of PTSD and how both CBD and THC can be effective at improving the wellbeing of individuals with this diagnosis. Drawing on both his clinical experience and the scientific literature. Dr. Hart provides an overview of how these cannabinoid medicines can be used to improve sleep, manage stress, reduce pain, and even help with trauma. In addition, Dr. Hart explains how he works with patients on an individual basis to create plans for transitioning off traditional pharmaceuticals such as SSRIs in cases where cannabinoid treatments are providing more relief with fewer side effects. Dr. Hart hopes to continue promoting cannabis education to help bridge the gap between the scientific research and popular awareness, allowing more people to take advantage of these treatment options. In this episode: How cannabis can be used to treat various symptoms of PTSD The different uses of CBD and THC How cannabis can release traumatic memories and prevent the formation of new trauma responses The unique effects of using CBD and THC in tandem How cannabis is providing better therapeutic benefits compared to traditional pharmaceuticals for many dealing with depression and sleep issues. Quotes: "Cannabis isn't a cure-all per se, but it's definitely a medicine that can help initiate you to have a healthier lifestyle overall." [8:59] "If someone does have really severe PTSD that includes nightmares, including some THC in their regime would likely be very, very effective for them." [16:52] "By using CBD you may be able to unlearn these things that you've learned and then you can learn new things so you can transform yourself and become a new person." [22:14] "Generally CBD actually does work better when you are in stressful environments." [26:11] "The one really nice thing with CBD is you're gonna notice it right away, on your very first dose." [37:38] Links: Dr. Hart's Website Dr. Hart's Book: Friendly Fire: Why Vets Are Ditching Pills and Lighting Up to Treat PTSD ReadyToGo Clinic Psychedelic Medicine Association Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui…
1 Working with an Integration Coach with Dr. Ryan Westrum 34:38
34:38
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
34:38In this episode of the Plant Medicine Podcast, Ryan Westrum returns to discuss the finer details of psychedelic integration. Ryan is a trained psychotherapist with a Doctorate of Transpersonal Clinical Psychology from Sofia University and an M.A. degree in Marriage and Family Therapy from the Adler Graduate School. He is also the founder of Healing Souls LLC and a registered integration therapist for Multidisciplinary Association for Psychedelic Studies, as well as the author of the Psychedelics Integration Handbook. Drawing on his 15 years of experience as a mental health practitioner, Ryan approaches integration with an intimate knowledge of human psychology, drawing on multiple modalities to best facilitate integration for his clients. In this conversation, Ryan talks about various roadblocks to successful integration and how these can be overcome, especially with the help of an integration coach. He emphasizes the importance of making the psychedelic experience one’s own as a central project in integration, explaining how this is essential for allowing new self-understandings to emerge. Ryan also discusses various practices he encourages as an integration coach, such as journaling, drawing mandalas, and movement practices, mentioning how these can all help better incorporate the work of integration into one’s life rather than keeping it an isolated project. Here again, Ryan emphasizes the importance of individual psychology and encourages people to choose practices that resonate and spur new insight. As a practicing therapist, Ryan also shares his thoughts on the distinction between psychedelic integration and therapy, noting how this boundary is often blurry. What Ryan stresses for both paradigms, however, is the interpersonal character of healing and growth. With the help of a skilled integration coach, the work of living out one's psychedelic insights and making lasting changes becomes all the more approachable. In This Episode: The purpose and value of an integration coach How to make psychedelic experiences tangible How to start the integration process Different practices to help spur integration The relationship between therapy and integration Quotes: “Integration to me is the act of taking one thing and another and finding wholeness or links to wholeness.” [4:55] “[Integration] is reconciling past memories and incrementally getting prepared for future stories.” [14:22] “Integration exercises can also challenge you to see what you’re afraid of, what you’re not ready to look at, what potentially are growth points.” [18:27] “I would never encourage anyone, no matter how many sessions you’ve sat or how many ceremonies or how many cups of tea you’ve drank, to do this on your own. There’s a benefit in community.” [23:33] “There needs to be a purpose-driven motivation for this work. Just because it’s being talked about in corners, doesn’t mean it’s necessarily right for everybody.” [31:30] Links: Ryan’s Website Psychedelic Integration Website The Psychedelics Integration Handbook Psychedelic Medicine Association Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui…
1 How Western Medicine and Indigenous Traditions Differ in their Approach to Mental Health and Healing with Adam Aronovich 1:15:03
1:15:03
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:15:03Adam Aronovich is a doctoral candidate at the Universitat Rovira i Virgili in Spain, focusing on Medical Anthropology and Cultural Psychiatry. He is an active member of the Medical Anthropology Research Center (MARC) and part of the Ayahuasca Community Committee at the Chacruna Institute for Psychedelic Plant Medicines. In the last four years he has conducted extensive fieldwork in the Peruvian Amazon, where he has been doing qualitative research in collaboration with ICEERS, the Beckley Foundation, and, more recently, the Centre for Psychedelic Studies at Imperial College. Beyond his work conducting and coordinating research, Adam regularly facilitates workshops at the Temple of the Way of Light, a prestigious healing center in the Iquitos area. In this episode of the Plant Medicine Podcast, Adam discusses a host of issues surrounding modern western paradigms of psychiatry and mental health and contrasts these with approaches taken by traditional cultures, such as those of the Shipibo people of South America. Adam has spent years studying traditional societies as an anthropologist and his research specifically focuses on the different approaches to medicine in various cultures, and how people in different cultural milieus experience health and illness differently. Through his work, Adam hopes to contribute to the field of medicine by translating the medical understandings of traditional cultures into terminologies and categories digestible by the Western medical establishment. In this conversation, Adam explains how the contemporary approach to mental health in the West is colored by a fixation on medicalizing peoples’ experiences into diagnostic categories and by a tendency to view health and illness exclusively on the level of the individual. In contrast to this approach, Adam draws on his ongoing research with the Shipibo people, showing how their approach to healing in ayahuasca ceremonies is much more communal and relational in nature. In this episode: How traditional cultures conceptualize mental suffering The limits of Western psychiatry when crossing cultural boundaries How the animist perspective of Shipibo healers informs their approach to healing Dangers of over-emphasizing the medicalization of psychedelics The relational, rather than an individualistic focus of ayahuasca ceremonies Confronting our individual and collective shadows Quotes “Every medical system or every medical approach is inseparable from the culture, the cosmology, the metaphysics that underlie the understanding of that culture.” [32:32] “The way the Shipibo medical system works… is that the healing doesn't necessarily only happen through the agency of the human healer, but the human healer works as a channeler of medical agency of different sources, of different spirits in the environment.” [36:34] “The most important benefits or the most important values that these substances have are not necessarily therapeutic in the sense of medical, or clinical, or psychological… but are actually much deeper than that and they’re epistemic, they’re ontological, they’re relational.” [52:25] “Ayahuasca oftentimes will get us to a place where we can actually experience that reconnection with the wider community of sentience that makes the ecosystem of our world.” [1:02:29] Links Adam’s lecture at Breaking Convention 2017 Adam’s lecture at the World Ayahuasca Conference 2019 Temple of the Way of Light Psychedelic Medicine Association Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui…
1 Addressing Addiction through the Ayahuasca Tradition with Carlos Tanner 1:04:26
1:04:26
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:04:26In this episode of the Plant Medicine Podcast, Carlos Tanner Joins to share his story of addiction, and how participating in ayahuasca ceremonies not only led him to personal healing but started him down a path of becoming a traditional healer himself. Carlos is the founder of the Ayahuasca Foundation, an organization based out of Iquitos, Peru, which hosts retreats and leads educational programs to pass along training in the Shipibo tradition. The Ayahuasca Foundation is also home to the Riosbo Retreat & Research Center, which has received funding from the Medical Research Council in the United Kingdom to conduct research on the epigenetic effects of ayahuasca ceremonies, with particular focus on anxiety, depression, and childhood trauma. Before becoming a pioneer in psychedelic science, Carlos had a long journey with addiction, leading him to seek healing in Peru through, Shipibo ayahuasca ceremonies. Participating in his first series of ceremonies in 2003, Carlos describes his challenging first experience with ayahuasca and the dramatic healings spurred by subsequent ceremonies. Going into these experiences very much in the midst of addiction, Carlos came face to face with childhood trauma and personifications of his illness. With the help of the plant medicine and the spiritual ambiance of the ceremonies, he was able to find incredible healing in the experiences. It was the profound impact of these first encounters with ayahuasca and the Shipibo tradition experienced curandero, and learning the intricacies of the ceremonies. In This Episode: How the inner environment greatly impacts the outcome of an ayahuasca experience Carlos' experience with an intensive series of ayahuasca ceremonies while struggling with addiciton Trauma in oneself vs trauma in one's relationships, and the different modes of healing for each The importance of the ceremony in shaping the healing experience Epigenetic change caused by ayahuasca ceremony, leading to decreased anxiety and depression Quotes: "That's the magic of it- you could walk into a ceremony with zero faith and walk out with one hundred percent." [13:05] "When I left the third ceremony I knew it was my path to be a healer and that I was going to dedicate the rest of my life to this tradition." [29:10] "It was easy for me to heal that trauma. I know that might sound crazy but inside the ceremony, it wasn't such a crazy, difficult ordeal for me." [34:42] "You can't separate ayahuasca from the culture of its use, you can't separate the ceremony from the medicine, and there's so much that comes from the ceremony." [49:33] "If you're in the world of addiction it's going to be almost impossible to stay in that environment and not be an addict." [1:01:35] Links: Ayahuasca Foundation Psychedelic Medicine Association Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui NOTE: I said I'd add links to the study findings Carlos was referencing, but those are unfortunately not yet published- links will be added when available.…
1 The Impact of Psychedelics on Autism with Aaron Orsini 56:14
56:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
56:14This week’s episode of the Plant Medicine Podcasts features guest Aaron Orsini, co-founder of the Autistic Psychedelic Community and author of Autism on Acid: How LSD Helped Me Understand, Navigate, Alter & Appreciate my Autistic Perceptions. In this interview, Aaron gives an overview of his own experiences with autism and how psychedelics changed his relationship with his condition, while also providing fascinating insights into some of the neuroscientific research on both autism and psychedelic experiences. Diagnosed with Autism Spectrum Disorder (ASD) later in life, Aaron describes the features of his condition as a dissociation from both his own inner experience and that of others (alexithymia), as well as a predisposition to getting lost in mental reflection and rumination. Four years after his diagnosis, Aaron tried LSD for the first time, and this experience helped him gain crucial insight into his condition and provided him with a different, more emotionally engaged and embodied sense of life. His improved quality of life following his explorations of psychedelic medicines inspired him to write a book detailing his experiences as someone with ASD. However, Aaron stresses that everyone’s experience of autism is unique, similar to how psychedelic experiences can differ from person to person. So in the overlap of psychedelics and autism, there is a wide variety of responses as these compounds come into contact with the unique brain chemistry of autistic individuals. As Aaron connected with other individuals with ASD who have explored psychedelic medicine, he realized this was a topic that deserved more attention, especially with how little information was available. As a result, he co-founded the Autistic Psychedelic Community, which is an online co-learning community for neurodivergent individuals who are interested in connecting on the topic of psychedelics. In this episode: How people with ASD experience psychedelics differently The intersection of trauma and ASD and how psychedelics impact both of these Quotes from people with ASD about their unique psychedelic experiences and the impacts What scientific research has been done on psychedelics and autism How ketamine differs from other psychedelics for people with ADS Quotes: “It’s not a cure for autism spectrum, I think it’s another vantage point to see. I call it a contact lens for my sensory awareness.” [10:09] “I’ve had experiences with other individuals who aren’t on the spectrum taking similar dosages and they’ll enter a much more hallucinogenic state, whereas I’ll enter more of what feels like home or an embodied state.” [19:40] “These changes are far more remarkable than the currently available pharmacotherapies for autistics.” [34:11] “The idea that these are hallucinogens exclusively is really being challenged by my story in terms of taking that dissociative state and bringing it into a point of awareness.” [41:25] Links: Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Aaron’s book Autism on Acid Autistic Psychedelic Community Psychedelic Medicine Association Porangui…
1 Announcing the Psychedelic Medicine Association with Dr. Lynn Marie Morski 25:28
25:28
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
25:28In this episode, host Dr. Lynn Marie Morski, who is also president of the soon-to-be-launched Psychedelic Medicine Association, discusses what services the association will be providing what needs it will address, and how the collaborations fostered in the association will contribute to real-world improvements in access to psychedelic therapies. With her background in the medical field, Dr. Moski outlines why it is so difficult for practicing clinicians to encounter information about treatments such as psychedelic therapy. As doctors mostly stay up-to-date through medical journals and association emails, the excitement around the therapeutic potential of plant medicines in the broader culture doesn't necessarily translate to clinicians knowing the subject in detail. The Psychedelic Medicine Association will seek to rectify this lack of awareness by providing content geared towards medical professionals- connecting them with the latest science and providing resources so they are better able to respond to patient questions regarding psychedelic therapies. The association will even provide a forum for clinicians to interact with each other as they navigate understanding these medicines, as well as a forum to connect health professionals with other experts in the burgeoning field of psychedelic therapy. To celebrate the launch of the Plant Medicine Association, they will be hosting a webinar at 1:00 PM Eastern on September 29th featuring a panel discussion on bridging the gap between the psychedelic science and clinical medicine worlds to introduce the association and begin discussing how to best address the barriers to getting these medicines in the hands of patients in need. In this Episode: Discussing the launch of the Psychedelic Medicine Association The barriers to clinicians being fully informed on psychedelic medicine Why clinicians are wary to discuss psychedelic therapy The importance of dialogue between healthcare workers and those working within psychedelic science, medicine, and law How the Psychedelic Medicine Association will fill this niche and work to better integrate psychedelic therapy into existing institutions of medicine and psychiatry Quotes "The vast majority of good-hearted doctors are not trying to keep their head in the sand when it comes to psychedelics — it just has not come across most of their journals." [6:57] "A big part of what the entire psychedelic science industry is trying to do is overcome that stigma which came from [psychedelics] being illegal for so long, and as you probably know, you overcome that stigma with education." [12:04] "We want doctors and clinicians and those on the front lines of patient care to be well-informed so that they can present a full range of options to their patients." [17:53] Links Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Psychedelic Medicine Association Porangui…
1 Treating Depression with Ketamine with Dr. Ken Adolph 43:24
43:24
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:24Dr. Adolph is a board-certified cardiac anesthesiologist and medical director of the Illumma Ketamine Clinic, as well as a member of the American Society of Ketamine Physicians. Dr. Adolph shares the brief history of how Ketamine was originally created, how it came to be used in the mental health arena, and its effectiveness for those with depression. He covers what the research has shown, as well as what he's seen in his clinic and in his own personal journey with the medicine. In this Episode: Ketamine's ability to extinguish suicidal ideation in 24 hours How Ketamine is one psychedelic that has an addictive potential The effects of Ketamine on BDNF and Glutamate, and how this can help heal the brain. The importance of integration. Quotes "By accident, they found that some of these patients (who were given ketamine) were able to work through some difficult issues and on the backside of that have less depression associated with their trauma" [10:07] "And then it begins to open them up to 'you know what, I'm ready. I'm ready to start taking a look.' Because that's what we see. Patients are more open to take a look at trauma. They're more open to see that their mindset is important in being able to produce a positive response." [22:04] Links Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Illumma Ketamine Clinic Daily Stoic Porangui…
1 Psychedelics' Ability to Help Heal Traumatic Brain Injury with Dr. Kate Pate 33:19
33:19
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
33:19Dr. Kate Pate is a neurophysiologist who has been conducting research for 15 years in a variety of different areas, including neurotrauma, respiratory neurobiology, mental health, redox biology, and combat trauma. She is the CEO and co-founder of Coruna Medical and the director of research for both the Heroic Hearts Project and Unlimited Sciences. In this episode, Dr. Pate discusses how traumatic brain injuries (TBI) share many commonalities with the symptoms of PTSD. She discusses why it may be wise to tend to heal the physical brain prior to or in parallel to attempting to heal one’s mental trauma. Dr. Pate also shares about the healing potential of the ayahuasca brew, independent of its DMT content. In this episode: How ayahuasca produces an anti-inflammatory effect in the body, which is incredibly helpful for healing TBI. How traumatic brain injury can predispose individuals to developing PTSD How psychedelics such as ayahuasca, psilocybin, and LSD promote neuroplasticity and even activate neurogenesis. Quotes: “Ayahuasca and other psychedelics that are acting on the serotonin system are actually promoting an incredibility anti-inflammatory profile in the body, which is extremely important, especially in the case of traumatic brain injury.” [15:00] “[Increased neuroplasticity] happens through the serotonin system and the ability of these plant medicines to activate this compound called brain-derived neurotrophic factor, called BDNF.” [19:54] Links: Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Psychedelic Medicine Association UnlimitedSciences.org Dr. Pate on Instagram Kate.Pate@heroicheartsproject.org Porangui…
1 CBD: Beyond the Basics with Cannabinoid Researcher Hunter Land 39:16
39:16
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
39:16Hunter Land is the director of cannabinoid research at Canopy Growth Corporation. He has devoted his career to researching cannabis-derived medicines and their application across a variety of conditions, leading the clinical development of the first FDA-approved CBD medication, Epidiolex. In this episode, Hunter shares the science-based reality of dosing guidelines for using CBD for various conditions and purposes. He answers questions regarding sublingual delivery, whether you can develop tolerance to CBD, the difference between broad-spectrum full-spectrum CBD, and much more. In this episode: The difficulty in establishing CBD dosing guidelines. A discussion of whether one can develop tolerance to CBD What to look for when choosing a CBD product. Whether the long-term use of cannabis affects CBD effectivity Quotes: “It’s tough to come up and say: “well you need this amount for sleep, you need this amount for anxiety, you need this amount for epilepsy.” So, with a lot of other medications, a lot of physicians, like yourself, probably know, it’s not uncommon to start low and go slow and see where you might land.” [5:00] “At low doses, we do think there might be some enhanced stimulation effect. But we also know it’s not like a stimulant like amphetamine or caffeine. It seems to function differently than that.” [6:20] “We don’t have guidance on pesticides either. So I think beyond just knowing what’s in products based on standardization techniques, also what contaminates could be present is also of importance.” [25:40] Links: Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Canopy Growth Corp Follow The Plant Medicine Podcast on Instagram Porangui…
1 Antidepressants and Psychedelics with Clinical Pharmacist Ben Malcolm, PharmD 54:58
54:58
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
54:58Dr. Ben Malcolm completed a Doctorate in Pharmacy and a Masters in Public Health, prior to post-graduate training and board-certification in psychiatric pharmacy. He currently holds a position in academia teaching psychiatric pharmacy, as well as providing consulting services for those seeking information about psychedelics at SpiritPharmacist.com . In this episode, Dr. Malcolm discusses how antidepressants react with MDMA, psilocybin, DMT, 5-MeO-DMT, ayahuasca, and ketamine. He also explains the risk profiles for interactions between psychedelics and medications such as benzodiazepines, sleep medication, antipsychotics, and lithium. In this episode: Why combining antidepressants with ayahuasca has a high physical risk profile. How antidepressants can diminish the effect of MDMA and why it is advised to not take a high dose of MDMA to attempt to workaround that effect. What serotonin syndrome is and how to avoid it. How one’s use of antipsychotics or lithium may be an indicator of possible contraindicated condition to psychedelic use. Quotes: “[A]ntidepressants like the SSRIs or SNRIs, in the long-term, create changes that makes the brain more resistant to using a psychedelic like MDMA” [9:14] “Most available and most antidepressant-friendly is [...] ketamine” [20:00] “With microdoses, you’re talking about using very very small doses, and you’re probably not talking about using something like MDMA that depletes serotonin. You’re probably talking about using psilocybin or LSD, and so for those, the drugs have great physical safety profiles in very very large doses. So if you’re thinking if there’s going to be some horrible interaction risk that kind of pops out of the closet with psilocybin or LSD with my antidepressant? Probably not.” [46:00] Links: Spirit Pharmacist Website Psychedelic School - Courses on pharmacology, safe use and integration Erowid Porangui Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine'…
1 Microdosing Q&A with James Fadiman 1:31:57
1:31:57
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:31:57James Fadiman, PhD, was a part of the first wave of pioneering psychedelic researchers in the 1960s in the US. He’s the co-founder of the Institute of Transpersonal Psychology, now known as Sofia University, and he’s the author of several well-known psychedelics books, including The Psychedelic Explorer’s Guide . From his initial rediscovery of microdosing and developing a protocol based on early reports, Dr. Fadiman teamed up with Dr. Sophia Korb to record and pattern-map the microdosing experiences of several thousand individuals from 51 countries. In this episode, Dr. Fadiman answers listener-submitted questions regarding microdosing psilocybin and LSD. He discussed dosing recommendations, tolerance, microdosing's general effects on healthy normals, and its specific effects on a number of conditions, ranging from depression to PMS. He also covered a variety of additional areas where people benefit from microdosing, including academic performance and athletics. In the last part of the episode, Dr. Fadiman discusses his new book, Your Symphony of Selves . He points out that we have not one, but a multitude of selves, and that we can learn to shift between them consciously. Further following this idea, he illustrates how we can save a lot of mental distress by not over-identifying with any particular one of our selves, and how we can extend that concept to those around us. This helps us not only forgive others when one of their selves may have acted in a displeasing way but also helps us forgive and go easy on ourselves when we act in a way that we later find distressing or shameful. In this episode: The reported benefits and risks of microdosing psilocybin mushrooms and LSD. Whether someone’s height and weight makes a difference on their dosage. The overwhelming number of those suffering from depression who reported significant improvements in their survey. Why microdosing may not be advisable for those with anxiety. Dr. Fadminan reports on study findings regarding conditions including depression, PMS, migraine headaches, and bipolar Quotes: “A lot of people have found that when they’re tapering off of an SSRI, which means taking it down very, very slowly over a period of maybe a couple of months from full dose to zero, that microdosing helps. That makes it easier. Makes it maybe even a little faster.” [14:13] “I’m an enthusiast for the effect of microdosing, but I never recommend that anyone microdose. That’s a personal decision based on information, but the nice thing is the risk/reward ratio, which is how dangerous versus how beneficial. It’s very good for microdosing. Meaning, if you take it, it’s very low risk, and yeah, from the reports, we have a lot of possibility of benefits.” [35:00] “What we’ve found is that about 80% of the people who come in with heavy depression, and again, most of them having failed medications or other therapies, we’ve about an 80% turnaround rate where they’re not depressed. That’s really striking.” [42:00] “They (students) say: “Microdosing is very much like Adderall, except with none of the very disturbing side effects.” Adderall includes crashing, by the way. And addiction.” [49:18] “Individual neurons in the laboratory, exposed to microdoses, grow into more healthy, more complex neurons with more dendrites, meaning more communication capacity.” [52:17] In discussing his new book, Your Symphony of Selves : “The inconsistencies you see in yourself and particularly in the people you love are not inconsistencies. It is that they have several selves, and you do too. And if you begin to think in that way, curiously, the world becomes easier. You understand things differently and you are kinder to yourself and more compassionate to others.” [1:10:43] Links: Psychedelic Medicine Association Microdosing Psychedelics James Fadiman’s website and email: jfadiman@gmail.com Cluster Busters - treatment for cluster headaches Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui Studies mentioned: Psychedelics Promote Structural and Functional Neural Plasticity Books Mentioned: A Really Good Day by Ayelet Waldman The Psychedelic Explorer’s Guide by James Fadiman PhD Your Symphony of Selves by James Fadiman PhD, Jordan Gruber JD…
1 Kambo Practioner Methods with Mike Salemi 1:26:58
1:26:58
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:26:58Mike Salemi is a certified kambo practitioner who utilizes a completely holistic approach when guiding and supporting his clients toward accessing their own inner wisdom to heal and grow. His motivation is to help all people discover their true potential from the inside out. In this episode, Mike discusses what a kambo ceremony looks & feels like, and how to both prepare for it beforehand and integrate it afterward. Mike shares how he was first introduced to kambo as “the warrior’s medicine” and the comprehensive training he underwent to be able to hold space for others. He also gives an overview of the uses of two other plant medicines called rapé and sananga. Kambo is an intense experience and Mike discusses who may benefit and who may be better served by other medicines. He also covers the importance of movement before the ceremony, the dietary recommendations for before and after kambo, and why it’s wise to find an experienced practitioner with whom you feel safe.…
1 Kambo Scientific Research with Caitlin Thompson 40:01
40:01
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:01Neurobiologist Caitlin Thompson is a certified kambo practitioner, administering unique traditional frog medicine rituals. Caitlin is also the founder of a nutritional supplement company called EntheoZen. She’s an independent scientific researcher and research associate at UCSD School of Medicine and is currently conducting research on the potential of psychedelic compounds as a novel approach to autoimmune conditions as well as the first human kambo studies. In this episode, Caitlin Thompson discusses what we know and what we don’t know about kambo is and how it actually works. Having served kambo over 800 times, she shares the physiological and psychological changes people undergo when they experience the cocktail of peptides present in kambo. Caitlin also discusses the progress being made on creating synthetic variations of kambo. She explains how she’s observed kambo to be most effective for those who have insufficient detox pathways and usually have trouble clearing out metals, mold toxins and toxins in general, and those who have fairly low neurotransmitter production. She also discusses how she titrates dosages in her ceremonies. In this episode: Where the kambo secretions come from and what ethical harvests are like. Why Caitlin uses the minimum effective dose as a kambo practitioner How leaky gut can lead to a herxheimer reaction after kambo use How often you may want to use kambo depending on your specific needs How kambo may be useful for those with chronic illness, autoimmune disorders, Lyme disease, and Epstein-Barr. Quotes: “I suffered with a chronic illness for most of my life and I sort of stumbled upon this [kambo] practice and accidentally started recovering from it. And the contrast between recovering from the illness and noticing how sick I used to be was quite startling. And that gap got bigger and bigger as time went on.” [4:00] “They [tribal hunters] would find that it [kambo] is a bit of an adaptogenic sort of substance with increased resilience, endurance and alleged reduced need for food or water, and I’ve also heard something about it covering their human scent, allowing them to hide from animals more effectively.” [17:30] “I try not to be dogmatic about anything but it’s hard because [...] it’s really great for inflammatory and immune dysfunction conditions, especially when there’s a psychosomatic element to it.” [33:45] “The kambo interfaces with the chemical systems that are the interface between our spirit and our physiology. I think psychedelics hit on that as well. They work with these molecular systems, these receptor-sites that happen to sort of tickle where the soul meets the meat. I see these amazing emotional and spiritual resolutions happen for people that results in these physiological and biological cascades throughout the body.” [35:10] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' Medicine Frog kambo - Caitlin’s Practice EntheoZen - Caitlin’s Supplement Company International Association of kambo Practitioners Porangui…
1 Kambo Patient Experience with Lucrecia 35:33
35:33
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
35:33Lucrecia has been on a long healing journey, both physically and spiritually. Physically, she had endured a number of chronic issues, like celiac disease and exposure to mold toxicity. She had felt like she had tried it all and did not know what else to do. In talking with some ayahuasca practitioners, she was introduced to a Kambo practitioner. Even though the intense experience of Kambo seemed scary for her, she was in a place where she was willing to try anything. At first, her physician recommended that she not try it and she concurred. Later, she found herself to be so depressed that she was willing to act irrespective of her physician’s recommendation. In having done so three different times (including once the day before this episode was recorded), she experienced such a significant reduction and even disappearance in her chronic migraines, gut, skin, and immune system issues that her own doctor voiced interest in trying Kambo as well. In this episode: What Kambo is, and the fact that it is already a legally allowed medicine How Lucrecia came to discover and trust her Kambo practitioner The intake process, preparation, experience, and after-effects of her Kambo journeys How physically-demanding (and rewarding) Kambo can be Why Kambo is not considered to be psychedelic Quotes: “The after-glow was so amazing. I finished the ceremony and I went home. I sat in silence for an hour - which is very uncommon for me. It wasn’t even a meditation, I was just sitting there, empty; which was a really nice break from myself, which doesn’t happen very often. After that hour, I grabbed my journal and started writing things down and suddenly, I just got this burst of energy, and I felt happy and clear and light. After feeling so crappy for so long, where it was really hard to get out of bed, this was amazing!” [19:16] “I was having chronic migraines, (after the Kambo ceremony) those started going away. A lot of the gut issues -I was having severe food allergies and sensitivities- and those calmed down too. It’s like my whole immune system relaxed ." [20:30] “Kambo is not psychedelic at all. At all. Which is different. Usually, with Ayahuasca, there’s a purging but then it’s like you’ve got these cool insights and cool visions. No. There is nothing cool with Kambo.” [30:45] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' Learn more about Kambo / find a practitioner - International Association of Kambo Practitioners Porangui…
1 How YOU Can Participate in The New Psilocybin Study from Unlimited Sciences and Johns Hopkins 40:48
40:48
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:48Del Jolly is co-founder and director of Unlimited Sciences, a psychedelic research non-profit. He was the outreach director for the Decriminalize Denver team that passed the historic legislation which decriminalized psilocybin in Denver, leading to a nation-wide movement. Before that, he worked for Charlotte’s Web CBD in business development and is on the board of community advisors for the Realm of Caring, a cannabis non-profit. Along with research, Unlimited Sciences hosts a webinar series called Unlimited Voices and produces content educating the general public on entheogens. Unlimited Sciences’ first study, in conjunction with Johns Hopkins’ Center for Psychedelic and Consciousness Research, intends to understand how the community is using psilocybin in real-world settings. The goal of the study is to learn more about the effects of using psilocybin outside of the research setting, and any potential factors that could affect those outcomes. By collecting data from individuals who are already planning to use psilocybin, the researchers aim to investigate variables such as demographics, lifestyle, mindset, and personality traits—as well as characteristics of the experience itself, such as dosage, ingestion method, intention, and setting. Anyone planning to use psilocybin (single dose; not a microdose regimen) outside a research laboratory in the next 6 months is invited to participate. In this episode: How in five years, Del went from being anti-cannabis to co-founding and directing a psychedelic research non-profit organization. Why community-provided data about how psilocybin is actually being used, and the effects people are experiencing with it, is crucial for informing future research studies. How data points collected through such studies can lead to aligning the financial incentives of insurance companies to support plant-medicine empowered therapies. Quotes: “As we were moving forward with the decriminalize initiative, I just knew and saw that there’s going to be this huge wave of psychedelic naive folks who are going to hear these stories that are going to come out, whether it’s veterans, or smoking cessation, or whatever it might be, and they’re going to need a safe place to land.” (11:01) "I continued to grow my knowledge of plant medicine and then I had a personal experience a couple years ago and that was it. I absolutely knew that there is so much potential in these entheogens, and our choice to not study them will go down as probably one of the biggest crimes against the human race." (16:07) "If you say: “Hey, how can I get involved in this cause? What can I do?” Most people don’t have time to petition, to collect signatures. They don’t have time to start a non-profit. Their focus is on other things but this is very important to them. This study is a really good opportunity to anonymously provide information on how you’re using psilocybin." (21:18) "People are not using psilocybin in a lab, on a couch, with one or two therapists. They don’t. It’s not happening. This way of collecting information allows us to see how the community is using it, what does that look like, and what can we learn from that type of information?" (22:18) "It’s not our role to get people to vote for psilocybin. It’s more our role to make sure they’re not necessarily voting against it, just like for me (referring to his past), if you’re on the fence, just stay there. If you don’t know, just stay on the fence. Don’t jump on one side because it’s what you think you’re supposed to do." (38:29) Links: Participate in the Unlimited Sciences/Johns Hopkins psilocybin research study Unlimited Sciences website Unlimited Voices webinar series Follow Unlimited Science on Instagram Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine Follow The Plant Medicine Podcast on Instagram Porangui…
1 DMT Scientific Research with Dr. Chris Timmerman 59:29
59:29
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
59:29Chris Timmermann, PhD, is a researcher at Imperial College, where he conducted the first neuroimaging studies of DMT in healthy volunteers and its potential for mental health interventions. He is also conducting research concerning the effects that psychedelics have on belief systems and the ethical implications associated with the mainstreaming of these substances. In this episode, Chris Timmerman discusses what happens neurologically when DMT is administered. He talks about his research into neuroimaging and how the brainwaves change during DMT experiences, and how those changes can help elucidate some of the mechanisms of psychedelic states. He also breaks down the concept of cortical activation and how DMT experiences lead to a pattern of cortical activation that mimics that of visual stimulation. Dr. Timmerman also discusses how DMT experiences are often compared to what happens to the body when it has a near-death experience. He explains some of the difficulties of studying these effects and how to ethically study the phenomenon of near-death experiences. In addition to his work on DMT, Dr. Timmerman also shares some of his research on the impact of music in psychedelic therapy, and how it can help comfort people facing trauma. In this episode: How DMT interacts with our physiology Current scientific research on DMT The correlation between DMT and near-death experiences How alpha, delta and theta brain waves are affected by DMT Why people think DMT use can lead to tolerance The role of music in psychedelic therapy What psychedelic apprenticeships are and how they can help with healing Quotes: "DMT is incredibly unique because it is able to generate simulations of sorts. The level of immersion is radical, complete. People with their eyes closed, they feel kind of detached from their environment, but they are experiencing a world of experience." [5:52] "We developed a map of this DMT story for each participant. We found three main components: one there was a visual component in the experience, we found a bodily component [a somatic effect], and an emotional effect. And we found that these different parts of the DMT story - the visual, the bodily, and the emotional - had different brain signatures." [18:55] "There have been some animal studies, or very promising ones, in which not only DMT but also LSD and ketamine has been shown to have important properties associated with neurogenesis." [35:09] "The use of psychedelics by western populations is fairly new. We don't have that know-how or that expertise like some indigenous cultures, has for generations." [46:49] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' Follow Dr. Timmerman on Twitter Follow Dr. Timmerman (and check out his music) on InstagramFollow Chris on Instagram and listen to his music Center for Psychedelic Research at Imperial College Porangui…
1 DMT Patient Experience with Adam Meredith 27:49
27:49
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
27:49Adam Meredith is an entrepreneur, podcasting consultant, speaker, photographer, health and movement coach, martial artist, and retired pro fighter based in St. Louis, MO. In addition to hosting Outside Perspective, Adam is also the founder and CEO of Imposed Will, a lifestyle brand dedicated to empowering others to impose their will on life, through mental strength and healthy habits. In this week's episode, Adam goes into detail about what he experienced during multiple DMT journeys. He talks about how intense his first experience was and what he felt in the DMT space. He also compares how different his later experiences were. Initially, Adam avoided setting expectations for his DMT experiences. However, he shares how it has helped him develop his spirituality and realize that he was more than just his physical body. In this episode: What a DMT journey can be like and what Adam experienced How DMT can vary between experiences. The benefits of having a guide for a first time experience. How DMT can help promote religious experiences Quotes: “I feel like expectations are the quickest way to disappointment. So it's like, I just wanted to be open to the experience and see what I actually get from it.” [7:25] "I look on the walls and I'm seeing the geometric patterns and all of a sudden I'm just yanked away from this physical space." [10:12] “This is a place that you can go to, and we are a part of that thing, whatever that is. Whether you call it the universe, you can call it God, you can call it energy, it's like, there is a whole lot more going on than we really understand, and maybe we will never be able to explain it with science, but it's there." [25:12] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' Outside Perspective Podcast Follow Adam on Instagram Follow Outside Perspective Podcast on Instagram DMT: The Spiritual Molecule Porangui…
1 Helping Veterans Access Treatment with the Founders of The Ketamine Fund 52:49
52:49
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
52:49Michael "Zappy" Zapolin and Warren Gumpel co-founded The Ketamine Fund, a 501(c)(3), that provides free ketamine treatments to veterans suffering from PTSD or having suicidal ideations, with the mission of lowering suicide rates by 75 percent. The Ketamine Fund has donated more than 400 free treatments to veterans suffering from PTSD. In this week’s episode, Zappy and Warren share their stories, and what led them to advocate for ketamine treatments. Noticing how expensive this therapy can be, Zappy and Warren wanted to help veterans who would benefit the most by subsidizing this treatment. Zappy and Warren also discuss some additional projects they work on to increase awareness of ketamine treatments, such as their upcoming documentary about Lamar Odom and their work with the Mind Army Movement. They also talk about why a proper ketamine facilitator is so important and how certain ketamine treatments are not as effective due to underdosing. In this episode: How Zappy and Warren became involved in advocating for ketamine. Their upcoming documentary about Lamar Odom and how ketamine helped him in his recovery. How ketamine addresses trauma and how it’s helping soldiers with PTSD. How the Ketamine Fund is supporting soldiers through partnerships with treatment centers in the US. Quotes: “After my ketamine treatments, my depression and anxiety were gone. Nothing had ever happened so quickly and so miraculously.” [7:29] "Probably the most beautiful thing about ketamine is it needs the least integration of what I've seen because some of the plant medicine takes a long time." [18:50] “It became very apparent to us that one of the most underserved communities in this country that deserves it [ketamine treatment] is the veteran community.” [25:38] "We think if we can fund that [the Ketamine Fund] properly, and then anybody in the country who says that they're having suicidal ideation; we can get them into a clinic, in our network, within 24 hours in a clinic and get a free treatment." [40:10] Links: Ketamine Fund Odom Reborn The Reality of Truth Considering Taking Psychedelics During the Quarantine? Porangui…
1 Mescaline History and Legality with Mike Jay 44:40
44:40
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
44:40Mike Jay is an author who has written widely on the history of science and medicine. His books include High Society: Mind-Altering Drugs in History and Culture and his latest, Mescaline: A Global History of the First Psychedelic . In this episode, Mike discusses his research into mescaline and its extended history. Mike shares the cultural significance of huachuma and peyote for indigenous tribes in Mexico and Peru dating back over 3000 years. He also talks about western research into mescaline starting in the 19th century, and even mentions how peyote was almost incorporated into the Mormon Church! Mescaline is considered a class A drug by many countries, and Mike discusses some of the legal "blurry areas" based on different types of cacti containing it. He also covers the environmental impact of improperly harvesting peyote, how industrial mining is destroying peyote’s environment, and what native tribes in Mexico are doing to protect this endangered plant. In this episode: The origins of mescaline-related terms including san pedro, huachuma, and peyote. The traditional uses of huachuma and peyote. How mescaline was discovered and what led to its criminalization. The differences between peyote and huachuma. Why peyote is endangered and what is being done to protect it. Quotes: “All those kind of great early accounts of peyote from the 1890s are all very full-on, first-person (what we would call trip reports), written by people who are often doctors, but who are also often poets and writers. People who are very, very good at medical description. So these are kind of beautiful pieces of psychedelic literature.” [6:14] "There are reports from the 17th/18th century of villages where everybody would get together, usually around a fire, usually at night. peyote would be passed around and people would sing and dance through the night." [21:04] “Your average cactus supplier, or sometimes even your cactus garden center will have huachuma. So the legal status of the cactus is kind of blurry.” [25:38] "We kind of go, 'Oh Psychedelics! That story started in the '60s or '50s.' If you look at mescaline it's like, no. I mean there are western stories starting way back in the 19th century." [36:50] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' Mike Jay’s Website Follow Mike Jay on Twitter Fundraiser for Peyote Conservation and Cultivation Mescaline: A Global History of the First Psychedelic Huicholes: The Last Peyote Guardians Porangui…
1 Mescaline Practitioner Methods with Tah and Kole Whitty 1:07:30
1:07:30
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:07:30Tah Whitty spent 25 years as a nurse in emergency medicine, and Kole Whitty has spent 17 years educating professionals about life’s addictions. Together, they have 17 years of combined experience in various shamanic traditions, guiding performance-driven entrepreneurs. In this week’s episode, Tah and Kole discuss how their paths led to facilitating huachuma (San Pedro) ceremonies. While they both were initially resistant to using plant medicine, they discovered how impactful huachuma ceremonies can be to resolve pent up trauma. Tah and Cole describe huachuma as more gentle compared to other plant medicines, though the effects of the medicine can often be present for 10-12 hours. They also discuss the pre-journey intake process, the preparation and support that goes into a participant’s experience, and the post-care support to help integrate the experience into their healing journey. In addition to explaining the huachuma ceremony, Tah and Cole talk about trauma and healing. They emphasize the importance of avoiding the Transformation TRAPP (Tirelessly Repeating A Painful Process) which can be harmful to an individual’s growth, and the importance of being in a state of relaxation to optimize healing. In this episode: What drew both Tah and Kole to working with huachuma ceremonies The origin of the terms huachuma and San Pedro. Some common experiences during a huachuma ceremony. The preparation and support facilitators provide before and during a huachuma ceremony, and the necessity of follow up support. The importance of relaxation and the use of TRE(Tension and Trauma Release Exercise) to help the body relax at the beginning of their ceremonies. How modern treatments promote “Transformation TRAPP.” and prevent true healing. Quotes: "When your nervous system is relaxed, you can actually get to the deeper space that you need to get to, and that's where healing takes place the most." [5:03] "You are not controlling the [Mescaline]experience. You are co-creating the experience." [13:03] “The trauma response, physiologically, is your response to an activity. Trauma is not what happens to you, it is how your body and your organism responds.” [27:56] “What does it feel like to be free of the conditioning, of the expectations, of the trauma, and drama? It doesn't mean you stop feeling, it means it stops being so much weight on your wings.” [42:06] "We have had countless people come to us and to work with us, and they're like 'I've got trauma that is holding me back!’ No, what is holding them back is that they are not allowing themselves to have fun." [43:16] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' Tah and Kole's website Mentor in the Mirror Podcast Take the Get Help Quiz Subscribe to Tah and Kohle’s Texting List by texting ‘Optimize’ to 22999 Follow Tah and Kole on Instagram Find Tah and Kole on Facebook Porangui…
1 Navigating Psychedelics for Clinicians with Joe Moore of Psychedelics Today 38:52
38:52
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
38:52Joe earned his BA in philosophy in New Hampshire. After stumbling upon the work of pioneering psychedelic psychiatrist Dr. Stanislav Grof in 2001, Joe began participating in Holotropic Breathwork workshops in Vermont in 2003 and he later began helping facilitate Holotropic and Transpersonal Breathwork workshops. In this week’s episode, Joe discusses how he and his co-founder, Kyle Buller started Psychedelics Today, and how their podcast led to them developing a number of online courses. Their upcoming course is Navigating Psychedelics for Clinicians and Therapists. This 8 week course is good for both those wanting to learn how to better understand a client’s needs as a physician or a therapist and for those looking to get a taste of what the psychedelic therapy world is like before embarking on official training. Joe also talks about how mystical and spiritual experiences can play a role in psychology. While often overlooked in the current psychiatric system, Joe believes these spiritual and mystical experiences may help to heal patients in certain situations. In this episode: How Psychedelics Today started, and what led to offering courses. What information Joe found lacking in the psychedelic community. What to expect in the Navigating Psychedelics course and who it is for. How psychological theories incorporate into the work of facilitation Spiritual Emergence and its potential benefit to the current psychiatric system Quotes: “We just thought the psychedelic world is really interesting, but it is really lacking regular discussion of Dr. Stan Groff and Holotropic Breathwork. So really it [The Psychedelics Today podcast] was a way that we could contribute and bring voices that we thought were important back to the foreground" [5:13] "I don't want to be the Tony Robbins telling you how, you know, this is exactly how you should be charging at your problems. It's like no - you need to take an individualized approach." [13:03] "If more people had a lot more support like we could see people self resolve things [trauma and psychological issues] instead of going into the psychiatric system for decades." [26:13] "You don't get educated and then you're done. This is a lifelong process." [36:53] Links: Get 20% off everything at Octagon Biolabs (octagonbiolabs.com) with coupon code 'plantmedicine' psychedelicstoday.com psychedeliceducationcenter.com Navigating Psychedelics: For Clinicians and Therapists Follow Psychedelics Today on Instagram Follow Psychedelics Today on Twitter Porangui…
1 Mescaline Patient Experience with Ian-Michael Hebert 36:06
36:06
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:06Ian-Michael Hebert is committed to healing the relationship between humanity and the Earth. His formal training has been in eco-resort design and he holds a Masters degree in Counseling Psychology and community mental health. He is the founder of Holos Global, a network of holistic healing centers. Ian-Michael has catalyzed many teams in creating enduring structures and institutions that will benefit generations to come. In this week’s episode, Ian-Michael describes his very personal journey as he experienced mescaline while hiking through the Grand Canyon. This Mescaline experience helped Ian-Michael work through his negative internalizations, reconnect spiritually to nature, and even helped him strengthen his relationship with his father. He also discusses how this experience led him to his current work with Holos Global and the services they provide. In this Episode: What a mescaline experience can be like and what Ian-Michael experienced The importance of reconnecting with nature How to reintegrate after a psychedelic experience The purpose of Holos Global Quotes: “What I find with this particular ally or this particular plant medicine, is that it deeply amplifies our feeling states.” [8:17] “That particular experience was less like an actual visual experience and more of a felt sense.” [18:47] “The overall journey of being on the Grand Canyon and that bigger context was very much a reset of my life, and I came out very inspired." [26:55] "The integration arc is as important as the journey. If you really want to mine the gems, if you want to, like, get the benefits of the medicine you really have the opportunity to reflect on it and to practice it." [28:33] Links: Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Holos Global Follow Holos Global on Instagram Wild Vessel The Body Keeps the Score Plant Medicine Podcast Episode with Eamon Armstrong Episode Music by Porangui…
1 5-MeO-DMT Scientific Research with Dr. Joseph Barsuglia 53:33
53:33
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
53:33Dr. Joseph Peter Barsuglia is a clinical psychologist focused on bridging ancestral medicines and wisdom with best clinical practices, in order to catalyze personal healing and spiritual awakening. He has worked as Research Director of a psychedelic treatment center which utilized 5-MeO-DMT and ibogaine for the treatment of addiction, as a psychotherapist in the MAPS-sponsored trials of MDMA-assisted psychotherapy for PTSD, and is an initiate of the African tradition called Bwiti which uses iboga as its sacrament. In this episode, Dr. Barsuglia discusses what happens to the body when 5-MEO-DMT is consumed. He also discusses the origins and history of 5-MEO-DMT, as well as some of the scientific research being conducted on the molecule. He also shares some research on how he observed the mystical effects 5-MEO-DMT had on patients and some of the consistent experiences patients described. The increasing popularity of this psychedelic often brings up a discussion on the environmental impact of harvesting Sonoran Desert toads. Dr. Barsuglia uses this to discuss differences between synthetic vs naturally occurring 5-MEO-DMT, and how synthetic developments can help protect the environment and preserve tribal tradition. In this episode: The sources of 5-MEO-DMT and how it is used The historical, cultural, and environmental significance of 5-MEO-DMT The effects of 5-MEO-DMT on the body and common experiences from participants Current scientific research on this plant medicine The differences between natural and synthetic 5-MEO-DMT Quotes: “This is one of the oldest psychedelics found in archeology.” [8:30] “Some kind of basic science studies on cell lines that showed that 5-MEO-DMT does in fact stimulate brain cell growth, antidepressant properties, and might boost the immune system.” [13:24] “In many psychedelics, you are getting formed visuals, you can kind of interact with what’s happening. This medicine kind of takes you beyond your biography, beyond your memory, beyond form into a very energetic experience.” [16:07] "80 percent, I think, of people that had this experience said it was profoundly sacred or holy." [28:48] “I also think that people don't need to be demonized that are using this medicine.” [51:31] Links: Find Dr. Barsuglia Online MAPS Scientific Journals relating to this episode: Angel of human health: current research updates in toad medicine The Development of Toad Toxins as Potential Therapeutic Agents New Therapeutic Aspects of Steroidal Cardiac Glycosides Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer The Development of a Pharmacological Approach for Rabies Treatment Bufotenine is able to block rabies virus infection in BHK-21 cells Porangui…
1 Trauma-Informed Plant Medicine Facilitation with Atira Tan 38:37
38:37
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
38:37Atira Tan is currently a PhD candidate in Expressive Arts Research at the European Graduate School in Switzerland. She possesses an MA in Art Therapy, has a background in Transpersonal Art Therapy and Holistic Counseling, and is a Somatic Experiencing Practitioner with decades of training in various somatic trauma-informed approaches. Atira worked as a trauma-informed integration specialist in retreat centers such as the Temple of the Way of Light, and she is currently the head of Ayahuasca integration at AYA Healing Retreats. In this episode, Atira discusses the concept of trauma-informed therapy, and how facilitators can respect and support participants in healing circles. As everyone experiences traumas in their lives differently, Atira discusses how trauma can impact an individual’s experience in healing circles. She also establishes the importance of communication between the facilitator and participants. Atira’s upcoming workshop covers several important topics to help teach facilitators how to integrate trauma-informed principles into their ceremonies. There will be a large focus on the core of the essentials of trauma and how to intervene. Some other topics that will be discussed include boundaries, safety, and consent during ceremonies, how trauma shows up in the body, identifying trauma and trauma recovery, and the cross overs of shamanism and mental health. In this episode: Explaining the definition and principles of trauma-informed therapy The importance of a facilitator to prepare and have a medical intake in healing circles. What may trigger people in a plant circle and how to support them Tips on how we can soften the collective trauma of Covid-19 Quotes Trauma happens when there is a boundary violation. [10:07] As part of the trauma-informed lens, facilitators need to kind of think about what's important to be communicated first. [19:59] Part of giving people's choice and agency is really about consent. [22:10] Links: Aya Healing Retreats Trauma-Informed Plant Medicine Facilitation Workshop Porangui…
1 5-MeO-DMT Practitioner Methods with Tricia Eastman 44:28
44:28
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
44:28Tricia Eastman is a medicine woman, author, and pioneer in the psychedelic movement. Eastman offers highly curated retreats in countries where use is legal, working with iboga, psilocybin mushrooms, and 5-MeO-DMT. She has been initiated into Bwiti Fang traditions and the Ngonde Missoko tradition, and she facilitated the psychospiritual iboga program for Crossroads Treatment Center in Mexico. She supports projects related to the preservation of the sacred medicines and sacred sites for future generations and working with the ancient wisdom traditions with respect and reverence. In this episode, Tricia discusses the start of her journey into becoming a healer working with psychedelics. At a 5-MeO-DMT retreat, she learned how to love herself, and decided she wanted to lead others on this healing experience. Since 2016 she founded Psychedelic Journeys, which offers guided retreats with a number of medicines. Tricia shares the many ways 5-MeO-DMT can be administered, and how facilitators can support participants during this ceremony. While she does discuss the positive experiences many people have, she speaks frankly about how 5-MeO-DMT can greatly affect others based on their previous experience, both with psychedelics and past trauma. One of Tricia’s passions is promoting sacred and ethical use of 5-MeO-DMT. She discusses how encroaching farming practices and unethical harvesting has impacted the source of 5-MeO-DMT, the Sonoran Desert Toad, and some practices for minimizing harm In this episode: How Tricia got started facilitating 5-Meo-DMT. Some methods facilitators use during a 5-MeO-DMT ceremony. What people may experience during a 5-MeO-DMT ceremony. How 5-MeO-DMT is contraindicated The ethical and environmental impact of 5-MeO-DMT extraction. Quotes: 12:00 "You are in a space of timelessness where your perception of where you are could feel like eons even though it has been seconds." 14:59 "I try not to be a character in the movie. I don't want it to ever be about me, or doing anything, because they are there to do their own healing work. 19:43 "We don't want to set you up in a way that you are going to get in your own experience, and not actually receive whatever the medicine wants to show you." 37:48 "For me, I really feel that it's important that everything is done in a sacred way. That they are done in an ethical thing." 41:14 Everything I do is a very deeply intuitive process of really following and listening, and that's just how you learn when you work in the shamanic traditions. Links: Third Eye Meditation Lounge- Third Eye Cacao- Use code PLANTMEDICINE to get 15% of orders over $50, and a free class at the meditation lounge. 3rd Eye Mushroom Immune Elixior Find Tricia Eastman online Follow Tricia on Instagram Ancestral Heart Terra Incognita Foundation World Bufo Alvarius Congress 5-MeO-DMT Patient Experience Music by Porangui…
1 5-MeO-DMT Patient Experience with Mikey 37:54
37:54
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:54In today’s 5-MeO-DMT patient experience episode, Mikey, a former Navy SEAL, shares his phenomenal story of how an experience with 5-MeO-DMT changed his life. Mikey explains what he experienced when he tried 5-MeO-DMT, and the effect that experience had on him. 5-MeO-DMT experiences have helped Mikey better understand and accept the presence of a higher power in his life, which has helped him accept his mistakes, grow as a person, and improve his outlook on life. Mikey also discusses how these experiences helped him come to a better understanding of acceptance and love for himself. In addition to accepting himself, he also discusses how this higher power and the concept of infinite love helped him learn to love and support others. In this episode: How Mikey's journey led him to try using 5-MeO-DMT to get help. What a 5-MeO-DMT journey can be like and what Mikey experienced. How 5-MeO-DMT can help bring one to an understanding of a higher power. How changing one’s mindset can help promote healing and improve one’s outlook on life. Quotes: "Where I am at today, there is a peace about me. There is a willingness to want to think of others, and to be of service." [4:09] My arms, my brain-- everything is like drifting and kaleidoscoping away. I feel like I am being turned inside out. Not in a painful way, but in an awareness way." [27:16] "You have never been judged a day in your life. There is no wrong you can possibly do. There is no wrong you can possibly do because there is no judgment. This is the stuff that is coming out of me!" [29:21] "I was literally jettisoned right into the lap of God. There is no other way to put it." [30:12] “For every situation that we find ourselves in, it is not about any one of us, but it involves all of us. We are all the star players in our own movie. We're all the co-star of everyone else's." [32:45] "When we heal, we heal others." [36:02] Links: Get 20% off everything at Proper Hempco CBD with coupon code “PLANTMEDICINE” Music by Porangui…
1 Ibogaine History and Legality with Dr. Thomas Kingsley Brown 27:18
27:18
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
27:18Dr. Thomas Kingsley Brown is back on the show to discuss the history and legality of ibogaine. With a master’s degree in chemistry and a Ph.D. in anthropology, he has conducted extensive research into altered states of consciousness, religious conversion, and the use of ibogaine in the treatment of opioid addiction. In this episode, Dr. Brown describes the origin of ibogaine which is derived from iboga, a plant indigenous to west-central Africa. Its bark has been sacramentally used by the Bwiti people for countless generations. At the turn of the 20th Century, ibogaine was first isolated from iboga. Various drugs were derived from this in Europe and North America throughout much of the century. During the war on drugs, this obscure psychedelic was regulated and criminalized in the United States in 1967. In 1970, the Controlled Substances Act declared ibogaine to be a Schedule 1 drug. In the 1980s, efforts to explore ibogaine’s potential to treat chemical addiction got underway. With opioid use linked to the transmission of HIV/AIDS, various groups began looking at ibogaine as a tool for recovery. There have always been a few countries where ibogaine remained unregulated. However, it wasn’t until 2009 that New Zealand became the first country to legalize it as a medicine for use in opioid recovery. In several US cities, such as Oakland, ibogaine was recently decriminalized. That said, its legal future remains uncertain. In this episode: The natural African roots of ibogaine How ibogaine was used in various medications during the 20th Century What led to the criminalization and regulation of ibogaine The movement to explore ibogaine’s use in addiction recovery How and where ibogaine was legalized or decriminalized in recent years Quotes: “It’s sort of a twisted history in a way. There are a lot of different things that go into it. But chemically ibogaine was first isolated and purified from the iboga shrub in 1901.” [4:09] “Psychedelics are not addictive, ibogaine among them. Ibogaine is usually a difficult trip, especially for people who are using it for getting off opioids.” [10:11] “I think it will be at least some time before we are able to see legal ibogaine treatment here in the US.” [24:03] Links: Episode 34: Ibogaine Scientific Research Dora Weiner Foundation ACT UP Episode 28: Decriminalize Nature MAPS Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Same Summit, Now Virtual! Chacruna Founder Bia Labate, Ph.D. tells us all about the upcoming Psychedelic Liberty Summit 37:25
37:25
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:25This week we discuss the upcoming Psychedelic Liberty Summit (April 25th and 26th) with Bia Labate, Ph.D. As the executive director of the Chacruna Institute for Psychedelic Plant Medicines , adjunct faculty at the California Institute of Integral Studies , public education and culture specialist at MAPS , co-founder of the Interdisciplinary Group for Psychoactive Studies in Brazil, editor of the Mexican blog Drugs, Politics, and Culture, and the author and editor of numerous books, special edition journals, and several peer-reviewed articles, Dr. Labate is a wealth of information and knowledge. Dr. Labate explains how she started the Chacruna Institute in 2017 with the mission of promoting education around plant medicines. With a focus on the cultural side of plant medicines, Chacruna works to help spread the idea that these plants have a place in society. This involves creating a bridge between traditional uses of plant medicine and scientific advances being made in the field. Chacruna’s upcoming conference might be the largest virtual event of its kind. There will be a large focus on the emerging politics of plant medicines. Other themes include the responsibilities that practitioners and patients have to use them in an informed and ethical way. With more than 70 speakers and 35 community partners, this will be an inclusive and expansive event. In this episode: The mission of the Chacruna Institute to bridge the gap between tradition and science The main focus and structure of the Psychedelic Liberty Summit The wide variety of organizations that are part of the summit Some of the summit speakers and their topics Quotes: “We’re trying to create legitimacy around the idea that these drugs are legitimate and should be respected as such and be incorporated into our legal and health systems.” [5:06] “We have activists, researchers, community leaders, lawyers, religious leaders, and practitioners. We have a really incredible lineup.” [22:00] “In the field of psychedelics science, we have often fetishized shamans from South America and forgotten the people of the land. So I’m really proud that we have a series of different Native American representatives.” [32:54] Links: Chacruna Institute for Psychedelic Plant Medicines MAPS Psychedelic Support The Psychedelic Society Psychedelic Seminars Horizons Wixárika Research Center Psychedelics Today Morning Star Conservation Sage Integrative Health Transform Drug Policy Foundation Drug Policy Alliance “The Emergence of a New Market: Psychedelic Science Conferences” by Bia Labate Ph.D. Episode: Decriminalization of Psilocybin with Attorney Sean McAllister Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Considering Taking Psychedelics During the Quarantine? A Discussion with Therapist Rebecca Kronman 31:32
31:32
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
31:32Thanks to the current pandemic, most of the population is quarantined at home. During this time, some may want to consider using psychedelics. However, there are some additional considerations to keep in mind when deciding whether to undergo a psychedelic journey during the quarantine. Rebecca Kronman is a licensed therapist and the founder of Plant Parenthood , a community of parents who use psychedelics. She is a psychotherapist with a private practice in Brooklyn, NY where she works with clients to help them prepare for and integrate after psychedelic experiences. In this episode, Rebecca discusses the concept of harm reduction. This means that no one is advocating what anyone else should or shouldn’t be doing. Rather, it is about asking that people explore the topic of psychedelics with all the information available. With the right knowledge and confidence, people will feel better prepared for whatever they decide to do. Given that hospitals are currently overtaxed and undersupplied, considering what might happen if a psychedelic experience goes wrong is more important than ever. Rebecca talks about how heightened levels of anxiety are going to play into this and how is more crucial that someone is attuned to their mindset before undertaking a psychedelic experience. Rebecca shares some tools that people can use to listen to what their mind and body are telling them. If, after taking everything into account you decide this isn't the proper time to be journeying for you, then it can still be used to prepare for one in the future or integrate one from the past. That being said, for some individuals this time may be too overwhelming for that and it might be best to wait for another time. Rebecca stresses that everyone needs to evaluate their own situation and make an informed decision. In this episode: What harm reduction means and how it relates to psychedelic use Important considerations if an experience goes awry Tools for evaluating mindset during times of heightened anxiety Using this time to prepare for a future experience or integrate a past one Quotes: “Are we okay with the fact that the hospital might not be available to us right now?” [6:20] “Any way that you can create space for yourself and pause - any kind of contemplative practice - is going to be extremely useful.” [11:10] “This is an entropic period for all of us. Our whole lives look different. We may be in a different place. Definitely, we’re doing different things. Our whole routine has shifted. Greater entropy gives us greater opportunity for shifting patterns. That’s what psychedelics are about.” [20:07] “If it feels accessible to us to add something new into our integration practices, this is a great time. If we’ve got too much on our plate, have compassion for ourselves and say ‘drop the technique.’” [22:27] Links: Plant Parenthood Follow on Instagram The Psychedelics Integration Handbook by Ryan Westrum, Ph.D. Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Iboga Patient Experience with Eamon Armstrong 55:45
55:45
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
55:45In this week’s iboga patient experience episode, we hear from Eamon Armstrong. He is the creator and host of the Life is a Festival Podcast , promoting a lifestyle of adventure and personal development through the lens of festival culture. Eamon’s belief in the transformational power of psychedelics led him to take part in a traditional Bwiti initiation in Gabon. He has since become a trained sitter with MAPS’ Zendo Project . Eaman describes how his desire for personal metamorphosis led him to seek out an iboga experience in Africa. However, he doesn’t recommend that others go to Gabon to do what he did. Rather, a more clinical setting is much safer. At any rate, he found that it was a truly transformational journey. Eamon describes what he went through during his ten-day experience and how it led to new and important insights. Eamon’s journey revived many forgotten memories. These memories brought back some suppressed fear and trauma. He feels that it was a very healing experience overall. Eamon found that iboga led him to recognize the source of his traumas which ultimately helped him deal with addiction. In this episode: Why it is safer to have an ibogaine experience in a clinical setting rather than elsewhere Preparation to take before an iboga journey The various steps to a traditional iboga experience How an iboga journey is a very personalized experience The important role that an integration coach can play in any psychedelic journey The distinction between iboga and ibogaine Quotes: “My pursuit of iboga had to do with certain aspects of myself that I wanted to transform. I wanted to transform them by going to the root.” [6:02] “It felt healing. I felt like I was moving through chunks of things that I had been carrying and holding inside me. It was hard work.” [26:28] “What iboga teaches you is that there is no such thing as addiction in the way that you think there is. There is only deep trauma and pain and patterns that you create to avoid them. Iboga goes to the root of that trauma and pain and shows you what it is.” [36:15] Links: Life is a Festival Podcast Zendo Project Iron John by Robert Bly Ayahuasca Scientific Research with Dr. Dan Engle Ibogaine Scientific Research with Thomas Kingsley Brown, Ph.D Unlimited Sciences Maya Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Psychedelic Science: Social Distancing Style- Discussing the Upcoming MAPS Psychedelic Science Webinar Series with Brad Burge 23:57
23:57
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
23:57As this episode airs, most of us are currently contained at home and much of the world has shifted online. This presents a very exciting opportunity to connect with MAPS . This organization is preparing to release its 2020 webinar series which runs April 9 through May 21. If you are wondering what MAPS is and what this webinar is about, Brad Burge is on today to share that with you. Brad is the director of strategic communications who began working with MAPS in 2009 to help expand their international public education and communication programs. He engages daily with journalists and media producers around the world to enhance public knowledge about psychedelic research while also helping develop MAPS brand and outreach strategy. In its upcoming online course, MAPS and the speakers will explore the latest advancements in psychedelic research, medicine, and policy. This will include talks by some of the foremost leaders in the psychedelic renaissance. They’ll provide insights into the latest research into the medical and therapeutic uses of psilocybin, MDMA, ketamine, and more. It also includes a sneak-peek at key issues affecting the wider availability of psychedelics for healing and spirituality. In this episode: Speakers and the topics they will cover in the webinar What is being discovered about the effect of psychedelics and the brain MAPS’ role in regulatory and decriminalization initiatives How MAPS provides peer support and harm-reduction Current research on the ability of MDMA to treat PTSD Quotes: “The topics were chosen based on what’s timely in the field of psychedelic therapy and clinical trials.” [4:40] “MAPS is about the research and science, but we’re also about much more than that. We’re also looking at and supporting different initiates to regulate psychedelics.” [7:15] “If we can take these so-called bad trips and turn them into learning experiences, then we can do a lot of good. We can heal trauma and help people explore their consciousness.” [12:01] “Where in this when, not if , situation. We’re in a final push after 33 years of work to actually make MDMA a legal prescription treatment for PTSD.” [18:27] Links: MAPS webinar signup Zendo Project Chacruna Institute for Psychedelic Plant Medicines LSD Scientific Research with Dr. Katrin Preller MDMA Scientific Research with Marcela Ot'alora Ayahuasca History and Legality with Ismail Ali Decriminalization of Psilocybin with Attorney Sean McAllister MDMA Practitioner Methods with Shannon Carlin MAPS Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ibogaine Scientific Research with Thomas Kingsley Brown, Ph.D 31:33
31:33
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
31:33With a master’s degree in chemistry and a Ph.D. in anthropology, Dr. Thomas Kingsley Brown takes a comprehensive approach to study topics of altered states of consciousness, religious conversion, and the uses of ibogaine in the treatment of opioid addiction. He joins us today to discuss the current research into ibogaine. Ibogaine is not one of the most well-known psychoactive compounds. Dr. Brown explains what this plant medicine is and what it is derived from. Ibogaine is most often derived from the root bark of the iboga shrub from west-central Africa. It was used by certain African populations in a ceremonial context for centuries. Dr. Brown delves into some of ibogaine’s more recent history as a treatment for opioid addiction. Its anti-addiction effects were anecdotally first discovered by accident in the 1960s by Howard Lotsof. After an experience with ibogaine, Lotsof found that he no longer desired heroin. This kicked off a career researching the anti-addiction effects of this compound. Dr. Brown shares what his research has gleaned concerning ibogaine’s mechanism of action. The full mechanism is still not entirely clear. However, he has found that it acts in two ways. First, there is a biochemical action in the brain and body. There is also a powerful psychoactive effect. These two effects seem to work in tandem to eliminate opioid desire and withdrawal symptoms. Research participants have reported several intriguing observations besides a drop in drug use, particularly an improvement in social wellbeing. In this episode: The natural and artificial sources of ibogaine How ibogaine became associated with opioid addiction recovery What is known about ibogaine’s mechanism of action Common experiences of people who have undergone ibogaine therapy Possible effects of ibogaine to promote neural health Thoughts on the efficacy of using medicines with tribal origins in a clinical setting Quotes: “It seems that this would facilitate rewiring of the brain. You could look at this as being a potential mechanism for creating new pathways where you’re not automatically going into your addictive behavior.” [12:46] “Even if you’re not using it to treat addiction, it will force you to confront things you’ve been avoiding.” [17:05] “As an anthropologist, it seems to me that the more we can set our intentions going in, really being careful about the setting, then the better we’ll do with these psychedelic therapies.” [29:32] Links: MAPS Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ayahuasca History and Legality with Ismail Ali 40:53
40:53
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
40:53Ismail Lourido Ali is the Policy Fellow at MAPS where he helps develop and implement strategies to create legal access to psychedelic substances in medical, sacramental, and personal contexts. Licensed to practice law in California, Ismail sits on the advisory committee of the Ayahuasca Defense Fund . In this episode, Ismail discusses the history and legality of ayahuasca. He explains how people in the Amazon have been using ayahuasca for thousands of years, often as part of religious, spiritual, and community ceremonies. In the mid-20th Century, ayahuasca found its way out of the jungle and into American and European popular consciousness. However, in just the past few years, ayahuasca has expanded to a near-global level. Naturally, these changes have led to a new context for this plant medicine. With the Controlled Substances Act of 1970, ayahuasca was swept up with other psychedelics for regulation. Interestingly, the plants themselves are not regulated under the 1971 International Convention on Psychotropic Substances, but the psychedelic compound it contains, DMT, is. Ismail explains why in the US, ayahuasca remains a Schedule I substance. There are legal exemptions, however. As a result of the Religious Freedom Restoration Act of 1993 and a 2006 Supreme Court case, certain religious institutions are permitted to utilize ayahuasca in a sacramental context. The legality of ayahuasca use among other communities is still unclear. The status of ayahuasca varies greatly outside of the United States. In theory, ayahuasca remains unregulated in any country that has not affirmatively regulated it. However, in general, ayahuasca is most commonly legally accepted in countries that have chosen to regulate it to a certain degree or permit it under particular laws. With decriminalization movements taking hold across the United States, the status of ayahuasca has become as murky as ever. In cases like Denver and Oakland, ayahuasca still remains illegal. However, new statutes mean that enforcing laws against it are no longer a law enforcement priority. What this will mean in the long run is still unclear. In this episode: How ayahuasca use has transformed from its origins in the Amazon to something that is known across the world How ayahuasca became a regulated substance in the United States Instances in which ayahuasca use is legally permitted The complexities involved in getting permission to legally use ayahuasca The legality of ayahuasca in various countries around the world How current and recent decriminalization efforts are changing the legal status of ayahuasca Quotes: “We’re in an interesting time. We’re looking at a case study in the expansion of something that is more than just a plant, drug, or medicine. It’s really a combination of so many different cultural, political, social, and historical realities.” [6:35] “Because there is really no effective structure to determine who does and doesn’t get an exemption, there are a lot of big questions that still need to be answered.” [15:58] “Right now, technically nothing has changed from a legal perspective. But it’s absolutely true that we’re experiencing a pretty significant conversation shift because of decriminalization.” [33:55] “It’s important to remember that part of the reason to do spiritual and healing work is so that we have the resilience to engage with the world as it is.” [36:51] Links: Follow Ismail Ali on Instagram | Twitter MAPS Ayahuasca Defense Fund “From Shock to Awe” Decriminalize Nature Boom Festival “Colonization Laid the Groundwork for the Drug War” MAPS Policy Reform Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ayahuasca Practitioner Methods with Dr. Joe Tafur 1:13:41
1:13:41
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:13:41In today’s ayahuasca practitioner episode, Dr. Joe Tafur shares his vast experience learning about this plant medicine. For the last decade, family physician Dr. Tafur, author of The Fellowship of the River , has been exploring the role of spiritual healing and modern healthcare. In Peru, Dr. Tafur learned how the ceremonial use of ayahuasca could be used to heal the emotional body, and in turn, the mind and physical body. He is co-founder of Modern Spirit , a non-profit organization dedicated to demonstrating the value of spiritual healing in modern healthcare. Dr. Tafur describes the traditional origins and uses of ayahuasca. Throughout the Amazonian basin, hundreds of tribes and religious groups incorporate ayahuasca in their healing and sacred practices. This naturally has led to quite a diversity in how this plant medicine is used. Many of these traditions stretch back countless generations and researches are still learning about their processes. There is a vast range of ailments that ayahuasca has been used to address. To treat these, ayahuasca is seldom used in isolation. With the diverse vegetation found in the Amazon, ayahuasca is often combined with specific plants to treat specific conditions. This has made it very versatile in its traditional uses. Related to his work with ayahuasca, Dr. Tafur explains what is meant by the emotional body. He has recognized many spiritual healing techniques that have value beyond plant medicine treatments. Dr. Tafur explains that addressing the emotional needs of the individual can have a profound impact on many of their physical ailments. In this episode: The traditional origins and uses of ayahuasca in South America What to expect during various traditional ayahuasca ceremonies The important role of music and communication during ayahuasca ceremonies The many different conditions that ayahuasca has been used to treat Addressing the emotional needs of the patient in order to treat their physical conditions Quotes: “In the wide world of nature, the plants, and tribal culture there’s a lot of variation. It’s very much dependant on the individuals.” [15:04] “It’s a very present practice. That’s part of the key to the engagement and the energy.” [28:29] “What the psychedelic therapeutic experience opens up for a lot of people is an opportunity to work through the emotional and spiritual dimensions of their health.” [44:50] Links: Modern Spirit The Fellowship of the River “From Shock to Awe” Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ayahuasca Scientific Research with Dr. Dan Engle 56:34
56:34
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
56:34Dr. Dan Engle is a psychiatrist with a clinical practice that combines aspects of regenerative medicine, psychedelic research, integrative spirituality, and peak performance. His medical degree is from the University of Texas at San Antonio. His psychiatry residency degree is from the University of Colorado in Denver, and his child and adolescent psychiatry fellowship degree is from Oregon Health & Science University. Dr. Engle is an international consultant to several global healing centers facilitating the use of long-standing indigenous plant medicines for healing and awakening. He is the Founder and Medical Director of Kuya Institute for Transformational Medicine in Austin, Texas; Full Spectrum Medicine, a psychedelic integration and educational platform; and Thank You Life, a non-profit funding stream supporting access to psychedelic therapies. Dr. Engle is the author of The Concussion Repair Manual : A Practical Guide to Recovering from Traumatic Brain Injuries, as well as his new book, A Dose of Hope : A Story of MDMA-Assisted Psychotherapy. Dr. Engle shares how he sees ayahuasca and other plant medicines as a bridge between traditional medical practices and contemporary medicine. This is particularly the case in the field of psychology. Ayahuasca can have the ability to create visionary states that lend insight into what individuals find most important at a deep subconscious level. There are ongoing efforts to understand the possible uses of ayahuasca as a tool in integrative therapy. Dr. Engle has particular experience applying it in TBI therapies. He describes what he has observed in how ayahuasca can create synaptic genesis and stimulate the growth of brain cells. This has huge implications for treating neurodegenerative conditions. Dr. Engle goes on to describe some of the scientific research surrounding ayahuasca. Its ability to treat a number of conditions has been closely examined in recent decades. This includes its effects on such a large range of issues including chronic inflammatory bowel conditions, addiction, depression, and brain injury. In this episode: The potential of ayahuasca to lend insight into unconscious desires Uses of ayahuasca in integrative psychology and TBI treatments What ayahuasca is and the active chemicals it contains Known contraindications of ayahuasca The findings of many of the research projects focusing on ayahuasca Ayahuasca’s potential to treat addiction The lasting positive and negative effects of ayahuasca use Quotes: “The opening that happens when medicines are facilitated well is orders of magnitude more powerful than the opening that I had experienced in talk therapy.” [6:30] “If you have brain trauma, or a neuro deficit or hypoactivity, many people feel like their brains come back online.” [19:16] “We started studying it. But we’re still in our infancy of understanding, whereas the traditional cultures have been working with this medicine for thousands of years.” [31:14] “The medicines are not here to save us. They aren’t here to fix us. The medicines are here to show us truth in our path. It’s still our work to do.” [50:05] Links: The Concussion Repair Manual “Fantastic Fungi” DMT: The Spirit Molecule “Embrace of the Serpent” Fellowship of the River Takiwasi Center Revive Centers Being True to You The Third Wave Check out the full episode post Keep up with everything Plant Medicine related here Porangui The information provided in this podcast is for general informational purposes only and does not constitute the practice of medicine or other professional health care services, including the giving of medical advice. The content of this podcast is not intended to be a substitute for professional medical recommendation, diagnosis, or treatment. The use of information in this podcast is at one’s own discretion, and is not an endorsement of use given the complexity inherent in these medicines, and the current variable widespread illegality of their usage.…
1 Ayahuasca Patient Experience with Heroic Hearts Project Founder Jesse Gould 34:07
34:07
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
34:07Today, Jesse Gould, the founder of Heroic Hearts Project , is here to share his story... Jesse is a former Army Ranger with a background in finance. After struggling with mental health issues stemming from his military career and finding little support at home, Jesse left it all behind and went to Peru. Hoping to find the answers he was searching for, Jesse discovered the therapeutic uses of ayahuasca. Jesse describes how his search for help eventually pointed him towards ayahuasca. While in Peru, Jesse spent a week at an ayahuasca retreat. He found that, although he was nervous and the process was difficult, the therapeutic supports throughout helped bring a new sense of clarity. In the end, Jesse found that the whole experience gave him useful tools for handling the anxiety that he previously found crippling. Once he came home, Jesse was inspired to share this experience with others like him. He started the Heroic Hearts Project with the intention of helping other veterans connect with reputable ayahuasca retreats and support their path towards healing. Over the past few years, Jesse has worked with many veterans who have experienced profound results from ayahuasca therapies. In this episode: The struggles that Jesse experienced as a veteran seeking mental health support What to expect from a week-long ayahuasca retreat The lessons of learning to surrender and give over control Helping veterans take advantage of ayahuasca therapies What many veterans are saying about the use of psychedelics to help treat PTSD Quotes: “I knew it was a big change. I knew the small changes I was making weren’t having an impact. I might as well try something and I’m glad I did.” [8:51] “You just come to the realization that you are not in control and that’s okay.” [11:13] “The psychedelic process can bring profound changes and some answers. But the person still has to implement these changes and make some hard life decisions for it to fully take effect.” [22:35] Links: Save 20% at Proper Hemp Co with the code “plant medicine”. Heroic Hearts Project Follow Heroic Hearts Project on Facebook | Instagram | Twitter Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 LSD History and Legality with Dr. Erika Dyck 37:57
37:57
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:57On today’s history and legality of LSD episode, we’re joined by Dr. Erika Dyck. As a professor in the Department of History at the University of Saskatchewan, Dr. Dyck focuses her research on 20th Century medical history with a particular interest in psychedelics, psychiatry, eugenics, and population control. Her books include Psychedelic Psychiatry: LSD from Clinic to Campus. She is also editor of A Culture’s Catalyst and Psychadelic Prophets . Dr. Dyck begins by explaining how LSD was first synthesized in 1938. By the end of the 1950s, LSD had been widely studied by numerous researchers who were interested in what this new compound might offer as a model psychosis or for treatment of alcohol addiction. During the mid-20th Century, it was used in multiple settings to help treat numerous conditions. It was even studied by the US military in a failed attempt to create a truth serum. During the 1960s, LSD found its way out of the labs and into the counter-culture of the era. Dr. Dyck tells the story of how this was largely due to the efforts of Timothy Leary who advocated for its widespread use. At this point, LSD had irreversibly left the clinical medical setting and became firmly entrenched in the world of illicit drug use. With a look to the future, Dr. Dyck examines recent changes in attitudes and laws surrounding LSD and other psychedelics. For the first time in over a generation, extensive research is being conducted into the potential therapeutic uses of these drugs. This is a significant shift that leaves open new possibilities for their future legal status. In this episode: What led to the original creation of LSD The early uses of LSD to treat and understand certain psychoses The origin of the term “psychedelic” How LSD became part of the counter-culture movement in the 1960s The use of LSD in secret military experiments What led to the criminalization of LSD in the United States and Canada What has changed in recent years surrounding attitudes towards the use of psychedelics Quotes: “One of these experiences of LSD was later described as worth ten years of psychotherapy.” [11:43] “Historians have tried to understand the relationship between the rising tide of social unease and frustration and civil rights protests that start to challenge the government and how the government responded by criminalizing these drugs.” [22:10] “Things have really changed in the last decade. There’s a return to questions around whether Schedule 1 is, in fact, the appropriate place for these.” [27:23] “This is a moment where there is a desire to think about those colonial tensions that have shaped our history. That might be another feature that will help us to reconcile, or at least appreciate, a different kind of relationship going forward.” [35:16] Links: Save 20% at Proper Hemp Co with the code “plant medicine”. Psychedelic Psychiatry: LSD from Clinic to Campus A Culture’s Catalyst Psychadelic Prophets The Search for the Manchurian Candidate The Trials of Psychadelic Therapy Episode: Psilocybin Research with Dr. Garcia-Romeu Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 BONUS EPISODE: Nationwide Decriminalization Efforts Decriminalize Nature founders Carlos Plazola and Larry Norris 47:00
47:00
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
47:00In today’s special bonus episode, we’re talking with the co-founders of Decriminalize Nature , Carlos Plazola and Larry Norris. Their mission is to promote human health and wellbeing by decriminalizing and expanding access to entheogenic plants and fungi. By utilizing political and community organizing, education, and advocacy, they are closer than ever to their goal. Carlos and Larry discuss how their organization began as an effort to help people reconnect with nature by way of using plants for their healing properties. This naturally led to them advocating for the removal of plants from their Schedule 1 status so that people can once again rediscover and utilize them as medicine. For anyone who is interested in organizing change in their community, Carlos and Larry share their advice on how to get started. It begins by gathering a small group of like-minded community members and developing a resolution. From there, it can be shared with a broader coalition of people from various parts of the community. Once it has gained wider support, it can be brought before the local government. As this movement increasingly spreads around the country, more and more organizations and individuals are getting involved. We talk about recent changes in attitudes that have taken place to make this possible and how this might lead to further developments in the near future. In this episode: The grassroots mission of Decriminalize Nature and how it has spread all over the country How Carlos and Larry became involved in advocating for decriminalization efforts Practical advice on how to organize for decriminalization at the community level What decriminalization means on the local and federal levels How the decriminalization movement has spread to cities around the United States Lessons learned from the decriminalization of cannabis How the decriminalization movement has become more diverse than ever Quotes: “This is a moment when we can stand up and say that these are important for us to be able to work with, on a personal level, a spiritual level, and healing level. And now the science is showing that.” [3:51] “This is not a fear-based movement. This is a movement about liberation, equitable access, and remembering our connection to nature.” [12:17] “The more news that comes out, the more people see that it’s possible. The more people see the support, then everyone gets excited to jump on it. It feels safe.” [26:25] “This is a non-political issue. It’s very much a human issue.” [32:49] Links: Decriminalize Nature Follow Decriminalize Nature on Facebook | Instagram MAPS ERIE Applying the Lessons of Legal Cannabis to Psychedelics Decriminalization VIDEO: Decriminalize Nature Addresses the Berkeley City Council Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 LSD Scientific Research with Dr. Katrin Preller 34:48
34:48
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
34:48Dr. Katrin Preller has worked for the University of Zurich where she investigated the neurobiological long-term effects of cocaine, MDMA, and heroin use. She also investigated the use of psychedelics on self-perception and social cognition at the neuro-psychopharmacology and brain imaging lab. She was appointed as the junior group leader at the University of Zurich and holds a position as a visiting assistant professor at Yale University. In today’s scientific research episode, Dr. Preller breaks down what is known about LSD and discusses her clinical studies. Because of its complicated molecular structure, LSD stimulates more serotonin and dopamine production than many other psychedelics. Dr. Preller describes what past and ongoing studies have discovered concerning LSD’s effect on different receptors on the subjective-behavioral and neurological levels. While Dr. Preller’s research examines the neurological effects of LSD, it also focusses on social cognition. Her findings indicate that certain psychedelics can reduce feelings of social exclusion and increase empathy. This has significant implications for possible use in treating depression. Dr. Preller also discusses how various doses of LSD may affect a person’s creativity as well as certain aspects of brain connectivity. In this episode: The implications of LSD’s molecular structure and chemical composition What the research says about the lack of addictive potential of LSD Possible effects of psychedelics on social cognition The links between LSD and working memory The difference between micro-dosing and regular-dosing on stimulating creativity Quotes: “It is basically impossible to get addicted to LSD just because you can’t use it on a daily basis.” [6:05] “We are very interested in how psychedelics can modify social cognition. It is a big part of human life in general. It is also a key criterium for psychiatric diagnosis.” [9:42] “What we have seen with LSD is that there is a blurring between the perception of oneself and the perception of other people.” [17:02] “Research on these compounds has reemerged recently. There are still very few studies out there. We definitely need more studies to be able to answer all these open questions.” [32:24] Links: Save 20% at Proper Hemp Co with the code “plant medicine”. Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
In today’s LSD patient experience episode, Arash tells the story of how he has interacted with this particular drug. He describes what led him to his decision to try LSD for the first time and the events that helped get him into the proper mindset to proceed with it. Arash explains what type of effect it had on him and why he decided to continue using LSD afterward. LSD experiences have helped Arash make sense of many things that he had previously ignored or took for granted. He explains the insight that this compound has given him and how it has brought him to what he feels is a greater understanding of human behavior and his own identity. Having been using LSD for some time now, Arash reflects on how it has changed his perspective on many things. He has created stronger inter-personal bonds that he feels he was not capable of before. Furthermore, LSD has also lent him new insight into many things that he feels most adults fail to see. In this episode: Arash describes why he first decided to use LSD The helpfulness of having someone to guide an LSD experience How an LSD experience helped Arash have more confidence in social situations The bonding power of psychedelic experiences How LSD has allowed Arash to see old things with new eyes Quotes: “The little ego-check was what I needed so that I went into LSD having relaxed some of my guard and I went in with more of a clear slate.” [9:12] “Before my trip, I was in this more insecure, scared, and vulnerable place. And then I felt completely confident in my body. I felt strong and experienced. I was finding myself taking more of a leadership role in interactions with people.” [21:17] “The assistance of psychedelics took my spirituality from a dial-up modem and upgraded it to highspeed cable wifi.” [36:22] Links: The Burner Podcast Follow Arash on Instagram Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 BONUS Episode: Sharing Stories of Healing with the Founders of the #ThankYouPlantMedicine Movement 43:23
43:23
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
43:23Today we have another bonus episode so that you can hear from the founders of the #ThankYouPlantMedicine movement. David Griot and Jonathan Glazer are two of the leaders of this movement which aims to remove the stigma around the use of plant medicine. On February 20, 2020, there will be an important event for people who have been affected by the power of plant medicines to come out and let the world know of their experiences. David and Jonathan strongly believe that, like so many other social movements, this can be instrumental in leading to progressive change. David and Jonathan believe that this is a crucial time for this movement because it seems that more people are using plant medicines than ever. However, the legal and pharmaceutical landscape still doesn’t support this. To that end, we talk about how to delicately approach this topic in circles where it might not be totally accepted. David and Jonathan explain the phases of their project and how many different people are coming together to make it happen. They are bringing in individuals and organizations from all around the world to make this a truly grassroots movement that reflects the diversity of all plant medicine users. In this episode: What the #ThankYouPlantMedicine movement is The implications of the gap between pharmaceuticals and psychedelics The connection between plant medicine and spiritual development The power of pant medicines to unite people around the world Addressing the need for discretion when discussing the use of plant medicine How people can get involved in this movement Quotes: “It’s time for the communities to unite and get out of the hidden spots and just tell the truth as it is.” [10:16] “The real underlying why in this for me is to create a change in consciousness on a global level to try to create a more collaborative, joyful, and pleasant world.” [17:26] “There’s no pressure -- it’s an invitation. Only people who feel comfortable with it and are not in legal risk should participate. This is going to be the beginning of what we hope to be a multi-year movement until we reach the point where people are not jeopardized by talking about it.” [22:34] Links: Find Thank You Plant Medicine online Find Thank You Plant Medicine on Facebook | Instagram The 5 Most Common Mistakes People Make when Trying Plant and Psychadelic Medicines World Ayahuasca Conference Chacruna Envision Festival Global Drug Survey Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 MDMA History and Legality with Natalie Ginsberg 29:57
29:57
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
29:57Natalie Ginsberg is the director of policy and advocacy at the Multidisciplinary Association for Psychadelic Studies (MAPS) . She works hard to disentangle science from political partisanship on Capitol Hill, the United Nations, and beyond. Today, she is joining us to discuss the history and current legality of MDMA. Unlike many other psychedelics, MDMA was actually legal in the United States for quite some time. It was originally developed in 1912 in an attempt by pharmaceuticals to create a blood-clotting agent. Later on, MDMA was redeveloped with attention paid to its potential therapeutic effects. Consequently, throughout the 1970s, MDMA was widely in therapy, particularly to address phobias and in couples therapy. This all changed in the early 1980s when MDMA found its way into the club scene. With the War on Drugs in full swing, the federal government, despite lobbying efforts by therapists, religious leaders, and activists, classified it as a Schedule 1 drug. There are now efforts underway by MAPS and other organizations to get MDMA back on a pathway for legalization. By citing government studies, collecting anecdotes, and running phase 1 and phase 2 studies, MAPS has shown that there is great potential for a rescheduling of this drug. In this episode: How MDMA was first used in a therapeutic setting The history of how MDMA became criminalized Current efforts to reclassify MDMA as a medicine Evidence that MDMA can be used to successfully treat PTSD What may happen to the legal status of MDMA if it is rescheduled Ways in which psychedelics are used in conflict resolution settings Quotes: “Throughout the 70s, MDMA was actually used across the US and the world in therapy.” [3:20] “Something that we were able to do was use the abundance of MDMA research that governments had sponsored to try to demonstrate harm but had actually demonstrated safety.” [12:20] “Everyone who we interviewed had a very clear intention with the process of taking it for self-healing. They weren’t going to save the world to do conflict resolution.” [25:43] Links: MAPS Follow Natalie on Instagram Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 MDMA Practitioner Methods with Shannon Carlin 33:00
33:00
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
33:00Shannon Carlin is the associate director of training and supervision at the MAPS Public Benefit Corp . In this role, she oversees the development and implementation of the programs that prepare mental health and medical professionals to deliver MDMA assisted psychotherapy in approved clinical settings. Today Shannon is sharing what the clinical and legal landscape currently is for MDMA trials. The discussions with the FDA are currently evolving, but Shannon is very optimistic about the direction things are going in. She also talks about the current model of trials that they are conducting and how this promises to yield innovative and tangible results. Shannon describes how these trials are conducted and what participants can expect throughout the process. Shannon acknowledges that its a complex and tedious process, but stresses that everything is done to ensure both the safety of the participants and the proper scientific gathering of data. To that end, she explains how they are currently running tests and how they are preparing to change once approval for expanded trials happens. In this episode: The current FDA regulations of MDMA The types of practitioners who are participating in ongoing studies What trial participants can expect as they prepare for an MDMA trial What takes place during a clinical trial with MDMA The importance of mindset for both the practitioners and the clinicians during trails How dosing is determined during clinical studies Quotes: “I really enjoy being in the therapy room with somebody who doesn’t have my same professional background because it broadens the competence that the two of us have together.” [7:21] “To me, it really does feel ceremonial. There is a certain amount of ritual or sacredness about it.” [13:25] “There’s a symbolic gesture. It’s subtle, but we don’t give the medicine, we don’t administer the medicine, we offer the medicine.” [19:13] Links: MAPS MDMA Therapy Training Program Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 BONUS Episode: How to Help Veterans Exploring Treatment Solutions through Plant and Psychedelic Medicines 36:34
36:34
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
36:34Marcus and Amber Capone are founders of a nonprofit organization, VETS, Inc. , which provides resources, research, and advocacy for U.S. veterans seeking psychedelic-assisted therapies. Marcus served 13 years as a Navy SEAL, and when the post-military challenges became seemingly insurmountable, Amber became intent to save him by pursuing unconventional treatment modalities. Marcus attributes psychedelic-assisted therapies to saving his life, and now the couple is determined to drive profound change in the veteran healthcare system as a whole. Marcus and Amber describe how they came about finding their way into getting Marcus into Ibogaine and 5-MeO-DMT treatment and the immense changes that have come about as a result of that therapy, both in Marcus’s own healing journey and now in their desire to help other veterans through their foundation, Veterans Exploring Treatment Solutions (VETS). In this episode: How traumatic brain injury was leading to neurologic symptoms that were treatment-resistant The experience of undergoing an Ibogaine session What it was like to do 5-MeO-DMT after the Ibogaine and why that sequence was helpful How Marcus keeps his symptoms at bay How the VETS nonprofit is aiming to spread the healing…
1 MDMA Scientific Research with Marcela Ot'alora 32:26
32:26
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
32:26Marcela Ot'alora G is a psychotherapist with over 20 years of experience working with trauma, specifically PTSD. Having dedicated her professional life to teaching and research, Marcela has served as principle investigator and therapist on various phase-II and phase-III MDMA assisted psychotherapy studies. In today’s MDMA scientific research episode, Marcela describes some of the history of the research into the uses and effects of MDMA. Before it became a Schedule I substance, MDMA was widely used in various therapeutic settings, particularly in couple’s therapy. That changed with its classification as a Schedule I drug in the mid-1980s. However, the research into MDMA’s potential uses in therapy continues. With her particular focus in treating PTSD, Marcela explains some of the neurochemistry behind MDMA’s use in treating this disorder. Research has shown that MDMA activates parts of the brain that are suppressed as a result of trauma and helps people suffering from it make healing connections that they previously were unable to. As an active researcher in MDMA, Marcela describes what has been gleaned from various recent and ongoing clinical studies. In this episode: Some of the early uses of MDMA in therapy The effects of MDMA in treating PTSD The results of recent phase-II and phase-III trial into the therapeutic possibilities of MDMA What it means to have breakthrough therapy status What the research says about how addictive MDMA actually is Potential adverse effects of using MDMA Quotes: “It was so powerful that I decided that I really wanted to advocate for this work and try to bring it to more people.”[1:25] “They are a grounding place for you to be able to access these traumatic memories that are very difficult or painful.” [7:44] “More research is needed and definitely more will be done. PTSD is just the focus at the moment.” [26:50] Links: Find Marcela Ot’alora G online MAPS ClinicalTrials.gov MDMA/PTSD Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
In today’s patient experience episode, Steven tells us about a therapeutic use of MDMA that you may not have heard of. A medical practitioner himself, Steven understands his own condition of IBS very well and what standard treatment is. However, when all these failed to produce results, Steven took the chance and set out to discover how he could better treat his condition. It was finally a decision to address the emotional and spiritual side of his health with his therapist that led Steven to try a guided MDMA experience. As a potent compound, MDMA can lead to significant psychological effects. Steven describes what it was like for him and how it led to significant improvements with his constant pain within a day of his initial experience. Steven explains how he found somebody to lead his journey. Because of legal issues, he had to use an underground network that his therapist pointed him towards. Steven shares how he vetted his guide and what he did to feel safe and supported throughout the experience. In this episode: What compelled Steven to take his health into his own hands Addressing past trauma with the guided use of MDMA to get a handle on physical health Why Steven ultimately decided that MDMA was the right psychedelic for him What an experience of a “heroic dose” of MDMA is What to look for in someone to lead an MDMA journey The value of having an integration session after the experience The protocol Steven followed before during and after his MDMA journey Quotes: “The human body, just because it’s not a machine, doesn’t make it any different. There’s a bunch of inputs and outputs. It’s kind of like electrical engineering systems.” [2:27] “For the first time in my life, I could feel bloating. It’s not that the bloating went away; it was that the pain associated with the bloating went away.” [10:06] “It’s a breakthrough therapy. It’s what the mavericks are doing.” [34:23] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Healthy Gut Company MAPS Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Decriminalization of Psilocybin with Attorney Sean McAllister 55:14
55:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
55:14In today’s episode, Sean McAllister explains the history of psilocybin’s legality in the United States and what its legal status is today. Sean is an attorney working for decriminalization efforts in California and Colorado. He was general counsel for the decriminalization movement in Denver and is a key figure in legalization efforts in California. Sean walks us through the history of psilocybin in the country over the past half-century. He explains how psychedelics became demonized in popular culture and politics. Throughout the sixties and seventies, psilocybin was branded as a dangerous drug and its use and sale were criminalized in the Controlled Substances Act of 1971. Sean explains how recent cultural shifts have opened up the possibility of looking at psychedelics such as psilocybin for their possible health benefits. He describes what went into decriminalizing psilocybin in Denver through a voter initiative and where it stands there legally at the moment. In many places, psilocybin’s legality occupies a gray area. Though decriminalized, it still remains technically illegal. Sean explains just what this means in the actual legal landscape and how there are still limits to what one can do with psilocybin. We also discuss some very current events. Only a few weeks ago, the effort to collect signatures to legalize psilocybin in California began. Sean has been instrumental in drafting the language for this initiative. He tells us where the effort is at the moment and what it would accomplish if passed. In this episode: The history of the study and use of psilocybin in the United States The efforts that led to the decriminalization of psilocybin in Denver The distinction between decriminalization and legalization The current state of legalization efforts in California and Oregon Quotes: “It’s nice that this renaissance is about a cultural and paradigmatic shift towards looking at drug use as a public health issue, not an incarceration issue.” [3:14] “What these elections do is they create so much positivity and hope because it proves that when people come together and when the message is right, the voters will do the right thing, even on a complicated topic like this.” [11:51] “It’s a very complex issue that we’re really only now beginning to unpack. The next five years are really going to be an amazing time to be involved in psychedelic reform. That’s why its the psychedelic renaissance right now.” [41:55] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Decriminalize Nature SPORE Drug Policy Alliance MAPS Decriminalize California Chacruna Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 BONUS Episode: Integration 101 with Dr. Ryan Westrum 41:12
41:12
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
41:12In today’s special bonus episode, we’re discussing integration with Dr. Ryan Westrum. Many guests on this show talk about the importance of integration as part of a psychedelic journey. However, integration is not always understood for what it is. As you’ll hear, it can serve as important scaffolding for a psychedelic experience, making it more meaningful than it might be otherwise. Dr. Westrum is the co-author of The Psychedelics Integration Handbook and an internationally recognized psychedelic integration expert. For more than fifteen years, his primary focus has been working with individuals and groups to facilitate experiential therapy and integrate psychedelic journies into healing and personal transformation. In this conversation, Dr. Westrum explains exactly what an integration therapist is. Simply put, they help prepare the patient for the psychedelic experience and assist in processing it afterward. What they do not do is actually administer the drug itself. In this role, what an integration therapist does can actually vary greatly. Whether they’re doing dream-work, CBT therapy, or even yoga, the integration therapist provides a degree of support and interpretation to make the experience more effective and meaningful. In this episode: What integration is and what an integration therapist does How an integration therapist helps tailor a specific experience to a particular patient’s needs Some of the factors that contribute to psychedelic experiences Some integration exercises that help make meaning of a psychedelic experience The importance of intention setting and mindset in a psychedelic journey Considerations for group versus individual experiences Quotes: “We’re not trying to put a square peg in a circular hole. We’re trying to individualize it.” [6:30] “Psychadelic experiences can bring out a tremendous amount of information that we’re not necessarily aware of. So any preparation is going to support that.” [9:14] “All experiences are challenging; they’re not bad. But if you invite yourself to compare and do the appropriate preparation within integration, you’re going to get something fruitful out of it.” [22:53] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ The Psychedelics Integration Handbook Psychedelic Integration Healing Souls Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Psilocybin Patient Experience with Dr. Lynn Marie Morski 29:50
29:50
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
29:50Today I'm sharing with you the psilocybin patient experience. Disclaimer: I’m not coming to you as a doctor, lawyer, or researcher in this episode, but simply as someone who has experienced psilocybin and is talking about the experience for educational purposes. This was my first (and to this date only) experience with a curated psilocybin ceremony, involving intention setting, a playlist specifically-designed for the journey, and a well-planned environment. It was actually that experience that ultimately led me to start this podcast. I describe how this psilocybin experience helped convey certain messages and led me into a sense of clarity through new introspection. During my psilocybin journey, I was able to deeply reflect on episodes in my life in ways that gave them the closure I hadn’t even been aware that I needed. It helped me gain perspective on my anxiety and actually be grateful for its source. I have since been able to carry some of the clarity of this experience forward with me in other aspects of my life. As a bonus, I discuss a bit about how a microdose of psilocybin led me to finally quit practicing medicine. In this episode: Setting intentions as part of a psilocybin ceremony The messages that the plants can convey during an experience The clarity that is imparted by psilocybin How psilocybin has affected my sense of anxiety The possible delayed introspective effects of psilocybin microdosing Quotes: “A lot of times the people who are guiding these ceremonies have a certain intuition to them.” [7:58] “Especially during this psilocybin journey, I felt like the plants were speaking to me. Not necessarily in a language but in very clear senses in what they were trying to convey.” [10:40] “When you’re in the effects, things seem so dramatic and real and you feel this sense of calm and oneness. It’s hard to realize that that’s going to wear off.” [16:39] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Psilocybin Scientific Research with Dr. Albert Garcia-Romeu 53:14
53:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
53:14Today’s episode is the first in our series focusing on psilocybin’s potential uses as medicine. You are going to hear from one of the premier researchers into this drug, how he runs his studies, and what he has discovered concerning its effects and uses as a medicine. Dr. Albert Garcia-Romeu is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine and a Guest Researcher at the National Institute on Drug Abuse Intramural Neuroimaging Research Branch. There, he studies the effects of psychedelic drugs in humans with a particular focus of psilocybin as a potential aid in the treatment of addiction. Dr. Garcia-Romeu explains the biochemical effects of psilocybin in the human body. He delves into what his research has uncovered about the drug’s potential to treat addiction disorders. What is noteworthy about his research is that is has shown that psychedelic treatments have been able to help some people make lasting changes in regard to alcohol and nicotine addiction. Dr. Garcia-Romeu also discusses psilocybin’s use in treating anxiety and depression. The research has shown that psilocybin has the potential to help patients with life-threatening and terminal illnesses cope with the psychological burdens of their disease. He also explains some of the ongoing research into the efficacy of psilocybin to have a lasting impact on depression in general. In this episode: How psilocybin works at a biochemical level What the research is saying about the uses of psilocybin to treat addiction disorders Possible reasons why some people respond more significantly to psilocybin treatments than others Psilocybin’s effect on treating mood disorders, such as anxiety and depression Safeguards to avoid possible adverse effects during psilocybin studies Quotes: “Administering high doses of drugs like psilocybin and LSD seemed to really help people make some breakthroughs into having greater insight into their alcohol abuse and having more plasticity in their ability to change their behavior going forward.” [7:06] “The more mystical effects that people are having, the better outcomes you’re seeing.” [23:25] “These were real improvements in the quality of life that were measurable, statistically significant, and enduring.” [28:42] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Johns Hopkins Center for Psychedelic & Consciousness Research clinicaltrials.gov Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ketamine History and Legality with Dr. Lynn Marie Morski and a BONUS Patient Experience 22:14
22:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
22:14Today’s episode discusses the history and legality of ketamine. Being so widely available and legal in many places, including the United States, ketamine’s story is different from many other medicines discussed in this show. With that being the case, we’ll also hear the experience of one more patient who has made use of ketamine therapy. When many people hear of ketamine they think of a horse tranquilizer, party-drug, or battlefield medicine. This diversity of uses reflects the varied history of this drug. Ketamine was patented for human and animal use in 1966 and approved by the FDA in 1970. It soon after found widespread use as a field anesthetic in Vietnam. It wasn’t long before the medical and non-medical uses of ketamine expanded worldwide. In the 1990s, researches found that ketamine has many effects in the treatment of depression and chronic pain. In the United States, ketamine is a Schedule 3 drug, meaning that it is widely available as long as a patient has a prescription from their physician. However, in Canada, Australia, and New Zealand, ketamine remains illegal. Many other countries restrict the drug to veterinary use only. The second part of this episode is a discussion with Jennifer about how she approached her physician about using ketamine and her journey with this medicine. While searching for relief from her chronic depression and anxiety, Jennifer came across ketamine treatments. While she initially faced pushback from her psychologist, Jennifer went ahead with her treatment. She discusses how ketamine was able to treat her depression as well as migraines in a way that the other drugs she had taken had not. In this episode: A brief history of the legality of ketamine in the United States What early studies into the various medical uses of ketamine uncovered Where ketamine is legal and in what forms The challenge of finding a doctor who agrees with a patient’s interest in alternative therapies The small but meaningful changes that one patient felt after starting ketamine therapy Quotes: “The fact that there are so many different ways that people have heard of ketamine is a testament to how many things it can do.” [5:11] “If you are considering ketamine, it is a matter of finding a physician or a center that offers it intravenously or intramuscularly. Or work with a psychologist or psychotherapist who offers it, often in the lozenge or nasal form.” [7:56] “So many little things. It felt like I could take deep breaths. I wasn’t always on edge with stress and anger and being defeated. When that little bit starts to lift -- that’s a lot!” - Jennifer [14:20] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Ketamine.com The Third Wave Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 BONUS Episode: Ketamine Practitioner Methods with Dr. Ben Kaplan-Singer 41:30
41:30
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
41:30In this bonus ketamine practitioner episode, you’ll hear from Dr. Ben Kaplan-Singer about the application of intramuscular ketamine. Dr. Kaplan-Singer practices integrative and functional medicine and has developed a “whole person” approach to helping his patients address a number of conditions. With a specialty in intramuscular applications of ketamine, Dr. Kaplan-Singer explains how this method is administered and how someone best prepares for it. As with many transformational experiences, intention setting is crucial. Dr. Kaplan-Singer shares his advice when it comes to setting intentions and explains how it helps with the process overall. Dr. Kaplan-Singer goes on to describe what someone going through an IM treatment of ketamine can expect. From the initial meetings with the doctor to the treatment itself to processing the experience afterward, Dr. Kaplan-Singer explains how he manages it all as a highly curated and supported process. In this episode: How ketamine works at both the biochemical and metaphysical levels The importance of intention setting when preparing for a transformational experience Relative contraindications and side-effects of ketamine to be aware of A walk-through of the process and experience of IM treatment from beginning to end The effects of ketamine on the central-nervous-system as well as the body Techniques and methods for processing the post-ketamine experience Quotes: “Ketamine is being rediscovered as one of the most potent and fastest acting anti-depressants that we know in the pharmaceutical world.” [4:37] “When used this way, we’re actually helping people get novel insights into who they are, what they are, why they’re alive, what their purpose is for being on this planet, what their relationship is to others, and what their relationship is to the cosmos.” [6:52] “I encourage people to embrace a view where whatever comes up is not necessarily looked at as a side-effect but rather as a portal for potential healing.” [15:36] “Ketamine doesn’t just seem to work on the mind. It also seems to work on the body.” [23:14] “When you have a big transformation, it’s not enough to just have a peak experience. It really matters how you apply those insights into daily living.” [26:17] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Find Dr. Ben Kaplan-Singer online Enzo Center Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ketamine Scientific Research with Dr. Jason Wallach 28:24
28:24
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
28:24This week’s episode delves into the science behind ketamine therapy with Dr. Jason Wallach. Dr. Wallach has a Ph.D. in Pharmacology and Toxicology and is an instructor at the University of the Sciences. His research focuses on the analytical and pharmacological characterizations of psychoactive drugs with a focus on dissociatives and the serotonergic classical hallucinogens. Dr. Wallach explains what the research says about the biochemistry of ketamine and how it actually works in the body. There’s still some debate about how ketamine’s various biochemical effects are involved in its therapeutic effects. Dr. Wallach shares what his research has discovered and the questions that he is still trying to answer. Specifically when it comes to examining the potential uses of ketamine to treat depression, Dr. Wallach sees a lot of promise for the drug. He explains some of what the research has shown with ketamine’s use as an anti-depressant and how its effects differ from other treatments. There has also been a lot of research into the difference between racemic mixtures of ketamine versus left-handed or s-ketamine. While racemic, which contains both the right and left-handed molecules, is what’s most widely used in the United States, new information is coming out regularly about the more targeted approach of s-ketamine. In this episode: What the current research says concerning ketamine’s biochemical effects in the body The connection between ketamine and glutamate receptors and what this could mean for its anti-depressant effects Studies into ketamine’s use as an anti-depressant and what this suggests about its efficacy Ketamine as a treatment for various chronic pain conditions The difference between racemic ketamine and s-ketamine The future of ketamine trials Quotes: “What ketamine does is it blocks the NMDA receptor preventing that flux of information from outside the cell to inside the cell.” [5:46] “Most existing anti-depressants have a delay in their onset. They take several weeks before you see any effect. Whereas with ketamine they can be observed within 40 minutes and peak within a day or so.” [10:45] “I suspect that maybe for a subset of people with depression, maybe even PTSD, chronic pain, or OCD, those experiences might have additional efficacy above and beyond what is occurring with the sub-hallucinogenic doses of ketamine that are currently being used.” [24:41] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ketamine Practitioner Methods with Dr. Steven Mandel 46:27
46:27
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
46:27In today’s ketamine practitioner episode, Dr. Steven Mandel describes some of the modern applications of ketamine. Dr. Mandel is the founder and president of Ketamine Clinics of Los Angeles and a founding member of the American Society of Ketamine Physicians . As an internationally recognized pioneer in the use of ketamine infusion therapy to treat depression, suicidality, PTSD, and chronic pain, Dr. Mandel has made numerous media appearances and has personally administered thousands of ketamine infusions. In this episode, Dr. Mandel recounts some of the history behind ketamine’s use in treating conditions such as PTSD and depression. While its use originated on the battlefield, an increasing number of physicians, including Dr. Mandel, soon discovered its other uses for anesthesia and psychological treatments. Dr. Mandel describes what goes on in his clinic and the common conditions that he uses ketamine infusions to treat. This ranges from depression to PTSD and even chronic pain. Dr. Mandel goes into what the research is saying concerning ketamine’s effects on these conditions and how he uses it to treat his patients. In this episode: The history behind ketamine’s use as a treatment for PTSD and depression The other therapies that should go alongside ketamine use in order to achieve lasting effects Common psychological conditions that ketamine may help to address Ketamine’s use in treating chronic pain The importance of priming a patient’s mindset in preparation for and during therapy Some of Dr. Mandel’s favorite success stories Quotes: “Ketamine very quickly became the darling of the battlefield medical community because ketamine in sub-anesthetic doses could very rapidly make a wounded soldier numb enough to participate in his own evacuation despite his wounds.” [8:35] “Ketamine is not a cure at all. It’s a treatment. It doesn’t fix anybody permanently.” [12:30] “You can go to very dark places with ketamine. Ketamine is a fuel. It’s a great enhancer of resilience but particularly the first experience with it can be offputting.” [28:04] “Ketamine can help you to become more open, more resilient. Your sense of worthlessness and helplessness goes away. Your ability to give yourself permission to experience pleasure gets much better.” [34:43] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Ketamine Clinics of Los Angeles American Society of Ketamine Physicians Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Ketamine Patient Experience with Michael Bledsoe 39:03
39:03
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
39:03Today’s episode explores the patient’s experience of using ketamine in a clinical setting. As a very health-conscious person, Michael was curious about how ketamine, applied at a clinic through an IV drip, could address issues with his overall health. In this episode, Michael describes what these experiences have meant to him. Michael shares his reasoning behind his decision to try ketamine and how he prepared mentally and physically for the experience. He walks us through the experience at the clinic getting his infusions and what it’s like from the patient’s perspective. These ketamine treatments have had a number of effects for Michael. He describes how they helped him gain clarity on a number of topics ranging from his business to the grieving of a friend’s death. These six treatments were very impactful for Michael, and he describes how he processed them immediately afterward and how he continues to think about them. In this episode What led to Michael’s decision to use ketamine What was involved in preparing for his initial treatment How ketamine compares to other psychedelics in Michael’s experience Common protocols around ketamine infusion treatments Quotes “You can cover a lot of ground. It’s really up to the person how much they’re willing to investigate in themselves.” [10:25] “I closed my eyes and it was a really easy experience to let go into because it’s a tranquilizer, you know.” [14:29] “They made it sound like I was going to be able to work the same day [as the treatments]. Definitely not the case! Really give yourself some space for the rest of that day.” [34:24] Links Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Cannabis History and Legality with Professor Mike Vitiello 54:46
54:46
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
54:46Distinguished Professor of Law Michael Vitiello is a nationally-recognized expert on criminal law, sentencing policy, and cannabis law. His work on California's three-strikes law has been cited by the United States Supreme Court and the California Supreme Court. This year, Prof. Vitiello along with two co-authors from the University of Michigan published cases and material regarding cannabis law. Today’s episode is an examination of the history and legality of cannabis in the United States. Prof. Vitiello starts off with a brief history of how people have grown and consumed cannabis throughout the ages. In fact, a couple of centuries ago, there were few regulations around cannabis and it was widely used for many purposes, including as medicine. Prof. Vitiello explains how that all changed towards the end of the 19th Century when regulations began limiting access to cannabis. He describes how attitudes about the plant have shifted and changed over the last one hundred years and how this is and isn’t reflected in the law. We then examine the shifts in regulations and attitudes of recent years that have allowed some states to decriminalize or even legalize marijuana for medical and recreational use. This has led to a divergence between federal law and many states’ law, something which further clouds the issue. To help make sense of this, Prof. Vitiello describes how we can navigate a situation in which state laws and federal laws diverge over the legal status of cannabis. In this episode The fascinating yet little understood history of marijuana in America The factors that initially led to the criminalization of marijuana How cannabis played a role in the culture wars throughout the 20th Century The legal rollercoaster that marijuana has gone through over time Recent developments that have led to states changing their laws concerning marijuana How to make sense of conflicting laws concerning the legality of cannabis Quotes “During the Civil War, there were more regulations of tea than there were on marijuana.” [4:12] “Marijuana got into Schedule 1 because of a political compromise. The government’s original position was that it couldn’t accept the petition to reschedule because it didn’t have the power to do that. It was an asinine position.” [25:19] “When we talk about legalization, we’re only saying that some states have decided not to make it a violation of state law.” [30:44] “The possibility of the federal government prosecuting you just based on you purchasing and using in-state is almost is almost certainly not going to happen.” [48:23] Links Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Cannabis Practitioner Methods with Dr. Adam Abodeely 37:56
37:56
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
37:56Dr. Adam Abodeely is the founder and CEO of Reserve:MD as well as a double board-certified surgeon specializing in gastrointestinal diseases and cancer. He is the chairman of the Dispensary Review Committee for the Association of Cannabis Specialists and is the author of A Surgeon’s Perspective on the Science & Truth of Cannabis . Dr. Abodeely recommends cannabis-based therapy for over one hundred different conditions. His journey with medical cannabis began when his patients started telling him about how they were benefiting more from cannabis than they were from the pharmaceuticals he prescribed for them. Since then, Dr. Abodeely has been conducting exhaustive research into the medical uses of cannabis. In this interview, Dr. Abodeely describes what he takes into consideration when deciding if a patient is a good candidate for medical cannabis. We examine some of the many medical conditions in which Dr. Abodeely has found cannabis, and specifically THC, to be helpful. As a GI specialist, Dr. Abodeely takes us on a deep dive of how THC and other cannabinoids specifically affect people with various gut issues. He describes the various ways in which THC can be administered and the benefits and drawbacks of different methods. We examine how cannabis can best be delivered and how to determine proper dosage. In this episode: Guidance to give patients when certifying them for medical cannabis Some of the conditions that Dr. Abodeely has found are treated well with medical cannabis How the various properties of cannabis can impact people with certain GI diseases If depression can be considered a form of chronic pain and be treated with cannabis Why different people respond differently to THC Whether or not cannabis can react negatively with other medications Quotes “What I realized is that patients were actually really benefiting from it. They were coming to me to receive care and my care was providing them with sub-optimal outcomes. But they were receiving great benefits from cannabis.” [5:50] “My goals are to at least minimize or reduce the opioid consumption or get rid of it all together [13:33] “Cannabis medicine is a very personal experience. Our bodies are all genetically different. We all have our unique cannabinoid receptors and genetic polymorphisms which means there’s differences in how my cannabinoid receptors may be compared to yours and how you’re going to respond.” [21:31] “Doses that are too low or too high tend to be non-therapeutic. There’s a sweet spot.” [29:57] Links Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Reserve:MD Adirondack Gastrointestinal & Surgical Group Association of Cannabis Specialists A Surgeon’s Perspective on the Science & Truth of Cannabis by Dr. Adam Abodeely Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Cannabis Scientific Research with Dr. Karyemaitre Aliffe 52:15
52:15
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
52:15Dr. Karyemaitre Aliffe is a multi-lingual physician and scientist who brings life to science and vitality to our concepts of medicine. He has over 35 years of experience as a researcher in natural products. His work has taken him across the globe from the biotech hub of Silicon Valley to some of the remotest corners of the Amazon, Australia, and Africa. Today’s episode explores some of the latest scientific research into medical THC. When it comes to examining the medical uses of cannabis, there is a lot more anecdotal evidence than clinical evidence available. Dr. Aliffe explains the value he sees in this anecdotal evidence and why it should not be overlooked in terms of scientific value. Dr. Aliffe explains what he knows about how THC actually interacts with the human body. There is still much to be discovered about this, but he describes what is known about the biochemical response that happens when THC and other cannabinoids are introduced into the body. Dr. Aliffe talks about a number of recent discoveries covering topics ranging from THC’s role in athletic training to managing stress factors. Since the endocannabinoid system helps modulate the emotional reaction to various circumstances, it has a number of implications in high-stress situations. With the many variations in cannabis products and individual physiology, it is very difficult, if not impossible, for studies to determine what is optimal for each person. Dr. Aliffe explains what he believes the role of an individual, as well as their physician, could be in this matter. In this episode: The important distinction between pharmaceuticals and botanical medicines The value of examining anecdotal evidence What is known about how THC actually interacts with the human body The impact of cannabis on the human response to high-stress situations The challenges of determining optimal dosing with THC The potential role of cannabis in treating aspects of PTSD, anxiety, and depression The implications of cannabis’ anti-inflammatory properties Quotes: “For me, anecdotal evidence is useful because medical practice is all anecdotal; it’s not a controlled trial.” [8:27] “There’s ample evidence that shows that when you have a person who’s relaxed but present and very centered, that’s when they have their optimal mind-body performance and cognitive athletic function.” [20:24] “The challenge is for people to feel comfortable to know how to proceed with a well-produced and well-documented product that actually does have the amount of THC and CBD and other components that it says on the label.” [34:54] “There’s all this conflicting physiology going on and the endocannabinoid system is trying to find that sweet spot of homeostasis in there where everything goes well in life.” [45:13] Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Check out the full episode post Keep up with everything Plant Medicine related here Porangui…
1 Cannabis Patient Experience with Leanna 25:14
25:14
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
25:14When Leanna was finishing up college she began experiencing severe nerve pain in her back. To help her deal with the pain and sleep through it better, Leanna turned to using medical cannabis. In today’s THC patient experience episode, I talk with Leanna about how she used THC to help her cope with this recurrent back pain. She even shares how her grandmother used it help with all sorts of pains and to get her more active than she had been in years. Not wanting to take potentially addictive opioids, Leanna started asking questions about cannabis as a possibly safer alternative. She soon found that THC was helping her feel better than she otherwise thought she could. Leanna and I talk about how she, as well as her grandmother, found their preferred forms of administering THC and why it’s different for everyone. She explains why using cannabis at different times of day helped her get out of bed in the morning and sleep better at night. In this episode: Coming to the decision to use cannabis to treat chronic pain How to deciding which form of THC to take Determining one’s ideal way of taking THC to maximize the results and minimize the side-effects Discussing the use of medical cannabis with family members How patients can talk with medical practitioners about their use of THC products Quotes “At the time I was just looking for other ways that I would feel safer than taking [opioids] long-term.” [6:08] “I had struggles with anxiety in the past and [cannabis] was something that always helped me with it a little bit too. Whereas I have friends who say it gives them even more anxiety.” [14:03] “So my grandma was someone who was able to handle THC better than a lot of people my own age.” [18:40] Links Check out the full episode post Keep up with everything Plant Medicine related here Porangui Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’…
1 CBD History and Legality with Dr. Lynn Marie Morski 17:23
17:23
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
17:23Today’s episode covers the history and legality of CBD. While this should not be construed as legal advice, you will learn about some of the background of CBD and where it fits into the current legal landscape. In order to understand the legality of CBD, it’s important to know the difference between hemp and cannabis. Hemp contains less than 0.3 percent THC content, while cannabis has more. Although CBD can be extracted from either of these plants, the majority of CBD on the market comes from hemp. The production of hemp in the United States has been greatly affected by various laws over the last one hundred years. In fact, it wasn’t until the Farm Bill of 2018 that hemp was removed from the Controlled Substances Act, allowing for the harvesting of CBD seen today. CBD has been known to have potential medical applications for decades, however recent changes in both state and federal laws have led to its new proliferation around the country. Since laws vary from state to state and not all CBD comes from legal sources, it’s important to know where each particular state stands. In this episode: The difference between hemp and cannabis and why this distinction matters A brief history of the word marijuana and why many people are avoiding its use A history of hemp production and how anti-drug laws have affected it The discovery and study of CBD as a compound with potential medical uses What to look out for when determining the legality of a CBD product in a particular state Quotes “CBD can be extracted from both marijuana and hemp as both of them have cannabidiol, or CBD, in them among other cannabinoids.” [4:34] “It is a rapidly developing area and the FDA is still working to develop a regulatory path for hemp-derived CBD.”[10:43] “In states where cannabis is not legal, then CBD from cannabis is also not legal.” [12:29] Links Keep up with everything Plant Medicine related here Porangui Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’…
1 CBD Scientific Research with Dr. Mallory Loflin 27:44
27:44
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
27:44Dr. Mallory Loflin is an assistant professor of psychiatry at the University of California, San Diego School of Medicine . Her research focuses on understanding cannabis as a plant containing multiple potential therapeutic agents, as well as being a substance of abuse. She is the primary investigator for a phase II clinical trial testing the efficacy of CBD as an adjunctive to psychotherapy in the treatment of PTSD in veterans. In today’s episode, we dive into what the research is telling us about CBD. Dr. Loflin shares how her current study is going, as well as her past work. She tells us what the science is saying about various applications of CBD to treat conditions such as epilepsy, anxiety, and depression. With her own research focusing on PTSD, Dr. Loflin is trying to answer some very intriguing questions. From determining if commercially available CBD products are appropriately labeled to studying how it affects people’s fear response as well as their mood in general. Dr. Loflin continues to explain how she is working to determine how CBD works in different dosages and how that can help patients in a number of fascinating ways. In this episode: The encouraging results of trials into the efficacy of CBD for treating PTSD symptoms Some of the ways CBD has been used to treat various conditions and illnesses in recent years What many of the recent and ongoing studies into CBD are looking at The different types of CBD and why it’s important to know the difference Figuring out the right dose for CBD and how it compares to THC treatments Just how habit-forming using cannabis, and CBD in particular, is on a regular basis Quotes “When you looked at the preclinical data, there had been some early work suggesting that potentially some cannabinoids could be helpful for the treatment of PTSD.” [5:00] “People are already experimenting with different kinds of CBD, so we have to both see what people are using and if it’s safe, if it’s potentially showing effects, differences in what people are using and then we also need to study it from an actual traditional drug development pathway.” [11:10] “Usually when you get [people with PTSD] on a route of change, you don’t start to really see big impacts in functioning until further down the road because you’re changing the trajectory of their life.” [25:39] Links Dr. Loflin’s CBD and PTSD study (currently enrolling) VA Center of Excellence, Stress, and Mental Health Santa Cruz Veterans Alliance Octagon Biolabs…
1 CBD Practitioner Methods with Dr. Rachna Patel 1:00:45
1:00:45
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
1:00:45Dr. Rachna Patel is a world-recognized expert in the field of medical cannabis and CBD oil. She’s also the author of The CBD Oil Solution . Dr. Patel offers courses and consultations to help people relieve their symptoms, transform their health and live a better quality life. After spending years training as an Emergency Medicine Doctor and working with patients to help alleviate pain, Dr. Patel ventured into the field of medical cannabis in 2012. Two years later, she started her own practice so that she could offer people care they otherwise wouldn’t have access to. We cover a lot of conditions in this episode. Whether you suffer from migraines, anxiety, PTSD, or pain, Dr. Patel shares what we know about using CBD as part of your treatment. Dr. Patel explains how CBD impacts hormonal pathways to help alleviate many chronic conditions associated with anxiety and PTSD. She describes how CBD effect migraines and how it can be used in a number of ways to this end. CBD even has a role in treating the type of pain that many patients take opioids for. It can even be applied topically for skin conditions. Dr. Patel also tells us why not all CBD products are created equal. Often there are additives and other chemicals present in the product that should be avoided in many circumstances. Dr. Patel explains what we should watch out for and consider, like reviewing lab test results and even making sure it has CBD in it at all. She also shares her thoughts on how to determine proper dosing and how to find the right doctor for you. In this episode: How you can tell if CBD oil can help you with anxiety, insomnia, and panic attacks The ways in which CBD can be used to help alleviate the symptoms of migraines and other types of hard to treat pain Which autoimmune conditions CBD has been used to treat Topical applications of CBD for helping hard to treat skin conditions The most important things to look for or avoid when considering a CBD product The importance of having a high quality CBD source and how to identify the best products How to find the right doctor to prescribe the proper cannabis products for you Quotes “You only have a certain window of time in which you need to take the triptan in order to actually affect the pain of migraines. If you miss that window, then you have to suffer through the pain -- not the case with CBD.” [13:53] “What ends up happening with these patients is that they’re able to wean off of their cocktails of medications that they’re on. Often times they’re using the CBD oil on a regular basis, but then they’ll have conventional medications just as a backup for when the pain gets really bad.” [20:10] “You want to make sure that you look at the laboratory test results for any form of CBD oil that you purchase. That’s because it’s not a regulated industry and anybody can sell anything. If the company cannot provide you with test results, then don’t buy it.” [35:14] “What you want to look for in a physician is experience, specifically experience treating the particular medical condition that you’re interested in treating with CBD oil or medical cannabis.” [57:02] Links Find Dr. Rachna Patel online Follow Dr. Patel on Facebook | YouTube The CBD Oil Solution by Dr. Rachna Patel Medical Marijuana Doctor: How to Find One that You Can Trust Octagon Biolabs…
1 CBD Patient Experience with Tony - How CBD helped alleviate his back pain and kept him out of surgery 30:29
30:29
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
30:29Today I’m talking with Tony about his experience using CBD to help alleviate his chronic back pain. After he hurt his back deadlifting, Tony tried everything he could think of to get rid of the pain. From functional exercise to dry-needle acupuncture, nothing worked. Almost by chance, Tony got his hands on some CBD and it has made all the difference ever since. After discovering CBD, Tony started investigating just how it’s been helping him. He tells us how he found the right products and dosages for him and how it’s turned his life around. Now, having experienced the benefits of CBD, Tony has become a true evangelist for the power of this product to help heal when other interventions can’t. In this episode How pain from an injury can lead to experimenting with numerous treatments What it was like finding CBD in the years before it was so popular Figuring out your best dose through trial and error Many common reasons that people (and sometimes animals) take CBD What to look for and consider when shopping for your CBD product Quotes “If you have it, there’s CBD in it right now. It’s all over the place, so it’s easy to find these days.” [7:19] “My back hurt every single day for at least two years. Now in this two or three day period, it was really the first time that I could say that I was pain-free.”[12:15] “It was so traumatic to go through chronic pain. It wears you down, it makes you depressed, it just puts an edge on everything where you’re a little bit unpresent. You’re just not all the way there because in the back of your mind you’re hurting. That really just wears you down.” [22:51] “This is something else that you can try. It’s such a low risk for such a high potential reward.” [29:15] Links Ben Greenfield Fitness Paleo Magazine Radio Podcast Episode 102: Health Benefits of Weed Octagon Biolabs…
1 Welcome to the Plant Medicine Podcast with Dr. Lynn Marie Morski 12:25
12:25
बाद में चलाएं
बाद में चलाएं
सूचियाँ
पसंद
पसंद
12:25Welcome to the first episode of the Plant Medicine Podcast with Dr. Lynn Marie Morski. This episode discusses the aims of the show - which are to demystify and destigmatize the use of plant and psychedelic medicines. Hemp-derived CBD is now legal in all 50 states, cannabis is legal for at least medical use in more than half of the states and in various countries around the world, psilocybin (magic mushrooms) were just decriminalized in two American cities and there are several ballot measures and groups aiming to increase that number, and MDMA and psilocybin have been given 'breakthrough therapy' status by the FDA. But as a medical doctor, I know that we weren't taught anything about any of these substances in medical school. So when patients come to doctors for advice, those doctors are often unaware of the non-pharmaceutical options available to treat some of the toughest conditions, like chronic pain, addiction, PTSD, and depression. This show aims to educate both the medical establishment and interested patients on the scientific research into the powers of these medications to help with various conditions, as well as the safe use of these substances. NOTE: This show is not medical nor legal advice and should not be construed as such. It is also not suggesting you participate in any illegal activities. The show is for education purposes only.…
प्लेयर एफएम में आपका स्वागत है!
प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।